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ABSTRACT 
The role of serotonin (51M in the physiological regulation of AVP secretion is 
controversial. Neuroanatomical studies, largely in rats but also in human 
brains, have suggested that 5HT may have a direct modulatory effect on 
magnocellular vasopressin (AVP) secretion. Pharmacological and 
neurophysiological studies in animals have provided further evidence to support 
this and suggest that increase in 5HT neurotransmission leads to a rise in plasma 
AVP and that 5HT may be important in osmoregulated AVP secretion 
Studies investigating the importance of 511T as a modulator of AVP release in 
humans have not be undertaken. Indirect evidence of a putative role derives 
from the occurrence of hyponatraemia, and possible inappropriate AVP 
secretion, associated with the clinical use of drugs, particularly antidepressants, 
which have effectson 5HT neurotransmission. In addition there has been some 
suggestion that AVP secretion may be abnormal in depression where there is a 
putative abnormality of the 5HT nervous system. 
This research has approached the study of anatomical and physiological 
relationships between 5HT and AVP in 3 ways. Firstly through studies in 
normal man, secondly by studies in depressed patients, as a putative disease 
model of 5HT neurotransmission, and thirdly to more extensively explore the 
effect of pharmacological manipulation of 5HT neurotransmission using an 
animal model of osmoregulation. 
Studies in man found no evidence that 7 days treatment with a 5HT reuptake 
inhibitor (Fluoxetine) had a significant effect on osmoregulated AVP secretion. 
Studies in elderly depressed patients showed that there was an apparent 
deficiency of osmoregulated AVP secretion with normal ageing but found no 
evidence that either moderate depressive illness, or treatment of the depression 
with Fluoxetine, had significant effect on water balance. 
Studies in the rat model of osmoregulation showed that acute 5HT reuptake 
inhibition stimulated basal AVP secretion and increased the osmotic sensitivity 
of AVP secretion but had no effect on the osmotic threshold of secretion. 
Chronic treatment (21 days) with the reuptake inhibitor had no significant effect 
on basal AVP secretion or on the osmotic threshold but significantly decreased 
the osmotic sensitivity of AVP secretion. 
Studies with the 5HT2/5HTIc antagonist, Ritanserin, and the 5HT2 agonist, 
DOI, suggested that this modulatory effect was not mediated through these 
receptor subtypes. Autoradiographic studies identified a low density of 5HT2 
and 5HTIa receptors in the vicinity of the magnocellular neurons of the rat 
hypothalamus. 
The results suggested that 5HT modulates AVP secretion indirectly, possibly by 
inhibition of inhibitory afferent stimuli. This is of little physiological 
consequence in the normal rat and probably in healthy man where there is rapid 
accommodation and autoregulation. In situations where there is a dysfunction of 
the normal adaptive mechanisms, such as in depression, the role of 5HT may be 
more important and occasionally may lead to severe hyponatraemia. 
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SECTION 1 
INTRODUCTION 
1 
SUMMARY 
Neuroanatomical studies, largely in rats but also in human brains, have 
suggested that serotonin (5HT) may have a role in regulation of vasopressin 
(AVP) secretion. Pharmacological and neurophysiological studies in animals 
have provided further evidence to support this hypothesis suggesting that 
increase in 5HT neurotransmission leads to a rise in plasma AVP and that 5HT 
may be important in osmoregulated AVP secretion 
Studies investigating the importance of 5HT as a modulator of AVP release in 
humans have not bundertaken. Indirect evidence of a putative role derives 
from the occurrence of hyponatraemia, and possible inappropriate AVP 
secretion, associated with the clinical use of drugs, particularly antidepressants, 
which have effect on 5HT neurotransmission. In addition there has been some 
suggestion that AVP secretion may be abnormal in depression where there is a 
putative abnormality of the 5HT nervous system. 
This section discusses the literature pertinent to the regulation of AVP secretion 
with particular discussion of normal and abnormal osmoregulation and 
hyponatraemia. The 5HT neurotransmitter system is discussed with the 
evidence for its modulation of AVP secretion and involvement in the 
pathophysiology and phenomenology of depression. The evidence for 
abnormalities of water balance and AVP secretion in mental illness is also 
discussed. 
The hypotheses drawn from the literature review are presented together with the 
aims of this research. 
2 
1.1 VASOPRESSIN AND THE MAINTENANCE OF A NORMAL 
OSMOTIC ENVIRONMENT 
Arginine vasopressin (AVP) is a nine aminoacid peptide hormone, secreted from 
the posterior pituitary together with its associated carrier protein neurophysin I. 
It has been found to have important actions in the maintenance of water balance 
and cardiovascular homeostasis. AVP-secreting neurons have been identified 
throughout the brain as have AVP receptors (Sofroniew 1985; Lawrence et al 
1988; Triýbollet et at 1988). This suggests that the peptide has a multitude of 
functions each of which may be regulated by separate systems and be responsive 
to independent stimuli (Buijs et al 1983). In the hypothalamus AVP-containing 
neurons have a variety of functions. Some have a role in the regulation of the 
pituitary-adrenal axis through synergistic action with corticotropin releasing 
factor on adrenocorticotrophic hormone (ACTH) release (Zimmerman & 
Silverman 1983; Schatzberg & Nemeroff 1988). AVP may also have a role in 
circadian rhythmicity since some neurons in the suprachiasmatic nucleus (SCN) 
have a high AVP content (Zimmerman 1976). Swanson & Sawchenko (1980) 
suggested that the AVP neurons in the paraventricular nucleus (PVN) may be 
involved in the integration of the autonomic nervous system as axons project to 
the brain stem and spinal cord. 
This review will concentrate on AVP"secreting neurons of the hypothalamic 
neurohypophysial axis, the magnocellular AVP system (Figure 1.1.1). 
1.1.1 ANATOMY 
The majority of research on the anatomy of the magnocellular AVP system has 
been carried out in rat and other animal brains. This will be discussed first and 
the differences in man will then be considered. 
Retrograde tracing experiments with dyes or horseradish peroxidase placed in 
the posterior pituitary have shown that large cell bodied neurons, the 
magnocellular neurons, in the supraoptic nucleus (SON) and PVN, together with 
accessory groups of similar neurons, are the source of the majority of nerve 
fibres in the hypothalamo-neurohypophysial tract (HNT) (Sherlock et al 1975; 
3 
Figure 1.1.1 
The location of the magnocellular AVP secreting neurons of the hypothalamo-neurohypophysial 
axis of the rat. 
SON: Supraoptic nucleus; PVN: Paraventricular nucleus; 
III: Third ventricle; OT: Optic tract; V: Ventricle; CC: Corpus callosum 
Rtton 
Armstrong& 1980; Sofroniew 1982). The accessory groups contribute about 
50% of the AVP fibres to the HNT (Fisher et at 1979; Rhodes et at 1981). Of 
the rest the majority originate in the SON. 
The magnocellular neuronal system comprises both oxytocin (OXY)-and AVP- 
secreting neurons. Research has shown that only one hormone type is secreted 
in any one neuron (Aspeslagh et at 1976; van Leeuwen & Swaab 1977; Morris 
et at 1977; Diericlix et at 1978) and that the neuronal cell bodies for each 
hormone type are unevenly distributed within the hypothalamic nuclei 
(Sternberger 1974; Vandesande & Dierickx 1975; Swaab et at 1975a+b). OXY 
cells are more concentrated in the rostra! part of each nucleus. At the mid 
rostro-caudal level of the SON, AVP cells are generally ventral, whilst OXY 
cells form a dorsal rim. The magnocellular neurons of the PVN lie at the lateral 
edge of the nucleus. AVP cell bodies form the central core of this neuronal 
cluster, rimmed by OXY neurons. The majority of the accessory groups of 
magnocellular neurons are OXY secreting (Rhodes et at 1981). 
Efferent fibres from the PVN, so called Greying tracts, pass laterally around 
and through the fornix, then move ventrally to join axons from the SON and 
form a tract converging on the zona interna of the median eminence. The 
pathway continues down the pituitary stalk to end on the basement membranes 
of the capillaries in the neurohypophysis (Silverman & Zimmerman 1975; 
1983). Neurons from the PVN do not appear to synapse in the SON but some, 
mostly AVP secreting, terminate in the median eminence (Vandesande et at 
1977). It is largely the OXY-containing fibres of the PVN, together with fibres 
from the SON, which innervate the neurohypophysis. 
Within the neurohypophysis there is specific arrangement of neuronal fibres 
from each nucleus. SON neurons are concentrated in the centre of the gland 
whilst PVN axons terminate in the periphery. Essentially this means that 
neurons secreting AVP are in the centre of the gland and those containing OXY 
are around the periphery (van Leeuwen & Swaab 1977; Van leeuwen et at 
1979). 
The anatomy of the HNT in man differs in many respects from that of the rat 
(Defendini & Zimmerman 1978). The SON is divided into anterior and 
posterior parts by the optic tract and the PVN is a long, thin column of cells 
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lying in the wall of the third ventricle. Although cell bodies of the SON are 
large, similar to those in the rat, identification of magnocellular neurons in the 
PVN is less obvious. Immunocytochemical studies have shown that neurons 
exhibit specificity of hormone type secreted (Dierk x& Vande sande 1977; 
Sofroniew et al 1981). In the SON, unlike the rat, the majority of neurons are 
AVP secreting and are located in the ventral portion of the nucleus. Regional 
topography of each neuronal type is not defined in the PVN. The, efferent fibre 
tracts of the two nuclei appear to be similar to those described in the rat brain. 
Thus although study of the anatomy of animal brains may give some insight into 
possible function of magnocellular AVP secretion some caution must be taken 
into extrapolation of these findings to man since there are important differences, 
particularly in the anatomy of the PVN and in the relative loss of OXY neurons. 
1.1.2 PHYSIOLOGICAL REGULATION OF AVP RELEASE IN HUMANS 
AVP is known to have both antidiuretic and pressor effects and the osmotic 
environment and circulatory pressure and volume have major roles in regulation 
of neurohypophysial secretion. In healthy humans the principal regulatory 
influence is the osmolality of extracellular fluid (Robertson & Athar 1976). 
1.1.2.1 Osmoregulation 
In 1947 Verney found that injection of hypertonic solutions into the carotid 
arteries of conscious dogs produced a prompt antidiuresis. This system was 
sufficiently sensitive to respond to changes in plasma osmolality (pOS) of 2% or 
less. Verney suggested that intracranial sensors of osmolality changes, 
osmoreceptors, directly influenced AVP secretion and allowed regulation of 
water excretion by the kidney to maintain osmotic homeostasis. 
Research has since found that osmotically sensitive cells lie within the 
circumventricular organs of the anterior hypothalamus, either in the organ 
vasculosum of the lamina terminalis (Thrasher et al 1982) or in the subfornical 
organ (Iovino & Steardo 1984; Ferguson & Kasting 1986). Changes in the 
osmotic mileux of these cells modulate firing activity of nerves projecting to the 
magnocellular neurons of the SON and to some extent to the PVN (Bicknell et al 
1984; Mason et al 1988). The magnocellular neurons themselves have also been 
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shown to be osmotically sensitive but the role of this in osmoregulation is less 
clear (Mason 1980; Leng et al 1982). 
In healthy adults plasma osmolality (pOS) is maintained at 287±2 mOsm/kg 
(Robertson et al 1973). For any individual the basal pOS is very tightly 
regulated with daily variation off 1.8 % (Robertson & Athar 1976). 
Initial work on the osmoregulation of AVP in humans was carried out 
subsequent to the development of a sensitive radioimmunoassay for AVP 
(Robertson et al 1970). Infusion of hypertonic saline leads to a rise in plasma 
AVP. The rate of rise, and the relationship to pOS was dependent on the rate of 
infusion of the saline ie. the rate of change of pOS (Robertson et al 1977). Fast 
infusion rates of infusion with an increase in pOS of >2% per hour caused 
exaggerated AVP secretion with a curvilinear relationship to pOS (Weicz. man 
& Fisher 1977). A rise in pOS of <2% per hour lead to a linear relationship 
between pOS and AVP (Robertson et al 1976; Thompson et al 1986). 
Linear regression analysis of the change in AVP with change in pOS provides 
data on the sensitivity of AVP secretion to unit change in pOS and allows 
calculation of the theoretical pOS (x-axis intercept) at which AVP might first be 
secreted, the osmotic threshold. This threshold is theoretical in part because 
most assays will not detect such low concentrations of AVP, but also because in 
very sensitive bioassay systems it has been shown that AVP is still detectable 
below this theoretical threshold (Baylis et al 1986). Nevertheless the osmotic 
threshold is a useful concept in physiological investigation and assessment of 
dysfunction (see Section 1.2.2.3). 
It has been found that for normal healthy adults the sensitivity of AVP secretion 
is 0.41 ±0.05 pmol/1 AVP per mOsm/kg change in pOS and the theoretical 
threshold of release is 285±1 mOsm/kg (Thompson et al 1986). Estimates of 
these values by other groups with different assays are of much the same 
magnitude (Robertson et al 1973; Robertson & Athar 1976; Baylis & Robertson 
1980; Baylis 1983). This means that a rise or fall in pOS of 1% (2.9mOsm/kg) 
leads to a change in AVP of over lpmol/1 and marked changes in water excretion 
(see Section 1.1.2.1.1). Maximal antidiuresis occurs at AVP concentration of 
4pmol/1(Baylis 1987) with pOS of 295mosm/kg. Maximal diuresis occurs with 
pOS <285mOsm/kg, the theoretical threshold for AVP release. 
Further studies have shown that for each individual the response to a 
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standardised rate of infusion of hypertonic saline (and rate of change of pOS) is 
highly reproducible although large differences between individuals are apparent 
(Robertson & Athar 1976; Thompson et al 1991). It is interesting that Zerbe 
(1985' showed that there was concordance in monozygotic but not dizygotic 
twins. These studies of normal osmoregulation have also shown that the basal 
pOS of any individual is highly correlated with the theoretical osmotic threshold 
for AVP release (Robertson 1977). It appears that a sensitivity of AVP release 
of < 0.2 pmol/l per mOsm/kg or > 0.7 pmol/1 per mOsm /kg is abnormal. The 
normal osmotic threshold for AVP release lies between 282mOsm/kg and 289 
mosm/kg (Figure 1.1.2). 
The regulation of AVP by change in pOS is, however, dependent on solute type 
(Zerbe & Robertson 1983). Hypertonic sodium chloride and mannitol have 
been shown to be equipotent at stimulating AVP (Athar & Robertson 1974; 
Robertson et al 1976), even though during mannitol infusion plasma sodium 
concentration falls. Infusion of hypertonic urea, despite causing a similar rise in 
pOS, has little or no effect on AVP concentration (Robertson 1977). Infusion of 
hypertonic glucose in non-insulinopoenic subjects, leads to a rise in pOS, a fall 
in plasma sodium and a significant faU in AVP (Athar & Robertson 1974). It is 
suggested that this apparent paradox is explained by the differential ability of 
solutes to diffuse into cells. Thus the effect of a particular solute on AVP will 
be a function of its net effect on the osmotic gradient across a selectively 
permeable cell membrane in the brain (probably the osmoreceptor cell wall). 
Any solute which penetrates the barrier slowly (sodium and mannitol) will cause 
a net increase in extracellular osmotic pressure, dehydrating osmosensitive areas 
and stimulating AVP release. Solutes which diffuse rapidly across cell 
membranes (eg. urea) have little effect on the osmotic gradient and provide little 
stimulus to AVP release, providing plasma sodium remains unaltered. Glucose, 
despite readily diffusing into brain cells in the presence of insulin, causes a drop 
in plasma sodium because of an osmotic gradient across somatic cell membranes. 
The net effect on the osmoreceptor is therefore cellular hydration, decreased 
neuronal firing and inhibition of AVP secretion. 
Alcohol has more complex influence on AVP release. Moderate plasma 
concentrations of ethanol (100mg\dl) appear to blunt the AVP response to 
osmotic stimulation by an elevation of the osmotic threshold by about 
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Figure 1.1.2 
The 95 percentiles of the relationship between plasma AVP and plasma osmolality during the 
infusion of hypertonic saline (SSSmmol/1) in healthy man. The osmotic threshold lies between 
282 and 289 mOsm/kg and the sensitivity of AVP secretion lies between 0.2 and 0.7 pmol/l per 
mOsm/itg. 
Adapted from Thompson et al (1986). 
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6mOsm/kg (Eisenhofer & Johnson 1982). Thus diuresis occurs as AVP 
concentration falls when pOS is normal. As pOS increases antidiuresis may 
occur. 
Studies of patients with apparent loss of osmoregulatory input to magnocellular 
neurons have a shown basal secretion of AVP to plasma concentrations of 1- 
1.5pmol/1 (Robertson 1987). This suggests that both excitatory and inhibitory 
afferent inputs are required for normal osmoregulatory function and 
maintenance of osmotic homeostasis. 
1.1.2.1.1 Niter metabolism 
The maintenance of normal water balance requires an ability to regulate both 
intake of fluids and excretion of water and solutes. In normal man maintenance 
of osmotic homeostasis relies on adjusting urinary excretion to daily fluid intake 
since the latter is regulated more by social factors than physiological 
requirement. 
a) Control of urine output by AVP 
AVP has a powerful facilitatory effect on the permeability of the distal renal 
tubule to water, allowing urinary concentration when present. An increase in 
plasma concentration of lpmol/l will cause a rise in urine osmolality of 
235mOsm/kg (Robertson 1977; Baylis & Robertson 1985). This 'gain' in the 
osmoregulatory system allows pOS to be maintained within very fine limits. 
Above 4.5pmol/l AVP has no further effect on urinary concentration. Between 
the pOS of 286mOsm/kg and 296mOsm/kg, with associated AVP concentrations 
of 0.3-4.5 pmol/l, there is extremely efficient osmoregulation 
b) Thirst and control of fluid intake 
Thirst is a complicated desire in man, modified by voluntary control. The 
conscious sensation derives from higher cortical centres where stimuli from the 
oropharynx, upper gastrointestinal tract and afferent inputs from the 
hypothalamus are integrated. The hypothalamus itself integrates afferent inputs 
from pressor and volume sensors, the renin-angiotensin system and osmotic 
stimulation. 
The osmotic regulation of thirst is closely associated with the osmoregulation of 
AVP. Osmotic sensitive cells for thirst reside in the anterior hypothalamus 
close to the osmoreceptors for AVP regulation. They do not appear to be the 
8 
same cells as absence of one function with preservation of the other has been 
documented (Halter et at 1977; Hammond et al 1986). 
The osmotic threshold for severe thirst was noted to be on average 298mOsm/kg 
(Robertson et at 1976; Baylis & Robertson 1980; 
Robertson 1984). This is just above the pOS which stimulates an AVP 
concentration sufficient to maximally concentrate urine (4.5pmol/1). Thus when 
no further body water can be preserved by concentration of urine, osmotic 
homeostasis depends on fluid intake and the desire to drink. The osmotic 
threshold for initiation of thirst was noted to be on average 293mOsm/kg 
(Thompson et al 1981) and has a very close relationship to the threshold for 
AVP secretion in each individual (Thompson et al 1986). 
Osmotic stimulus to thirst is, like AVP secretion, solute specific and dependent 
on the net osmotic gradient across the osmoreceptor cell membranes. (Zerbe & 
Robertson 1983). 
Thus in healthy man the osmotic mileux is maintained by alteration of the 
plasma AVP concentration and adjustment of free water excretion by the 
kidney. Thirst stimulation is probably only truly important when pOS has 
increased outside of the range of normal homeostatic control. 
1.1.2.2 Non-osmotic regulation 
1.1.2.2.1 Baroregulation 
The stimulation of high-pressure baroreceptors in the carotid sinus and aortic 
arch, sensitive to changes in blood pressure, has been shown to reproducibly 
regulate AVP release (Schrier & Berl 1975; Schrier et al 1977). Change in 
activity of low-pressure baroreceptors in the left atrium, sensitive to change in 
blood volume without change in blood pressure, has also been shown to alter 
AVP release (Share et al 1974). These haemodynamic stimuli are conveyed to 
the brain in the glossopharyngeal and vagal nerves to the tractus solitarius 
(NTS) in the brain stem. 
It is a matter of some controversy as to whether changes in blood volume or 
blood pressure are the more sensitive and more important baroregulatory system 
in man. A fall in mean arterial blood pressure by as little as 5% stimulates 
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significant AVP release whereas a 10-15% reduction of central blood volume is 
required for the same effect (Robertson 1977). Blood pressure changes have a 
curvilinear relationship to AVP release however, since a 15-20% drop is needed 
to achieve maximal antidiuresis. Changes in blood volume are difficult to assess 
and leads to further difficulty in conclusion to this debate. 
Alteration in these cardiovascular parameters influences the secretory activity of 
magnocellular neurons through second order afferent neurons from the NTS (see 
Section 1.1.3.2. ) 
1.1.2.2.2 Nausea 
Nausea, produced by a variety of chemical and physical stimuli, is an extremely 
potent stimulus to AVP release leading to plasma AVP concentrations of up to 
500pmol/l. The purpose of, and mechanisms underlying this massive release of 
AVP are not well understood (Faull & Baylis 1991). AVP concentrations of 
this magnitude will have pressor effects as well as antidiuretic action. It may 
also have effect on gluconeogersis and possibly direct effect on the gut. 
Dopamine (DA) may play some role in the neuroendocrine mechanism since 
apomorphine, a DA2 agonist is a potent stimulus to both nausea and AVP. 
However the effect on AVP is dependent on the degree of nausea not on the 
drug dose (Rowe et al 1979). 
Ipecachuana, a potent stimulus to nausea, has been shown not to stimulate 
concomitant AVP release (Nussey et al 1988) accentuating the very limited 
nature of the understanding of this physiological stimulus to AVP release. 
1.1.2.2.3 Hypoglycaemia 
Hypoglycaemia in man causes a 3-4 fold rise in plasma AVP (to 8pmol/l) 15 
minutes after the blood glucose falls to 2.2 mmol/1 (Baylis & Robertson 1981). 
The response is independent of concomitant changes in pOS. There is great 
variability in individual response and there is also poor intra individual 
reproducibility of response (Thompson et al 1991). 
The mechanism of AVP stimulation is thought to be intra-neuronal glycopaenia 
since administration of 2-deoxy-D glucose produces a similar AVP response 
(Thompson et al 1981). The significance of hypoglycaemia-stimulated AVP 
response is unclear. Although AVP may effect hepatic glycogenolytic activity 
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(Hems et al 1976), circulatory AVP concentrations of the order of magnitude of 
8pmol/1 would appear to have no effect on plasma glucose (Spruce et al 1985). 
1.1.2.2.4 Oropharyngeal reflex 
Oral fluid ingestion causes an immediate, and probably total, suppression of 
AVP release irrespective of pOS (Thrasher et at 1981; Thompson et at 1987). 
This does not appear to be due to a rise in blood pressure or a volumatic 
inhibitory stimulus (Thompson et at 1987), nor to gastric filling. It is also 
independent of changes in portal blood osmolality since it occurs after ingestion 
of hypertonic fluid and in dogs with gastric fistulae (Thrasher et at 1981). It is 
explained by an inhibitory stimulus subsequent to the oropharyngeal stimulation 
of fluid ingestion (Seckl et at 1986; Thrasher et at 1987) and cold rather than 
warm fluids are more effective (Salata et at 1987). 
1.1.2.2.5 Stress 
The role that stress may have in AVP regulation is subject to much controversy. 
Rydin & Verney (1937) suggested that non-specific and emotional stresses lead 
to antidiuresis in dogs. The findings from many other studies have been 
difficult to interpret due to the confounding variables of pain and alteration in 
blood pressure (Husain et al 1979). Some authors would suggest that since 
AVP is involved in the stimulation of ACTH secretion and its release is 
provoked by the physical stressors of hypoglycaemia, hypoxia and exercise, it 
does have a role as a hormone of the stress response (Gibbs 1986). A number of 
studies in animals have suggested that AVP is not a stress hormone in the same 
way as cortisol and prolactin (Brennan et al 1975; Keil & Severs 1977; Lang et 
al 1983; Alexander et al 1987; Parrott et al 1988). A recent study has suggested 
that emotional stress suppresses AVP secretion in rats (Yagi & Onaka 1991). 
There have been few studies on man to investigate stress as a stimulus to AVP 
release. Raskind et al (1977) showed that hospitalised patients with anxiety 
disorders had normal plasma AVP concentrations. 
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1.1.2.2.6 Other influences 
Acute hypoxia has been shown to stimulate baroreceptor"mediated AVP release, 
possibly through a general increase in sympathetic tone (Anderson et al 1978). 
Pain may also be associated with AVP release (Hayward) 1973; Yagi & 
Onaka 1991. 
Visceral afferents from the kidney have also been shown to influence AVP 
QcEýezý 4ý 
secretion, as havejhepatic cells which are apparently osmosensitive and gastric 
mechanoreceptors. 
1.1.2.3 The interaction of osmotic and non-osmotic regulation 
It seems likely that osmotic and non-osmotic stimuli have afferent input to the 
same magnocellular AVP secreting neurons since there is sophisticated 
interaction of stimuli. In addition electrophysiological studies in vivo of single 
neurons have shown response to both types of stimuli (Kannan & Yagi 1978). 
a) Osmotic and barometric stimuli 
Osmotic stimulation has no apparent effect on the sensitivity of baroregulated 
AVP. Mild hypovolaemia alters the osmoregulation of AVP with a reduction in 
threshold of 3-4mOsm/kg (Dunn et al 1973; Robertson & Athar 1976; 
Goldsmith et al 1987). There is no effect, however, on the sensitivity to 
change in pOS. A 15% drop in blood pressure will similarly effect the osmotic 
threshold but not the sensitivity (Robertson et al 1977). Hypervolaemia (eg 
secondary to hyperaldosteronism) may lead to a rise in osmotic threshold of 
AVP release (Ganguly & Robertson 1980). 
These two stimuli to AVP secretion may interact through summation and 
integration of afferent inputs in the hypothalamus (Sawchenko & Swanson 
1983), or possibly through the effects of each system on, and sensitivity to, other 
hormones such as atrial naturietic peptide (ANP) which may effect AVP release. 
For example an increase in blood volume causes a rise in ANP which may alter 
osmoregulated AVP (Williams et al 1988). 
b) Nausea and osmotic stimuli 
The emetic stimulus to AVP release will override both osmotic and 
baroregulated control of AVP secretion leading to inappropriate antidiuresis and 
hyponatraemia (Robertson 1977; Rowe et al 1979). There have been no studies 
to explore further the functional nature of the effect on osmoregulated AVP but 
12 
it seems likely that the linear relationship to pOS is lost. Both hypo-osmolality 
and ethanol appear to attenuate the emetic stimulus to AVP release (Rowe et at 
1979). 
In the clinical setting it has been shown that loss of one modality of AVP 
stimulation may occur without apparent effect on the others (Halter et al 1977; 
Puritz et at 1983; Bannister et at 1984). 
1.1.2.4 Species differences in physiological regulation of AVP 
It has been found that in humans, monkeys, sheep, dogs and rats pOS, blood 
volume and blood pressure are major influences on AVP release. The 
functional properties of each stimulus differ slightly between the species but the 
pattern of evoked AVP release and interaction of the stimuli appear to be fairly 
constant between the species although there are some important differences. 
a) Osnsoregulation 
Each animal species has a different mean basal pOS but all are subject to control 
within fine limits. Each species does, however, have a different threshold and 
osmotic sensitivity of AVP release. In rats there is an increase in osmotic 
threshold and increase in sensitivity compared to humans (Dunn et at 1973). In 
rats, and possibly other rodent species, OXY may have a role in maintenance 
of osmotic homeostasis and is secreted in response to osmotic as well as other 
stimuli. This is not so in man (Nussey et al 1986). In rats, but not in other 
animals and humans, glucose, at very high concentration, exerts an osmotic 
stimulus and hyperglycaemia causes a rise in AVP (Charlton et at 1989; 
Robertson & Vokes 1991). The osmoreceptor cells in rats may have differences 
to those of other animal species (see Section 1.1.2.1 ) 
b) Non-osmotic regulation 
The relative importance of stimuli from intravascular volume receptors and of 
blood pressure may differ between the species and, similar to osmoregulatory 
function, the threshold and sensitivity to baroregulatory stimuli also varies 
between animal species. 
In humans, monkeys, dogs and some other animals nausea is a potent stimulus 
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to AVP release. In rats however, the emetic reflex is incomplete (food 
avoidance but no vomiting) and OXY and not AVP is released by such stimuli 
(Verbalis et al 1986b). 
In addition to these differences in regulation there are some species differences 
in the biological action of AVP. There are many similarities in structure 
between the species in particular rat and human AVP is essentially identical. 
The potency of antidiuretic effect is also similar between species however, 
synthetic antagonists to AVP do not block effects with equal potency in different 
animal species (Allison et al 1988). It is therefore important that care is taken 
in the use of animal models of AVP regulation, function and pathology to 
explain physiology and dysfunction in humans. 
1.1.3 NEUROENDOCRINE REGULATION OF AVP RELEASE 
In comparison to the understanding of physiological stimuli to AVP release, 
knowledge of the nature of neuroendocrine regulation is sparse (Renaud & 
Bourque 1991). Neurotransmitters may have direct effect on magnocellular cell 
bodies or on AVP secreting axons and dendrites in the hypothalamus and 
neuropituitary. In addition many neurotransmitters may have indirect, 
multisynaptic influence on AVP release through effects on locally acting 
pathways. 
1.1.3.1 Afferent pathways to AVP magnocellular neurons 
There is a large, clearly defined noradrenergic projection arising from Al 
neurons in the ventro-lateral medulla (Swanson & Sawchenko 1983; 
Cunningham & Sawchenko 1988). Both catecholamine (Swanson & Sawchenko 
1983) and pepti ergic neurons (Sawchenko et al 1990) project from the nucleus 
tractus solitarius to the SON and PVN. Histaminergic fibres arise from the 
tuberomamillary nucleus and innervate both SON and PVN (Pannula et al 
1984). Cholinergic neurons have been shown to innervate SON and PVN AVP 
secreting neurons (Armstrong 1985; Hatton & Mason 1985). Little is known of 
the origin of these cholinergic fibres but it seems that those to the SON may 
originate immediately dorsal to the nucleus (Hatton & Mason 1985). As 
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discussed below (Section 1.4.1) serotonin fibres project from raphd nuclei in the 
brain stem to the SON and PVN (Sawchenko et al 1983). 
Both the SFO and OVLT innervate the SON and PVN (Miselis 1981; Swanson 
& Sawchenko 1983; Tribollet et al 1985). The chemical nature and functional 
aspects of the OVLT fibre tract are unknown. The SFO projection is possibly 
of angiotensin II (Jhamandas et at 1989). 
Efferent fibres from the median preoptic nucleus in the anterior third ventricle 
also project to the SON and PVN (Swanson & Sawchenko 1983; Tribollet et at 
1985; Weiss & Hatton 1990). These appear to be GABA type neurons (Nissen 
& Renaud 1989). Other GABA fibres from the nucleus accumbens also project 
to the SON, and many GABA neurons arise immediately adjacent or intrinsic to 
the SON (Meyer et al 1980). Both SON and PVN neurons receive a modest DA 
innervation. These fibres arise from cells in the periventricular zone and in the 
perinuclear area around the SON and PVN (Buijis et at 1984). 
Several other regions of the brain are also known to have direct projection to the 
magnocellular nuclei, but the chemical nature of these connections is not well 
established. Of particular relevance to this thesis is the evidence that there is a 
direct afferent pathway from the limbic system to the PVN (Ferreyra et al 1983; 
Oldfield et al 1985). Many other direct neuronal inputs have been identified but 
their source is as yet uncertain (Zaborsky et al 1975; Sladek 1983; Renaud et al 
1991'+b). 
1.1.3.2 Neurotransmitters and secretion of AVP (Table 1.1.1) 
The neuroendocrine regulation of AVP secretion is an extremely complex 
integration of multiple excitatory and inhibitory afferent stimuli which may have 
effects on the magnocellular neurons in the hypothalamus, on their axons or on 
neuronal terminals in the neurohypophysis. They may also have indirect effects 
through pituicytes or by alteration of blood flow. Some neurotransmitters may 
also act as autoregulators due to co-secretion with AVP. 
The role of serotonin in AVP secretion will be discussed in Section 1.4. 
1.1.3.2.1. Noradrenaline (NA) 
Evidence initially pointed to an inhibitory role for NA on AVP release (Sladek 
1983) but more recent work indicates a complex but predominantly facilitatory 
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role (Renaud et at 1991). Electrophysiological studies have shown al mediated 
excitatory response and ß adrenoreceptor depression of magnocellular AVP 
neurons in vivo (Day et at 1985). In vitro (Randle et at 1986) and in vivo 
(Willoughby et at 1987) studies, have confirmed these effects of al and ß 
agonists applied to the SON on AVP release from the neurohypophysis. 
Studies of the neurohypophysis in vitro have suggested that norepinephrine 
stimulates AVP release, possibly through ß-adrenoreceptors (Racke et at 1982; 
Bridges et at 1976). 
NA appears to have little effect on osmotically stimulated AVP (Armstrong et at 
1982) although destruction of NA neurons by selective toxin reduces the AVP 
response to osmotic stimulus (Miller et at 1979). 
Norepinephrine neurons from the Al cells in the brainstem are excitatory to 
AVP release. Selective toxin lesion of these neurons reduces the AVP response 
to hypovolaemic stimulus (Miller et at 1979) and lesion of the dorsal NA 
pathway inhibits the AVP rise subsequent to haemorrhage (Lightman et at 
1984). Stimuli from baroreceptors have been shown to excite these neurons 
(McAllen & Blessing 1987; Leng et at 1991). 
Studies in man have been limited because of confounding effects of NA on 
cardiovascular status and the fact that circulating monoamines do not cross the 
blood brain barrier (Carter & Lightman 1985). Patients with Shy-Drager 
syndrome, with loss of central ascending catecholamine pathways, have been 
shown to have normal osmoregulated AVP (Bannister et at 1984) but blunted 
baroregulatory responses (Puritz et at 1983). 
1.1.3.2.2. Acetylcholine (Ach) 
It is well recognised that Ach stimulates AVP release both in the hypothalmo- 
neurohypophysial complex (HNC) in vitro model (Sladek & Knigge 1977, 
Gregg 1985; Gregg 1986) and in vivo (litake et al 1986). Some studies have 
suggested that nicotinic receptors mediated the stimulus (Sladek & Joynt 1979b) 
but more recent studies have shown a role for muscarinc receptors (Shoji et al 
1989). It is possible that both receptor subtypes are facilitatory to AVP release 
and that there is a complex interaction of stimuli. It may also be that nicotinic 
receptors predominate on the SON neurons and muscarinic receptors on 
magnocellular neurons in the PVN. This latter is supported to some extent by 
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autoradiographic receptor studies (Michels et al 1986). 
Ach has also been demonstrated to stimulate AVP release from the isolated 
neurohypophysis. The response is mediated through muscarinic cholinergic 
receptors (Gregg 1985). 
The release of osmotically stimulated AVP in the HNC model is blocked by the 
nicotinic receptor antagonist hexamethonium (Sladek & Joynt 1979a). Atropine, 
a muscarinic receptor antagonist, does not have this effect. In vivo studies in 
the rat have not confirmed that Ach nicotinic receptors are important in osmo- 
regulated AVP release (Bisset et al 1988). 
Hexamethonium has been shown to inhibit the AVP release in response to 
hypotension in rats (Bisset & Chowdj+ 1984). 
Studies in man have confirmed that nicotine acutely stimulates AVP release 
(Burn et al 1945; Lightman et al 1982). However, chronic administration (ie 
smoking) does not have similar effects (Lightman et al 1982; Rowe et al 1980). 
1.1.3.2.3. Dopamine (DA) 
Electrophysiological studies of the SON have shown that DA modifies firing of 
magnocellular neurons both in vitro (Sakai et al 1974) and vivo. DA2 receptor 
subtypes appear to mediate this response (Yang et al 1989). In vitro HNC 
models have shown that DA and DA agonists cause dose-related AVP release 
(Bridges et al 1976). In vivo studies have been contradictory with both 
inhibitory and excitatory effects shown. This may be in part because of 
confounding effects of DA on other monoamine systems, but species differences 
and differing effects in the hypothalamus and neurohypophysis may also playa 
part (Carter & Lightman 1985). 
Dopaminergic neurons from the arcuate nucleus of the hypothalamus have been 
shown to innervate AVP-secreting axons and pituicyte process in the 
neurohypophysis (Baumgarten et al 1972). Studies of the effect of DA on AVP 
release from the pituitary have been contradictory but generally support an 
inhibitory role (Carter & Lightman 1985). It has also been suggested that DA1 
receptors function as autoreceptors facilitatory to AVP release and DA2 
receptors inhibitory to release (Racke et al 1982). 
DA antagonists prevented the AVP response to plasma hyperosmolality in rats 
suggesting that DA is important it osmotically stimulated AVP release (Moos & 
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Richard 1982). 
Lightman & Forsling (1980b) suggested that L-DOPA suppressed basal AVP 
release in man and inhibited baroregulated AVP secretion probably by effect on 
the median eminence or neurohypophysis. Nomura et at (1984) and Norbiato et 
at (1986) have shown that metaclopramide causes a rise in plasma AVP 
concentration independent of pOS or blood pressure. However, Coiro et at 
(1989) have suggested that this is mediated through muscarinic Ach receptors 
and not by DA antagonist effects. 
1.1.3.2.4. Opioids 
The role that opioid peptides have in AVP release is relatively well explored; the 
conclusions are, however, contradictory. Initial studies indicated a stimulatory 
role but more recent work have revealed inhibitory actions (Forsling 1985; 
Sladek 1983). It is clear that opioids have effectson AVP release from the 
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neurohypophysis (Arnauld et al 1983; Carter & Lightman 198 and since 
certain opioids are located within AVP secreting neurons (Watson et al 1982; 
Whitnall et al 1983), it has been suggested that they may act as autoregulators 
(Brownstein et al 1980). Supportive evidence for this role is lacking (Carter & 
Lightman 1985). In the Brattleboro rat, where there is a deficiency of AVP, 
opioid concentrations in the neuropituitary are lower than in normal rats, 
suggesting a functional interaction of opioids and AVP (Weber et al. 1983). 
The evidence that opioids have a functional effect in the hypothalamus has been 
more difficult to establish (Carter & Lightman 1985) since both inhibition and 
potentiation of osmotically stimulated AVP release has been found (Forsling 
1985). 
Observations of the effects of opioids on AVP release in man are no less 
confusing (Forsling 1985). Naloxone has been shown to inhibit baroregulated 
AVP (Lightman & Forsling 1980o, ) but has no significant effect on 
osmoregulated AVP or basal AVP secretion (Lightman et al 1980). Other 
studies however, have not confirmed this (Forsling 1985). 
1.1.3.2.5. Angiotensin 11 (All) 
All is a potent stimulus for AVP release (Bonjour & Malir(1970) The major 
mode of its action appears to be through its effects on the SFO and OVLT 
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(Simpson et al 1979). Direct application of All to the SON does provoke AVP 
release and excites magnocellular neurons (Simmonet et al 1979). Sladek & 
Joynt (1980) have shown that All stimulates AVP release from HNC models but 
a functional direct role of All in AVP release remains controversial since 
systemic All does not cross the blood-brain barrier and no neuronal pathways 
have been characterised in the hypothalamus (Chowd & Lightman 1989). It 
has been argued that All mediates AVP release by direct effects on receptors on 
AVP axon terminals in the neurohypophysis (Sladek 1983) but the results are 
contradictory. 
Both infusion of renin and administration of All have been shown to potentiate 
osmotically stimulated AVP release (Shimizu et al 1973; Claybaugh 1976; 
Andersson & Westbyte 1979; Simonnet et al 1979; Akaishi et al 1980). Similar 
results have been found in in vitro models where osmotically stimulated AVP 
release was inhibited by the All antagonist saralasin (Sladek & Joynt 1980). It 
does not, however, inhibit suppression by plasma hypo-osmolality (Henalch et al 
1979). 
Infusion of All in dogs caused an increase in AVP despite hypertension (leading 
to AVP suppression) (Ramsay et al 1978) 
All infusions in man have been shown to stimulate AVP release (Uhlich et al 
1975; Padfield & Morton 1977) but only at pharmacological concentrations. 
1.1.3.2.6. Gamma amino butyric acid (GABA) 
It has been show that GABA has inhibitory effects on AVP neuronal firing 
(Bioulac et al 1978; Sakai et al 1974; ). It has inconsistently been shown to 
decrease AVP release from HNC models (Sladek & Armstrong 1983) but 
antagonists repeatedly stimulate AVP release in this model (Sladek & Armstrong 
1987). GABA also has been shown to have inhibitory effects on AVP release 
from the neurohypophysis, possibly secondary to effect on pituicytes (Mathison 
& Dreifuss 1981). 
GABA appears to have inhibitory effects on osmoregulated AVP release (lovino 
et al 1983; Haywood & Brennan 1985). 
GABA may be involved in baroregulation of AVP by inhibitory influences on 
the Al cells and other neurons mediating the cardiovascular stimuli since intra- 
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cerebro-ventricular injection of GABA suppressed hypovolacmic induced AVP 
secretion in vivo (Knepel et al 1980). 
1.1.3.2.7. Other putative regulators 
Histamine and substance P have both been demonstrated to increase AVP 
release (Sladek 1983). Aspartate and glutamate are also excitatory to AVP 
secreting neurons (Carter & Lightman 1985). 
Sex steroids modulate AVP release but the mechanism is not well understood. 
Prostaglandins have a modulatory effect on AVP release in vivo and in vitro 
(Carter & Lightman 1985). Brain naturietic peptide may have a direct inhibitory 
effect on magnocellular neurons (Yamamoto et al 1991) and ANP may inhibit 
AVP secretion, but this is contentious (Baylis & Burrell 1991). 
The release of AVP is regulated by the integrated sum of inhibitory and 
excitatory afferent inputs and autoregulatory processes. Dynorphin or other 
transmitters, co-secreted with AVP from magnocellular neurons, may mediate 
local negative feedback and AVP itself may have local inhibitory effects (Abe et 
al 1983; Carter & Lightman 1985), or inhibitory effects through alteration of 
CSF concentration (Bhar . gava et al 1977). AVP has also been shown to 
have a 
facilitatory effect on its own release (Ramtcetet al 1990). These autoregulatory 
processes are still relatively unexplored and not well understood (Renaud & 
Bourque 1991; R*, mzc3 Q. c a\ VARO " 
Studies using HNC models have allowed some exploration of the interaction and 
physiological roles of these neurotransmitters although knowledge of those 
transmitters that have functional importance is still very much in its infancy. 
That the integration of the system is so complex ensures that osmotic 
homeostasis is maintained within very fine limits even if there is an imbalance in 
known stimulants eg. cigarette smoking, ingestion of neuroactive drugs. 
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1.1 VASOPRESSIN AND ABNORMAL OSMOREGULATION 
Abnormalities of AVP secretion may result in a plasma insufficiency or an 
"excessive" plasma concentration. The former, diabetes insipidus, results in 
polyuria and osmotic homeostasis relies on ingestion of large quantities of fluid. 
Excessive or osmotically inappropriate secretion of AVP results in 
hyponatraemia and is the subject of this section. 
1.2.1. HYPONATRAEMIA 
Hyponatraemia is a common medical problem and if severe (< 120mmol/1) has 
a substantial mortality, independent of any underlying disease (Arieff et al 
1976). Even if moderate and asymptomatic there is an increased risk of death 
(Anderson et al 1985). It is plasma hypo-osmolality that is of prime importance 
since hyponatraemia with normal pOS, which occurs where there is an increase 
in other osmotically active plasma constituents (eg. glucose), is not clinically as 
dangerous. 
Hyponatraemia with hypo-osmolality reflects an increase in plasma water 
relative to sodium. It can be due to solute loss or water excess but is usually 
due to a combination of both. 
1.2.1.1. Solute loss 
Extracellular fluid (ECF) losses such as diarrhoea, vomiting and inflammatory 
exudates do not lead to hyponatraemia since there is loss of isotonic solute. 
Replacement of such losses is most often with hypotonic fluids such as water 
and this leads to hyponatraemia as fluid, but not solute, is replaced. Such 
patients are usually hypovolaemic but some may have replaced fluid sufficiently 
to be normovolaemic. In these patients urinary sodium is conserved and the 
urine osmolality is low. 
Renal sodium loss due to tubular defects, hypocortisolaemia, cerebral salt 
wasting or most commonly diuretic therapy, leads similarly to hypovolaemic 
hyponatraemia but with a relatively high urinary osmolality and sodium 
excretion. 
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1.2.1.2 Water excess 
The kidneys have the capacity to excrete up to 301 of water a day (Robertson & 
Berl 1986) and under normal circumstances excess fluid intake is seldom a cause 
of dilutional hyponatraemia (see Section 1.6). When the renal excretory 
capacity is impaired, however, fluid intake may be in excess of functional body 
needs and insensible loss and hyponatraemia and hypo-osmolality ensue. 
A reduction in the volume of renal tubular fluid due to nephron loss or poor 
glomerular perfusion, leads to increased reabsorption of both sodium and water 
in the proximal tubule (enhanced by increased aldosterone concentration in some 
disease states), and decreased distal nephron load with consequent decreased 
free water excretion. 
Another important mechanism of water retention is the impairment of the distal 
nephron to dilute urine due to increased AVP concentration. Hypocortisolaemia 
also inhibits free water excretion in the distal tubule independently of AVP 
concentration (Linas et al 1980). 
In disorders where solute retention in the proximal tubule is the primary 
abnormality, there is a tendency to hypervolaemia and oedema, whereas patients 
with distal tubular impairment of free water clearance are usually 
normovolaemic. 
The volume status of patients with hypovolaemia is, inevitably, not -Ostraight 
forward as described above since once established the primary dysfunction often 
leads to a mixture of compensatory mechanisms. A primary solute loss with 
hypovolaemia leads to poor renal perfusion with decreased free water clearance 
and exaggeration of the solute depletion hyponatraemia. Excess plasma AVP 
will expand ECF with consequent renal sodium loss and a further lowering of 
plasma sodium. Diseases such as cardiac failure, with low effective 
intravascular volume will have primary solute retention and decreased free 
water clearance but will also have elevated AVP because of hypovolaemic, non- 
osmotic stimulation, leading to further inhibition of distal tubular free water 
excretion (Bichet & Schrier 1985; Bichet 1981). 
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1.2.2 THE SYNDROME OF INAPPROPRIATE ANTIDIURESIS 
Schwartz et at (1957) described the syndrome of inappropriate antidiuresis 
(SIAD) in patients who despite plasma hypo-osmolality, produced hypertonic 
urine with inappropriate nat resis. They suggested that this syndrome resulted 
from endogenous release of AVP which was inappropriate to the pOS, since it 
was identical to the features observed in people given neuropituitary extract 
(Leaf et at 1953). The group further defined the criteria for the syndrome 
(Bartter & Schwartz 1967). 
Decreased plasma osmolality (<27SmOsm/kg) 
Inappropriate urine osmolality (> 100mOsm/kg) 
Absence of hypo or hypervolaemia 
Inappropriate urine sodium excretion 
Absence of other possible causes (eg. hypocortisolaemia, renal failure, 
hypothyroidism, diuretic therapy). 
Measurement of basal AVP is j part of the diagnosis since, as discussed 
above, AVP may be elevated or inappropriately high in many causes of 
hyponatraemia (Verbalis 1989). As discussed below the absence of AVP in the 
plasma does not refute the diagnosis. 
1.2.2.1 Aetiology 
There are four major groups in the aetiology of SIAD; tumour related, CNS 
disorders, pulmonary disease related and drug related. 
Tumour related SIAD in many cases is due to the production of ectopic AVP or 
AVP-like peptide by malignant cells. As discussed below it may also arise 
through other mechanisms. 
A great variety of localised and diffuse, apparently unrelated CNS disorders are 
associated with SIAD. It seems likely the these diseases cause disruption to the 
inhibitory afferent inputs to magnocellular neurons with consequent 
dysregulation of AVP secretion (Verbalis 1989). 
SIAD associated with pulmonary disease in many cases is probably due to the 
hypoxia and/or hypercapnia of respiratory failure. However some specific lung 
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pathologies have be found to secrete AVP-like factors or stimulate AVP release 
from the neurohypophysis (Zerbe 1985 The occurrence of the syndrome in 
milder pathologies such as viral and atypical pneumonias is poorly understood. 
1.2.2.2 Drug Induced SIAD 
There are a great many drugs which have been associated with hyponatraemia 
(Moses 1985). Some have been fully investigated and the pathophysiological 
mechanisms are understood. Others, such as the tricyclic and other antide- 
pressants have a less clear mode of action (Section 1.6). The data is discussed 
in detail by Moses (1985). 
Some drugs directly stimulate AVP release and have similarities to 
neurotransmitter systems known to modulate AVP release. Nicotine and opiate 
drugs would be examples. Some antineoplastic agents (vincristine and 
cyclophosphamide) have been shown to cause antiduresis due to elevated plasma 
AVP levels. This may be due to a direct neurotoxic effect on magnocellular 
neurons (Rufener et al 1972; Moses & Miller 1974). Other drugs have been 
shown to potentiate the action of AVP on the distal renal tubule (eg. 
prostaglandin inhibitors), or to have a direct effect on the kidney (eg dDAVP, 
oxytocin). 
Many drugs have a combination of effects. Carbamazepine has been shown to 
increase AVP in patients with CDI (Kimura et al 1974). The mechanism of this 
is not known. In normal people carbamazepine appears to cause a reset of the 
osmostat and to enhance the renal effects of AVP (Stephens et al 1978). 
Chlorpropramide also causes AVP release and potentiates renal tubular effects 
(Moses et al 1973b). Tolbutamide, but not other sulfonylureas has a similar but 
less potent effect. The central stimulatory mechanism of these drugs is not 
understood but its action on the tubule is clearer (Lozada et al 1972). Clofibrate 
also stimulates AVP release through an unknown mechanism (Moses et al 
1973a). 
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1.2.2.3 Pathophysiology 
Hypertonic saline infusion studies in patients with clinically diagnosed SIAD 
have shown that there are four patterns of AVP secretion (Figure 1.2.1). 
a) Random hypersecretion (A) 
In this type of SIAD secretion, AVP has no apparent relationship to pOS. 
Although this is often seen in cases of ectopic AVP production, only about 30% 
of those patients with this pattern will have malignant disease (Zerbe et at 
1980). 
b) Reset osmostat (B) 
In this, the commonest form of the syndrome (Zerbe et al 1980), AVP has a 
linear relationship to change in pOS, and is secreted with normal sensitivity. 
The osmotic threshold for initiation of the secretion is, however, lowered. Thus 
for any given pOS AVP concentration will be higher than normal. 
Patients who have hypovolaemic hyponatraemia (by definition nQ1 SIAD), may 
have a reset osmostat due to non-osmotic AVP stimulation (Robertson & Athar 
1976; Robertson et at 1982; Bichet & Schrier 1985; Uretsky et at 1985, Bichet 
1989). A reset of the osmostat also occurs in nomovolaemic patients. It has 
been proposed that chronic hypo-osmolality leads to a readjustment of the 
osmoreceptor cells, although studies in animals have not found this (Verbalis et 
at 1986). Resetting may occur due to an interruption of inhibitory pathways to 
the osmoreceptor cells or magnocellular neurons. 
Patients with this form of SIAD differ from the other three groups since they 
can dilute urine when plasma becomes sufficiently hypo-osmolar (Defronzo et at 
1976) 
c) Hypersecretion/normoresponsive (leafy hypophysis) (C) 
In this group of patients AVP is secreted at a high level below the normal 
osmotic threshold for release, but above this threshold there is a normal 
response to change in pOS. This could be due to an ectopic source secreting a 
'background 'concentration, however it is seldom seen in patients with 
malignant disease. It seems more likely that this pattern of secretion is due to a 
selective loss of inhibitory neurons. 
d) Undetectable AVP (D) 
Clinically diagnosed SIAD occasionally occurs in the apparent absence of 
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Figure 1.2.1 
A schematic representation of the patterns of AVP secretion during infusion of hypertonic saline 
observed in patients with the syndrome of inappropriate AVP secretion (SIAD). A; Random 
hyper secretion. B: Reset of the osmostat. C: Leaky hypophysis. D: Undetectable. The shaded 
area represents the 95 percentiles of the normal response to the infusion (see Figure 1.1.2) 
Adapted from Robertson et al (1976). 
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plasma AVP (Zerbe et al 1980). This may be due to altered immunoreactivity 
of the peptide, the presence of another antidiuretic factor or increased renal 
tubular sensitivity to AVP. This pattern of the syndrome is poorly understood. 
No good correlation has been found between the aetiology of SIAD and the 
pattern of AVP secretion. Indeed bronchogenic carcinoma has been found to be 
associated with any of the four types in different patients (Robertson 1978; 
Zerbe 198? ). In addition more than one type of defect may coexist in some 
patients (Baylis & Robertson 1979; Zerbe 198. 
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1.3 THE SEROTONIN NEUROTRANSMITTER SYSTEM 
Serotonin is so named because of its vasoconstrictive properties. It was 
recognised in the late 191 century that there was a factor in serum which had 
tonic properties and in the 1940's its structure was identified as 5- 
hydroxytryptamine (5HT) (Rapport 1949). It was found to be chemically 
identical to 'enteramine', an amino acid found in the enterochromaffin cells of 
intestinal mucosa (Erpsamer & Asero 1952). The synthetic production of 5HT 
allowed an explosion of research into the physiological function of the 
compound and localisation studies soon showed the presence of high 
concentrations in the brain, with regional variations, highly suggestive of a 
functional role in the central nervous system (Amin et al 1954). This section 
discusses the 5HT nervous system with particular reference to 5HT receptors 
and function and regulation of the system. 
1.3.1 ANATOMY 
The 5HT nervous system is phylogenetically ancient and has shown remarkable 
stability through evolution. The anatomical detail and classification was first 
outlined using new histochemical techniques by Dahlstrom & Fuxe (1964; Fuxe 
1965). Since then there have been many reviews of the subject in various 
species of animal, primate and more latterly in man (Bjorklund & Hokfelt 1984; 
Azmitia & Gannon 1986; Azmitia 1987; Tork 1990). The cell bodies of the 
system are clustered into nuclei in the brainstem and form a rostral group, with 
ascending projections, and a caudal group with descending projections. Initially 
the nuclei were classified B1-B9 (Dahlstrom & Fuxe 1964) but it is more usual 
now to name them as specific raphd nuclei (Table 1.3.1 Figure 1.3.1 ). The 
rostral nuclei comprise 4 groups of serotonergic cells of which the dorsal raphd 
nucleus (DRN) is the most prominent. 
The ascending projections from the rostral nuclei have an extensive and complex 
pattern of innervation to almost all cerebral areas, although the frontal lobe 
appears to have a low density of fibres. This comprises the most expansive 
neuronal network yet described. High fibre density is found in the cerebral 
cortex, basal ganglia, limbic system structures and diencephalon (Steinbusch 
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Table 1.3.1 The brainstem nuclei with 5HT-containing cell bodies 
Rostral nuclei 
Dorsal raphe 
Median raphe 
Caudal linear 
Supralemniscal region 
classification by 
Dahlstrom & Fuxe (1964) 
(B6&7) 
(B5&8) 
(B8) 
(B9) 
Caudal nuclei 
Raphe obscuris 
Raphe magnus 
Caudal ventrolateral medu I la 
Rostral ventrolaterial medulla 
Raph6 pallidus 
(B 1,2,4) 
(B3) 
(B 1) 
(B3) 
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1981; Azmitia & Gannon 1986). These fibres travel in the median forebrain 
bundle and in the dorsal raphd cortical tract and ascend through the 
hypothalamus to the cortex and subcortical areas. In rats most of the nerve 
fibres are unmyelinated but in higher animals and primates an increasing 
percentage of fibres are myelinated (Azmitia & Gannon 1983). It has also been 
found that in some mammals, primates and man there are at least three types of 
axon present in the forebrain. The most common, thin with fusiform 
varicosities, extend profusely over large areas of the forebrain and arise from 
the DRN. The second type of fibre, which appears to arise from the median 
raphe nuclei (MRN), have very thin axons with weak immunocytochemical 
staining for 5HT but have large, round or oval varicosities which stain very 
strongly for 5HT. These beaded axons innervate highly restricted, discrete 
cortical layers, possibly having selective contact with GABA cells. The third 
type of fibre, which is relatively thick and non-varicose, is found only in small 
numbers and usually in or close to the major 5HT tracts (Kosofsky & Molliver 
1987). Not only are these fibres dissimilar in anatomical respects but they have 
differing susceptibility to neurotoxins (Mamounas et al 1991). 
Although the 5HT nervous system has been well preserved through the animal 
species there have been some subtle and potentially important changes. In lower 
invertebrates there is one neuronal cell body with extensive branching and 
connections to motor and sensory ganglia. Any stimulus to the cell body will 
cause widespread ramifications. The system has become more organised 
through the animal hierarchy and in rats there are tight clusters of many cell 
bodies (the raphd nuclei) each with interconnecting projections, functioning as 
one unit but with more subtle interactions and regulatory features. In higher 
animals, and man, the system has developed further. The cellular organisation 
is more distinct, the projecting pathways are more varied and some are 
myelinated, and the innervated tissues have very intricate and subtly varied 
architecture (Soghomonian et al 1988). It seems that there is cytoarchitectural 
evidence for at least two 5HT subsystems which may act independently, at 
different speeds, and each may have highly specific and discrete roles (Tork 
1990; Mamounas et al 1991). Although the lower mammals, such as the rat, 
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may act as a relatively good model for the 5HT system in man, there are 
important differences in the anatomy which mean that results must be 
interpreted with caution. 
1.3.2 SYNTHESIS AND METABOLISM 
5HT is a monoamine formed, intraneuronally, from the neutral amino acid 
tryptophan, of which the major source is dietary protein. The majority (85%) 
of plasma tryptophan is bound to albumin and only free tryptophan is available 
for transport across the blood brain barrier. The uptake system for this 
transportation is not specific to tryptophan and the ratio to other large, neutral 
amino acids, and the unbound percentage of tryptophan, determines the 
concentration of tryptophan entering the brain. 
The peripheral availability of tryptophan is controlled in part by metabolism in 
the liver to kynurenine, and other metabolic products, by the enzyme tryptophan 
pyrrolase. Most dietary tryptophan enters this pathway and a minority is 
actually converted to plasma 5HT. Influences on this metabolic pathway (eg 
corticosteroids) may alter central nervous concentrations of tryptophan, 5HT 
and 5HIAA by altering the ratio of tryptophan to other neutral amino acids or by 
altering the protein binding of tryptophan. 
Following uptake into the brain tryptophan is converted to 5HT by a two-step 
process (Figure 1.3.2). Firstly hydroxylation by tryptophan-5-hydroxylase (TH) 
to 5-hydroxytryptophan (5HTP) and then by decarboxylation to 5HT. High 
concentrations of TH have been found in the brain stem, hypothalamus, caudate 
nucleus , amygdala, pineal and pituitary glands. The enzyme is localised at 
5HT specific nerve endings, has low activity and is not normally saturated. TH 
appears to be specific for tryptophan and is the rate-limiting step in its synthesis. 
5-hydroxytryptophan-decarboxylase (TD) is also located in nerve terminals. It 
has 80-100 times higher activity than TH but has been shown to be non-substrate 
specific as both TD and the decarboxylase enzyme present in dopamine nerve 
terminals can metabolise both 5-HTP and L-DOPA. Thus infusion of 5-HTP 
increases 5HT in both 5HT and dopamine neurons, likewise infusion of L- 
DOPA leads to an increase of dopamine in both neuronal types. 
Following release into the synaptic cleft, SHT, like other monoamines, is 
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Figure 1.3.2 
The synthesis and metabolism of serotonin (5. hydroxytryptamine) (5H7I). 
TH: Tryptophan-5-hydroxylase; 51ITP: 5-hydroxytryptophan; 
TD; 5-hydroxytryptophan decarboxylase; SHIAA: 5-hydroxyindole acetic acid; 
MAO; monoamine oxidase. 
inactivated via a high affinity reuptake process into the nerve ending (Iversen 
1975). 5HT is then metabolised by a two step-process to its major metabolite 
5-hydroxyindole acetic acid (5HIAA), firstly through oxidation by monoamine 
oxidase (MAO) and secondly rapid dehydrogenation takes place by aldehyde 
dehydrogenase (Figure 1.3.2). MAO is located on or in close proximity to 
mitochondria. There is some, but limited substrate specificity. MAO type A is 
able to deaminate 5HT and noradrenaline whilst MAO type B is more specific 
for dopamine. 5HT neurons probably contain both enzyme subtypes but under 
normal circumstances metabolism occurs predominantly by MAO type A. Astro 
glial cells also deactivate 5HT by active reuptake (Kimelberg 1988) but the 
importance of this in physiological and pathological function is as yet unclear. 
Increasing the concentration of tryptophan in the brain by peripheral infusion 
has been found to increase the rate of 5HT synthesis (Grahame-Smith 1971). It 
has been proposed however, that 5HT is synthesised in excess of functional 
needs, and is metabolised intraneuronally without release (Green & Gralme- 
Smith 1975), since despite marked increases in 5HT synthesis no behavioural 
changes are seen in rats unless MAO is also inhibited (Marsden et al 1979; 
Grahame-Smith 1971). Thus studies on changes in synthesis and metabolism do 
not necessarily reflect or have clinical implication for alteration in function of 
the 5HT nervous system. 
Table 1.3.2 shows the drugs which have been developed on the basis of 
knowledge of 5HT synthesis and metabolism. Many of these are used as tools 
in research for further understanding of function and pathology of the 5HT 
nervous system. 
1.3.3 SEROTONIN RECEPTORS 
Since the first pharmacological characterisation of 5HT receptors (Gaddum & 
Picarelli 1957) considerable progress has been made in knowledge of subtypes, 
physiology and anatomical localisation as well as the beginnings of 
understanding of regulatory processes and changes in pathological states and 
therapeutic interventions. Much of this knowledge stems from the development 
of ligand binding techniques both in vitro and increasingly in and ex vivo 
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Table 1.3.2 Pharmacology of 51T neurotransmission related to synthesis 
and degradation processes. 
1. Precursors 
Tryptophan 
5-hydroxytryptophan (5HTP) 
2.5=depleting sip 
Parachlorophenylalanine (pCPA) 
synthesis inhibitor - blocks TH 
5,7-Dihydroxytryptamine (5,7 DHT) 
neurotoxin 
Fenfluramine 
releases 5HT with store depletion 
neurotoxic effect 
inhibits TH 
Reserpine 
releases 5HT with store depletion 
Tetrabenazine 
releases 5HT with store depletion 
p-Chloramphetamine (pCA) 
inhibits TH 
releases 5HT with store depletion 
3. MAO type A inhibitors 
Clorgyline 
irreversible 
Hormaline 
FLA336 
selective to 5HT neurons 
4. Uptake inhibitors 
Selective serotonin reuptake inhibitors (SSRI) 
Tricyclic antidepressants 
(Snyder 1983; Hamon 1984). 
The absolute identification of a receptor requires it to have a unique amino acid 
sequence and cloned sequences must mimic the actions of natural receptors 
(Peroutka 1988). This is available for some 5HT receptors but many putative 
ones have not been structurally identified as yet (Hantig 1989; Huang & Julius 
1991). A high degree of probability that a receptor is present depends on the 
identification of functional correlates such as 2"J messenger linkage, delineation 
of physiologic effects at neuronal membranes and behavioural effects in vivo. 
The suggestion that a receptor exists rests on pharmacological identification of a 
binding site with high affinity (nM) for a ligand which is saturable, reversible 
and stereoselective; that there is a specific pharmacological profile of binding to 
agonist and antagonist drugs; that there is a distinct regional distribution of the 
site concurrent with innervation and species variations; that there is equipotency 
of ligand binding affinity and pharmacological and physiological effects. 
Such criteria have been used to describe a series of 3, or possibly 4,5HT 
receptor families for which the basis of classification depends on 
pharmacological characteristics (Leysen 1984; Peroutka 1991). Each family also 
shares similarities in molecular biology and physiological properties. In 1986 a 
committee presented suggestions of a consensual classification and nomenclature 
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based on pharmacological and functional properties (Bradleyý1986). The speed 
of development in the field has meant that this has had to be updated 
(SEROTONIN CONFERENCE 1991, to be published) particularly because of 
new developments in molecular biology (Hartig 1989; Peroutka 1991) which 
have lead to some differences in classification (Hantig 1989). Frazer et at 
(1990) have proposed a scheme that would classify receptors of all 
neurotransmitter and neuropeptide systems and would emphasise similarities in 
neurotransmitter type and second messenger systems . This has not 
been 
adopted as yet. 
1.3.3.1 Radioligand binding studies ('Fable 1.3.3) 
The first successful ligand binding analysis of 5HT receptors was reported by 
Bennett & Aghajanian (1974) who showed [3H]LSD binding to be saturable, 
reversible and stereoselective with a high affinity for the membrane prepared 
from neuronal material. Brain areas with a high density of 5HT neuron 
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terminals were found to have a high density of ligand binding sites. 
The second radioligand employed for receptor studies was [3H]5HT. This too 
showed binding sites suggestive of 5HT receptor function but discrepancies 
between the binding of [3H]5HT and [3H]LSD were noted (Bennett & Snyder 
1976; Fillion et al 1978). It was proposed that the ligands labelled two different 
' states' of the same receptor. [3H]spiperone, a dopaminergic ligand, was found 
to label a population of receptors where it was potently displaced by, 5HT 
antagonist drugs but was only weakly displaced by 5HT and related tryptamines 
(Leysen et al 1978; Creese & Snyder 1978) suggesting that there was a third 
' state' or type of receptor. 
The ligand binding and displacement characteristics of [3H]5HT, [3H]LSD and 
[3H]spiperone lead Peroutka and Snyder (1979) to describe 5HT1 and 5HT2 
receptor types. The binding sites of [3H]5HT were designated 5HT1 sites and 
those labelled by [3H]spiperone 5HT2 receptors. [3H]LSD could label both 
receptor types with equal affinity. Unlabelled dLSD displaced all three ligands 
with equipotency (IOnM). 5HT was 300 times as potent at displacing [3H]5HT 
from binding sites than displacing [3H]spiperone. Its potency at the [3H]LSD 
site was intermediate between these, approximately 50 times less potent than 
[3H]5HT displacement. The converse pattern of displacement potency was true 
for unlabelled spiperone. 
Using similar principles of rank potency of ligand binding and displacement and 
an increasing variety and specificity of agonist and antagonist ligands, 5HT1 
receptors have now been classified into four (possibly 5) subtypes. [3H]5HT 
binds to all subtypes with nM affinity but is displaced from the different sites by 
varying concentrations of other ligands (Schmidt & Peroutka 1989) (Table 
1.3.3). Although there is still some debate, 5HT2 receptors appear to have two 
subtypes. 
1.3.3.1.1 The 5HT1 receptor family 
a) 5HT1a 
5HT1 binding sites were divided into two subpopulations on the basis of the 
binding of [3H]spiperone. Those with a high affinity for [3H]spiperone were 
named 5HTla and those with a low affinity 5HTlb (Pedigo et al 1981). Highly 
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specific ligands for 5HTla binding sites have since been developed (Gozlan et at 
1983) (fable 1.3.3). 
5HT1a receptors in the rat are of high density in the CAI and dentate gyros of 
the hippocampus, the septum, cerebral cortex and raphd nuclei (Deshmukh et at 
1983; Marcinkie%ic. z et at 1984; Pazos & Palacios 1985). The hypothalamus 
has been found to contain a moderate density of receptors. In the human high 
density has been found in the CAI hippocampus and the raphd nuclei as in the 
rat. High levels are also in the cerebral cortex but in layers different from the 
rat. Some nuclei of the thalamus and amydala also have high 5HT1a receptor 
density. The claustrum and posterior hypothalamus have a moderate density of 
5HTla receptors (Hoyer et at 1986a; Pazos et at 1987a). In the human the 
density of binding sites does not correlate well with the concentration of 
endogenous 5HT in the area but there is a good correlation with the density of 
neuronal terminahidentified by histochemical techniques (Pazos et at 1987a). 
Palacios et at (1990) have concluded that the anatomical information would 
suggest that 5HTla receptors have functional importance in emotional 
mechanisms. Localisation on the raphd cell bodies would suggest a role in 
regulation of 5HT function. Other sites of high density would suggest 
involvement in hypothalamic function, nocioception and integrative functions of 
the neocortex. 
The effect of lesion of 5HT neurons on 5HTla binding sites is contradictory. A 
decrease on the raphd cell bodies occurs (Verge et at 1985; Verge et at 1986). 
No change in density in the neocortex or hippocampus was shown by one 
group(Weisman-Nanopoulos et at 1985), but Verge et at (1986) have shown a 
decrease in 5HT1a receptors in both cortex and hippocampus. This would 
perhaps suggest that the density of presynaptic 5HT1a receptors was low, or that 
a postsynaptic upregulation masks the loss of presynaptic sites. Studies with 
toxins to postsynaptic neurons have shown that there is a marked decrease in 
density of 5HTla sites after kainic acid treatment (Forloni et at 1983; Hall et at 
1985) which would confirm that presynaptic 5HT1a sites are not numerous. 
Recent studies have suggested that there may be an interaction with 5HT3 site 
since chronic administration of 5HT1a selective agonists leads to a decreases in 
density of 5HT3 binding sites (Barnes et at 1991). 
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b) 5HT1b 
The 5HT1b site is selectively labelled by [12SI]cyanopindolol (Sills et at 1984; 
Hoyer et at 1985; Pazos et at 1985b). Unlike other 5HT1 sites it has a 
relatively low affinity for dLSD. Binding sites have been demonstrated in the 
rat and mouse brain but are not present in the brains of several other animal 
species or humans (Heuring et at 1986; Hoyer et at 1986a). In the rat brain the 
5HT1b sites are thought to be presynaptic and to act as an autoreceptor (Engel et 
at 1986; Raiteri et at 1986) (See Section 1.3.4.2) However lesion of 5HT 
neurons does not apparently affect the density of 5HT1b binding sites (Verge et 
at 1986). 
Palacios et at (1990) have suggested that the 5HT1b site in rats is involved in 
the control of movement since it has a high density in the basal ganglia. 
c) 5HT1d 
The 5HT1d binding site was identified in bovine brain in 1987 (Heuring & 
Peroutka 1987). Specific ligands for the 5HT1d receptor subtype are in their 
infancy. Some studies of ligand binding and molecular biology have been 
carried out in the human and animal brain (Pazos et at 1987a; Waeber et al 
1988a+b; Palacios et al 1990). These have suggested a high density in the 
basal ganglia implying that, similar to 5HTlb in the rat, the 5HT1d receptor 
may have an important role in control of movement. 
5HTld receptors are thought to act as terminal autoreceptors but, like the 
5HTlb sites in rodent brain, lesion of 5HT neurons does not significantly affect 
'the density of binding sites suggesting that the great majority of sites are either 
post synaptic (Price et al 1991), or have a role in presynaptic regulation of other 
neurotransmitter systems (Palacios et al 1990). 
The 5HT1d receptor is also thought to play a role in the vasoconstriction of 
cerebral blood vessels in migraine (Doenicke et al 1988). 
d) 5HTlc 
Pazos et al (1984b) found that [3H]5HT bound with high density to the choroid 
plexus. The pharmacological characteristics of the site were found to differ 
markedly in drug rank potency from the 5HTla and 5HTlb sites. Hoyer et al 
(1985) and Pazos et at (1984b) characterised the receptor further using a variety 
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of ligands and displacing agents since there is no site specific ligand. The 
5HT1c binding site shares similar characteristics to the 5HT2 receptor with high 
affinity binding to 5HT antagonists. The 5HT1c site also has physiological and 
structural similarities to the 5HT2 receptor and is sometime considered as part 
of that receptor family (Royer 1988). 
The SHTIc receptor was one of the first to be structurally characterised and 
cloned (Hoyer 1988). 
In addition to the high receptor density in choroid plexus, the limbic system and 
regions associated with motor function have a moderately high density in the rat 
(Pazos & Palacios 1985). In the human there is a high density in the substantia 
nigra and the globus pallucidus as well as the choroid plexus. The ventromedial 
hypothalamus also has a high density (Hoyer et al 1986b; Pazos et al 1987a). 
The location of the receptors would suggest that it has a role in the regulation of 
motor behaviour. 
1.3.3.1.2 The 5H72 receptor family 
5HT2 receptor subtypes display a high affinity for serotonergic antagonists (see 
Table 1.3.3) as well as for spiperone. Recent evidence has suggested that there 
are two subtypes. 
a) 5HT2a 
Binding studies using [3H]DOB and related agents have suggested that there are 
two distinct population of 5HT2 receptors, the 5HT2a site having high affinity 
for this ligand (Titeler et al 1985; Titeler et al 1987; Peroutka et al 1988; Pierce 
& Peroutka 1989a). [3H]ketanserin also shows a bimodal binding affinity ýºecca. $ 
Peroutka 1989b; McKenna & Peroutka 1989). The 5HT2a site has a much 
greater affinity for 5HT than the 5HT2b site (Titeler et al 1985; Lyon et al 
1987). Although binding studies have not been carried out in the human brain 
evidence would suggest that the 5HT2 subtypes exist and that the 5HT2a 
receptor may be involved in the action of hallucinogenic drugs and possibly in 
psychotic illness (Glennon et al 1984). 
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b) 5HT2b 
5HT2b sites have a similar or slightly lower affinity for [3H]ketanserin than 
5HT2a sites (Pierce & Peroutka 1989b) and a very low affinity for DOB and its 
derivatives. There are no specific ligands for the receptor. 
Studies with [3H]ketanserin have shown a high density of 5HT2 (both a and b) 
receptors in both rat (Pazos et at 1985a) and human cortex in frontal, parietal, 
temporal, occipital and entorrhinal areas (Schotte et at 1983; Hoyer et at 1986b; 
Pazos et at 1987b) although there may be some species differences in ligand 
binding characteristics (Biegon et at 1986; Pazos et at 1984a). Human brains 
also have a high 5HT2 receptor density in the claustrum and amygdala. There 
is a moderate density of receptors in the hippocampus and some of the basal 
ganglia. In the human brain there is a weak correlation of 5HT2 receptor 
density with 5HT or 5HIAA tissue content. All areas of high receptor density 
have a high density of 5HT neuronal terminals but not all terminal rich areas 
have high 5HT2 density (Pazos et at 1987b). 
Lesion studies in rats using 5,7-DHT have shown no significant change in post 
synaptic 5HT2 receptor density in most studies ( Blackshear et at 1981; Quick & 
Azmitia 1983; Seeman et at 1980), although some studies have shown an 
increase in number. It has been suggested that the receptors are present on 
intrinsic neurons, possibly of GABA or somatostatin type (Palacios et at 1990). 
It is thought that 5HT2 receptors have a role in the limbic system, motor control 
and visual function. 
1.3.3.1.3 The 5HT3 Receptor Family 
5HT3 receptors were first recognised in the periphery but in 1987 binding sites 
in brain were identified in the rat (Kilpatrick et al 1987). A variety of specific 
ligands exist for the 5HT3 receptor (see 'T'able 1.3.3). Regional binding studies 
suggest a high density in the entorrhinal cortex and lower brain stem in the rat 
(Kilpatrick et al 1987,1989). 
Lesion of 5HT neurons by 5,7, DHT has shown no subsequent change in 
hippocampal 5HT3 receptor density, nor after lesion of post synaptic neurons by 
kainic acid suggesting that 5HT3 receptors, in this area at least, may lie on non- 
5HT neurons, probably GABA. 
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There is some evidence that 5HT3 and 5HT1a receptor subtypes may interact 
since chronic administration of the selective 5HT1a agonist, 8OHDPAT, lead to 
a decrease in 5HT3 receptors density (Barnes et at 1991). 
5HT3 receptors have not been shown in human brain but 5HT3 antagonists have 
proved to have an important therapeutic role in chemotherapy induced nausea 
and are presently being discussed as having potential role in a variety of 
psychiatric and cognitive illnesses (Jones et at 1988). 
1.3.3.1.4 Other receptor subtypes 
In addition to the three major families a variety of other receptors and subtypes 
have been hypothesised. Some of the data suggests that it may be species 
differences not receptor class or subtype differences that are being examined 
(Royer & Middlemiss 1989). 
5HT4 binding sites were described by Dumuis et al (1988). The 
pharmacological profile is dilmilar from other families but as yet it is not fully 
characterised as a receptor (Clarke et al 1989). 
It is likely, especially with the application of molecular biology techniques, and 
with the development of more specific and selective ligands, that many more 
receptor subtypes and possibly major families will become evident. 
1.3.3.2 Physiological correlates of binding sites and assessment of receptor 
function 
1.3.3.2.1. Second messenger systems 
Biochemical events within the cell are triggered by activation of 5HT receptors. 
The 5HT1 family, with the exception of the 5HT1c receptor, are coupled to 
adenylate cyclase with the production of cAMP as an intracellular second 
messenger. 5HT2 and 5HT1c receptors are coupled to phosphatidylinositol 
hydrolysis. The 5HT4 receptors may also act in this way. 5HT3 receptors have 
a much more rapid membrane action as activators of ligand-gated ion channels 
(Sanders-Bush & Conn 1987; Hamon et al 1988; Sanders-Bush 1988'+b; 
Cornfield & Nelson 1991). 
The study of such biochemical events within neurons has lead to increasing 
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understanding of receptor physiology and pathology a discussion of which is 
beyond the scope of this review. 
1.3.3.2.2 Monitoring of SHT release and metabolism 
In vivo monitoring of 5HT and 5HIAA by perfusion collection, voltc*MV\etc, 4or 
CSF sampling allows some assessment of 5HT metabolism and function in a 
dynamic system. These techniques can be used to study pharmacological drug 
action and effectsof physiological and behavioural stimuli. Microdialysis 
measurement of 5HT has been shown to closely approximate to firing activity of 
neurons (Sharp et al 1989). Importantly these techniques can be used to gain 
insight into dynamic neurotransmitter interactions (Marsden 1985). 
1.3.3.2.3 Electrophysiological studies 
Early studies, using extracellular recordings combined with iontopheresis, 
examined the effects of 5HT on neuronal firing activity and found 
predominantly inhibitory responses (Haigler & Aghajanian 1977; Bloom et at 
1972). Excitatory responses were observed however, which appeared to act 
through different receptor populations as they were blocked by 5HT antagonists 
whilst inhibitory responses were not (Roberts & Straughan 1967). It was 
proposed that the site which caused neuronal excitation was the 5HT2 site since 
its affinity for antagonist parallelled ligand binding findings. The inhibitory 
responses were thought to be due to 5HT1 subtype activation (Peroutka et at 
1981). The truth is probably far more complex than this. Aghajanian et at 
(1987) have put forward an argument that electrophysiological studies have 
provided evidence of receptor cooperation and modulation such that 5HT2 
receptors oppose inhibitory 5HT1 responses but enhance 5HT1 excitatory 
effects. Based on electrophysiological studies, Aghajanian (1981) has proposed 
another function of 5HT2 receptors through which 5HT increases the electrical 
excitability of post synaptic neurons to other neurotransmitter substances, 
particularly glutamate. This function is apparent in motor neurons and perhaps 
the reticular formation. The 5HT3 system may be an independent system 
conducting 5HT transmission with a high velocity (Andrade & Chaput 1991; 
Aghajanian et al 1990). Further refinement of knowledge of 5HT receptor 
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function has been hampered by the lack of specific antagonist and agonist 
compounds. 
Electrophysiological studies allow an exposd of intraneuronal events at specific 
sites (usually examined at raphd and hippocampus) but some studies have 
assessed a more overall function of 5HT neurotransmission by single unit 
activity (Jacobs 1987; Fornal & Jacobs 1988; Jacobs et al 1990). These studies 
have examined the role of 5HT in specific physiological processes and 
behaviours (see Section 1.5.1). They have also examined the possibility that 
neuronal firing may not reflect synaptic function when subject to alterations in 
synthesis and metabolism of 5HT and local influences at nerve terminals. 
Combining studies of neuronal unit (raphd) activity with microdialysis 
measurement of changes in ECF 5HT in vivo, Jacobs et al (1990) found no 
evidence that release of 5HT from nerve terminals could be uncoupled form 
nerve firing activity. In contrast Crespket al (1990) have shown that stimulation 
of the neuronal terminal autoreceptor decreased 5HT release in vivo without 
affecting neuronal firing in the DRN. 
Neurophysiological studies have provided strong evidence that activation of the 
5HT1a receptors on the raphd cell bodies (identified by ligand binding and 
autoradiographic techniques), completely suppresses activity of DRN neurons 
(Sprouse & Aghajanian 1987; Dourish et al 1988) and antagonism at this 
receptor enhances activity. This supports the suggestion that 5HT1a are 
somatodendritic autoreceptors (Jacobs et al 1990). 
Marsden et al (1991) have shown that pharmacological and behavioural 
modification of 5HT neuronal firing results in both autoreceptor and post 
synaptic receptor changes. The need for in vivo assessment of functional 
changes in 5HT neurotransmission in experimental procedures is apparent from 
these elegant studies. 
Electrophysiological single cell studies after 5,7, DHT lesion of 511T neurons 
have shown a supersensitivity of postsynaptic neurons (Wang et al 1979). The 
effect of lesioning may be regionally specific however, since no supersensitivity 
was found in hippocampal cells (de Montigny et al 1980). A component of this 
supersensitivity may be the added loss of presynaptic reuptake sites in neuronal 
lesioning (ie loss of degradation regulation) since inhibition of 5HT synthesis 
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alone does not lead to supersensitivity of post synaptic response (Lorens 1978; 
Ferron et al 1982). 
1.3.3.3 Behavioural studies 
Central 5HT stimulation provokes' a complex behavioural and motor syndrome 
in animals (Jacobs 1976; Green 1984) Some aspects of the behaviour are 
believed to occur because of particular 5HT receptor subtype stimulation. 
5HTla stimulation leads to forepaw treading and flattened body posture 
(Tricklebank 1985; Green & Heal 1985; Green 1988; Wilkinson & Dourish 
1991) whilst 5HT2 receptor stimulation leads to "wet dog shakes" and head 
twitching (Yap & Taylor 1983). Other behaviour patterns probably arise as a 
combination of receptor effects. Indeed more than other methods of assessment 
of 5HT function, behavioural studies identify the complexity of receptor co- 
operation and modulation. (Green & Heal 1985; Berendsen et al 1988; Backus 
et al 1990; Wilkinson & Dourish 1991). The effect of pharmacological agents 
on other neurotransmitter systems will also have a role in the behavioural effects 
observed. 
Behavioural studies are useful pharmacological 'screening' models for the 
probable effects of drugs Green 1988). As understanding of receptor interaction 
develops, and drugs of high specificity become available, it may be that 
behavioural models will become useful in exploring dynamic function of the 5HT 
neurotransmitter system. 
Behavioural studies have also shown that there is functional supersensitivity of 
5HT neurotransmission after denervation procedures (Trulson et al 1976). 
1.3.4 FUNCTION AND REGULATION OF 5HT NEUROTRANSMISSION 
1.3.4.1 What is the function of the S1IT nervous system ? 
Voyt (1982) suggested that 5HT plays a role in homeostasis, enabling the 
organism to modulate excessive stimuli of a wide variety. Several unique 
anatomical and electrophysiological properties of 5HT neurons support a 
modulatory role in the CNS. Firstly, the widespread distribution of 5HT 
terminals in the brain allows influence on nearly every brain function; secondly, 
the non-synaptic nature of many 5HT terminals suggests that, upon release, 5HT 
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may potentially interact with several post synaptic neurons (Soghomonian et al 
1988; Descarries et at 1990), and thirdly, individual 5HT neurons have been 
shown to project to more than one target site (van der Kooy & Kuypers 1979). 
In addition the slow and regular activity of the neurons, together with their slow 
conduction velocity and long-durätion of synaptic action is compatible with a 
tonic maintenance role rather than rapid and phasic action (Aghajanian et al 
1987). 5HT is thought generally to have an inhibitory modulatory effect on 
behaviours, either directly or via stimulation of GABA secreting or other 
inhibitory neurons. Some experimental evidence would also suggest that 5HT 
can modulate the sensitivity of neurons to other afferent inputs. 
Numerous specific behaviours appear to be modulated by 5HT (Barchas & 
Usdin 1973) including mood, appetite, sleep, sexual function, pain, circadian 
rhythms, body temperature and endocrine functions (see Section 1.5.1). There 
is evidence which suggests that this modulatory effect on behaviours varies with 
the general level of arousal (Formal & Jacobs 1988) which would lead to smooth 
adjustments of the internal mileux and behaviour patterns to sleep/wake cycles 
and other influences on the behavioural state. 
The 5HT nervous system does not function in isolation, however, and many 
studies have shown that normally function and responsiveness relies on the 
integrity of other neurotransmitter systems (Kellar et al 1983; Green & Heal 
1985). 
1.3.4.2 Autoreceptors 
Endocrine and neurotransmitter systems are subject to feedback regulation as a 
consequence of end organ function or concentration of substance in the 
immediate environment. This autoregulation may be direct or indirect through 
inhibitory afferent stimuli. 
1.3.4.2.1 Terminal autoreceptors 
Endogenous 5HT release or exogenously applied 5HT or 5HT-like compounds, 
leads to inhibition of further stimulated 5HT release in brain slice and 
synaptosomal preparations, suggesting the presence of an autoreceptor on the 
terminal nerve process (Gothert & Weinheimer 1979; Cerrito & Raider 1979). 
This in vitro observation has been confirmed by both neurochemical and 
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electrophysiological techniques in vivo (Monet 1985; Middlemiss 1988). 
Although the degree of sensitivity of the autoreceptor to synaptic concentration 
of 5HT is debated (Auerbach & Rutter 1990). 
The terminal autoreceptor has been identified in brain preparations from all 
areas and the receptors appear to have consistent pharmacological 
characteristics. Studies in the rat have shown that the receptor is probably the 
5HTlb subtype since In vitro electrically evoked 5HT release is inhibited by 
drugs with rank potency similar to that of the 5HT1b receptor (Engel et al 1986; 
Raiteri et al 1986), and 5HT1a agonists do not activate these receptors 
(Middlemiss & Fozard 1983). In non-rodents and humans the terminal 
autoreceptor is thought to be of the 5HT1d subtype (Hoyer & Middlemiss 
1989). There have been no autoradiographic studies however, that have 
identified the presence of these receptors subtypes on neuronal terminals (see 
Section 1.3.3.1.1). 
The terminal autoreceptor is thought to exert a tonic inhibitory effect on 5HT 
release since antagonists to the receptor given alone enhance 5HT release 
(Gothert 1982) in addition to enhancing stimulated release (Cerrito & Raiteri 
1979). Post-synaptic inhibition of firing after 5HT release is also enhanced by 
5HT autoreceptor antagonist administration (Chaput et al 1986a). 
A close functional link between the terminal autoreceptor and the 5HT reuptake 
site has been observed since uptake inhibitors act also as terminal autoreceptor 
antagonists leading to the loss of the inhibition of endogenous 5HT release 
(Galzin et al 1985: Langer & Moret 1982). However, stimulation of the 
autoreceptor has no apparent modulatory effect on the reuptake site (Briley & 
Moret 1983). Other drugs with 5HT activity do not have effects on the terminal 
autoreceptor (see Section 1.5.3.2). Chronic antagonism of the autoreceptor 
evidently has no effect on the sensitivity of the receptor (Hagan & Hughes 
1983). 
1.3.4.2.2 Somatodendritic autoreceptors 
5HT and LSD were observed to decrease firing activity in the DRN when given 
systemically or iontophoretically (Wang & Aghajanian 1977; Haigler & 
Aghajanian 1977). This effect has been found to be mediated through 5HT1a 
somatodendritic autoreceptors (Verge et al 1985; Sprouse & Aghaganian 1987), 
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although it has been suggested that the effect may be mediated through 5HTlb 
receptor subtype in MRN (Pazos & Palacios 1985). Autoradiographic studies 
have identified a high density of these receptors on raphd cell bodies 
(Macinkiewicz et al 1984). 
Chronic exposure to 5HT1a agonists have produced contrasting results in the 
changes in somatodendritic autoreceptors. Blier & Montigny (1987) showed 
that there was a significant decrease in SHT inhibition of DRN activity. Hamon 
et al (1990) have suggested that there was no change in biochemical measures of 
somatodendritic function. The differences in results remain unexplained. No 
5HTla selective antagonist are available at the present time to explore the 
effects on the somatodendritic receptor. 
Administration of drugs which enhance synaptic 5HT have an indirect effect on 
the somatodendritic receptor. This is thought to be through the action of 
collateral inhibition from dendrites on DRN cell bodies . Chronic 
administration of MAOI leads to a decrease in somatodendritic autoreceptor 
sensitivity as does chronic exposure to uptake inhibitors. Chronic antagonism of 
the terminal autoreceptor (with increased 5HT release due to loss of inhibition) 
does not have effect on the somatodendritic autoreceptor (Hagan & Hughes 
1983). 
The studies of Blier and de Montigny have lead them to believe that the role of 
the somatodendritic autoreceptor is to control the firing activity of 5HT neurons 
whereas the role of the terminal autoreceptor is to control the amount of 5HT 
released by the action potential (de Montigny & Blier 1991). 
1.3.4.2.3 Other autoreceptors 
The presence of a2 adrenoceptor, inhibitory to 5HT release, have been 
identified on 5HT nerve terminals (Gothert & Huth 1980; Frankhuyzen & 
Mulder 1980). These receptors are also desensitised after prolonged exposure 
to 5HT reuptake inhibitors (Blier et al 1990b). 
1.3.4.3 Uptake sites 
After 5HT is released from nerve terminals and has acted at post synaptic 
receptors it is transported out of the synaptic cleft back into nerve terminals, and 
into glial cells, by a specific, high affinity membrane uptake carrier. The 
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uptake site has been found to be ATP dependent and oubain sensitive. Sodium 
ions, generated by the action of Na+/K+ ATPase, may be co-transported with 
5HT (Graham & Langer 1988). 
Many tricyclic antidepressant drugs non-selectively block the 5HT uptake site. 
In the past 10 years there has been a great interest in the development of drugs 
with selectivity for inhibition of the uptake site. This has seen the development 
of a group of selective serotonin reuptake inhibitors (SSRI) which have proved 
to have many therapeutic uses and have aided the further understanding of the 
dynamics of 5HT neurotransmission. Radiolabelled SSRI can also be used in 
ligand binding and autoradiographic studies of uptake site density and 
localisation in the brain and other tissues. 
Acute inhibition of reuptake has been shown to increase 5HT in the synaptic 
cleft as measured by histofluorescence (Geyer et al 1978), voltoM ' 'cc% 
(Marsden et al 1979) and push-pull cannula collection (Guan & McBride 1988) 
as well as observation of effects on function. Increased synaptic 5HT rapidly 
leads to autoregulatory changes in the 5HT neuron and within 2 days of 
treatment there is a marked decrease in firing of DRN (Clemens et al 1977). 
Chronic administration of SSRI in animal studies has shown that the uptake site 
does not apparently undergo upregulation subsequent to inhibition (Graham et 
al 1980). The firing of DRN returns to normal levels after 14 days of treatment 
apparently due to two effects of SSRI. Firstly the somatodendritic autoreceptor 
is desensitised (Chaput et al 1988). This change in sensitivity is parallelled by a 
decrease in numbers observed in autoradiographic studies (Weiner et al 1989). 
Secondly prolonged exposure to SSRI apparently decreases the ability of the 
terminal autoreceptor to inhibit 5HT release (Chaput et al 1986b; Blier et al 
1988). These studies suggest that the effect of SSRI is an initial increase in 
synaptic 5HT rapidly followed by a return to normal levels due to inhibition of 
neuronal firing, followed after longer exposure to SSRI by enhanced 5HT 
neurotransmission as autoreceptors are inhibited and DRN return to normal 
firing activity. 
There is mixed evidence of the effect of increased 5HT in the synapse on post 
synaptic function. Chaput et al (1986b) have shown that there was no 
desensitisation of function, nor have changes in density of 5HT1a or 5HT2 
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receptors been found in most studies (Waj sley et al 1987). Wong & Bymaster 
(1981) did find a small decrease in 5HT1 receptors in the frontal cortex. 
1.3.4.4.5HT neurotransmission. 
Figure 1.3.3 shows a stylised 5HT neuron with the receptors and regulatory 
processes involved in neurotransmission. 
Increase in concentration of 5HT precursors is known to increase 5HT 
synthesis, much of which is degraded within the neuron resulting in increased 
5HT turnover (increased 5HIAA) but not necessarily an increase in synaptic 
function (Green & Grahame-Smith 1975). 
Release of SHT into the synapse leads to postsynaptic effects, principally on 
5HT1 receptors since these have a much greater affinity for 5HT than 5HT2 
receptors, presynaptic effects at the terminal autoreceptor (5HTlb in the rat 
5HT1d in human), uptake site and other presynaptic receptors. There is thought 
to be post-synaptic modulation and co-operation between 5HT1 and 5HT2 
receptors. 
Administration of receptor subtype selective and non-selective agonists leads to 
discernible behavioural and physiological changes in animals and humans, whilst 
administration of 5HT2 antagonists causes little change in behaviour. 5HT2 
receptors appear to be unlike other 5HT receptors or receptors of other 
neurotransmitter systems in that exposure to antagonists causes a decrease in the 
number of receptors (Leysen et al 1986). 
Leysen & Pauwels (1990) have suggested that the 51177 receptor has a unique 
role in neurotransmission. Despite low affinity for 5HT they are extremely 
sensitive to it and administration of selective agonists causes a rapid and 
prolonged down regulation (Leysen et al 1989; Buckholtz et al 1988). It may be 
that under normal circumstances, because of low affinity for SHT, 5HT2 
receptors are not stimulated, thus 5HT2 antagonism causes little discernible 
change in behaviours. Exposure to 5HT2 agonists cause rapid and marked 
effects with a compensatory down-regulation. 
The regulation of 5HT transmission is through a variety of possible routes: 
a) Neuronal cell firing activity. Regulated by somatodendritic 5HT1a 
autoreceptors. Stimulation of the receptor leads to a decrease in neuronal firing 
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Figure 1.3.3 
A stylised serotonin neuron showing the receptors of neurotransmission and regulation. 
and a decrease in 5HT release into the synapse. 
b) Terminal autoreceptors. Stimulation leads to a decrease in 5HT release from 
the neuron. 
c) Presynaptic uptake sites. The affinity and number of uptake sites does not 
appear to change in experimental settings. Uptake sites may also influence 5HT 
release by an effect on the terminal autoreceptor. 
d) Post-synaptic receptors. Alteration in stimulation of the post-synaptic 
receptors leads to a change in receptor number. There is probably a high 
degree of receptor co-operation and modulation. 
e) Other neurotransmitter systems. Alteration in 5HT transmission has been 
shown to lead to changes in other neurotransmitter systems both indirectly and 
directly by effect on 5HT receptors present on the neurons of other 
neurotransmitter systems (Quirion & Richard 1987). In addition to 5HT itself 
many other neurotransmitters and neuropeptides may influence the release of 
5HT through receptors present on 5HT cell bodies and nerve terminals. 
It is known that drugs with similar effects on the concentration of synaptic 5HT 
have differing effects of these regulatory processes (see Section 1.5.3.2). Drugs 
with apparently the same pharmacological mode of action also have different 
effects on these processes. It is only by consideration of all of these effects, 
together with electrophysiological study of the net effect on post-synaptic 
transmission that we can understand the functional change in 5HT 
neurotransmission. Examination of only one process may lead to apparently 
contradictory findings and erroneous conclusions of functional change since it 
may be that even though drugs may appear to cause different effects in any one 
part of the system, the net result of these changes allows identical changes in 
increase or decrease of 5HT function. 
Lesion of 5HT neurons appears to cause electrophysiological and behavioural 
supersensitivity to 5HT, but without apparently major and consistent changes in 
post synaptic receptor density. The mechanism for this is not fully explained 
but could be related to changes in receptor affinity. 
There is a need in the future study of 511T function regulation and pathology for 
the development of a model which takes into account the following: 
46 
1. That the anatomy of the 5HT system suggests that there are discrete but 
interacting subsystems. Each raph6 nucleus may serve specific functions and 
have discrete neuronal type and innervation pattern. It has been suggested that 
DRN are particularly associated with the 5HT2 receptor (Molliver 1987). 
2. That there are a host of receptor subtypes. In the light of point 1 it may be 
that the subtypes have different function and pattern of response in different 
anatomical location. Indeed 5HT neurons of the MRN have been reported to be 
less sensitive to 5HTla agonists than neurons of the DRN (Blier et al 1990a). 
3. That a high receptor density does not necessarily correlate with functional 
importance of 5HT nor a low density with absence of a functional role for 5HT 
since receptors may down-regulate with high availability of the monoamine and 
upregulate where there is a deficiency. 
Conclusions about function and pathology must consider all available indicators 
of synaptic function including measurement of turnover, neuronal and receptor 
density and physiological and behavioural assessment of receptor processes. 
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1.4 SEROTONIN AS A MODULATOR OF VASOPRESSIN RELEASE 
1.4.1 ANATOMICAL EVIDENCE 
5HT nerve fibres innervate almost every area of the brain and pass in two major 
tracts from the brain stem through the hypothalamus to cortical and subcortical 
structures (Azmitia & Gannon 1986). There is evidence that 5HT innervates 
many of the hypothalamic nuclei and specific innervation of the SON and PVN 
has been shown in the rat, cat and monkey (Conrad et at 1974; Zaborsky et at 
1975; Bobillier et al 1976; Azmitia & Segal 1978; Kent & Sladek 1978; 
Steinbusch 1981). There have been no studies of the human brain which have 
looked at the 5HT innervation of the SON or PVN specifically. 
Van de Kar & Lorens (1979) suggested that the MRN project to the anterior 
part of the hypothalamus in the rat although others have suggested that the DRN 
are more important in innervation of the SON (Bobillier et at 1976; Pal kovits et 
at 1977). Sawchenko et at (1983) found evidence that these hypothalamic nuclei 
were innervated by both DRN and MRN in the midbrain but not raph6 neurons 
situated more caudally. 
Two detailed studies in rats have shown that the 5HT innervation of the PVN is 
less dense than that of the surrounding cell groups (Steinbusch 1981) and that 
5HT terminal are predominantly associated with parvocellular neurons 
(Sawchenko et at 1983). Although there is a low nerve fibre density in the 
magnocellular region they have a distinct distribution, which may be 
preferentially related to the distribution of oxytocin secreting cells (Sawchenko 
et al 1983) (see Section 1.1.1). Zaborsky et al (1975) estimated that 30% of the 
afferent fibres to the SON were of noradrenaline or 5HT type. These appear to 
be associated with oxytocin secreting cells in the anterodorsal part of the nucleus 
(Sawchenko et at 1983). In the monkey brain 5HT fibres have been found in 
the lateral PVN and dorsal SON areas (Kawata et at 1984). 
In the hypothalamus studies of the 5HT content and the enzymes of synthesis 
and degradation have shown there to be high concentration in all animal and 
human brains (Bertler 1961; Azmitia & Gannon 1986). Initial measurement of 
these substances specifically in the SON proved to be negative (Dahlström & 
Fuxe 19610 but later studies have identified their presence in both the PVN and 
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SON (Carlsson et at 1962; Saavedra et at 1974; Brownstein et at 1975; Saavedra 
1977). Since surgical isolation of the hypothalamus decreases the concentration 
of these substances it would seem that 5HT originates from neurons with cell 
bodies in other areas (Brownstein et at 1976). 
5HT nerve fibres have also been found in the neurohypophysis of many animal 
species (Bjorklund 1968; Steinbusch & Nieuwenhuys 1981; Sano et at 
1982; Saland et at 1986). These nerves appear to originate in the DRN (Saland 
et at 1987). 5HT and the enzymes of synthesis and degradation have also been 
found in the neurohypophysis in moderate concentrations (Bjorklund et at 1967; 
Piezzi & Wurtman 1970; Saavedra et at 1975; Payette et at 1985; Koulu et at 
1989). 
The OVLT and SFO receive a moderately dense 5HT innervation (Bosler 1978; 
Bouchard & Bosler 1986). Its function is not known but it may be related to the 
control of LHRH secretion rather than osmoregulation. 
Schotte et at (1983) and others (Pazos & Palacios 1985; Pazos et at 1985b; 
Pazos et at 1987) have found evidence that receptors for 5HT are present in low 
concentration in the regions of the magnocellular neurons in the hypothalamus 
of rat and man but in a higher concentration in the neurohypophysis of rats (De 
Souza 1986). 
These anatomical findings suggest that 5HT may have a direct role in the 
regulation of AVP release. Because of the diffuse nature of 5HT innervation 
many areas of the brain which have afferent input to the magnocellular neurons 
may be influenced by 5HT. Thus 5HT could also indirectly modulate AVP 
release in a variety of ways. 
1.4.2 EVIDENCE FOR A PHYSIOLOGICAL ROLE 
Early studies to explore the role of 5HT in AVP secretion found that electrical 
stimulation of the raph6 diminished urine output (Sharpless & Rothballer 1961), 
and lesion of the raph6 nuclei increased urine output and water intake 
(längapregassom et al 1974). This appeared to be due to an inability to release 
AVP since there was an accumulation of neurosecretory material in the 
magnocellular neurons subsequent to the 5HT neuron loss (Tangapregassom 
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al 1974). Iovino & Steardo (1985) found that lesion of 5HT neurons with the 
neurotoxin 5,7-DHT or inhibition of synthesis with pCPA (see Table 1.3.2), 
prevented the normal rise of AVP in response to water deprivation. This was 
confirmed in another study using a hypertonic saline stimulus (Brownfield et al 
1987). However, depletion of brain 5HT either by neuronal lesion or synthesis 
inhibition had no effect of basal AVP concentration (lovino & Steardo 1985; 
Brownfield et at 1987). 
Water deprivation in rats has been found to increase SHT turnover (SHIAA: 5HT 
ratio) (Handley et al 1991) and cause a depletion of 5HT in the neurohypophysis 
(Piezzi & Wurtman 1970). 
Exogenously applied 5HT has been shown to alter the discharge rate of some 
magnocellular neurons (Moss et at 1972) although there have been conflicting 
results as to the excitatory or inhibitory nature of the effect (Barker et at 1971). 
It has been suggested that only magnocellular neurons secreting oxytocin are 
stimulated by the 5HT (Barker et at 1971). 
It would seem from these studies that 5HT has a role in osmotically stimulated 
AVP release. SHT did not appear to be involved in the hypovolaemic 
stimulation of AVP release in one study in rats since this was preserved after 
5HT neuron lesion (Brownfield et al 1987). In another study haemorrhage 
caused an increase in 5HT concentration in the SON of the rat, suggesting a role 
in baroregulation responses (Kendrick & Leng 1989). 
The work by Tangapregassom . (1974) might suggest that 5HT loss 
inhibited 
AVP release but not synthesis. However Carter & Murphy (1989) have shown 
that 5HT synthesis inhibition blocked the increase in AVP mRNA in the magno- 
cellular neurons which occurs with osmotic stimulation. This would suggest 
that 5HT was also important in AVP synthesis. 
Studies with exogenous 5HT application have provided variable results. Urano 
& Kobayashi (1982) injected 5HT into the SON and found a biphasic response 
with an initial brief diuresis followed by a prolonged antidiuresis. Montes & 
Johns, on (1990) have confirmed this finding and showed that 
intracerebroventricular (ICV) 5HT stimulated AVP secretion in water-loaded 
rats. However, Bhargava et al (1972) found that ICV infusion of 5HT had no 
effect on AVP release in dogs and others have similarly found no effect of urine 
flow in normal or water-loaded animals (Olsson 1970; Ruoff et at 1974; 
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The isolated rat neurohypophysis has been shown to release AVP when 
stimulated by 5HT (Lemay et at 1979) but incubated hypothalamic fragments did 
not release AVP with 5HT stimulation (Hillhouse & Milton 1989). 
The inconclusive and contradictory nature of these results is compounded by the 
use of differing animals and techniques of 5HT administration. It is assumed 
that 5HT given ICV will increase synaptic 5HT which is possibly erroneous. 
However, even the studies which use locally applied 5HT are not in agreement. 
Recently it has been suggested that the cardiovascular effects of 5HT (increase 
in mean arterial pressure, decrease in heart rate) are mediated, at least in part, 
by AVP since V1 receptor antagonists inhibit the effects (Dedeoglu & Fisher 
1991; Pergola & Alper 1991). Plasma AVP was not measured in either of these 
studies. 
1.4.3 PHARMACOLOGICAL STUDIES 
The advent of sensitive assays for AVP and selective 5HT agonist and 
antagonist drugs has allowed further exploration of a possible role for 5HT in 
the regulation of AVP secretion. 
Gibbs & Vale (1983) found a rise in peripheral and portal AVP concentration in 
anaesthetised rats after acute administration of the SSRI Fluoxetine. In a study 
using un-anaesthetised rats, Fluoxetine was found to have no effect on urine 
flow rate (Stein et al 1987). Quipazine and d-fenfluramine, both of which 
increase 5HT neurotransmission, have been shown to cause a dose-related rise 
in plasma AVP in conscious rats (lovino & Steardo 1985). This effect was 
completely blocked by prior treatment with pCPA. A decrease in urine volume 
was found after administration of another 5HT stimulator PCA. However, this 
was nal inhibited by prior treatment with pCPA (Stein et al 1987). PCA has 
also been shown to cause a rise in plasma AVP in rats (Steardo & Iovino 1986; 
Brownfield et al 1988). This effect was prevented by hypothalamic 
deafferentation with transection of 5HT and other pathways to the hypothalamus 
(Brownfield et al 1988). High dose of another agonist (TFMPP) was also been 
shown to cause a rise in plasma AVP (Hashimoto et al 1982). 
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Selective 5HT1a and 5HT1b agonists did not cause a rise in plasma AVP but 
MK212, a mixed 5HT1 and 5HT2 agonist did stimulate the release of AVP in 
conscious rats (Brownfield et al 1988). Whilst a 5HT2 antagonist had no effect 
on plasma AVP when given alone, it did block the effect of MK212 on plasma 
AVP release (Brownfield et al 1988). Bagdy et al (1992) found that ritanserin, 
a 5HT2 and 5HT1c antagonist, partially inhibited the AVP response to the 5HT 
agonist mCPP. 
It would appear from these studies that an intact 5HT system is necessary for 
normal osmoregulation of AVP although basal concentration is apparently 
independent of 5HT neurotransmission. An increase in synaptic 5HT leads to a 
rise in plasma AVP. This effect is apparently mediated centrally since depletion 
of neuronal 5HT prevents the agonist stimulated rise. Although many of the 
drugs used in pharmacological studies do have effect on other neurotransmitter 
systems the balance of evidence would suggest that 5HT does modulate AVP 
release. The work by Brownfield et al (1988) has suggested that this is 
mediated by 5HT2 receptors. Although mCPP, which has 5HT2 agonist 
properties, did stimulate AVP release in one study (Bagdy et al 1992) it did not 
stimulate AVP release in another (Saydoff et al 1989). Similarly DOI, a 5HT2a 
agonist, did not alter plasma AVP concentration (Saydoff et al 1990; Bagdy et al 
1992). A recent study has indicated that the 5HTlc receptor subtype may 
mediate the response (Bagdy et al 1992). 
It is by no means conclusive from anatomical and pharmacological studies that 
5HT causes a rise in AVP by a direct effect on magnocellular neurons. It does 
not appear to have an effect which is mediated through alteration of blood 
pressure (Brownfield et al 1988; Stein et al 1987), nor through the renin- 
angiotensin system since angiotensin II antagonists did not inhibit the 5HT 
stimulated rise of plasma AVP (Steardo & lovino 1986). 
1.4.4 STUDIES IN HUMANS 
There have been only two studies in humans which have explored the possible 
role of 5HT in AVP regulation and release. Thompson et al (1992) showed that 
the 5HT2 and 5HT1c antagonist ICI 169,369, did not alter the osmotically 
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stimulated AVP response . At high dose however, the antagonist blunted the 
AVP rise consequent to insulin-induced hypoglycaemia in normal men. The 
AVP response to hypoglycaemia is not, however, a reproducible phenomena 
(Thompson et al 1991) and this result must be interpreted with caution. 
Coiro et al (1989) have shown that the metaclopramide stimulus to AVP is not 
mediated through 5HT receptors. 
Circumstantial evidence for the possible importance of 5HT in AVP regulation 
comes from the reports of hyponatraemia associated with the clinical use of 
some, but not all of the SSRI (Section 1.6.2.1). Hyponatraemia has not been 
reported with the use of other SHT active agents such as fenfluramine and 
5HTP. It is possible that drugs which are 5HT agonists may non-osmotically 
stimulate AVP release because of their tendency to cause nausea. However this 
was not cited as a significant factor in the case reports. Unlike the tricyclic 
antidepressants the SSRI, and other drugs which increase 5HT 
neurotransmission, do not cause a drop in blood pressure and would not 
stimulate AVP through changýin baroregulation. 
The role of 5HT in osmotically regulated AVP secretion both in normal man 
and in states of AVP dysfunction such as cranial diabetes insipidus and SIAD, 
and in diseases such as depression where there is a putative abnormality of 5HT 
function, requires further investigation. 
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1.5 SEROTON1N AND DEPRESSION 
It was first proposed that serotonin might have a role in mental illness (Wo4 Icy 
& Shaw 1954; Coppen 1967) after two drugs which had major effects on mood 
were found to have a profound effect on 5HT neurotransmission. LSD, which 
caused a variety of disturbances of mental function, was found to have a similar 
chemical structure to 5HT (Shave 1955), and reserpine, which caused 
depression in many subjects, was found to deplete brain 5HT (Shave et al 1955; 
Pletscher et al 1956). Both "deficiency" and "excess" of serotonergic activity 
have been proposed as predisposing to, or causing depressive illness. With 
increase in knowledge of the intricacies of 5HT neurotransmission and 
regulatory processes, particularly receptor physiology and regulation, it has 
been possible to marry some of the previous, apparently contradictory findings. 
This section discusses some of the evidence for an abnormality of 5HT 
neurotransmission in depression. 
1.5.1 CHANGES IN BEHAVIOUR AND THE ROLE OF 5HT 
Depression is characterised by significant changes in a variety of behaviours. 
There is evidence to suggest that 5HT may have a role in these changes. 
1.5.1.1 Mood 
Depressed mood is obviously a major feature of affective illness. There is some 
evidence that in normal people changes in the availability of plasma tryptophan, 
by dietary manipulation or 1-tryptophan administration, affects mood. Elevation 
of mood occurs with tryptophan loading (Smith & Prockop 1962; Charney et al 
1982) and mild depression may occur with tryptophan deficiency (Young et at 
1985). These results have not always been replicated in other studies and, in 
view of the fact that changes in 5HT synthesis appear to have little effect on 
function due to a vast excess of synthesis over requirements, (see Section 
1.3.2), the results are controversial. 5HTP administration has also been shown 
to have mood elevating effects in normal subjects (Trimble et at 1975; Purhringe 
et at 1976). 
A recent study in depressed patients showed that the availability of dietary 
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tryptophan was important in the maintenance of mood improvement during 
antidepressant treatment (Delgado et al 1990). Inhibition of 5HT synthesis by 
pCPA was found to block the mood response to antidepressants (Shopsin et at 
1976). Thus in depressed patients, and perhaps also in normal people, the 
synthesis of 5HT has effect on mood with an increase in 5HT leading to mood 
elevation and a decrease leading to depression. 
1.5.1.2 Appetite 
Decreased appetite is a frequent symptom of major depression although some 
patients have increased appetite with a change of desire for specific food types, 
particularly carbohydrates. 
In general increased 5HT activity appears to decrease food intake and decreased 
activity leads in increased appetite (Blundell 1984). This may suggest that in 
depression there is an increase in 5HT activity. It is possible that the 'appetite 
system' is an independent 5HT system and that although other aspects of 
behaviour in depression suggest a decrease in 5HT activity, this system does 
have an increase in activity, or it may be that there is much more complex 
regulation and receptor interaction in the control of appetite. The latter seems 
more likely in view of recent findings that 5HT,, agonists have been shown to 
increase food intake. 
1.5.1.3 Sleep 
Disturbed sleep with insomnia and early wakening is a classic feature of major 
depression, particularly decreased latency of rapid eye movement sleep (REM)- 
Increased 5HT activity promotes total sleep time and decreased 5HT activity 
produces insomnia (Koella 1988). Many drugs which increase 511T availability 
selectively lengthen REM latency. 
1.5.1,4 Circadian rhythms 
There is much evidence that circadian rhythms are disturbed in affective 
disorder with abnormalities of sleep cycle, endocrine secretory patterns and 
temperature rhythms (Healy & Williams 1988; Gold et at 1988). The SCN, 
thought to be the major co-ordinator of circadian rhythm, is richly innervated by 
5HT neurons. Destruction of 5HT pathways in animals is known to ablate 
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normal light/dark cycles. 
5HT may be involved in the abnormalities of circadian cortisol secretion that 
occur in depression (Meltzer et al 1984; Montange & Calas 1988). 
1.5.1.4 Anxiety 
Anxiety is a common symptom of depressive disorders. There is evidence from 
animal studies that "stress" may increase both pre and post synaptic 5HT 
activity (Kennett et al 1985) . 5HT, 1 agonists, predominantly 
used as anxiolytic 
drugs, appear also to have antidepressant action (Kennett et at 1987). Failure of 
5HT neurotransmission to respond appropriately to stressors may be a factor in 
depression 
Thus alteration of 5HT activity is consistent with many of the changes in mood, 
behaviour and somatic function observed in depressed people. 
1.5.2 STUDIES OF ABNORMALITIES IN 5HT ACTIVITY IN DEPRESSED 
PATIENTS 
1.5.2.1 SHIAA in the CSF 
The concentration of 5HIAA in the CSF has been studied as an indicator of 
central 5HT activity. Lumbar CSF SHIAA levels have been found to correlate 
with brain 5HIAA concentrations in humans, although as much as 50% may 
originate from the spinal cord. Many other factors such as diet, height, gender, 
environmental stressors and previous drug treatments may influence lumbar CSF 
5HIAA levels. There is thus much disagreement in the data and much 
controversy with regards to interpretation (Anderson et al 1990). In addition, as 
discussed above (Section 1.3.2), 5HT metabolism shown by 5HIAA 
concentration, does not necessarily reflect function at the synapse. 
Agren (1980) and Asberg et al (1984) have found decreased 5HIAA 
concentrations in large populations of drug free unipolar and bipolar depressed 
patients compared to normal controls. These findings were not replicated in 
other studies some of which were examined by Rothpearl(1981) who suggested 
that many studies were not large enough to detect <30% change in 5HIAA 
concentration, and that there was possibly a subgroup of depressed patients 
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whose CSF 5HIAA levels correlated with the severity of depression. This had 
been suggested previously by Asberg et al (1976) and also by Gibbons & Davis 
(1986). 
In follow-up studies of depressed 
. 
patients Trilskman-Bendz et al (1984) found 
thatwhilst CSF 5HIAA levels remained relatively stable in controls and most 
depressed patients, some of those patients with low 5HIAA levels when ill had a 
moderate rise on recovery, suggesting that there was a subgroup of patients with 
an unstable 5HT system. Van Praag & de Haan (1979) showed that those 
patients who had a persistent low SHIAA concentration when euthymic, had a 
higher risk of subsequent relapse than depressed patients with normal CSF 
5HIAA. 
An inverse relationship between CSF 5HIAA concentration and suicidal 
behaviour has been found (Asberg et al 1987; Roy et al 1988). Reduced 5HIAA 
levels have been reported in the CSF of suicide attempters without depression 
and this may suggest that suicidal behaviour, and not depression per se, 
correlates with decreased CSF 5HIAA. 
Low CSF 5HIAA concentration may predict good response to certain therapies. 
Van Praag & de Haan (1980) found that treatment with 5HTP, of euthymic 
patients with persistently low CSF 5HIAA, reduced the risk of subsequent 
relapse compared to placebo treatment. Maas et al (1982) found that low CSF 
5HIAA predicted good clinical response to imipramine but not to amitryptiline. 
1.5.2.2 Plasma tryptophan 
It has already been discussed that an increase in available plasma tryptophan 
leads to increased synthesis but not necessarily to increased synaptic function 
(Section 1.3.2), and that plasma tryptophan concentration may have effect on 
mood in both normal and depressed people (Section 1.5.1.1). 
Moller et al (1983) summarised the 20 or so studies of measurement of plasma 
tryptophan concentration in depressed patients. About half of these studies 
showed that there was a decreased concentration of free tryptophan in the 
plasma of depressed patients, the concentration still, however, fell within the 
normal range. 
Some studies have show a reduced ratio of tryptophan to other neutral amino 
acids in depression (Joseph et al 1984). De Meyer et al (1981) found an inverse 
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correlation of this ratio with the severity of depression. 
There has been some evidence to suggest that depressed patients with low 
plasma tryptophan have abnormalities of metabolism after either oral or 
intravenous administration (Smith & Stromgren 1981; Koyoma & Meltzer 
1986). These authors found a larger volume of distribution and longer half life, 
resulting in a decreased availability in depressed patients. Other studies have 
failed to confirm this (Hoes et al 1981; Moller et al 1982). 
1.5.2.3. Studies in platelets 
Blood platelets have many features in common with 5HT neurons and are 
sometimes used as a model of neuronal function (Sneddon 1973; Stahl 1977). 
Several studies have reported a reduction in 5HT uptake into platelets from 
unmedicated depressed patients (Coppen et at 1978; Meltzer et at 1981; Stahl et 
at 1982). This appears to be due to a decrease in number not a change in 
affinity of the uptake site. This abnormality appears to remain after recovery 
and may be a trait marker in some patients (Coppen et at 1978; Scott et at 
1979). There is no apparent correlation between uptake site changes and 
severity of depression nor does it predict response to treatment (Aberg-Wiste& 
1982). 
If these findings were extrapolated to suggest that uptake sites on central 5HT 
neurons are decreased in depression this could lead to increased concentration of 
synaptic 5HT since less was removed by reuptake, or decreased reuptake could 
lead to diminished presynaptic stores and thus decreased 5HT availability. The 
decrease in uptake site could, however, be a secondary compensation in 
response to a primary deficiency in 5HT activity. There is no experimental 
evidence to support any of these possibilities although a change in uptake site 
number as a regulatory phenomenonhas not been observed in experimental 
manipulations (Graham & Langer 1988) 
1.5.2.4 Neuroendocrine studies 
The release of many anterior pituitary hormones is influenced, at least in the 
experimental situation, by 5HT (Meltzer et al 1982a; Tuomisto & Mannisto 
1985; Murphy et at 1986; Van Praag et at 1987; Cowen 1987; Montagne & 
Calas 1988; Van de " Kar 1991). Administration of agents which affect 5HT 
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neurotransmission, and the measurement of consequent hormone responses has 
been used to assess three features of psychiatric illness. Firstly abnormalities of 
neuroendocrine function in mental illness, secondly the function of central 5HT 
systems in depression or other disorders and thirdly the effects of treatment. 
a% 'Co % \c'o% . Neuroendocrine studies allow the so called "window on the brain" (Checkley 
1980; Meltzer et al 1982b). Such studies are made difficult by the absence of 
5HT receptor subtype specific agonist and antagonist drugs. Cowen et al (1990) 
have suggested that 5HT1a and 5HT2/lc receptors facilitate ACTH and PRL 
release but 5HT1a receptors alone have a more prominent role in GH secretion. 
These receptor subtypes may have variable pre and post synaptic functions , and 
opposing influences on hormone release, leading to variability and contradiction 
in results in different studies using different ligands. 
In general the cortisol response to 5HTP has been found to be augmented in 
unmedicated depressed patients (Meltzer et al 1984) and the response is 
inversely correlated to CSF 5HIAA concentration (Koytama et al 1987). It has 
been found to return to normal after antidepressant treatment of the depression 
(Meltzer et at 1984). A decreased PRL response to serotonergic agents has 
been found in depression (Heninger et at 1984) and this was normalised by 
treatment of the depression (Charney et al 1984; Cowen & Anderson 1991; 
Cowen & Charig 1987). A diminished GH response to both 5HTP and insulin- 
induced hypoglycaemia has also been found in depression (Koyo, & Meltzer 
1986). 
The involvement of 5HT in the abnormal cortisol regulation and dysfunction of 
the HPA axis in depression is an important line of research. Brown et al (1986) 
have suggested that failure of post dexamethasone suppression of cortisol is due 
to 5HT dysfunction but it is possible that the antithesis is true since cortisol is 
known to have effect on 5HT receptor subtype sensitivity and 5HT uptake 
(Biegon 1990). 
Meltzer (1990) has suggested that, although there is evidence of dysfunction in 
the 5HT system, results are difficult to interpret and no clear conclusions can be 
drawn about the status of pre or post synaptic 5HT mechanisms in depression on 
the basis of these studies. Further studies are needed to elucidate precise 
mechanisms and interactions with other neurotransmitter systems. 
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1.5.2.5 Post mortem neurochemical and receptor studies 
The studies discussed so far have given only indirect evidence of abnormalities 
of 5HT function occurring in depression. Studies of post mortem brain tissue 
have provided more direct evidence of putative neurochemical disturbances 
(Mann et al 1989; Mann eV o, \ 1986). 
Early studies of neurochemical changes in depression relied on brain material 
from suicide victims. For many reasons study of this material has drawbacks; 
poor documentation of mental state and previous therapeutic interventions, the 
possibility of drug overdose at suicide, post mortem delay and the fact that 
suicide itself, rather than depression, may have distinct associated 
neurochemical changes (Mann et al 1989) (Section 1.5.2.1). Shaw et al (1967) 
reported a reduction in 5HT concentration in hind brain of suicide cases who 
had previously been diagnosed as depressed. Pare et al (1969) replicated this 
but other studies have failed to do so. The changes in 5HIAA concentration are 
even more variable (Ferrier et al 1986; Stanley et al 1986). 
Studies of receptor changes have perhaps proved more robust. Stanley & Mann 
(1983) reported an increase in 5HT2 receptors in the frontal cortex of suicide 
victims and confirmed this in a later study (Mann et al 1986). Cooper et al 
(1986) found no significant changes in receptor density in frontal cortex or 
hippocampus of suicide victims and in a further study of depressed patients 
dying from natural causes (Crow et al 1984). In a study of 16 patients with 
depression, dying of natural causes but with "active" depression, Ferrier et at 
(1986) found a non-significant trend of an increase in 5HT2 receptors in the 
frontal cortex. A more significant increase in 5HT2 receptor concentration was 
found in a later study of similar patients (Yates et al 1990) and also by another 
group Arora & Meltzer (1989). 
The 5HT1 receptor has not been found to differ in depressed compared to 
control patient brains (Crow et al 1984; Cooper et al 1986). The 5HT1a 
subtype has not been found to change in the frontal cortex (Yates & Ferrier 
1990) but may be decreased in the hippocampus of depressed patients 
(Cheetham et al 1991). 
5HT1d subtype have been shown to be significantly increased in violent suicide 
deaths in the globus pallidus in one study (Lowther et al 1991). 
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Thus post mortem studies would add some weight to the hypothesis that there is 
a dysfunction of 5HT neurotransmission in depression. An increase in 5HT2 
receptors might suggest that there is an upregulation as compensation for 
diminished synaptic availability of 5HT or the increase could be the primary 
abnormality, suggesting excessive 5HT neurotransmission occurs in depression. 
The regulation of 5HT neurotransmission has already been discussed in some 
detail (Section 1.3.4. ) and it is likely that the apparent increase in 5HT2 
receptors in depression is a complex interaction of a variety of putative 
abnormalities of 5HT and dysfunction of other neurotransmitter systems. 
1.5.3. STUDIES OF 5HT ACTIVE AND OTHER TREATMENTS IN 
DEPRESSION 
1.5.3.1 SHT precursors 
There is little evidence that, given alone, tryptophan has antidepressant effects 
(Cole et al 1980) but it has been found to facilitate that effect of MAO inhibitors 
(Glassman & Platman 1969; Baldessarini 1984). It does not, however, 
potentiate the antidepressant response to tricyclic or other antidepressant 
treatments. 5HTP does appear to have antidepressant efficacy when given alone 
or in combination with other 5HT active drugs in major depression (Van Praag 
1981; 1984; Meltzer & Lowy 1987). It may also be useful prophylactically in a 
subgroup of depressed patients (Section 1.5.2.1) 
1.5.3.2 Studies on the mechanism of action of antidepressant drugs 
Many, but not all, effective antidepressant (AD) drugs have acute 
pharmacological effect on 5HT synaptic concentration and neurotransmission 
(Ogren & Fuxe 1985). However, it is apparent from clinical studies that 
therapeutic action takes 14 days or more of continuous treatment. This has been 
attributed to changes in neurotransmitter systems as a consequence of the acutely 
enhanced 5HT neurotransmission. Research into the therapeutic mode of action, 
and the search for understanding of the pathophysiology of depression, has 
consequently focussed on changes in 5HT neurotransmission after chronic 
administration of AD therapies. 
Studies of changes in monoamine turnover with AD treatment have provided 
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inconsistent results and no conclusions can be drawn to account for the 
therapeutic mechanism of action of these drugs (Hcninger & Charney 1987). 
Studies of changes in receptor processes have proved more consistent and the 
time course of such changes closely mirrors the delay in clinical effects. 
1.5.3.2.1 Receptor binding studies 
Chronic administration of many AD drugs has been found to cause a decrease in 
ß-adrenoceptor binding density in rat cortex and other areas (Charney et al 
1981). A decrease in 5HT2 binding sites is also frequently, but not invariably, 
found (Peroutka & Snyder 1980 
Charney 
et al 1981; Kellar et al 1981; Lloyd et 
al 1985; McDonald et a1 1985; ). More variable changes have been observed 
in the density of ligand binding to other 5HT and neurotransmitter receptor sites 
(Anderson 1983; Ogren & Fuxe 1985; Heninger & Charney 1987). 
Although decreased 5HT2 and ß-adrenoceptor binding is a common finding not 
all AD have the effect and the changes may be regionally specific. In addition 
ECT has been found to produce a consistent increase in 5HT2 receptor number 
although it too decreases ß-adrenoceptor density (Kellar et al 1981; Green et al 
1983; Kellar & Bergstrom 1983). Thus changes in 5HT2 receptor or ß- 
adrenoceptor density can not fully explain the mode of action of AD therapies. 
It is interesting that 5HT2 antagonists, which paradoxically cause down 
regulation of 5HT2 receptors, appear to have antidepressant properties 
(Reyntjens et al 1986). 
1.5.3.2.2 Behavioural studies 
Most AD, except SSRI appear to potentiate acl-adrenoceptor and postsynaptic 
DA receptor mediated behaviours, but decrease ß-adrenoceptor effects. 5HT1a 
receptor mediated behaviours are also diminished by chronic exposure to AD 
(Goodwin et al 1987). The effects of AD on 5HT2-mediated behaviour are less 
conclusive. Many AD drugs appear to decrease 5HT2-mediated functions but 
ECT enhances such behaviours (Goodwin et at 1984). 
As discussed above (Section 1.3.3.3) behavioural studies are difficult to 
interpret because of the interaction of multiple receptor, neurotransmitter and 
physiological effects and it may be for this reason that the functional effects of 
chronic AD administration are inconclusive. 
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1.5.3.2.3 Neurophysiological studies 
Studies of postsynaptic neuronal response have suggested that chronic AD 
treatment with tricyclic antidepressants (TCA) and ECT leads to potentiation of 
both inhibitory (De Montigny & 'Aghajanian 1978; De Montigny 1984) and 
excitatory responses (Menkes et al 1980). The effect on post synaptic responses 
is not seen after chronic SSRI or MAOI treatment (Aghjanian 1981; Charney et 
al 1981; Blier & de Montigny 1985). Chronic treatment with SSRI leads to 
decreased sensitivity of both the somatodendritic and terminal autoreceptors and 
treatment with MAOI changes the sensitivity of the somatodendritic autoreceptor 
alone (see Section 1.3.4.3). Neither of the autzreceptors is apparently affected 
by chronic administration of other antidepressant drugs or ECT (Blier & de 
Montigny 1980). 
Blier et al (1987) have reviewed electrophysiological evidence that suggests the 
net effect of any AD treatment is an enhancement of 5HT neurotransmission. 
TCA, "atypical" AD and ECT sensitise postsynaptic neurons to 5HT but have 
no effect on the presynaptic neuron, whereas MAOI and SSRI desensitise 
neuronal presynaptic autoreceptor responses ('cable 1.5.1). 
In keeping with this hypothesis is the fact that 5HT1a agonists, developed as 
anxiolytic drugs but which have antidepressant properties, desensitise the 
somatodendritic autoreceptor after prolonged use and enhance 5HT 
neurotransmission through an increase in DRN firing activity and direct 
postsynaptic receptor agonist effects . The drugs have no effect on postsynaptic 
5HT1a density or electrophysiological responses to SHT, although the agonist 
drugs themselves directly activate postsynaptic 5HT1a receptors (Blier et al 
1990a). 
Electrophysiological studies have also shown that chronic AD treatment leads 
to an increased sensitivity of al-adrenoceptor responses (Charney et at 1981; 
Aghajanian 1981) and a decrease in ß-adrenoceptor (Aghajanian 1981) and 
presynaptic DA receptor responses (Willner 1983). 
It seems then that in animal models alteration in 5HT neurotransmission is an 
important mode of action of AD therapies. Neuroendocrine challenge studies in 
humans have provided some evidence that these conclusions may hold true for 
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Table 1.5.1 The effect of antidepressant drugs and ECT on aspects of 511T 
neurotransmission 
Treatment Post-synaptic Terminal Somatodendritic Net effect 
type responsiveness autoreceptor autoreceptor on Siff 
responsiveness responsiveness neurotransmission -' .- 
TCA T00T 
ECT T00T 
MAOI 00T 
SSRI 0/1 1 .11 
5HT, a 00'. 1 
agonists 
Adapted from Blier ct al (1990) 
their action in normal and depressed patients although the results are much more 
conflicting (Meltzer et at 1982b; Charney et at 1984; Cowen & Andersson 
1986). The advent of PET scanning may allow further exploration of their 
mechanism of action and of the implication that this might have for the 
pathophysiology and aetiology of depression. The full effect of such treatments 
undoubtedly is much more complex than an isolated effect on 5HT 
neurotransmission. Some of the changes in other neurotransmitter systems have 
been mentioned above. It is apparent that the 5HT neurotransmitter system has 
intimate links with the noradrenaline neurotransmitter system (Sulser 1987). 
Changes in ß-adrenoceptors with chronic AD treatments requires an intact 5HT 
system (Nimgaor%kar et at 1985; Stockmeier et at 1985; Sulser 1987) and the 
reduction in 5HT2 receptors with AD is dependent on an intact noradrenaline 
system (Green & Deakin 1980; Gravel & de Monygny 1987). 
Despite enhancement of 5HT neurotransmission 
being 
the apparent mechanisms 
of action of antidepressants it is not possible to predict therapeutic response in 
depressed patients who appear to have a deficiency of 5HT function (Hasio et at 
1987; Joyce & Paykel 1989). There are also other effective antidepressant 
treatments which do not appear to have a mechanism of action, at least directly, 
through 5HT transmission. This, together with the fact that selective 5HT 
reuptake inhibitors have no marked superior clinical effect over less selective 
drugs, would suggest that the effect of antidepressant drugs is compatible with 
an important deficiency of 5HT function in depression but it does not mean that 
it is the only important factor. 
1.5.3.3 Lithium and electroconvulsive therapy 
Lithium is a useful drug in 50% of patients with major depression who do not 
respond to single therapy . It appears to have an enhancing effect on post- 
synaptic 5HT receptors (De Montigny et al 1983; Price et at 1989; Wood & 
Goodwin 1987). ECT, as discussed above, also has effect on 5HT turnover and 
receptors although whether it augments or diminishes function is less clear. It 
also has effect on many other neurotransmitter systems (Grahame- Smith et al 
1978; Green & Heal 1985). 
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1.5.4 CONCLUSIONS 
There is substantial evidence that there is a dysfunction of 5HT in depression. 
It is less clear exactly what this dysfunction is and the mechanism of action of 
therapeutic interventions. The data would suggest that a deficiency of synaptic 
5HT transmission is the most likely pathology and that antidepressant treatments 
correct this in a variety of different ways. Deakin (1989) has gone further to 
suggest that there is excessive 511T2 neurotransmission, probably by increase in 
ceceekair numbers in depression, and a deficiency of 5HT1 mediated function although 
not a decrease in numbers of these receptors. The action of antidepressant 
therapies is to rectify this imbalance. 
5HT may also have an important role in a variety of other psychiatric disorders 
(Coccoro & Murphy 1990). Thus it is unlikely that dysfunction of 5HT 
neurotransmission is the full explanation of the pathophysiology or the aetiology 
of depressive illness. It is clear from anatomical evidence that the 5HT system 
comprises several subsystems with regional and receptor specificity and 
independence of function, but with interactions, modulation and co-operation 
between receptor subtypes and perhaps system subtypes (Aghajanian et at 
` 1987; see Section 1.3.4.4). The 5HT system(s) also interact with 
other neurotransmitter systems, particularly the catecholamine system (Sulser 
1987; Yamamoto et at 1988), and it may be that clues to the further 
understanding and therapeutic advances may lie in study of these interactions. 
It is also clearly important to consider that "depression" may not be a single 
entity and, although at present defined by phenomenology and symptomatology, 
it may be that future classification on biochemical or pathological features may 
show that there are subtypes of the disease and that the syndrome of clinical 
depression may be the final common pathway of a variety of pathologies. 
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1.6 MENTAL ILLNESS, WATER BALANCE AND VASOPRESSIN 
Abnormalities of fluid intake, and sometimes fluid balance, are a feature of 
several mental illnesses and have been noted for over 60 years (Sleeper & 
Jellinek 1936). The importance of the clinical problem is three fold . Firstly 
that life threatening emergencies may arise with coma, seizures and sometimes 
death (Raskind 1974); secondly that a significant number of long term 
complications are associated with polyuria (Blum & Friedland 1983; Illowsky & 
Kirch 1988); and thirdly that many of the symptoms of milder hyponatraemia 
may be attributed to the mental illness (eg weakness, lethargy, anorexia, nausea) 
and consequently both the hyponatraemia and depression or other illness may be 
inappropriately managed. 
Estimates of the prevalence of hyponatraemia associated with mental illness are 
poor and much of the information and hypotheses of aetiology and 
pathophysiology rests on case reports. Crammer . (1991) noted 
that 10% of a hospital population of longterm mentally ill (mostly chronic 
schizophrenia) had polydipsia. Others have shown that polydipsia occurs in 
3-18% of chronic psychiatric inpatients and that 25-50% of these patients had 
episodes of water intoxication (Jose & Perez-Cruet 1979; Hariprasad et al 1980; 
Jos et al 1986). There is a mortality of about 10% over 2 years in patients with 
episodic water intoxication. Approximately 20% of deaths in schizophrenic men 
under 50 years old are attributable to the consequences of abnormal fluid 
balance (Vieweg et al 1985). 
The following disturbances of psychological function have been reported to have 
associated abnormalities of drinking behaviour and/ or water balance: - 
Unipolar depression 
Bipolar affective disorder 
Schizophrenia 
Other psychotic disorders 
Anorexia Nervosa 
Chronic alcoholism 
Organic brain syndromes 
In addition abnormal drinking behaviour is seen in the psychogenic polydipsia 
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syndrome and in some patients with attention seeking behaviours of either 
neurotic or psychopathic origins (Crammer 1991). 
1.6.1 FLUID INTAKE 
1.6.1.1 Thirst 
Alterations in thirst sensation or perception in association with mental illness 
have not been researched to any large extent. It is rarely advanced by patients 
as the reason for drinking, except in patients with lithium toxicity where renal 
tubular insensitivity to AVP leads to an increase in plasma osmolality and 
consequent osmotic stimulation of thirst (Singer et al 1972; Gold et al 1983d). 
Goldman et al (1988) have suggested that in chronic schizophrenic patients with 
polydipsia and intermittent water intoxication there is evidence of a decreased 
osmotic threshold for thirst although the 'sensitivity' (Section 1.1.2.1) remains 
unchanged. This did not explain the degree of fluid ingestion in half of the 
subjects whose desire for water did not seem to be related to osmotic stimulus. 
Many other drugs used in the treatment of mental illnesses (tricyclic 
antidepressant, phenothiazines) have anticholinergic side effects which cause a 
dry mouth and often lead to a moderate increase in fluid intake. Interestingly 
the SSRI are also noted to cause a dry mouth in 11 % of patients (placebo 7%) 
(Cooper 1988) despite the absence of anticholinergic activity in these serotonin 
selective drugs. 
Hypodipsia may be a feature of severe depressive illness and catatonic stupor 
where fluid intake is much decreased but no documentation has been carried out 
in these conditions. 
1.6.1.2 Non-thirst 
It has been documented that excessive fluid intake occasionally occurs in 
episodes of mania, not apparently explained by increase in physical activity or 
increase in thirst (Dingman et al 1957; Santy & Schwartz 1983; Zubenko et al 
1984; Crammer 1986; Keshavan & Keshavan 1986). 
There have been no studies of changes of fluid intake in depression. There are 
occasional case reports of polydipsia occurring in psychotic depression which 
resolves with adequate treatment of the affective disorder (Zubenko et al 1984). 
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Probably about 10% of psychiatric longstay patients exhibit polydipsia. In the 
search for physiological disturbances in schizophrenia Hoskins & Sleeper (1933) 
found marked differences in daily urine volumes between schizophrenic patients 
and normal controls. A greater than normal variation in daily urine output was 
also found. Other studies have shown that there may be a diurnal pattern with 
increasefluid ingestion from morning to evening, confirmed by weight increase 
through the day by as much as 0.5kg per hour, and plasma sodium changes 
(Delva & Crammer 1988). The reason for-this excessive fluid ingestion is-not 
always clear. Patients with persisting delusions may report that they were 
"told" to or that it is a means of cleansing (Dubovsky et al 1973; Alexander et al 
1973; Smith & Clark 1980; Hariprasad et al 1980) .A number of authors have 
reported that polydipsia increases when the psychosis is worse. This may be as 
part of the delusional construct, or it has been suggested that fluid ingestion may 
be anxiolytic (Lee et al 1989). It has also been suggested that polydipsia is a 
late development in schizophrenic pathology (Vieweg et al 1987). Others have 
shown that a personal or family history of alcohol abuse is associated with 
polydipsia in chronic schizophrenia (Ripley et at 1989). These authors 
suggested that the drinking behaviour may be learned and/or that mild 
overhydration is pleasurable to these schizophrenic patients. Other have 
suggested that the drinking behaviour is a facet of institutionalisation and 
boredom and when distracted the behaviour ceases. Some patients are 
apparently unaware of their excessive fluid intake (Hariprasad et at 1980). 
Sleeper & Jellinek (1936) found that schizophrenic patients with polydipsia were 
more likely than other schizophrenic patients to have a high IQ, fewer negative 
symptoms and more affective symptoms. These findings were confirmed by 
Lawson et at (1985) but were not by Kirch et at (1985). This latter group 
suggested that polydipsic schizophrenics were a subpopulation with more 
marked neurological disturbances. 
Psychogenic polydipsia occurs in a variety of psychological disturbances which 
are not psychotic or affective disorders. There has been little research done in 
this very mixed group of patients. It is poorly understood and difficult to 
manage (Barlow & De Wardener 1959; Crammer 1991). 
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1.6.2 WATER BALANCE 
1.6.2.1. Affective disorder, antidepressants and hyponatraemia. 
The psychiatric and medical literature frequently reports the occurrence of 
hyponatraemia in patients with depression, usually associated with 
antidepressant or other drug treatments (Sandiffer 1983). The following have 
been associated with case reports of hyponatraemia and depression. 
Fluoxetine Amitriptyline Nortriptyline Trazadone 
Fluvoxamine Phenelzine Desipramine 
Dothiepin Lofepramine Clomipramine 
Imipramine Amoxapine Doxepin 
The range of drugs, often with very different putative pharmacological and 
therapeutic modes of action would perhaps suggest that the pathology arises 
from the disease rather than the drug. 
There are no reports of hyponatraemia occurring with these drugs when used in 
non-depressive illness (eg. in dysaesthetic pain). This could, however, be a 
reporting deficit rather than confirmation of disease specifi y. Only occasional 
studies have sought to determine whether drug or illness was responsible for the 
hyponatraemia. Cohen et al (1990) rechallenged a depressed patient with 
Fluoxetine after 8 days drug free treatment of hyponatraemia. Serum sodium 
began to fall after 5 days and returned to normal again 5 days after 
discontinuation of the Fluoxetine. Staab et al (1990) did not find that 
hyponatraemia recurred in a patient who was rechallenged with Fluoxetine. It is 
interesting that in many case reports of hyponatraemia patients are often 
changed, without adverse effect, to antidepressants which have been previously 
reported as associated with hyponatraemia (Abbott 1983; Fort et al 1985). This 
may suggest either an idiosyncratic effect or a disease state-dependent 
mechanism. 
There have been few studies which have considered the possibility that affective 
illness leads to fluid retention and hyponatraemia. Hyponatraemia has very 
occasionally been noted to occur in drug free depression, usually when there 
have been psychotic features (Brown et al 1983; Zubenko et al 1984). 
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Mania, with psychotic features, has also been reported to be associated with 
hyponatraemia (Zubenko et al 1984). In both of these disorders the 
hyponatraemia resolves with appropriate treatment of the disordered mental 
state, together with fluid restriction. 
The mechanism of hyponatraemia associated with affective disorders is not 
clear although some studies have shown abnormalities in the osmotic regulation 
of AVP. Gold et al (1983c) - looked at the pattern of AVP secretion in response 
to a hyperosmotic stimulus in drug free patients with different classifications of 
affective disorder. They found no differences in patients and controls in 
baseline plasma or urine biochemistry or in plasma AVP concentrations. There 
was also no difference in 24 hour urine output. Although there was no apparent 
abnormality in the threshold for, or sensitivity of, AVP release in the depressed 
group as a whole 50% of those with a bipolar depression showed either a 
diminished sensitivity or increased threshold of release. The loss of osmotic 
sensitivity was, however, not clinically important (remained >0.2pmol /ml per 
mOsm/kg) (Section 1.1.2.1). The subjects with bipolar disorder who were in a 
manic episode showed no group differences compared to normal controls but 
50% of the subjects showed a slight increased sensitivity of AVP release and 
one subject had an abnormally high threshold. No abnormalities were found in 
patients who were euthymic or who had unipolar depression. Bipolar patients 
studied in both affective phases showed significant changes when depressed 
compared to during hypomania (Gold et al 1984). Lamelle et al (1990) found a 
decreased concentration of the AVP associated neurophysin in plasma of 
depressed patients compared to controls and suggested that this gave a more 
overall assessment of AVP secretion than isolated plasma AVP measurements. 
Crammer (1986) and Keshavan & Keshavan (1986) noted marked weight gain, 
sodium retention and sometimes oedema in some patients with mania. The 
metabolic abnormality appeared to be reversed in the depressive phase of the 
bipolar illness with demonstrable sodium excretion. It seemed likely that the 
metabolic changes were secondary to, and not aetiological in, the mood state since 
the sodium imbalance was observed shortly after the change in mental state 
(Crammer 1991). Changes in NA+/K+ ATPase activity in both bipolar and 
unipolar affective disorders have been the subject of much research in the 
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1970's. The findings from this work are inconclusive but point to a possible 
abnormality of sodium metabolism in affective disorders in a subgroup of people 
(El Mallakh 1983; Naylor & Smith 1981). 
Thus abnormalities of water balance in affective disorders remain largely unex- 
plained. It is not a common problem and may sometimes be drug associated. It 
may be that there is a subgroup of people who have abnormalities . -of either 
osmotically regulated AVP secretion or sodium metabolism and it is these indi- 
viduals who are at risk of hyponatraemia during acute illness whether or not 
they receive antidepressant medication. 
1.6.2.2. Psychosis and water intoxication 
Water intoxication in psychiatric patients most frequently occurs in association 
with acute psychotic, non-affective illness (Barahal 1938; Murphy & Zelman 
1964; Alexander et at 1973; Dubovsky et at 1973; Raskind et at 1975; Fowler 
et at 1977; Smith & Clark 1980). Whether these patients have polydipsia at 
other times and what percentage of those chronic psychiatric patients with 
polydipsia have intermittent episodes of water retention is not clear from the 
literature (Crammer 1991). In some of the reported cases AVP is detectable in 
the plasma (Goldman et at 1988, Delva et at 1990) in others SIAD does not 
appear to be a feature of the fluid retention (Smith & Clark 1980). 
Several drugs have been associated with the occurrence of hyponatraemia in 
these patients and may cause non-osmotic AVP release (Rao et at 1975; De 
Rivera 1975; Matuk & Kalyanaraman 1977; Vincent 1978) or possibly other 
modes of water retention (Deveraux & McCormick 1972; Mendelson & Deza 
1976) . Withdrawal and rechallenge studies have often not been able to show 
alteration in free water clearance after reintroduction of the drug (Miller et at 
1973; Fowler et at 1977; Kendler et at 1978; Kosten & Camp 1980). Two 
studies have however shown impaired free water clearance on rechallenge with 
thiothixene and haloperidol (Ajlouni et at 1974; Peck & Shenkman 1979). No 
measurements of AVP or of blood pressure were made in these studies and the 
results must be interpreted with caution. In contrast it has been noted that the 
commencement or increase of phenothiazines in acute psychosis has prevented 
dilutional hyponatraemia occurring in patients with previously documented 
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episodes (Dubovsky et al 1973; Hariprasad et at 1980). 
There have been several studies in normal people to explore further the 
possibility that these drugs cause AVP release. Dubovsky et at (1973) showed 
that haloperidol did not increase plasma AVP although plasma PRL did rise. 
Similarly Rowe et at (1979) showed no effect of fluphenazine on plasma AVP. 
In both of these studies blood pressure remained constant. Dorsa & Raskind 
(1985) found that chlorpromazine did not effect plasma AVP finless there was 
also a hypotensive effect. In a prospective study in five acute psychotic 
schizophrenic patients Dorsa & Raskind (1985) found that antipsychotic 
medication did not cause a rise in AVP, and two patients with initially elevated 
AVP had normal levels 24hr after drug administration. It seems therefore that, 
in the absence of hypotension, antipsychotic drugs are unlikely to lead to AVP 
secretion. In an unconfirmed study Kovacs et at (1957) found that 
chlorpromazine potentiated the peripheral effect of AVP irrespective of its 
origin. Dyball (1968) found that chlorpromazine inhibited AVP release in 
animals but other phenothiazines stimulated release. The possibility of drug 
induced effects on AVP needs still further investigation. 
The occurrence of hyponatraemia has been noted in drug free patients (Chinn 
1974; Nielsen 1974; Rendell et at 1978). Is it possible then that psychosis itself 
may cause AVP release? Dorsa & Raskind (1985) have reported that two of 
five acutely psychotic patients had elevated plasma AVP. Robertson (1979) 
reported two psychotic patients one with plasma AVP concentrations not related 
to plasma osmolality and one with a reset osmostat. Several other workers have 
reported the occurrence of SIAD in drug free psychotic patients (Dubovsky et al 
1973; Raskind et al 1975; Hariprasad et al 1980). It could be that the severe 
psychological distress and anxiety caused by the psychosis and hospitalisation is 
responsible for the elevated and abnormally regulated AVP (Mandell et al 
1964). This seems unlikely as AVP concentrations in hospitalised psychotic 
patients were found to be much greater than patients who were admitted with 
anxiety disorders (AVP concentration similar to normal controls) despite similar 
levels of anxiety shown by rating scales (Raskind et al 1977). 
Other authors have suggested that inappropriate release of AVP is a facet of the 
cerebral pathology of schizophrenia in a subgroup of patients (Vieweg et al 
1987). Some case studies have explored more thoroughly the pathology and 
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shown that an osmostat reset and possibly also non osmotic reset may occur 
(Hariprasad et at 1980). Hobson & English (1963) showed not only an 
abnormal excretion of a water load in a drug free schizophrenic patient but also 
evidence of acute autonomic dysfunction with increased core temperature and an 
absence of sweating. This supports the theory of Kirch et al (1985) who 
suggested that patients with polydipsia and water intoxication are a subgroup of 
schizophrenics with evidence of neurological damage and dysfunction. 
Goldman et al (1988) performed an-elegant study of chronic schizophrenic 
patients who were not acutely psychotic or water intoxicated but had had 
previous documented episodes of fluid intoxication. The control group were 
matched schizophrenic patients without fluid balance problems. The authors 
showed that subjects with polydipsia were unable to excrete a water load 
normally, despite suppression of AVP. This suggested that there was increased 
renal tubular sensitivity to AVP in these patients. A 5% saline infusion showed 
there to be no change in sensitivity of AVP release but a substantial reduction of 
osmotic threshold in those patients with polydipsia (mean change of 
11 mOsm/kg). 
Thus water intoxication in chronically disturbed psychiatric patients is a 
fluctuating and unpredictable abnormality although it appears to have some 
relationship with episodes of acute psychosis. The mechanism of the fluid 
retention is unclear and may be multifactorial. To overwhelm the excretory 
ability of the kidney more than 800ml1hr or 201 /day must be ingested. It would 
seem that excessive drinking is the primary abnormality in these patients but an 
extra mechanism, possibly abnormal AVP secretion and altered renal tubular 
sensitivity, leads to water intoxication. The reason for these abnormalities is not 
clear. Raskind et al (1975) have suggested that psychosis, inappropriate AVP 
secretion and polydipsia are linked by a common disturbance of CNS function, 
possibly dopaminergic hyperactivity. Recent reviews of the subject have further 
expanded the hypothesis (Illowsky & Kirch 1988; Crammer 1991). It is an 
attractive theory but does not explain all abnormalities, particularly a possible 
renal tubular hypersensitivity to AVP. Further research in this area is needed 
since 20% of deaths in young schizophrenics are due to fluid retention and the 
move towards community care may mean a delay in management. 
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1.6.2.3 Eating disorders and water balance 
Abnormal water balance has been noted in anorexia nervosa. Vigersky et at VC' Shoýn 
(1976) that partial CDI occurred in some patients with an inability to 
concentrate urine adequately and an impaired secretion of AVP. Gold et at 
(1983b) studied the response of AVP release to 5% saline infusion and showed 
that some patients with the abnormality. had an insensitivity of AVP to osmotic 
stimulation and others had random fluctuations of AVP release, independent of 
plasma osmolality. It has been postulated that the abnormal regulation of AVP 
release may be related to weight loss rather than to the pathology of anorexia 
nervosa . There have been occasional reports of water intoxication (Silber 
1984) which would suggest that there may be more than one pathology of fluid 
balance in this condition. There have been no studies of osmotic regulation of 
AVP in bulimia nervosa and no reports of abnormal water balance in these 
patients. 
1.6.3 MENTAL ILLNESS AND AVP SECRETION 
In 1978 Gold & Goodwin put forward the hypothesis that AVP was directly 
involved in affective illness. Their argument was based on the following: - 
a) That therapeutic drugs may change AVP activity and sensitivity. 
b) That AVP has effects on cognitive function. 
c) That central opiate release is increased by AVP, with implications for 
reward/punishment perception. 
d) That AVP has effect on circadian rhythms. 
The authors suggested that AVP function may be diminished in depression and 
augmented in mania. This group went on to try AVP analogs as a treatment for 
depression. They found subtle, but clinically insignificant improvements in 
cognitive function. (Gold et al 1979; Weingartner et al 1981). There was 
improvement in mood in only two of nine patients (Gold et al 1979; 1983c). 
Despite this apparent a1$e nce of therapeutic benefit there is evidence to suggest 
a role for AVP in the pathophysiology of depression and other mental illnesses. 
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1.6.3.1 AVP In the CSF of patients with mental illness 
AVP is present in the CSF although its origin, regulation and function are 
poorly understood in the human (Robinson 1983). Studies have suggested that it 
is probably not derived from plasma since intravenous infusion of large doses 
does not increase CSF concentration (Luerrson & Robertson 1980; Jenkins et at 
1980). CSF concentrations are high in CDI where plasma levels-are 
undetectable (Luerrson & Robertson 1980). This would suggest that " AVP - in the -, 
CSF derives from anatomically distinct population of cells . 
Immunohistochemical studies have shown that extra-hypothalamic AVP 
pathways, extending from PVN to 3rd and lateral ventricles, originate in 
magnocellular neurons different from those which project to neurohypophysis 
(Sofroniew 1980) and these pathways may be the source of CSF AVP. Animal 
studies have shown a circadian rhythm of AVP in CSF but not in plasma 
(Reppert et at 1981; Seckl & Lightman 1987). This is entrained by the 
light/dark cycle and is reversed in nocturnal animals. It appears that the rhythm 
may be controlled, and possibly directly secreted into the CSF, by the SCN 
(Reppert 1985). 
CSF AVP, like plasma AVP, increases with haemorrhage and vagal nerve 
stimulation but does not have a direct relationship with plasma or CSF osmotic 
change. Inappropriate concentrations of plasma AVP are reflected in elevated 
CSF levels (Luerrson & Robertson 1980). There are, therefore, some 
regulatory pathways in common. 
The function of CSF AVP is speculatory. It is possible that the CSF acts as a 
method of conveying peptides to distant areas of the brain (Robinson 198)and 
CSF AVP may be involved in memory consolidation or possibly reproductive 
activity in the female. Because of the circadian rhythm it may be involved in 
regulation of other behaviours which have a circadian pattern (Reppert 1985). It 
has also been thought to be involved in regulation of cerebral water permeability 
(Raichie & Grubb 1978) and in maintenance of intracranial pressure (Moto et at 
1978; Sorensen et at 1984). 
There have been few studies which have looked at CSF AVP or neurophysin 
levels in mental illness. All of these have considered data at isolated time 
points. The data is essentially contradictory and no pattern emerges to suggest 
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pathophysiological mechanisms. 
There is much evidence that in affective disorder there are disturbances of 
circadian rhythm with abnormalities of sleep cycle, endocrine secretory 
patterns, mood variations and temperature rhythms (Healy & Williams 1988; 
Gold et at 1988). It could be postulated, although with no evidence, that CSF 
AVP maybe related to this circadian dysrhythmia, either directly or indirectly 
via a common dysfunctional regulator ie the SCN. 
It has been noted that in psychotic, bipolar depression, CSF AVP 
concentrations were higher than in normal controls and in non-psychotic, 
bipolar, depression the levels were lower than in controls (Gold et at 1983a). 
The latter group returned to near normal levels on recovery. CSF AVP levels 
are normal in unipolar depressed patients. Concentrations in mania were not 
significantly different from controls in this study but were elevated in another 
(Sorensen et at 1985). These authors found similar levels to controls in 
depressed and schizophrenic patients (both acute and chronic). Another group 
have found significantly lower CSF AVP concentrations in both endogenous and 
non-endogenous depression but no significant changes in manic illness (Gjerris 
et at 1985). Legros et at (1983) found increased concentration of Neurophysin 
II (oxytocin-associated) in the CSF of bipolar depressed compared to unipolar 
depressed patients. This was confirmed in a second study (Linkowski et at 
1984) where lower neurophysin i (AVP associated) levels were seen in unipolar 
depression, and higher levels in bipolar depression, compared to controls. 
In schizophrenic patients Neurophysin I levels were found to be decreased but 
neurophysin II levels increased compared to controls. It is difficult to interpret 
Q°. ýcý. ýecl, 
changes iný 's proteins and extrapolate to changes in the peptide since 
disease states could possibly alter the normal relationships and regulatory 
mechanisms. 
Gold et at (1983c) observed that there was an abnormal plasma: CSF ratio of 
AVP in anorexia nervosa with much greater levels in the CSF than in plasma. 
These changes correlated with mild abnormalities in the osmoregulation of 
plasma AVP. The abnormalities were apparently corrected by weight gain. 
Abnormalities of CSF AVP in psychosis and anorexia Nervosa remain 
unexplained. Their correction with improvement of the disease state could 
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suggest aetiological importance but is more likely to suggest secondary changes 
to underlying pathology. 
1.6.3.2 Magnocellular secretion and plasma AVP 
AVP is known to be involved in the release of ACTH in conjunction with CRF 
(Lamberts et al 1984; Antoni 1986). It has been reported that in some de- 
pressed patients the cortisol ý response to AVP is absent (Krahn et al 1985) and it 
is postulated that the abnormalities of cortisol secretion in depression may be 
linked to dysfunctional hypothalamic AVP secretion (Schatzberg & Nemeroff 
1988; Meller et al 1988; Kathol et al 1989). Laruelle et al (1990) found no 
evidence of excessive AVP secretion in depressed patients with abnormal 
dexamethasone suppression of plasma cortisol. 
Abnormalities of plasma and osmoregulated AVP secretion in mental illness 
have been discussed above (Section 1.6.2). The return of plasma AVP 
concentrations to normal concomitant with improvement of psychosis may 
suggest a primary role for AVP in psychotic disorders. This is difficult to 
establish or refute without the availability of AVP antagonists or suppressants. 
It would seem than that AVP is important in disturbances of fluid balance, with 
potentially lethal consequences, in a variety of psychiatric disorders, at least in a 
subgroup of patients. Whether these marked abnormalities and the minor, less 
clinically significant changes have any role in the primary pathophysiology of 
the disturbed mental state is not resolved. It would seem more likely that 
disturbance of AVP regulation, both in plasma and CSF, is linked to the mental 
illness by a common abnormality in regulatory pathway. Whether abnormalities 
in 5HT neurotransmission are the common link is purely speculative since there 
is no research on this. 
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1.7 GENERAL HYPOTHESES 
1. That 5HT acts as a modulator in the physiological control of AVP secretion 
in response to changes in plasma osmolality. 
2. That manipulation of total brain 5HT content, synaptic availability of 5HT or 
5HT receptor sites by pharmacological means, may cause abnormalities in the 
physiological regulation of AVP secretion in response to osmotic stimuli. 
3. That this modulatory action is mediated through the 5HT2 or 5HTlc 
receptors. 
4. That there is an abnormality in the 5HT central nervous system of depressed 
people which, by itself or together with 5HT active agents used as 
antidepressants, may lead to an abnormality in the modulatory role of 5HT on 
AVP secretion in response to the osmotic milieu. 
The objective of this research was to explore the hypothesis that 5HT is 
involved in osmoregulated AVP secretion. This was to be approached in three 
ways. Firstly through studies in normal man, secondly by studies in depressed 
patients, as a putative disease model of 5HT neurotransmission, and thirdly to 
more extensively explore the effect of pharmacological manipulation of 5HT 
neurotransmission using an animal model of osmoregulation . 
AIMS 
1. To study the effect of pharmacological manipulation of central 5HT 
neurotransmission on osmoregulated AVP secretion in normal man. 
2. To study osmotic homeostasis in depression with reference to the effect of 
treatment and disease state on water balance, basal osmotic status and 
osmoregulated AVP secretion. 
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3. To explore the putative role of 5HT in osmoregulatcd AVP secretion in an 
animal model using 5HT active drugs with relevance to antidepressant therapy, 
with particular reference to the role of the 5HT2 receptor. 
4. To explore the possibility that 5HT directly modulates AVP secretion by 
study of 5HT receptors on the magnocellular neurons in the SON and PVN of 
the hypothalamus with particular reference to the 511T2 receptor subtype. 
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SECTION 2 
METHODOLOGY 
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2.1 THE ASSESSMENT OF OSMOREGULATION AND AVP 
SECRETION 
2.1.1 ASSESSMENT OF OSMOREGULATION IN MAN 
The osmoregulation of AVP secretion in man has been discussed in Section 
1.1.2.1. Two standard methods of dynamic assessment-of osmoregulatory 
function have been developed for clinical and research purposes. 
2.1.1.1 Water load test 
The study of osmoregulatory ability after ingestion of a standardised volume of 
water (20ml/kg) has allowed assessment of disorders of hypersecretion of AVP 
ie SIAD. The test has proved particularly useful where baseline pOS and pNa 
are within normal limits (Robertson 1981). 
Ingestion of the fluid leads to a fall in pOS of z5mOsm/kg within 15-30min 
(see Figure 2.1). In normal man this inhibits AVP secretion. The time to 
minimal AVP concentration in plasma will depend on basal concentration since 
circulating AVP has a half life of (2 20min. Under normal circumstances this is 
reached about 60min after plasma hypo-osmolality (75-90min after ingestion of 
fluid load). The suppression of AVP secretion allows diuresis which reaches a 
peak, with urine osmolality S 100mOsm/kg, at 60-90min after fluid ingestion. 
In normal man approximately 90% of the ingested water load is excreted within 
4 hours. Failure of either urinary dilution to < l00mOsm/kg or a cumulative 
urine output of <90% at Or is considered to be abnormal. 
Free water clearance 
Free water is the volume of urine which is excreted over and above that 
required for the excretion of the solute content of the urine. Solute excretion is 
controlled by proximal tubular function whilst free water excretion is dependent 
on the permeability of the distal tubule ie on AVP concentration. 
Calculation of free water clearance (CH20) is from the equation Uvol/time x(l- 
uOS/pOS). 
CH2O is a helpful measure of distal tubular function and as such an indirect 
measure of AVP function. 
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Figure 2.1 
The 9S percentiles in normal man of the effect of a standard oral water load (20m1/kg) on 
plasma osmolality (a), plasma AVP (b), urine osmolality (c) and free water clearance (d). The 
cumulative excretion expressed as % water load ingested is also shown (e). 
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Adapted from Robertson (1981). 
2.1.1.1.1 Protocol 
a) Subjects fasted and refrained from drinking from midnight. 
b) At 9AM venous cannula was inserted for blood sampling. 
c) After an equilibration period, sitting for 30min, a baseline blood sample was 
taken. The bladder was emptied and urine sample collected. 
d) Subjects drank 20m1/kg water over 15-20min. 
e) Blood samples were taken at 30,. 60,, 90, -120,480 and 240min after the start 
of fluid ingestion. 
f) Urine was collected at 60,90,120,180 and 240min after the start of water 
load ingestion. 
g) Blood pressure was monitored at 10min intervals in the first hour and 
thereafter at 30min intervals. 
h) A. subjective assessment of nausea was made at standardised intervals during 
the test by a visual analogue scale (10cm line) (Appendix 1). 
i) Subjects remained seated throughout the study except when voiding urine. 
Blood samples were collected as described in Section 2.2.5. Aliquots of plasma 
were stored at 4°C for measurement of pOS and pNa in batch. Aliquots of 
plasma for AVP measurement were stored at -40°C for extraction and assay. 
Urine samples 
At each time point the volume of urine collected was measured and a cumulative 
account was made as percentage of oral load ingested . 
Aliquots of urine for measurement of osmolality (uOS) and calculation of C, o 
were stored at 4°C. 
2.1.1.2 Hypertonic saline Infusion 
Section 1.1.2.1 has discussed in some detail the use of infusion of hypertonic 
fluids to assess AVP secretion. The rise in AVP concentration is linearly 
proportional to the change in pOS provided that the rate of change of pOS is 
<2% per hour (Robertson et at 1976; Thompson et at 1986). The measurement 
of pAVP and pOS during an infusion of hypertonic fluid allows calculation of 
the sensitivity of AVP secretion to change in pOS and the theoretical osmotic 
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threshold of AVP secretion. In normal man the sensitivity of AVP secretion lies 
between 0.2 and 0.7pmol/1 per mOsm/kg and the threshold of release is between 
282 and 289mOsm/kg (see Figure 1.1.2). 
Thompson et al (1986; 1991) have shown that a reproducible, linear response of 
AVP to change in pOS (r=0.96 p <0.001) is achieved during infusion of 5% 
NaC1(855mmol/1) at 0.06m1/kg/hr. Infusion at this rate increases pOS by 
15mOsm/kg over 2hr (approximately 2.5%). 
The test can be used to assess both hyper and hyposecretion of AVP (Baylis & 
Robertson 1980; Baylis 1983). 
2.1.1.2.1 Protocol 
a) Subjects fasted and refrained from drinking from midnight. 
b) At 9AM two venous cannulae were inserted, one for collection of blood 
samples and one for infusion. 
c) After 30min recumbent equilibration a baseline blood sample was taken. 
d) 5 %NaC1(855mmol/1) was infused at 0.06m1. kg/hr for 120min. 
e) Blood samples were taken at 30min intervals. 
f) Blood pressure was taken at 5min intervals. 
g) A subjective assessment of nausea was made at standardised intervals during 
the test by a visual analogue scale (10cm line) (Appendix 1). 
h) Subjects remained recumbent throughout the study. 
Blood samples were collected as described in Section 2.2.5. Aliquots of plasma 
were stored at 4°C for measurement of pOS and pNa in batch. Aliquots of 
plasma for AVP measurement were stored at -40°C for extraction and assay. 
In all studies of osmoregulation in this research subjects abstained from alcohol 
for 24hr before assessment. None of the subjects in Section 3 smoked 
cigarettes. Those in Section 4 who did smoke abstained from cigarettes from 
midnight prior to the study until after completion of the study. None of the 
subjects in Section 3 took any medication other than study drugs. Any 
concomitant drug therapy was noted for subjects in Section 4. 
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2.1.2 AN ANIMAL MODEL OF OSMOREGULATED VASOPRESSIN 
The osmoregulation of AVP in the rat is relatively well understood. As 
discussed in section 1.1.2.4 the regulation of AVP secretion in the rat has 
many similarities to man but there are some differences. There is perhaps some 
difference in the solute specificity of the osmoreceptor cells in the two species. 
In rats, but not in man, glucose stimulates AVP secretion but this occurs only at 
very high plasma concentrations (Robertson & Vokes 1991). AVP secretion in 
both rat and man is sensitive to change in plasma osmolality consequent to 
alteration of plasma sodium concentration. 
Dunn et al (1973) investigated dynamic osmoregulation of AVP secretion in the 
rat by intraperitoneal (IP) administration of fluid of differing sodium content and 
showed reproducible changes in pOS and pAVP. Basal pOS in this strain of rats 
was found to be 293.6±1.4 mOsm/kg and basal pAVP was 2.3±0.9pg/ml. 
The estimated osmotic threshold of AVP release in the rat was higher than in 
man, but remained remarkably constant and reproducible, at least within a 
particular strain (mean 292±1.3 mOsm/kg in Sprague-Dawley rats). The 
sensitivity of AVP release was shown to be a more variable feature but it was 
consistently greater in rat than in man (mean 1.3±0.5 pmolll per mOsm/kg). 
This has become a well accepted model of osmoregulation in the rat (Robertson 
& Vokes 1991) and has been used repeatedly by my fellow researchers (cg 
Charlton et al 1989) 
The time course of changes in pOS and pAVP, derived from Dunn et al (1973) 
is shown in Figure 2.2. A hypertonic stimulus causes a significant rise in pOS 
by 15min and there is still a marked elevation of pOS at 30min. Plasma AVP is 
similarly elevated at 15 and 30min but, unlike pOS, has returned to basal 
concentration by 60min after the IP stimulus. 
A hypotonic stimulus does not lead to a significant change in pOS until 30min 
after IP injection, however pAVP is significantly suppressed at both 15 and 
30min. 
*The injection of intraperitoneal fluid is obviously not solely an osmotic 
stimulus but causes pain, abdominal distension and perhaps psychological 
distress. These stimuli may perhaps have effect on osmoregulated AVP 
secretion but they have not been found to be a significant factor by these 
authors. 
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2.1.2.1 The protocol 
Intraperitoneal administration of 20m1/kg fluid using 23G needle into left iliac 
fossa. 
Hypotonic stimulus; distilled water 
Hypertonic stimulus; 3% NaCI approximately 1000mOsm/kg 
Normal control; 0.9% NaCl approximately 290mOsm/kg 
30min after fluid administration rats were killed by-guillotine, decapitafion. No "I 
anaesthetic was administered since this may cause elevation of pAVP due to 
effect of drugs or hypoxia (Toth 1937; Rose et at 1984). 
Trunk blood was collected by a heparinised funnel into chilled, heparinised 
tubes. Duplicate haematocrit samples were taken into heparinised 
microhaematocrit tubes (Hawksley, Surrey) and the remaining blood centrifuged 
within 30min at 2000g, 4°C for 15min for separation of plasma and cells. 
Plasma was aliquoted into 1.5m1 eppendorf tubes and stored as appropriate for 
analysis. 
Plasma samples 
0.5m1 aliquots of plasma were stored at 4°C and pNa and pOS were measured 
within 24hr in batche. 
1.2m1 aliquots of plasma were stored at -40°C for pAVP measurement. Samples 
were extracted and assayed within 3 weeks in batches of 20. (See Section 2.2.6 
for assay data). 
Collection of brain samples 
Guillotined rat heads were immediately dissected in the following manner. 
Scalp skin was cut to expose the cranium. 
Bone was removed using nail clippers to expose undamaged brain in situ. 
The olfactory bulb and optic nerves were severed from the forebrain using a 
sharpened spatula. 
The brain was then gently lifted intact from the skull and placed on a chilled 
petri dish. 
The frontal pole was removed using a scalpel blade. Olfactory cortex was 
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removed and remaining sample of frontal pole placed in two cppcndorf vials, 
chilled over solid CO2. Samples were frozen in liquid N2. 
The pituitary remained in the skull and the neurohypophysis was removed using 
forceps, placed in chilled eppendorf vials and frozen in liquid N2. 
Samples were stored at -80°C. 
Unless otherwise stated male, albino Wistar rats were used in this research 
work. The University Comparative Biology Centre provided some of the rats 
but some were 'imported', supplied by Bantin and Kingman ltd (Aldbrough, 
Hull). All were housed in the University facilities and kept in sawdust bed 
cages, in conditions of 12hr light/dark cycle, constant humidity and temperature 
with ab libitum food and fluid supplied. 
The research was carried-out under Home Office regulations according to 
project licence numbers PPL 50/00237 and PPL 50/0201. All Studies except 
Study 5.6 were carried out with Dr JA Charlton, appointed as the Project 
Licence Holder's deputy. 
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2.2 THE MEASUREMENT OF PLASMA AVP 
The plasma concentration of AVP was measured by means of a 
radioimmunoassay (RIA) the details of which are described by Rooke & Baylis 
(1982). 
2.2.1 RADIOIMMUNOASSAY :. 
The principle of measurement of a substance by RIA requires competitive 
binding of a specific antibody to an unknown concentration of antigen in a 
sample with a known concentration of radiolabelled antigen. 
A specific and sensitive antibody is added in excess to the sample containing 
antigen of unknown concentration. Labelled antigen of known concentration is 
added and binds in competition to the unlabelled antigen to the antibody sites. 
A second antibody is added which binds only to the first antibody and allows 
formation of a precipitate of antigen and antibody complex. After centrifugation 
the supernatant, with any unbound labelled antigen, is aspirated and the 
radioactivity of the precipitate is measured. The level of radioactivity, in 
comparison to that of the total labelled antigen added to the sample, is inversely 
related to the concentration of unlabelled antigen in the sample. Comparison of 
the radioactivity of the sample to radioactivity of standard concentrations of 
antigen allows estimation of the antigen concentration in the sample. 
2.2.2 ANTIBODY 
The antibody used in the assay of AVP was raised 'in house'. Synthetic AVP 
(Ferring AB, Sweden) was conjugated to bovine thyroglobulin using a 
carbodiimide reaction and injected into rabbits. Resultant antisera exhibited 
high cross-reactiviity to synthetic AVP (100%) and very low cross-reactivity to 
AVP related analogues (LVP, DDAVP, OXY) and had minimal reactivity with 
other hormones. 
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2.2.3 EXTRACTION FROM PLASMA 
The physiological plasma concentration of AVP is very low (0.3-lOpmol/1) and 
extraction with consequent concentration of AVP is required to measure the 
concentration in small volumes (1-2m1) of plasma. In this research AVP was 
extracted by absorption to magnesium trisilicate (Florisil 100-200 mesh: Sigma 
Chemical CO. ) Details of the procedure are in Appendix 2. At normal 
physiological AVP concentrations there is no significant loss of AVP in the 
extraction from 2m1 of plasma. Recovery progressively declines with increasing 
plasma concentration (86% @10pmol/l; 72% @ 100pmol/1) and with decreasing 
volume of plasma sample. 
2.2.4 THE ASSAY OF AVP 
2.2.4.1 Standard curve 
Estimation of unknown concentration in samples requires reference to AVP 
standards of known concentration. A standard curve is constructed with the 
following components: 
a) Total Count: The total radioactivity of the labelled antigen added to each 
standard and sample. 
b) Non-specific binding (NSB): The binding of the second antibody to labelled 
antigen and assay tube. 
c) Initial binding (Bd: The binding of labelled antigen to the specific antibody 
when no competing, unlabelled antigen (sample or standard) is present. 
d) Standards: Serial dilution of synthetic AVP of known concentration (final 
concentration 0.03-16 pg/assay tube) 
e) Interassay control: Sample of synthetic AVP prepared in batch. Final 
concentration 2pg/tube 
2.2.4.2 Samples 
Sample extract resuspended in assay buffer (800µ1). 
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2.2.4.3 Protocol 
a) Aliquots (2O01il) in triplicate of sample and AVP standards, and equivalent 
volume of assay buffer in Bo tubes, incubated with 100µ1 specific antisera for 
24hr, 4°C (final dilution antisera 1: 500,000). 
b) 100141 radiolabelled AVP incubated with all samples and standards 18hr, 4°C 
(0.5-1fmol 1 'IAVP per tube, 2000 cpm). 
c) 1001l goat antirabbit IgG incubated with samples and standards for 48-72hr, 
4°C (final dilution antisera 1: 200). 
d) Precipitate separated by centrifugation and supernatant, containing the free 
fraction, removed by aspiration. Residue ie the bound fraction, is counted on r 
counter. 
e) Ratio of specifically bound 125IAVP to total ' IAVP activity calculated for all 
standards and plotted as percentage of Bo against AVP standard concentration. 
(Standard Curve) 
f) Sample binding calculated and 200µl extract concentration estimated with 
reference to the standard curve. Actual sample concentration calculated as 
4xassay value in the volume of plasma extracted. 
Details of the assay protocol and reagents are found in Appendix 2. 
2.2.5 STORAGE OF SAMPLES 
All blood samples from humans were taken in chilled syringes, transferred to 
chilled heparinised tubes and centrifuged immediately at 2000RPM, 4°C 15min. 
Plasma was separated from cells and stored at -40°C. Plasma collected in this 
way, and extract residues can be stored for at least 3 months with no significant 
decrease in concentration of immunoreactive AVP. 
2.2.6 DETECTION LIMITATIONS AND REPRODUCIBILITY 
The sensitivity of the antibody allows detection of as little as 0. lfmol/assay 
tube. Using 2m1 plasma samples this allows a detection limit of 0.2-0.3pmol/l. 
The interassay control sample allows between assay comparison of standard 
curves and the use of extraction controls (@5pmol/1) ensures validation of 
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results. The coefficients of variation (cv) of extracted plasma will vary between 
assayeurs. 
The AVP samples in Section 3 were measured by Mrs P Rooke with an intra- 
assay cv of 9.7% and interassay cv of 15.3% @5pmol/l. Samples in Section 4 
were measured by Mrs C Holmes with intra-assay cv of 10% @2pmol/l and 
8.5 % 0lOpmol/1. Inter assay cv was 9.4 % @5pmol/l. 
The measurement of AVP concentration in rat plasma samples in Section 5 was 
carried out by me using Iml plasma aliquots. The extraction recovery was. 
reduced to 85-90% and the limit of detection was raised to 0.6pmol/l. Intra- 
assay cv was 22% @2pmol/1 and 20% @ 14pmol/1. Interassay cv was 17% 
@5pmol/l. 
For the purpose of data analysis all samples with AVP concentration below the 
limit of assay detection were attributed the value of the detection limit. 
2.2.7 DRUG INTERFERENCE WITH MEASUREMENT OF PLASMA AVP 
Experiments were carried out with pooled plasma, spiked with synthetic AVP, 
to study the effect of addition of the drugs to be used in this research on the 
assay and measurement of AVP concentration. 
2.2.7.1 Extraction experiments 
2.2.7.1.1 Fluoxetine 
Plasma concentrations of 51000ng (1µg) /ml of Fluoxetine and Norfluoxetine 
are found in humans during therapeutic use and do not exceed this concentration 
even in overdose (see tables 3. and 3. ). Addition of 1µg/m1 and 10µg/ml of 
these drugs alone or in combination had no significant effect on the recovery of 
AVP measured @lpmol/1 or @5pmolll. 
Since rats will receive much greater doses of fluoxetine (10mg/kg) higher 
plasma concentrations would be anticipated. Assuming full absorption and 7% 
blood volume a plasma concentration of approximately 140µg/ml might be 
found. However, in a small study, plasma concentration in rats was found to be 
0.486µg/ml at 30min after 10mg/kg IP and declined thereafter (Fluoxetine 
investigators manual 1990). Addition of 140µg/ml of Fluoxetine to AVP spiked 
90 
plasma lead to a 32 9 greater estimation of AVP @1pmol1(p <0.001) and 12% 
higher estimation @10pmol/1(p <0.001). 
2.2.7.1.2 Ritanserin 
The addition of 14µg/m1 of Ritanserin to pooled, AVP spiked plasma had no 
effect on the measurement of low concentrations of AVP but increased the 
measurement of high concentration (@ lOpmol/1) by approximately 10% 
(p=0.006). .; _ 
2.2.7.1.3 DOI (1-(4-iodo-2,5-dimethoxyphenyl)-2-aminopropane 
hydrochloride) 
DOI, 141ig/ml plasma, had no effect on the measurement of AVP by RIA assay 
at high or low concentration of AVP. 
2.2.7.2 Addition to AVP standard curve 
Fluoxetine (14014g/ml), Ritanserin (14µg/ml), DOI (14µg/ml) or equivalent 
volume of assay buffer were added to each concentration of AVP in the standard 
curve and the AVP assay carried out in the usual way. 
Figure 2.3 shows the effect of each drug on the binding of labelled AVP. 
Whilst Ritanserin and DOI appear to have no significant effect on binding, 
Fluoxetine decreases binding, most noticeably at low concentrations of AVP. 
2.2.7.3 Discussion 
The effect of high concentration of Fluoxetine on the measurement of AVP by 
RIA is intriguing. It is known that measurement of Fluoxetine in plasma 
requires careful storage and assay because the compound binds to a great variety 
of substances including plastic. It is unlikely that Fluoxetine increased the assay 
measurement of AVP by an increase in extraction recovery. It is more probable 
from these experiments that at least some Fluoxetine was extracted with AVP by 
binding to florisil, and then bound to the specific antibody to AVP in the assay 
and consequently lowered binding to AVP. This interference lead to a falsely 
high estimation of AVP concentration, particularly at low plasma concentrations 
of AVP and high concentrations of Fluoxetine. 
In the research that follows it is likely that in samples collected from humans 
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Figure 2.3 
The effect of the addition of Fluoxetine (140µg/m1) (*), Ritanserin (14µs/ml) (v) or DOI 
(14µg/m1) (+) on the binding of ['"I]AVP in the standard curve for the assay of AVP. 
and rats much of the Fluoxetine in plasma has bound to the plastic sample tube 
and little remained to interfere with the assay of AVP. In addition Fluoxetine 
appeared to interfere with the assay of AVP only at high concentrations, 
approximately 700 fold that in human plasma and probably 300 that in rat 
plasma. The effect of Fluoxetine on the measurement of AVP must, however, 
be taken into consideration in all experiments in this research. It is possible that 
Fluoxetine in plasma samples may cause up to a30% increased estimate of AVP 
concentration @lpmol/l (ie assay value of 1.3pmol/l when true plasma 
concentration lpmol/1), and a 12% higher estimate of plasma concentration 
lOpmol/l (ie assay value of 11.2pmol/1 when true plasma concentration 
lOpmol/1). The effect is likely, however, to be yg much less than this in both 
human and rat samples. 
The effect of Ritanserin on the measurement of plasma AVP has not been 
explained by interference with the assay of AVP. The effect was numerically 
very small, although statistically significant, and may well have occurred by 
chance. In the experiments that follow some consideration must be given to the 
effect of Ritanserin on the measurement of plasma AVP. It could be anticipated 
that a maximum error of 10% overestimation of AVP concentration may be 
made @lOpmol/l (ie an assay value of Ilpmol/1 when true plasma concentration 
was lOpmol/1). 
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2.3 SEROTONIN ACTIVE DRUGS 
2.3.1 FLUOXETINE 
Nomenclature 
Fluoxetine hydrochloride 
(f)-N-methyl-3-phenyl-3-[(a, a, a-trifluoro-p-tolyl)-oxy] propylamine 
hydrochloride 
C17H18F3NO-HCL 
LY110140 
Fluoxetine is one of a group of chemically unrelated drugs which selectively 
inhibit the reuptake of 5HT from the synaptic cleft into the neuron, so called 
selective serotonin reuptake inhibitors (SSRI). 
2.3.1.1 Absorption, metabolism and pharmacokinetics (Benfield et al 1986) 
Studies in man have shown that Fluoxetine is well absorbed with > 75 % 
bioavailability after oral administration. Fluoxetine is metabolised in the liver, 
by N-demethylation, to Norfluoxetine. This metabolite is also a SSRI but has 
approximately 25% of the potency of its parent compound. Peak plasma 
concentration of fluoxetine occurs 6-8hr after a single oral dose but peak 
norfluoxetine concentration occurs after 24-96hr. Steady state plasma 
concentrations are reached after 2-4 weeks of daily oral dosing. 
Administration of a single dose of 10mg/kg IP to rats resulted in highest plasma 
concentration (0.486µg/ml) at 30min after dosing declining to 0.03911g/ml at 
24hr. Norfluoxetine concentration increased slowly to a similar concentration 
as fluoxetine at 4hr after dosing. Peak tissue concentration of fluoxetine 
occurred lhr after IP administration and were 200-1000 times that of plasma. 
In man after a 40mg oral dose the t, h Fluoxetine is 1-4 days and t/ 
Norfluoxetine 7-9 days. In rats after 10mg/kg IP t, is 26hr for Fluoxetine and 
40hr for norfluoxetine. 
The drug is excreted mostly in the urine and only 2.5 % is excreted as 
unmetabolised Fluoxetine. 
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2.3.1.2 Pharmacodynamics 
The effect of Fluoxetine on 5HT reuptake has been demonstrated in vitro by the 
complete inhibition of [3H]5HT uptake into rat brain synaptosomes (Wong et al 
1975) and into human brain slices (Harms 1983). Fluoxetine has been shown to 
have a potency of effect similar to clomipramine and to have little effect on NA 
and DA uptake processes with 2-300 fold lower potency for these sites that the 
5HT uptake site (Wong et al 1974). 
In vivo studies in animals have confirmed the effect on 5HT uptake by 
demonstration of prevention of pCA induced depletion of brain 5HT, an effect 
which depends on the reuptake site as a means of penetrating into the 5HT 
neuron (Fuller et al 1975). In vivo studies have also shown the highly specific 
nature of the effect on 5HT uptake sites compared to NA sites and in 
comparison to other drugs such as clomipramine (Wong et al 1975; Fuller et al 
1975; Bowsher et al 1985). Phase I clinical studies in normal man have shown 
that Fluoxetine is a specific inhibitor of 5HT uptake in vivo (Lemberger et al 
1978; Bowsher et al 1985; Bergstrom et al 1988). 
Dose response studies in animals have shown that fluoxetine has significant 
effect on 5HT uptake into rat blood platelets at lmg/kg with maximal effect 
(50% inhibition) at 10mg/kg (Horng & Wong 1976). In mice an ED,, of 
0.4mg/kg was found to prevent pCA brain 5HT depletion. Complete prevention 
was achieved with doses of 2mg/kg (Fuller et al 1974a). 
Time response studies have shown significant effect of Fluoxetine on 5HT 
uptake (20% inhibition) within 15min of intraperitoneal (IP) injection with 
10mg/kg. Maximal inhibition (57%) occurred at 4hr after drug administration 
and persisted for a minimum of 24hr after one dose administration (Wong et al 
1975). 
Wong et at (1975) have shown that Fluoxetine has significant regional variation 
in effect on 5HT uptake. Synaptosomes prepared in rats pretreated with 
Fluoxetine showed that cortical and brainstem were most affected with 70% and 
50% reduction in 5HT uptake respectively. Uptake inhibition in the 
diencephalon was 23 % whilst in the cerebellum there was no apparent effect on 
5HT uptake. The regional concentration of Fluoxetine in brain tissue is not, 
however, variable (Fluoxetine investigators manual 1990). 
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2.3.1.2.1 Receptor affinity 
In vitro studies in rats have shown that Fluoxetine has very weak affinity for 
adrenergic, histaminergic, opioid, muscarinic, DA, GABA and SHT receptors 
(Wong et al 1983). 
2.3.1.2.2 Effect of Fluoxetine on SHT metabolism 
In vivo studies have shown that synaptic 5HT concentration is increased after 
Fluoxetine administration (Marsden et al 1979; Guan & McBride 1988). 
Fluoxetine appears to reduce 5HT turnover (ratio 5HIAA to 5HT) after acute 
treatment. Fuller et al (1974b) found that brain concentration of 5HIAA was 
significantly reduced one hour after 10mg/kg IP with maximal reduction at 4hr. 
The effect on 5HT turnover of this single treatment lasted 24hr. Dose response 
studies showed that 2.5mg/kg had a significant effect but 10mg/kg produced 
maximal effect of 5HT turnover. These effects were regionally specific with 
significant reduction in 5HIAA concentration occurring only in the cerebral 
hemispheres and midbrain. 
Fluoxetine has also been shown to inhibit 5HT synthesis from tryptophan, in 
part due to non-competitive inhibition of tryptophan uptake (Hwang et al 1980; 
Bymaster & Wong 1977). 
The effects of chronic treatment will be discussed in Section 
r. 
2.3.1.3 Adverse effects (Wernicke 1985) 
The most frequently occurring adverse effects in man are nausea, nervousness 
and insomnia. These occur in 15-25% of drug users. Headache is occasionally 
a moderately severe side effect but occurs infrequently. The occurrence of 
hyponatraemia will be discussed in Section 3.1. There are no apparent adverse 
effects in rats of daily doses up to 10mg/kg other than a decrease in daily food 
intake with reduction in weight gain. This observation has now been exploited 
clinically with the use of Fluoxetine as an appetite suppressant. 
The data sheets for Fluoxetine are presented in Appendix 3. 
Fluoxetine and Norfluoxetine were generously provided for the purposes of this 
research by Lilly Research (Eli Lilly & Co), Windelsham, Surrey. 
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Solutio of fluoxetine used for studies in Section 5 were made from crystalline 
solid as follows: - 
1mg/ml in 0.9%NaC1 pH 6.9 (Study 5.2) 
10mg/ml in water pH 6.8 (Study 5.2) 
10mg/ml in 10% ethanol in 20mMol t taric acid pH 3.0 (Study 5.4 and 5.7) 
Plasma concentration of Fluoxetine and Norfluoxetine were measured in Study 
3.1 by reverse phase HPLC with UV detection based on Lilly protocol HPA-O 
(Orsulak et al 1988), and in Study 3.2 by Gas chromatography with electro 
capture detection based on Lilly protocol NHC-3 (Nash et al 1982). 
Measurements were made on 2ml plasma samples stored at -20°C. All samples 
were analysed by Simbec research Ltd, Glamorgan (courtesy Lilly Research). 
2.3.2' RITANSERIN 
Nomenclature 
Ritanserin 
6-[2-[4-[bis(4-fluorophenylOmethylene] -1-piperidinyl]ethyl] -7-meth yl-5H- 
thiazolo[3,2-a]pyrimidin-5-one 
R 55667 
2.3.2.1 Pharmacodynamics 
Ritanserin is a derivative of methylenepiperidine and has been characterised by 
receptor binding studies as a potent 5HT2 antagonist (Leysen et al 1985). The 
most sensitive expression of central 5HT2 antagonism in vitro has been found to 
be reversal of tryptamine-induced lesions. The ED50 of Ritanserin for 
inhibition of clonic seizures of forepaws in rats was 0.037mg/kg and body 
tremors 0.11mg/kg. Both phenomena were completely inhibited by a mean dose 
of Ritanserin 3.5 times greater than the ED,, (Awouters et at 1988). 
Time response studies showed that Ritanserin had significant antagonist effect 
30min after subcutaneous injection (SC) but peak responses were achieved 2-4hr 
after SC injection (Awouters et al 1988). 
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2.3.2.1.1 Receptor binding 
Leysen et al (1985) showed that Ritanserin had low affinity in rat frontal cortex 
tissue for 5HTla and 5HT1b receptors and very low affinity for other 
neurotransmitter receptor types. It has been shown to have a relatively high 
affinity for the rat 5HT1c receptor subtype (Royer 1988). Receptor subtype 
specificity is maintained in rats up to doses of 10mg/kg (Awouters et al 1988) 
and perhaps central functional 5HT2 receptor specificity up to 160mg/kg in 
animal studies (Janssen 1985). 
Ritanserin was obtained from Cambio, Cambridge. The data sheets are 
presented in Appendix 3. 
Solution of Ritanserin for use in the studies of Section 5 were made from 
powder in the following manor: - 
r 
1mg/ml in 4.3% ethanol 5OmMo1 tgtaric acid pH 2.7 (Study 5.3) 
1mg/ml in 10% ethanol 20mMol tartaric acid pH 3.0 (Study 5.7) 
2.3.3 DOI 
Nomenclature 
DOI hydrochloride 
(f)-1-(4-iodo-2,5-dimethoxyphenyl)-2-aminopropane hydrochloride 
2.3.3.1 Pharmacodynamics 
DOI is a derivative of the hallucinogen 1-(2,5-dimethoxyphenyl)-2- 
aminopropane. It provokes reproducible, dose dependent behaviour effects in 
rats, termed "wet dog shakes". ED50 0.17mg/kg SC with maximal effect of 
0.4mg/kg SC (Arnt & Hytel 1989). Acute IV administration in vivo in rats 
decreased DRN firing with complete inhibition at 0.1mg/kg (Wright et al 1990). 
IV administration has been found to stimulate ACTH secretion with peak effect 
at 10min after administration continuing for 60min. Dose response studies 
showed ED50 of 0.2mg/kg iv with maximal effect of 1mg/kg (Bagdy et al 1989). 
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2.3.3.1.1 Receptor binding 
s 
Studies in rats have shown that DOI has a high affinity for binding sit labelled 
by the 5HT2 antagonist ketanserin and a very low affinity for 5HT1a and 
5HT1b sites (Shannon et al 1984; Pierce & Peroutka 1989). These studies 
suggested that DOI might have higher affinity for a subpopulation of 5HT2 
receptors, the 5HT2a site. DOI also has affinity for the 5HT1c receptor (Royer 
& Karpf 1988; Hoyer 1988) although this is probably 40-fold lower than its 
affinity for the 5HT2 receptor (Titeler et al 1988). It has a very low affinity for 
receptors of other neurotransmitters (Pierce & Peroutka 1989'. 
2.3.3.1.2 Effect of DOI on brain SIHT 
Wright et al (1990) have shown that acute administration of DOI 0.1mg/kg 
decreased frontal 511T concentration by 40% and 5HIAA concentration by 32%. 
The data sheets for DOI are presented in Appendix 3. DOI was obtained, under 
Home Office licence, from Semat, St Albans, Herts. 
Solution for use in experiments in Section 5 were made from solid as follows: 
1mg/ml in water pH 6.3 (Study 5.5) 
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2.4 OSMOLALITY 
The osmolality of plasma and urine samples was measured by depression of 
freezing point using a Roebling osmometer. The osmometer was standardised 
to 300mOsm/kg. Intra-assay cv 0.32% @293mOsm/kg. 
2.5 PLASMA SODIUM 
Plasma sodium concentration was measured by an ion selective electrode 
(Hitachi 718) by the Department of Clinical Biochemistry, Royal Victoria 
Infirmary, Newcastle upon Tyne. 
2.6 HAEMATOCRIT 
Blood haematocrit was measured by drawing duplicate samples of blood into 
heparinised microhaematocrit tubes (Hawksley, Lancing, Sussex) and 
centrifugation in Hawksley microhaematocrit centrifuge . Samples were 
measured on a Hawksley microhaematocrit reader. 
2.7 MEASUREMENTS ON RAT NEURAL TISSUE SAMPLES 
2.7.1 5HT CONTENT AND TURNOVER 
5HT and 5HIAA were measured in homogenates of rat brain samples and 
neurohypophyses by HPLC with electrochemical detection according to the 
method of Wagner et al (1982). All assays were carried out by Mr M Leitch, 
Department of Psychiatry, University of Newcastle upon Tyne. The ratior of 
5HIAA; 5HT is considered to be a good index of the rate at which 5HT is 
released into brain synapses and thus an indirect measure of 5HT 
neurotransmission (Reinhard & Wurtman 1977). 
2.7.1.1 Membrane preparation 
Tissue samples were homogenised in mobile phase buffer using a ultrasonic cell 
disrupter. 
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An aliquot of homogenate was taken for protein estimation. The remaining 
homogenate was centrifuged @10,000g for 5min and the supernatant collected 
and stored at -80°C until assay. The pellet was discarded. 
2.7.1.2 HPLC conditions 
Autosampler: Gilson 231/401 
Injection loop: 20141 
Pump: Gilson 302 flow 1.5m1/min 
Inline filter: Rheodyne 0.2µm 
Column: Spherisorb 5µm ODS2 25cmx4.6mm 
Detector: AmoR ECD Potential +0.75V Range IOnA 
Standards: 5HT and 5HIAA lOpmol/20µ1(Sigma 
Detection limit: 0.5pmol/201i1 
Mobile Phase : 50mmol NaH2PO4 
1mmol NaCI 
0.3mmol Octane sulphuric acid 
14 % methanol 
pH 3.3 (H3PO) 
2.7.2 HOMOGENATE LIGAND BINDING 
The binding of radiolabelled ligands to 5HT receptor subtypes in rat brain 
homogenate preparations was performed by Mr A Leake, MRC Neurochemical 
Pathology Unit, Newcastle General Hospital. 
The assessment of the 5HT1a and 5HT2 receptor site binding was by an 
adaptation of the method of Leake et at (1991). The variations in buffer 
constituents, incubation conditions and specific high affinity displacers are 
outlined below. 
2.7.2.1 Membrane preparation 
Brain tissue was homogenised in 50mmol Tris 0.25m sucrose pH 7.4 at 4°C 
using a teflon pestle. The suspension was centrifuged @1000g 10min 4°C and 
the aspirated supernatant was centrifuged @35,000g 10min 4°C. The 
supernatant was discarded and the pellet resuspended 1: 5 vol/wt buffer using an 
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ultrasonic cell disrupter. 
An aliquot of homogenate was taken for protein estimation and remaining 
sample stored at -40°C until assay. 
2.7.2.2 Receptor binding assay 
All incubations were performed in quadruplicate with total assay volume of 
4O0µ1. 
5HT1a: [3H]8OHDPAT binding (8-hydroxy-2(di-n-propylamino) tetralin) 
(Amersham International). 
Homogenate was diluted to 1: 50 vol/wt with buffer A (Appendix 4). 
8nmol/1 [3H]8OHDPAT (240Ci/mmol) was used to estimate 5HT1a binding. 
Non-specific binding was measured in the presence of 21imol/1 unlabelled 5HT. 
Samples were incubated for 30min at 25°C. 
5H1'2: [3H]ketanserin binding (NEN). 
Homogenate was diluted to 1: 50 vol/wt with buffer B (Appendix 4). 
8nmol/1 [3H]ketanserin (6OCi/mmol) was used to estimate 5HT2 binding. Non- 
specific binding was determined in the presence of 50µmol/1 methysergide. 
Samples were incubated for 15min at 37°C. 
All samples were filtered through Whatman GF/B filters with vacuum assistance 
and washed with 3x5ml of buffer B 4°C. Filters were equilibrated with 
scintillant for 48hr 20°C prior to counting on 0-scintillation counter. 
Results were expressed as fmol/mg protein. 
2.7.3 PROTEIN ASSAY 
The measurement of the protein content of samples for HPLC and ligand 
binding was carried out using the method of Bradford (1916). This relies on 
measurement of the change in optical density, proportional to the protein 
concentration, of a protein sensitive dye (Appendix 5). 
101 
SECTION 3 
STUDIES OF THE EFFECT 
OF A 5HT REUPTAKE INHIBITOR 
ON OSMOREGULATED AVP SECRETION 
IN NORMAL MAN 
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INTRODUCTION 
The evidence discussed in Section 1.4 has suggested that 5HT may have 
physiological importance in the maintenance of water balance. As yet there has 
been little work in humans to explore further the physiological implications 
either in normal man or in possible disease states. This has, to some extent, 
been because of the lack of specific and safe serotonergic or 5HT antagonist 
compounds. The availability of SSRIs (eg. Fluoxetine), used clinically in the 
management of depression, has allowed further exploration of this area. The 
recent reports of hyponatraemia and possible SIAD associated with clinical use 
of Fluoxetine has made research into the role that 5HT may have in 
physiological AVP release particularly timely 
Hyponatraemia occurring, sometimes with profound severity (< 110mmol/1), in 
association with the treatment of depression by Fluoxetine is a rare occurrence. 
During intensive drug monitoring in the USA 20 cases were reported to the drug 
company (Eli Lilly, Indianapolis). The Committee on Safety of Medicines 
(London) have received fewer than 10 reports. The literature contains six 
reports of nine patients (Hwang & Magraw 1989; Cohen et al 1990; Gommans 
& Edwards 1990; Staab et al 1990; Marik et al 1990; Vishwanath et al 1991). 
The reports suggest that hyponatraemia occurs early and persists, with 
presentation of patients from 1-60 days after the commencement of 20-80mg 
Fluoxetine treatment. Approximately 40% of reported patients were taking 
concomitant diuretic therapy. 
Many of the reports have occurred in patients over 50yr suggesting that age is 
an additional risk factor. However, since Fluoxetine has few anticholinergic 
and antihistaminergic side effects it has been particularly recommended for the 
treatment of depression in the elderly, and consequently there may be over- 
representation of older people in reports of hyponatraemia. Some cases of 
younger people with Fluoxetine associated hyponatraemia have been reported. 
There has been very little exploration of the possible mechanism(s) for the 
occurrence of hyponatraemia. Most literature reports are of patients who 
appeared to be clinically normovolaemic with excretion of urine which was 
inappropriately concentrated with respect to plasma osmolality, thus suggestive 
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of SIAD. Patients usually responded to fluid restriction alone although oral 
sodium was given to some who had a particularly slow rate of rise of plasma 
osmolality. Some patients responded to fluid restriction with return to normal 
plasma sodium concentration in 48hr, but most took 5 days to return to normal 
osmotic status. 
The majority of patients were noted to have normal renal, adrenal and thyroid 
function and none were noted to be polydipsic. In addition nausea was not 
specifically mentioned as a prominent symptom in any of the case reports. 
In one of four patients reported by Cohen et at (1990) rechallenge with 
Fluoxetine was carried out. Hyponatraemia recurred within 5 days and 
worsened to 10 days when Fluoxetine was ceased. Staab et at (1990) reported 
the rechallenge of a patient who had developed pNa 125mmol/l within 20 days 
of treatment with 80mg Fluoxetine daily. Reintroduction of this dose had no 
significant effect on pNa up to two months of subsequent follow-up. 
Vishwanath et at (1991) documented the occurrence of pNa 122mmol/l two 
month after the start of Fluoxetine treatment at the same dose which had been 
used in a previous episode of depression with no adverse effect. 
None of these studies explored water balance and osmoregulated AVP secretion 
in these patients either during the episode of hyponatraemia or after apparent 
recovery. In addition there has been no attempt to identify whether the drug or 
disease state (depression) alone may be responsible for the occurrence 
hyponatraemia or whether the two are additive. 
The first step in further exploration of this phenomena is to study the effect of 
Fluoxetine in normal man. 
GENERAL HYPOTHESES 
1. That Fluoxetine increases central 5HT neurotransmission in normal man. 
2. That increase in 5HT activity modulates osmoregulated AVP secretion in 
normal man. 
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STUDY 3.1 TIIE EFFECT OF A SIIT REUPTAKE INHIBITOR, FLUOXETINE, 
ALONE AND IN COMBINATION WITH A DIURETIC, ON WATER BALANCE IN 
NORMAL MAN. 
SPECIFIC AIMS 
1. To investigate the effect of an increase in SHT neurotransmission, by 
reuptake inhibition, on the excretion of an oral water load in normal man. 
2. To investigate the possible additive effect of a diuretic on 5HT modulated 
water balance in normal man. 
MATERIALS AND METHODS 
Subjects 
Thirteen healthy male volunteers aged 18 to 40 yrs gave written, informed 
consent for the study. Exclusions were made on the basis of serious illness (past 
or present), previous head injury or bacterial meningitis, regular medication or 
clinical abnormality of serum electrolytes, liver function tests, lipids, blood 
glucose, full blood count or urinalysis. 
Treatments and study design 
The treatment order for each volunteer was randomised independently of the 
researchers. Each subject took a treatment before breakfast, once daily for 7 
days. There was a minimum washout period between treatments of 4 weeks. 
All adverse symptoms were recorded and a direct measure of nausea was made 
daily by a visual analogue scale (10cm line, Appendix 1), before taking the 
day's treatment dose. 
Identical capsules for each of the 4 treatments were pre-packed (Eli Lilly). 
Treatments were: - 
Fluoxetine 40mg (F) 
Placebo (P) 
Hydrochlorothiazide 50mg (D) 
Hydrochlorothiazide 50mg and Fluoxetine 40mg (C) 
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Plasma samples for measurement of drug and metabolite concentration were 
taken at the start of each drug period and at the start of water load assessment. 
Samples were analysed as described in Section 2.3.1. 
Water load assessment 
Twenty four hours after the last of 7 doses of treatment subjects underwent the 
protocol for water load assessment as described in Section 2.1.1.1. 
Ethical approval 
Ethical approval was obtained from Newcastle Health Authority Joint Ethics 
Committee. 
Statistical analysis 
The results of biochemical analysis were compared by randomised blocks 
analysis of variance with patients as blocks and factorial treatments (with and 
without Fluoxetine, with and without diuretic). This has allowed separate 
estimation of the effect of diuretic, of Fluoxetine and of any interactive effect. 
Except where stated results are shown as mean with standard error. 
RESULTS 
Nine subjects completed all 4 treatment studies. One subject completed only 
three treatment studies, the study omitted was with Fluoxetine alone. The 
reason for non-completion for this subject was not because of adverse effects. 
One subject declined to continue the study after two assessment. Two subjects 
withdrew from the study because of adverse effects. One had marked nausea 
after the first dose (Fluoxetine and diuretic) which did not abate after 3 daily 
doses. The other subject developed a severe headache after the first dose of 
treatment (Fluoxedne). The data for the nine subjects who completed the study 
and the tenth subject who completed three parts is included in the analysis the 
follows. 
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Excretion of water load 
Figure 3.1 shows the mean percentage of the water load cleared after Or in 
each treatment group. Subjects excreted 92.8±7.3% of the ingested water load 
after placebo treatment. After factorial analysis of this data a significant effect 
of diuretic treatment on excretion of the water load was shown (19±6.9% 
reduction p<0.001). The reduction in load excretion after combination 
treatment (C) is entirely attributable to the effect of the diuretic. Fluoxetine 
alone or in combination with a diuretic had no apparent significant effect on the 
ability to excrete a water load (p=0.372 and p=0.391 respectively). 
Similarly free water clearance was significantly reduced at 90 and 120min in 
those taking diuretic with or without Fluoxetine (Figure 3.2a). 
Plasma sodium and osmolality changes 
Basal data (Able 3.1) 
There was no significant difference between treatments in pOS at the start of the 
water load test after 7 days treatment. Although mean pOS after Fluoxetine 
treatment was lower this just failed to reach significance (p=0.055). 
There was a statistically significant decrease in pNa of approximately 1 mmol/l 
attributable to diuretic treatment. 
There was no apparent interaction of the effects of Fluoxetine and diuretic 
treatments (for pNa p=0.531, for pOS p=0.959). 
Dynamic data 
During the Or assessment pOS changed in a similar pattern after all treatments 
(Figure 3.2c). The lowest pOS achieved was significantly affected by 
Fluoxetine treatment ('Table 3.2), however the change in pOS during the water 
load was not significantly affected by Fluoxetine. By the end of the Or test 
period pOS was no longer different between treatments. 
The baseline significant difference in pNa after diuretic treatment persisted 
throughout the water load and there was a slight increase in magnitude (Figure 
3.2e: Thble 3.2). 
In none of the measurement comparisons was any significant interaction 
apparent between Fluoxetine and diuretic treatment. Although there were trends 
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Figure 3.1 
P-MACEBO 
TREATMENT 
The percentage of the oral water load excreted in the 4hr after ingestion after 7 days treatment 
with each drug (Mean+SEM). Factorial analysis showed a significant reduction in excretion 
after Diuretic treatment (p<0.001). Fluoxetine treatment alone or in combination with the 
diuretic had no significant effect on the volume excreted. 
P: Placebo; F: Fluoxetine; D: Diuretic; C: Fluoxetine and Diuretic. 
PFDC 
Figure 3.2 
The effect of an oral water load (20ml/kg) on renal function, plasma biochemistry and 
plasma AVP after 7 days treatment with Placebo (0); Fluoxetine ("); Diuretic (q); or 
Fluoxetine and Diuretic ('v). See text for statistical details. 
a) Free water clearance; b) Urine osmolality; c) Plasma osmolality; d) Plasma AVP; 
e) Plasma sodium. 
Results are presented as mean ± SE. 
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Table 3.1 The effect on plasma and urine biochemistry of 7 days 
treatment with Fluoxetine, diuretic or both treatments 
combined. Analysis by randomised block analysis of variance 
with factorial treatments. 
q 
MFAN 
with Fluoxetine without Fluoxetine difference 95%Cl p value 
POs(mosmhg) 288.0 289.7 1.7 -0.1.33 0.055 
PNa(mmol/1) 137.6 137.8 Q2 -0.6-1.0 0.642 
Pavp(pnoV1) 1.8 2.0 Q2 -0.6-1.0 0.577 
UOs(mosm/kg) 862 823 37 . 63.137 0.462 
with diuretic without diuretic 
POs(mosm/kg) 288.4 2893 0.9 -0.9-2.7 0.278 
PNa(mmol/1) 137.0 138.4 1.4 0.6-2.2 0.002 
PavP(pmoUI) 1.9 1.9 0.0 -0.8-0.8 0.845 
UOs(mosm/kg) 834 853 19 -81-119 0.697 
mean effect of mean effect of 
Fluoxeüne alone combination 
POs(mosmi1 g) -1.8 -1.7 0.1 -3.4-3.6 0.959 
PNa(mmoU1) 0.1 . 0.4 0.5 0.531 
PavP(pmoU1) -0.9 0.3 12 -0.4-2.8 0.147 
UOs(mosmhg) 23.0 52.0 29.0 -171.229 0.765 
Table 3.2 The effect of treatments on nadir plasma and urine 
biochemical changes showing mean data(±SEM) for each 
treatment group and by factorial analysis the differences 
between treatments and the combination treatment. 
4 
PLACEBO FLUOXETINE DIURETIC COMBINATION 
POi(mosm/kg) 286.6±13 282.1±1.1 2823±1.6 280.8±1.4 
PNa(mmol/1) 136.6±0.4 135.9±0.6 134.7±03 134.0±0.3 
Pavp(pnol/1) 0.4±0.1 0.4±0.1 0.330.1 0.4±0.1 
UOsmosm)kg) 62.413.3 64.5±5.6 71.9±3.8 77.1±6.4 
mean effect of mean effect of difference 95%CL p value 
Fluoxetine alone cambinabon 
POs(mosmA(g) -4.5 -1.7 2.8 -28-8.4 0325 
PNa(mmol/1) -0.7 -0.7 0.0 -1.7.1.7 
Pavp(pmol/1) 0.0 0.1 0.1 -0.1-0.3 0.345 
UOs(mosmlkg) 2.1 5.2 3.1 -7.9-14.1 0379 
MEAN 
with Fluoxetine without Fluaxetine 
POs(mosm/kg) 281.4 284.6 3.2 0.4-6.0 0.036 
PNa(mmol/I) 135.0 135.7 0.7 -0.1.1.5 0.104 
Pavp(pmol/1) 0.3 0.4 0.1 -0.1-0.3 0.874 
UOs(mosm/kg) 70.8 67.1 3.7 -1.9-9.3 0.197 
with diuretic without diuretic 
POs(mosm/kg) 281.7 284.3 2.6 -02-3,4 0.067 
PNa(mmoU1) 134.4 136.3 1.9 1.1.2.7 <0.001 
PavP(PmoUI) 0.4 0.4 0.0 -0.2-0.2 0.430 
UOs(mosm/kg) 74.5 63.53 11.0 5.4-16.6 <0.001 
to lower pOS and pNa after combined treatment than after either treatment alone 
factorial analysis has shown these effects to be due to the individual treatments 
(Table 3.2). 
Plasma vasopressin 
Initial pAVP showed large variation between individuals but there was no 
significant difference between treatments nor was there an interactive effect of 
combined diuretic and Fluoxetine treatment (p=0.147 Table 3.1). After the 
water load subjects suppressed AVP in a similar way after all treatments. There 
was no indication of failure of suppression in response to plasma hypo- 
osmolality after any of the treatments (Figure 3.2d: 'Fable 3.2). 
Urine osmolality 
There were no significant differences between treatments in the uOS at the start 
of the water load (Table 3.1). All treatments allowed minimal dilution of urine 
(< l00mOsm/kg) although slightly less dilute urine was achieved after diuretic 
treatment (74.5mOsm/kg compared to 63.5mOsm/kg standard error of 
difference 2.76 p<0.001). There was an initial delay in urine dilution after 
treatment C but the time to maximal dilution was not delayed (Figure 3.2b). 
Blood pressure 
There was no significant fall in blood pressure during any of the 39 studies. 
There was no significant difference between the treatment groups in the mean 
arterial pressure at time zero. 
Nausea 
One subject included in this data analysis experienced nausea during the first 
three days of treatment with the combination of diuretic and Fluoxetine but by 
the time of water load test no nausea had been experienced for 48hr. During the 
water load some subjects recorded significant nausea on the analogue scale 
(> 10mm). Excluding their data from the analysis did not alter the results of 
statistical analysis. Since our findings have shown no evidence of SIAD and 
significant nausea would, by non-osmotic stimulation of vasopressin, have 
produced a false positive result, we have included all data in our calculations. 
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Plasma Drug concentration 
Measurement of the plasma drug level at the start of each treatment period and 
during the water load test showed there to be no carry-over effect between 
treatment periods. 
DISCUSSION 
There was no evidence from' this study that Fluoxetine modifies osmoregulated 
AVP secretion. There is no apparent alteration in the ability of normal man to 
maintain osmotic homeostasis in basal conditions since 7 days of Fluoxetine 
treatment had no significant effect on baseline pOS or pNa. Fluoxetine alone or 
in combination with a diuretic had no significant effect on the ability of normal 
man to excrete a water load or on the suppression of AVP in response to plasma 
hypo-osmolality achieved by an oral water load. 
Statistical analysis by randomised blocks with factorial treatments has allowed 
evaluation of any interactive effect. As this was shown to be not significant we 
were able to look at the effects of Fluoxetine and Diuretic by factorial analysis. 
The small numbers in this study may however be insufficient to allow interactive 
effects to reach significance. 
There is a trend in the data to suggest that Fluoxetine in combination with a 
diuretic leads to lower pOS and pNa and higher pAVP concentrations relative to 
pOS after seven days treatment, and possibly increased plasma biochemical 
changes after a water load, than after either treatment alone. This trend however 
failed to reach significance and the changes in plasma biochemistry seem to be 
attributable to diuretic treatment. It is interesting to speculate, however, that 
there might be an interactive effect. One possible mechanism for this might be 
that, by the non-osmotic stimulus of hypovolaemia, diuretic treatment might 
"prime" magnocellular AVP release so that in this situation 5HT may stimulate 
inappropriate AVP secretion and lead to hyponatraemia. 
Plasma osmolality has been found to be non-significantly reduced (from 
290mOsm/kg to 288 mOsm/kg) after 7 days treatment with Fluoxetine. It is 
possible that this small reduction after 7 days may continue with further regular 
administration and become statistically and clinically significant. 
The effects of diuretic treatment onwater balance and plasma biochemistry are 
109 
intriguing. 24hr after the last of 7 daily doses there was significant (19%) 
retention of a water load. This was apparently due to mechanisms other than 
dehydration or inappropriate AVP, secretion since there were no differences in 
initial pOS, uOS or pAVP to suggest fluid depletion and no failure of 
suppression of AVP in response to'the hypo-osmotic stimulus. Presumably the 
mechanism of fluid retention is due to increased activity of the 
renin-angiotensin-aldosterone system. 
There was a statistically significant reduction in pNa after 7 days treatment with 
diuretic. This is in keeping with other studies which have associated thiazide 
diuretics with reduction in pNa concentration (Abramow & Cogan 1984: 
Friedman et al 1989). In this study the actual change was just over 1 mmol/1 
and has little biological significance. 
There was a suggestion from the data that diuretic treatment prevented maximal 
urine dilution although mean nadir uOS was still < lOOmOsm/kg. At such low 
osmolality there is increased inaccuracy in measurement and this result can be 
interpreted as no more than an interesting finding. 
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STUDY 3.2 THE EFFECT OF SIIT REUPTAKE INhIIBITION BY FLUOXETINE, ON 
THE AVP RESPONSE TO HYPEROSMOTIC STIMULUS 
SPECIFIC AIMS 
1. To study the effect of 7 days treatment with a 5HT reuptake inhibitor, 
Fluoxetine on basal osmotic status and AVP secretion in normal man. 
2. To study the effect of Fluoxetine on the sensitivity of AVP response to 
increase in plasma osmolality in normal man. 
3. To study the effect of Fluoxetine on the theoretical osmotic threshold of 
AVP release in normal man. 
MATERIALS AND METHODS 
Subjects 
Eleven healthy male volunteers aged 20 to 35yr gave written, informed consent 
for the study. Exclusions were made on the basis of serious illness, previous 
head injury or bacterial meningitis, regular medication or clinical abnormality of 
serum electrolytes, liver function tests, lipids, blood glucose, full blood count or 
urinalysis. 
Treatments and study design 
Each subject took, in random order, Fluoxetine 40mg (F) or placebo (P) before 
breakfast, once daily for 7 days. There was a minimum washout period 
between treatments of 4 weeks. All adverse symptoms were recorded and a 
direct measure of nausea was made daily by a visual analogue scale (10cm line, 
Appendix 1), before taking the day's treatment dose. 
Placebo capsules were identical to Fluoxetine (courtesy Eli Lilly). Plasma 
samples for measurement of drug and metabolite concentration were taken at the 
start of each drug period and at the start of hyperosmotic stimulus assessment. 
Samples were analysed as described in Section 2.3.1. 
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Hyperosmotic stimulus 
Subjects were studied 24hr after the last dose of treatment. The protocol is 
described in Section 2.1.1.2.1. 
Ethical approval 
Ethical approval was obtained from Newcastle Health Authority Joint Ethics 
Committee. 
Statistical analysis 
The relationship between pAVP and pOS for each subject was analysed by 
linear regression. Results were compared by ANOVA for cross over design 
studies for investigation of treatment, order and carry-over effects. Unless 
other wise stated results are shown as mean±SEM. 
RESULTS 
Ten subjects completed both studies. One subject withdrew from the study after 
the first dose of treatment (Fluoxetine) due to marked nausea. No other adverse 
effects were experienced by subjects. All subjects tolerated the hyperosmotic 
studies well with no significant ill-effects. 
Basal data (Thble 3.3) 
Seven days of treatment with Fluoxetine caused no significant change in baseline 
pOS, pAVP or pNa. Table 3.3 shows similar data for study 3.1 for comparison 
of similar groups. (These results are slightly different to those presented in 
Table 3.1 due to the factorial analysis of the data in study 3.1). 
Dynamic data 
The infusion of hypertonic saline caused a rise in pOS of 15.8±0.42 mOsm/kg 
after placebo and 15.9±0.38 mOsm/kg after Fluoxetine treatment (p=0.879). 
There was no significant difference in the magnitude of osmotic change between 
the first and second assessment for each subject. 
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Vasopressin response 
The AVP response to change in pOS is shown for each subject after each 
treatment in Figure 3.3. There was a total increase in pAVP of similar 
magnitude after both treatments in, response to increase in pOS (5.6± 1. lpmol/1 
(P), 6.0±0.9pmol/1(F), p=0.337). 
Calculation of the linear regression equation for each test allows comparison of 
the sensitivity of the AVP response (slope of the regression line) and the 
theoretical osmotic threshold of AVP release (abscissal intercept) as discussed in 
Section 1.1.2.1. Tables 3.4 and 3.5 show these parameters for each subject. 
There was no apparent significant effect of the Fluoxetine on either the 
sensitivity (0.33±0.06 (P), 0.36±0.06 pmol/1 per mOsm/kg (F), p=0.347) or 
the threshold (287.0±1.2 (P), 286.9±1.1 mOsm. kg (F), p=0.700) of AVP 
release. Nor was there any evidence of significant order or carry-over effects. 
Blood pressure 
There was no significant fall in blood pressure during any of the 20 studies. 
There was no significant difference between the treatment groups in the mean 
arterial pressure at time zero. 
Nausea 
None of the subjects experienced nausea during the 7 days of treatment. During 
the saline infusion significant nausea (> 10mm) was experienced on both 
occasions to a similar degree by subjects 2,8 and 9. 
Exclusion of their data from the analysis did not alter any of the results as 
described above. 
Haematocrit 
Haematocrit values fell slightly in all subjects in both tests (-5.2+0.2% (P), 
-6.0±0.3% (F)) reflecting the increase in intravascular fluid consequent to 
hypertonicity. There was no significant effect of Fluoxetine on this change 
(p=0.053) and in none of the tests was there any suggestion of a fall in blood 
volume. 
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Table 3.4. The sensitivity of each individual's AYP response per unit 
change in plasma osmolality during infusion 5%NaC1 
(855mmol/I) after each 7 day treatment. P=0.347 for treatment 
effect and p=0.128 for order effect. 
SUBJECT PLACEBO - FLUOXETINE- DIFFERENCE 
01 0.37 0.53 0.16 
02 0.67 0.62 -0.05 
03 0.35 0.43 0.08 
04 0.20 0.18 -0.02 
05 0.24 0.26 0.02 
06 0.16 0.21 0.05 
07 0.18 024 0.06 
08 0.07 0.21 0.14 
09 0.67 0.65 0.02 
10 0.40 0.29 -0.11 
MEAN 0.33 0.36 0.03 
Table 3.5 The theoretical osmotic threshold of AVP release for each 
subject after each 7 day treatment. 
Treatment effect p=0.700 and order effect p=0.631 
SUBJECT PLACEBO FLUOXETINE DIFFERENCE 
01 291.9 291.4 -0.5 
02 292.9 293.1 0.2 
03 286.1 282.2 -3.9 
04 287.5 283.0 -4.5 
05 288.6 288.1 -0.5 
06 287.0 286.3 -0.7 
07 285.9 284.7 -1.2 
08 279.4 285.8 6.4 
09 286.8 288.6 1.8 
10 283.8 286.1 2.3 
MEAN 287.0 286.9 -0.1 
DISCUSSION 
There was no evidence from this study that Fluoxetine had modulatory effect on 
the release of AVP in response to a rise in pOS. Nor does Fluoxetine have 
significant effect on basal osmotic status since 7 days treatment had no 
significant effect on pOS, pNa or pAVP. 
The reproducibility of individual response to hypertonic saline stimulation is 
established (Thompson et al 1991). The magnitude of inter and intra individual 
variation in our study is remarkably similar to the work of these authors 
reinforcing the finding that increase in 5HT neurotransmission has no 
significant effect on osmotically stimulated AVP release. The sample size that 
we have used in this study with the standard deviation of sensitivity and osmotic 
threshold of AVP release as shown would have allowed us to discern a 
difference of sensitivity of AVP response of ±0.07pmol/1 per mOsm/kg (20%) 
and difference in threshold of AVP release of ±2.4 mosm/kg (0.9%). 
The AVP response to nausea is rapid and usually to plasma concentrations of 
>20pmol/l. Nausea of a mild degree may cause a distortion of the 
physiological AVP responses not only because of high plasma concentrations but 
also because nausea is a more potent stimulus to AVP release than other stimuli 
and will take dominance in effect (Rowe et al 1979: Faull & Baylis 1991). 
Subjects 2 and 9 have good linear correlation of the AVP response to change in 
pOS and like other, non-nauseated, subjects the regression lines after Fluoxetine 
and placebo treatment are very similar. Subject 8 has a less linear pattern of 
AVP response with coefficients of correlation of 0.95 (placebo) and 0.87 
(Fluoxetine). There is a possibility that the AVP response to increase in pOS 
may be modified by the nausea experienced by this subject. However exclusion 
of this subject from data analysis does not alter any of the results as described 
above. The effect of nausea in this studies is therefore likely to be of little 
significance. 
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3.3 DISCUSSION 
The apparent absence of an effect of 5HT on AVP release is in contrast to in 
vitro and in vivo animal studies which suggest that 5HT has a stimulatory effect 
on AVP release (Section 1.4). These studies have largely been in rats and have 
perhaps used higher doses of drugs which increased 5HT neurotransmission than 
we have done in this study in normal men which could explain the difference in 
findings. Some of the agents administered in the animal studies have been 
shown to have effects on other neurotransmitter systems in addition to their 
serotonergic or 5HT antagonist properties. Fluoxetine, however, is a very 
specific 5HT uptake inhibitor with minimal effects on other neurotransmitter 
systems at the dose used in these studies. In addition some, but not all, of the 
animal experiments were performed under anaesthetic which is known to have 
an effect on the hypothalamo-neurohypophysial-axis in its own right (Toth 1937: 
Rose et al 1984). 
In this study we have given 7 days of treatment with a 5HT reuptake inhibitor. 
Animal studies have manipulated central 5HT concentrations by administering a 
single dose of pharmacological agent. It is possible that an initial disequilibrium 
occurs in the system which is quickly compensated by receptor down regulation 
or other mechanism similar to the regression of many other adverse drug effects 
thought to be due to increased synaptic availability of 5HT (eg. nausea, sleep 
disturbance). The effect of acute and more prolonged SSRI administration on 
5HT neurotransmission has been discussed in Sections 1.3.4.3 and 1.5.3.2.3. 
The literature would suggest that Fluoxetine administration acutely increases 
5HT neurotransmission. However, there is rapid adaptation of the system and 
within 2 days a significant reduction in 5HT neuronal firing with a decrease in 
5HT neurotransmission (Clemens et al 1977). An increase in 5HT 
neurotransmission returns after 10-14 days continued treatment due to specific 
effects of the drug on autoregulatory processes. These studies, in normal 
healthy men after 7 days treatment with Fluoxetine, show either that there is no 
physiologically relevant interaction between 5HT and osmoregulatory AVP 
release, or that equilibrium has been adequately re-established. However, 
Fluoxetine associated hyponatraemia has been reported after 5 to 60 days of 
treatment (over 50% within 10 days) suggesting that, at least in its clinical usage 
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in depression, the hyponatraemia occurs rapidly and persists. 
If the mechanism of this hyponatraemia in depression is failure of normal AVP 
suppression in response to hypo-osmolality it could be that, in this group of 
people, equilibrium of 5HT transmission and AVP release cannot be re- 
established. 
There was no evidence from these two studies that Fluoxetine might have non- 
osmotic stimulatory effects on AVP secretion, although this was not specifically 
assessed. There were no significant differences in blood pressure during 
Fluoxetine treatment nor were there changes in blood volume as assessed by 
haematocrit measurements. The incidence of nausea, about 13%, was perhaps 
less than might have been anticipated from the literature (Wernicke 1985). It 
would have been interesting but obviously not possible nor ethical to have 
studied osmoregulated AVP secretion in the two subjects who withdrew from 
the study because of nausea. The subject who continued with the study, despite 
initial nausea, exhibited no significant differences in response to oral water load 
after that particular treatment (C) than after other treatments, nor were his 
responses significantly different from other subjects. 
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SECTION 4 
STUDIES OF OSMOREGULATION 
IN THE ELDERLY, 
THE ELDERLY DEPRESSED PATIENT 
AND THE INFLUENCE OF THE 
SELECTIVE SHT REUPTAKE INHIBITOR 
FLUOXETINE 
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INTRODUCTION 
Abnormalities of water balance associated with depression and its treatment by 
antidepressant medications, have been discussed in Section 1.6.2.1. It is clear 
that hyponatraemia occurring in depressive illness is poorly understood. 
Clinically serious hyponatraemia is rare, usually arising in association with drug 
therapy and may be related to bipolar affective disorder and psychotic 
depression. 
The reports of hyponatraemia associated with the clinical use of Fluoxetine have 
increased awareness of this clinical problem in the treatment of affective illness, 
but have done little to increase understanding of its aetiology or 
pathophysiology. The reports in the literature, to the drug manufacturers and 
Committee on Safety of Medicines, as discussed in Section 3, are generally of 
patients over 50yr who were often taking other medications suggesting that 
many have physical illness in addition to their mental illness. The literature 
reports have included patients with major depression (unipolar), bipolar 
affective disorder and depression with associated obsessive-compulsive features. 
Thus it is far from clear if patients who developed hyponatraemia with 
Fluoxetine had a particular mental illness, a vulnerability due to other factors, 
such as age, concurrent physical illness or additive effects of other medications, 
or if the problem was more idiosyncratic 
The putative abnormalities of 5HT neurotransmission that occur in depression 
have been discussed in Section 1.4. The balance of evidence falls strongly in 
favour of a dysfunction of the 5HT system, although the manner of the 
dysfunction is less clear. 
The SSRIs are a group of antidepressant medications which have recently been 
developed and have shown good therapeutic results (Lader 1988). The highly 
specific mode of action of Fluoxetine (Section 2.3) and its association with 
hyponatraemia might suggest that alteration of 5HT neurotransmission is the 
factor that leads to hyponatraemia by direct or indirect stimulation of AVP 
secretion from magnocellular neurons. 
In Section 3 the effect of 7 days treatment with Fluoxetine on osmoregulation 
was explored in normal man and no significant changes were found. As 
discussed in Section 3.3 it is possible that the abnormal effects of Fluoxetine on 
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water balance, and possibly also other antidepressant associated with 
hyponatraemia in depression, are present only following their administration to 
depressed people. Neuroendocrine and other abnormalities related to 
hypothalamic dysfunction are well documented in depression (Brown et at 
1988). It has been suggested that AVP, through its synergistic action with CRF 
on ACTH release, is, at least in part, responsible for the abnormal secretion of 
cortisol which occurs in depression (Schatzberg & Nemeroff 1988). It would 
not be surprising therefore if other functions of the hypothalamus, including 
osmoregulatory function, were disturbed in depression. 
The objective of this section of the research was to examine osmoregulation in 
depression and the effect of treatment on osmoregulated AVP secretion by the 
SSRI, Fluoxetine, as a putative model of a "disease state" of 5HT 
neurotransmission. 
GENERAL HYPOTHESES 
1. That there is an abnormality in 5HT biochemistry in the central nervous 
system of depressed people. 
2. That this abnormality is affected by the SSRI Fluoxetine. 
3. That 5HT has a modulatory role in the physiological control of AVP 
secretion in response to osmotic stimuli. 
4. That this modulatory role is affected by Fluoxetine which may be only 
apparent or more pronounced in depressed people due to their underlying 
abnormality of central 5HT biochemistry. 
5. That the hyponatraemia occasionally observed in depressed people taking 
Fluoxetine is due to inappropriate secretion of AVP consequent to the influences 
of depression and Fluoxetine on 5HT balance. 
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STUDY 4.1 A RANDOMISED SINGLE-BLIND STUDY TO DETERMINE TILE 
EFFECT OF FLUOXETINE, COMPARED TO DOTIIIEPIN, ON WATER BALANCE IN 
ELDERLY, UNIPOLAR DEPRESSED PATIENTS. 
SPECIFIC AIMS 
Major 
1. To study the response of drug free older unipolar depressed patients to 
plasma hypo-osmolality achieved by water loading. 
2. To study the effect of Fluoxetine , in comparison to 
Dothiepin, an 
antidepressant with putative low central 5HT activity (Ishikawa et al 1986), on 
the ability of older, unipolar depressed patients to respond to hypo-osmolality 
achieved by water loading. 
Minor 
3. To see if there is any relationship between dexamethasone non-suppression 
and abnormality in control of water balance in unipolar elderly depressed 
patients. 
Study design 
A randomised, single blind study. Psychiatrists and patients were "unblinded" 
to treatment type but the researcher was "blinded". 
This was to be a longitudinal, prospective study of water balance in drug free, 
unipolar depression and the subsequent effects of treatment with Fluoxetine in 
comparison with Dothiepin, an equally efficacious antidepressant with low 
central 5HT activity. The recruitment of patients was from psychiatric in and 
outpatient departments. The comprehensive study design, presented in Appendix 
6, would have provided data to answer questions about the effects alone, and in 
interaction, of the disease state and antidepressant treatments, on water balance 
in depression. 
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Unfortunately no patients were enrolled into the study during the four months of 
recruitment. 
There were a variety of reasons for this: - 
a) Most patients with major depression, of the severity required to fulfil the 
inclusion criteria of this study, were commenced on antidepressant medication 
by their General Practitioner (GP) before referral to a psychiatrist, thus drug 
free patients rarely attended psychiatric outpatients. 
b) Elderly patients were frequently taking a variety of other medications, 
particularly diuretics, which excluded their entry into the study. 
c) At the time of the study Fluoxetine was a relatively new drug in the UK and 
psychiatrists were not using it as a first line of treatment. 
The study design was modified to adapt to these practical problems. In doing so 
the aims of the study were simplified. 
STUDY 4.2 THE STUDY OF THE RESPONSE TO AN ORAL WATER LOAD OF 
ELDERLY PATIENTS WITH UNIPOLAR DEPRESSION, TREATED WITH 
FLUOXETINE OR DOTIIIEPIN, COMPARED WITH A CONTROL GROUP OF 
HEALTHY ELDERLY VOLUNTEERS 
SPECIFIC AIMS 
To study the effect of Fluoxetine, in comparison with an antidepressant of lower 
serotonergic activity (Dothiepin), on the ability of elderly depressed patients to 
respond to hypo-osmolality achieved by water loading. 
MATERIALS AND METHODS 
Study design 
An open, unblinded study of three groups: 
1. Depressed patients treated with Fluoxetine (FLUOXETINE). 
2. Depressed patients treated with Dothiepin (DOTIIIEPIN). 
3. Normal, healthy elderly controls (ELDERLY). 
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Patients 
Men or women aged 50 to 75yr, referred to outpatient psychiatry clinic with an 
episode of major depression defined by DSM-R III criteria (Appendix 7), with 
no history of mania. 
Patients were taking Fluoxetine or Dothiepin at the time of attendance at 
outpatient clinic or their management required change to either of these 
medications. 
Patients continued taking prescribed medication of either Fluoxetine or 
Dothiepin and each patient was studied after a minimum of two weeks 
treatment. 
Normal controls 
Men or women aged 55 to 75 yr, were recruited from the general public 
through contact with Age Concern (Mea House, Newcastle and High Street, 
Gateshead). 
Exclusions 
Patients and Controls were excluded from the study if they were currently 
taking any of the following medications: - 
Diuretics 
ACE inhibitors 
Anticonvulsants 
MAOI 
Lithium 
In addition Controls could not be taking, or have taken in the previous 4 
weeks: - 
Antidepressants 
Neuroleptics 
Benzodiazepines except a small dose as an hypnotic 
Patients or Controls could have no significant other illnesses in particular; 
ischaemic heart disease, respiratory disease, liver disease or central nervous 
disorder, nor clinical abnormality of serum electrolytes, liver function tests, 
blood glucose, full blood count or urinalysis. Other exclusions applied as for 
Study 4.1 (Appendix 6). 
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Ethical approval 
Ethical approval was obtained from Newcastle Health Authority Joint Ethics 
" Committee. 
PROTOCOL 
Initial assessment 
After written, informed consent had been obtained a physical examination was 
carried out for all subjects to exclude significant physical illness and a blood 
sample was be taken for analysis of electrolytes. 
The consent forms and information given to each subject are included in 
Appendix 8. 
Water load assessment 
The protocol for the water load assessment is described in Section 2.1.1.1.1. In 
addition urine and plasma was collected for calculation of creatinine clearance 
(C,. 
1) 
during the period of maximal diuresis (60-120min after the start of water 
load ingestion). Creatinine was measured in both urine and plasma by an 
alkaline picrate spectrofluorometric method, Department of Clinical 
Biochemistry, Royal Victoria Infirmary. 
During the water load test the severity of depression of all patients was assessed 
by a standard interview rating scale (Hamilton Rating Scale for depression 
(HRSD) (Hamilton 1960), (Appendix 9). The HRSD is the most widely used 
scale for patient selection and follow-up in research studies of treatments for 
depression. In numerous studies the total HRSD score has proved to have a high 
degree of concurrent validity (Carroll et al 1973). The scale relies on 
interviewer rating of the intensity and frequency of 17 depressive symptoms 
yielding a total possible score of 52. For the purposes of this research 
symptoms pertaining to sexual function were omitted and only 16 items were 
used with a total score of 50. 
The interviewer was trained in the use of the scale by rating videoed subjects 
and comparing HRSD score with that of a psychiatrist, and by reference to a 
structured interview guide (Williams 1988). Appropriate revisions to interview 
technique were made until there was 90% agreement in the scores of the 
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interviewer and the trainer. 
Due to the variability of depressive symptomatology during the course of the 
illness and its improvement it was decide to elicit from the patients symptoms 
pertaining to the 2 weeks prior to the water load assessment. 
Follow-up 
The clinical management of the Patients was not altered by this study and 
patients continued to attend outpatient psychiatry clinics in the usual way. If 
however the water load test was abnormal advice was given to both the patient 
and the Consultant psychiatrist about fluid intake and the biochemical status of 
the patient was monitored by the researcher. 
The GP of all Patients and Controls was informed of their participation in the 
study. Appendix 8 contains letters relevant to the psychiatrist of Patients and 
the GPs of Patients and Controls. 
After three months of recruitment into this amended study protocol only two 
patients had been enrolled. At this time the inclusion criteria were broadened to 
include: - 
a) Patients with a current episode of major depression, treated with Fluoxetine 
or Dothiepin. 
b) Patients with a previous episode of major depression who were taking 
Fluoxetine or Dothiepin as a maintenance therapy. 
The exclusion criteria were unchanged. 
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4.2.1. THE NORMAL ELDERLY 
The incidence of both hyper and hyponatraemia increases in the elderly 
population (Leaf 1984) . There are currently two lines of thought emerging 
from the literature on the changes in homeostatic mechanisms of water balance 
with increasing age. 
It has been repeatedly documented that there is a decrease in the thirst response 
to osmotic change with age and it is possible that perception of other stimuli to 
fluid ingestion are also diminished (Phillips et al 1984). There is, however, 
more controversy regarding changes in osmoregulation of AVP secretion and 
the ability to conserve and excrete water appropriately. Early studies by 
Helderman et al (1978) suggested that there was in an increase in sensitivity of 
AVP secretion in response to a rise in pOS. More recent studies have failed to 
confirm this, and indeed have suggested perhaps the converse may be true 
(Mclean et al 1991). 
Studies which have explored the ability of elderly people to excrete a water load 
have indicated that it is impaired and that more time is required for full 
excretion of the load (Crowe et al 1987). 
Since this research has provided important data on the normal elderly 
(ELDERLY) the results of this group are presented in comparison to the normal 
young (YOUNG) previously presented in Section 3.1. 
Statistical analysis 
The results of each group were compared by two tailed t-tests. 
Unless otherwise stated results are shown as mean ± SEM. 
RESULTS 
21 healthy normal elderly completed a water load assessment. All subjects 
tolerated the test well with no adverse effects. The mean age of the ELDERLY 
was 68yr (58-74yr). 
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Basal data 
At the start of the water load the ELDERLY had a significantly higher pOS and 
lower uOS than the YOUNG. Plasma AVP concentration was significantly 
lower in the ELDERLY than in the YOUNG despite the higher pOS (Table 
4.1). The relationship between baseline plasma AVP and uOS is shown for the 
two groups in Figure 4.1. 
Excretion of the water load 
Figure 4.2 shows the pattern of excretion of the water load as the 95 percentiles 
of excretion of the water load (mean ± 2SD) for the two groups. There was 
close approximation at most time points, but at lhr, there was a significant 
difference between the groups at which time the YOUNG excreted 12±3% but 
the ELDERLY 21±2% (p=0.031). By 90 mins there was no longer a 
significant difference and this persisted throughout the rest of the study. At 4hr 
both groups had excreted over 90% of the load ingested (YOUNG 92.8±7.6% 
ELDERLY 91.9 ±4.6 %, p>0.05). 
The pattern of water load excretion showed marked differences between the 
groups in the changes in CH20 and uOS (see below) as demonstrated in Figure 
4.3 (c and d) . The ELDERLY had a significantly higher baseline CH20 
(ELDERLY-0.35 ±0.18 ml/min, YOUNG -0.95±0.1 ml/min, p =0.036), 
consistent with lower urinary concentrating ability. The CH20 of the 
ELDERLY is significantly greater at 60min than in the YOUNG (ELDERLY 
1.6±0.4, YOUNG -0.03±0.4 ml/min, p=0.028) consistent with the higher 
%water load excreted at 60min by the ELDERLY. After this time, however, 
the YOUNG achieved a significantly greater CH2o. The increased CH20 
persisted for longer in the ELDERLY and this group was still excreting free 
water at 4hr. 
The YOUNG therefore achieved excretion of the water load by a sharp increase 
in CH20 but of short duration, the ELDERLY achieved the same end result by a 
lesser but more prolonged increase in CH2o. 
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Table 4.1. Plasma and urine biochemistry at the start of water load 
in normal YOUNG and ELDERLY subjects (mean±SEM). 
mPOS osm/kg mp 
Na 
mol/I mosm/kg pP 
YOUNG 290.5±0.8 138. to"w 842±52 2.3±0.6 
ELDERLY 293.5±0.5 139.4±0.3 508±47 0.5±0.1 
pß. 004 p=0.076 pc0.001 pc0.001 
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Figure 4.1 
The relationship between urine osmolality and plasma AVP after overnight abstinence from 
drinking in ELDERLY (0) and YOUNG (0). 
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Figure 4.: 
The 95 percentiles of cumulative urine excretion of the YOUNG and ELDERLY in the 4hr 
after water load ingestion (20miilg) expressed as a percentage of the oral water load. Only at 
60min was there a significant difference between the two groups (p=0.031). 
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Figure 4.3 
The effect of an oral water load (20ml/kg) on renal function, plasma osrnolality and plasma AVP 
in YOUNG (0) and ELDERLY (") subjects. 
a) Plasma osmolality; b) Plasma AVP; c) Urine osmolality; d) Free water clearance. 
Results compared by t-test *p<0.05 **p<0.001. 
Results are presented as mean ± SEM. 
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Plasma AVP 
At all time points AVP in the ELDERLY was significantly lower than in the 
YOUNG. There also appeared to be a longer suppression of AVP to minimal 
levels in the ELDERLY than the YOUNG (Figure 4.3b) 
Plasma and osmolality sodium 
Figure 4.3a shows that the initial significant difference in plasma osmolality was 
not apparent after ingestion of water load and did not recur after the load was 
excreted. The magnitude of fall in pOS after ingestion of water load was 
however significantly different in the two groups (YOUNG 5.1 ±0.7mOsm/kg 
ELDERLY 7.7±0.4 mOsm/kg p=0.003). The YOUNG returned to a mean 
pOS 1.8±0.7 mosm/kg lower than that at starting (p=0.035) but the 
ELDERLY remained at a pOS 3.5 ± 0.5 mosm/kg lower than baseline 
(p<0.001). The difference between the two groups was not, however, 
significantly different. 
Plasma sodium concentrations were not significantly different between the two 
groups at any point in the study (data not shown). 
Urine osmolality 
Figure 4.3c shows the change in uOS with respect to time after the water load. 
The YOUNG achieve a greater urine dilution than ELDERLY but this failed to 
reach significance (YOUNG 72±6, ELDERLY 91±8 mosm/kg, p>0.05). 
The ELDERLY, however, maintained a lower urinary osmolality for a longer 
period than the YOUNG and there was again a significant difference in uOS at 
Ohr (YOUNG 392±53, ELDERLY 228±23, p=0.002). 
Blood pressure 
There was no significant fall in blood pressure in any of the studies of 
ELDERLY or YOUNG. 
Nausea 
During the water load one YOUNG subject experienced a significant degree of 
nausea (> 10mm on linear scale). Excluding his data from the analysis did not 
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alter the statistical significance of any of the results. None of the ELDERLY 
experienced more than a very mild degree of nausea. 
Sex differences 
As expected, since all female subjects were post-menopausal, there were no 
significant differences in the ELDERLY between male and female subject 
results. Data was thus combined for the statistical analysis. 
DISCUSSION 
There were three remarkable observations from this study. Firstly, there was 
no effective difference in the ability of healthy ELDERLY or YOUNG to 
excrete an oral water load except in the very early stages when the ELDERLY 
began to excrete water more rapidly than YOUNG. Secondly, the 
osmoregulatory mechanisms of achieving this result were quite different 
between YOUNG and ELDERLY, and thirdly, the baseline differences 
between the two groups were substantial. 
After ingestion of the water load the ELDERLY achieved a concentration of 
AVP sufficient to allow urinary dilution more rapidly than the YOUNG and 
consequently diuresis began more rapidly in this group. The pattern of water 
excretion then changed between the two groups. The YOUNG had a short but 
marked increase in CH2o, the ELDERLY a less marked but more prolonged 
change. The magnitude of maximum CH2O in YOUNG and ELDERLY is 
similar to that found in other studies (Lindeman et al 1966; Crowe et al 1987). 
This might be solely a consequence of a reduction in glomerular filtration rate in 
the ELDERLY or it could be secondary to a reduction in maximal dilutional 
ability with age . Crowe et al (1987) found that if the reduction with age 
in 
C. 
«,, was taken 
into account, no significant differences in CH20 were found 
between young and elderly. Figure 4.4 shows the CH20max for each group and 
CH2O adjusted for C,. 1 
in the ELDERLY. It can be seen from this that there is 
no simple relationship in this study between reduction in renal function and 
reduction in CH2omax since there is still a significant difference between 
YOUNG and ELDERLY. 
There was no significant difference between the YOUNG and ELDERLY in 
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The peak free water clearance after the water load of YOUNG (a). ELDERLY (p) and the mean 
ELDERLY value adjusted for variation in renal function (C.. ) (0. Comparison by t-tests of 
the two ELDERLY groups to the YOUNG shows that only some of the significant difference in 
peak free water clearance is explained by a deterioration of renal function with age. 
Results are presented as mean ± SEM. 
minimum urine concentration but there was a trend for the ELDERLY to have a 
significantly higher urine concentration during maximal CH20. Other studies 
have found similar results after a water load (Lindeman et al 1966) and there is 
evidence that the aging kidney has a diminished ability to dilute urine due to an 
impaired sodium conservation mechanism (Macias 1980; Weinstock Brown et at 
1985). 
It would seem that the potential problem of incomplete bladder emptying was 
not a source of error in this study since this would lead to an under estimate of 
water load excretion in the ELDERLY. The dilution of urine to 
< l00mOsm/kg would also militate against incomplete urine collection at each 
time point. 
Despite these changes in osmoregulatory mechanisms with age there was no net 
effect on the ability to excrete the water load. It might be anticipated, however, 
that a large volume of water or salt deplete fluids (eg. 5% dextrose) would lead 
to a deficit in excretion by the ELDERLY compared to the YOUNG due to the 
diminished maximal CH20. This may be particularly relevant to the occurrence 
of hyponatraemia in the hospitalised elderly (Sunderam & Mankil<ac 1983: 
Anderson 1985). 
As expected the ELDERLY had a substantially higher baseline pOS than the 
YOUNG. Baseline AVP is, however, significantly lower in the ELDERLY. 
This is in contrast to other studies which have shown either no difference in 
basal AVP concentrations in the elderly (Helderman et at 1978; Rowe et at 
1982; Chiodera et at 1991) or higher concentrations (Frolkis et at 1982; 
Kirkland11984). One study has found a lower concentration of AVP in the 
elderly than in the young (Li et at 1984). These differences in findings may be 
explained in part by differences in the age group studied. The AVP 
concentrations observed in the ELDERLY would not be expected to achieve 
urinary concentration greater than 400mOsm/kg (Thompson 1989). In this 
study we found a mean urinary concentration of over 500mOsm/kg at baseline 
in ELDERLY which suggests that urine was concentrated by a mechanism 
independent of AVP, or that renal AVP receptors were upregulated. 
Low plasma AVP concentration, high normal pOS and greater than expected 
uOS would suggest that ELDERLY are in a similar biochemical and hormonal 
state as to that seen in patients with partial cranial diabetes insipidus (CDI) 
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where despite "inadequate" plasma concentrations of AVP compared to normals 
urinary concentration can occur to a limited extent (Miller et at 1970; Zerbe & 
Robertson 1981). This is thought to be due to an increased renal tubular 
sensitivity to AVP due probably to AVP receptor up-regulation (Block et al 
1981). This increased tubular sensitivity to AVP was reported in early studies 
of water balance in the elderly where infusion of submaximal concentration of 
vasopressin during sustained maximal diuresis lead to a much greater rise in 
urine osmolality in the elderly than in a young population (Lindeman et al 
1966). Patients with mild partial CDI pass 2.5-4 litres of urine per day and 
maintain, by adequate fluid intake, a high normal plasma osmolality. 
This is the first study to our knowledge that has investigated physiological 
osmoregulation in the elderly in such a large group of healthy, non-hospitalised 
subjects. The biochemical and hormonal findings which suggest that partial 
AVP deficiency develops with age are controversial. Previous research has 
shown that there maybe an increased AVP response to rise in pOS (Helderman 
et al 1978; Phillips et al 1984; Bevilacqua et al 1987) and this is the view 
expressed in many standard texts (Miller 1985). Not all studies have confirmed 
this however. Li et al (1984) showed that the elderly had a smaller increase in 
plasma AVP than the young after 14hr water deprivation and these authors 
suggested that the elderly may be in a state of incomplete CDI. Two recent 
reports have also indicated that there is perhaps a decreased sensitivity of AVP 
release to rise in pOS in the elderly (Mclean et al 1991; Duggan et al 1992). 
Studies of non-osmotic stimulation of AVP by orthostatic stimulus have shown a 
failure of AVP secretion with age (Segar & Moore 1968; Rowe et al 1982; 
Bevilaqua et al 1987). Other studies have shown an age related augmentation in 
AVP release in response to metaclopramide stimulation (Bevilaqua et al 1987; 
Chiodera et al 1991) but no age effect on AVP release stimulated by 
hypoglycaemia (Chiodera et al 1991). Miller (1985) and others (Chiodera et al 
1991) have argued that the apparent changes with age of osmotic regulated AVP 
secretion are related to an imbalance of afferent inputs to AVP secreting 
neurons in the hypothalamus secondary to reduction of afferent impulses from 
arterial baroreceptors. This imbalance leads to altered sensitivity to other 
stimuli to AVP secretion , possibly mediated by increased endogenous opioid 
activity. Such an hypothesis is not incompatible with the findings of this study 
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and further work to explore all facets of AVP secretion in individual elderly 
rather than population studies may elucidate the complex and probably variable 
interrelations and pathophysiology. 
Many elderly people complain of polyuria, especially at night . As well as to 
urological problems such as prostatism, this has been usually attributed to a 
decrease in urinary concentrating ability subsequent to a diminished GFR which 
is well recognised to occur with age (Lindeman et at 1960; Rowe et at 1976; 
Phillips et at 1984). This study has provided evidence that at least part of the 
diminished urinary concentrating ability may be due to a deficiency of AVP. 
Miller & Shock (1953) suggested that renal tubular concentrating ability in the 
elderly was relatively insensitive to AVP administration. This was not 
confirmed however, in a later study (Lindeman et at 1966) . This difference 
in 
findings remains unexplained. Similar to the argument used to explain the 
inadequacy of urine concentration after exogenous AVP in both CDI and 
primary polydipsia (Zerbe & Robertson 1981), failure of exogenous AVP to 
increase further urine osmolality in the elderly (Monson & Richards 1978) may 
be explained by a relatively hypo-osmolal renal medullary interstitium (a 
consequence of both renal aging and polyuria itself, de Wardener & Herxheimer 
1957). It does not necessarily confirm either a renal resistance to AVP nor does 
it necessarily imply that the senescent loss of concentrating ability can not be 
due to inadequate plasma AVP concentrations. 
Together with the well documented decrease in thirst perception with age, and 
the difficulty many elderly people may have with the practicalities of toiletting 
the possibility that a deficiency of osmotically stimulated AVP occurs in the 
elderly has very important implications for the maintenance of fluid balance and 
further research in the normal elderly is called for. 
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4.2.2 THE DEPRESSED ELDERLY PATIENTS 
Ten patients treated with Dothiepin and six patients treated with Fluoxetine were 
recruited into the study. Unless otherwise stated results were compared by 
unpaired t-tests and presented as mean±SEmean. 
4.2.2.1 PATIENTS TREATED WITH DOTHIEPIN (DOTHIEPIN) 
Four male and six female patients volunteered to take part in the study. Mean 
age was 65yr (52-77yr). The mean age and age range were not significantly 
different from the ELDERLY. 
All patients tolerated the water load without adverse effect. None experienced a 
significant fall in blood pressure or a significant change in degree of nausea 
during the water load test. 
Basal data 
The plasma and urine biochemistry and plasma AVP concentration of the 
DOTHIEPIN and ELDERLY groups are shown in Table 4.2. There were no 
significant differences between the groups in any of these parameters. 
Excretion of the water load 
Both the ELDERLY and DOTHIEPIN groups achieved a mean excretion of 
over 90% of the water load in the Or after ingestion (ELDERLY 91.9±4.6%, 
DOTHIEPIN 92.0±6.1%9 P=0.988). At no time point were there significant 
differences between the two groups in the percentage of the load excreted. 
Similarly, at no time point were there significant differences in the mean Cx2o 
of the two groups (Figure 4.5). 
Plasma osmolality 
Figure 4.6a shows the pattern of change in pOS of the DOTHIEPIN group 
compared to the ELDERLY. There were no significant differences between the 
two groups at any time point. 
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Table 4.2 The baseline plasma and urine biochemistry and AVP in 
normal ELDERLY controls and depressed patients treated 
with DOTHIEPIN (mean±SEM) 
pOS pNa uOS pAVP 
mosm/kg mmol/l mosm/kg pmol/l 
ELDERLY 293.5±0.5 139.4±0.3 508±47 0.5±0.1 
DOTHIEPIN 291.9±1.2 138.6±0.6 608.9±60 1.0±0.6 
pß. 238 p=0.258 X0.202 p=0.401 
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The excretion of an oral water load (20ml/kg) by healthy ELDERLY subjects and depressed 
subjects treated with DOTHIEPIN. 
a) The cumulative urine excretion in the 4hr after the oral water load expressed as a percentsge 
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Figure 4.6 
The effect of an oral water load (20ml/kg) on plasma and urine osmolality and plasma AVP in 
the 4hr after fluid ingestion in healthy ELDERLY and depressed elderly treated with 
DOTHIEPIN. 
Results are presented as mean t SEM. 
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Plasma AVP 
The changes in pAVP are shown for the DOTHIEPIN and ELDERLY groups 
in Figure 4.6b. There was a statistically significant difference in pAVP between 
the two groups at 30min after the start of ingestion of the water load 
(ELDERLY 0.2±0. Olpmol/l, DOTHIEPIN 0.28±0.09pmol/l, p=0.031). 
The limit of detection of pAVP by RIA used in this study was 0.2pmol/l 
(Section 2.2.6). For the purposes of data analysis in this research any individual 
measurement of pAVP below the limit of detection was attributed the value of 
the detection limit ie. 0.2pmol/l. Thus statistical analysis was perhaps not valid 
at such low concentrations of AVP, where many individual measurements were 
below the detection limit of the assay. What is important, however, is that both 
groups appropriately and adequately suppressed AVP in response to plasma 
hypo-osmolality. 
Urine osmolality 
The DOTHIEPIN group showed changes in urinary concentration in response 
to oral water loading which were remarkably similar to those of ELDERLY 
(Figure 4.6c). At 120min after the start of water load ingestion uOS was 
significantly different between the two groups (ELDERLY 87.7±7.7mOsm/kg, 
DOTHIEPIN 65.8±2.7mOsm/kg, p=0.013). At such low osmolalities there is 
considerable error in measurement and the results must be interpreted with 
caution. What is important is that both groups diluted urine to < l00mOsm/kg 
(Section 2.1.1.1). 
Depression and water balance 
The HRSD score was used as an estimate of the severity of depression of each 
patient. The DOTHIEPIN group had HRSD scores ranging from 2 to 16 out of 
a possible score of 50, suggestive of mild to moderate depression at the time of 
water load assessment. Figure 4.7 shows that there was no linear relationship 
between this score and either the basal osmotic status as measured by pOS 
(r=-0.410, p>0.05), or the percentage of the water load excreted after 4hr 
(r=-0.284, p>0.05). 
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a) The relationship between the basal plasma osmolality and the severity of depression (HRSD 
score) for each patient treated with Dothiepin. 
b) The relationship between the percentage of the water load excreted after 4hr and the severity 
of depression (HRSD score) for each patient treated with Dothiepin. 
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DISCUSSION 
There was no evidence from this study that patients with depression, treated 
with Dothiepin, had any abnormality in basal osmotic status or in their ability to 
respond to an oral water load and consequent plasma hypo-osmoality, when 
compared to a group of healthy people of similar age. Indeed the two groups 
had remarkable similarities in osmoregulatory function. 
There was no evidence that the severity of depression was related to any change 
in osmoregulation. However, since the number of patients in this study was 
small and the HRSD scores were over a very small range of mild to moderate 
depression, it is not possible to conclude that osmoregulatory function is not 
related to severity of depression. 
4.2.2.2 PATIENTS TREATED WITH FLUOXETINE (FLUOXETINE) 
Four female and two male patients were recruited to take part in the study. 
Fluoxetine treatment had usually been commenced after a trial of other 
medications and therapies. Thus some of the patients had complex and resistant 
psychiatric illness. Others were treated with Fluoxetine because of physical 
frailty and the occurrence of adverse effects with other antidepressants. Some 
patients therefore had a variety of physical illnesses in addition to their 
depression. 
Subjects had received Fluoxetine for 20-300 days. 
The results of the individual subjects are presented here as brief case histories 
since the complex nature of their illness and the small numbers make statistical 
analysis of the group as a whole inappropriate. 
Subjects 
EL 
64yr female. 
Medical problems: partial gastrectomy for peptic ulcer disease, glaucoma. 
Other medications: Thioridazine 25mg QID. Raz idine 300mg nocte. 
Psychiatric problems: Several episodes of unipolar depression previously treated 
with tricyclic antidepressants. Current episode resistant to tricyclic medications. 
134 
HRSD score 17. 
Fluoxetine treatment: Dose 20mg BD, duration 20day. 
60yr male. 
Medical problems: None. 
Other medications: Thioridazine 100mg nocte. T 
Psychiatric problems: Recurrent unipolar depression over 5yr. Current episode 
prolonged and resistant to other medical treatments. 
HRSD score 12. 
Fluoxetine treatment: Dose 20mg BD, duration 300day. 
64yr female. 
Medical problems: Hypertension, duodenal ulcer, arthritis. 
Other medications: Aetenolol 50mg OD, Distalgesic 2tab QID, Temazepam 
10mg nocte. 
Psychiatric problems: No previous episode of depression. Equivocal diagnosis 
of dementia or pseudodementia secondary to depression. CT scan suggested 
generalised atrophy with some suggestion of multiple small infarcts. 
HRSD score: 20. 
Fluoxetine treatment: Dose 20mg nocte, duration 157day. 
52yr female. 
Medical problems: Arthritis. 
Other medications: Naproxen 250mg BD. 
Psychiatric problems: No previous episode of depression. Treated with ECT 
prior to Fluoxetine. 
HRSD score: 0 
Fluoxetine treatment: Commenced as maintenance or prophylactic therapy after 
ECT. Dose 40mg, duration 140day. 
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M 
69yr female. 
Medical problems: Arteriopath. Previous bi-femoral bypass graft. Partial 
gastrectomy for peptic ulcer disease. 
Other medications: None. 
Psychiatric problems: No previous episode of depression. 
HDSR score 13. 
Fluoxetine treatment: Dose 20mg OD, duration 112day. 
M 
50yr male. 
Medical problems: Peptic ulcer disease. 
Other medications: Temazepam 10mg nocte. 
Psychiatric problems: Longstanding anxiety. First episode of depression. 
HDSR score: 10. 
Fluoxetine treatment: 20mg OD, duration 72day. 
Basal data 
The plasma and urine biochemistry and plasma AVP of the six subjects at the 
start of the water load are shown in Table 4.3. The data for ELDERLY and 
DOTHIEPIN from Table 4.2 are included for ease of comparison. The pOS of 
subject F4 was just below the 95 percentile of the ELDERLY (288.4- 
298.4mOsm/kg). This subject was the youngest of the group (52yr) and, since 
pOS increases with age (Section 4.2.1) this may have accounted for the 
difference. The pAVP concentration of subject F5 was greater than the 95 
percentile of the ELDERLY (0.2-1.4pmol/1). This subject also had a high basal 
pOS and the pAVP concentration appeared to be appropriate to this. 
There was no evidence of true hypo-osmolality or SIAD in the basal 
measurements of any of the subjects. 
Excretion of the water load 
The percentage of the oral water load excreted after 4hr is shown for each 
subject in Figure 4.8. The data for ELDERLY and DOTHIEPIN groups are 
also shown. Subject F5 excreted a significantly lower percentage of the load 
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Figure 4.8 
The percentage of the oral water load (20ml/kg) excreted in 4hr by each depressed elderly 
subject treated with Fluoxetine (Fl-F6) compared to healthy ELDERLY and depressed patients 
treated with DOTIIIEPIN. 
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Figure 4.9 
The percentage of the oral water load excreted after 4hr by healthy ELDERLY, depressed 
patients treated with DOTIHIEPIN and depressed patients treated with Fluoxetine (F1-F6) 
adjusted for variation in renal function (C. ). 
than that of ELDERLY (95 percentiles 50.1-133.7%). All other subjects 
achieved a total excretion volume within these limits. Figure 4.9 shows the 
percentage of the water load excreted adjusted for Ccrut for all FLUOXETINE 
subjects and the DOTIIIEPIN and ELDERLY groups. The abnormality 
volume of the water load excretion by subject F5 was largely explained by her 
very abnormal C... 1(19m1/min). 
The pattern of water load excretion- for each individual in comparison to the 95 
percentiles for the ELDERLY at each time point is shown in Figure 4.10. 
There was much inter-individual variation in the pattern of excretion. Subject 
F5 showed an abnormal excretion of the water load from 90min after the start of 
water load ingestion. None of the other subjects showed any apparent delay in 
excretion of the water load. 
Changes in plasma and urine 
The changes in response to the water load of pOS and uOS, plasma AVP and 
CH2O for each individual are shown in figures 4.11-4.16. The 95 percentiles of 
response of the ELDERLY are shown for comparison. 
Subject Fl: (Figure 4.11) 
The pattern of change of all parameters was similar to that of the ELDERLY at 
all time points. There was no evidence of any abnormality of response to the 
oral water load and no evidence of inadequate suppression of AVP in response 
to plasma hypo-osmolality. 
Subject E2 
. 
(Figure 4.12) 
The change in pAVP in response to decrease in pOS was slightly abnormal in 
this subject. pAVP concentration at 120min was inappropriately elevated at 
0.7pmol/l. This subject had not been nauseated nor experienced a fall in blood 
pressure to account for the rise in pAVP. At 4hr the pAVP had suppressed to 
below the limit of detection. The subject achieved excretion of 89% of the 
water load at 4hr and although his pOS remained 5mOsm/kg lower than at the 
start of the water load test, this fell within the distribution of the ELDERLY 
(pOs 3.5±0.5mOsm/kg less than baseline at 4hr) (see Section 4.2.1). Thus 
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Figure 4.10 
The cumulative excretion of the water load (20ml/kg) in the 4hr after ingestion expressed as a 
percentage of the water load for each depressed subject treated with Fluoxetine (Fl-F6). 
The 95 percentiles for the healthy ELDERLY are shown for comparison (--). Subject FS 
showed an abnormal pattern of excretion from 90min after fluid ingestion. 
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Figures 4.11-4.16 
The effect of an oral water load (20ml/kg) on function, plasma osmolality, plasma AVP and the 
changes in free water clearance and urine osmoality in the 4hr after fluid ingestion for each 
elderly depressed subject treated with Fluoxetine (Fl-F6). The 95 percentiles of the normal, 
healthy ELDERLY are shown for comparison. The individual responses are discussed in the 
text. 
a) Urine osmolality; b) Plasma AVP; c) Free water clearance; d) Plasma osmolality. 
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Figure 4.16 
although the rise in pAVP at 120min remains unexplained it did not appear to 
have significant effect on osmotic status. 
Subject (Figure 4.13) 
This subject was unable to pass urine at the start of the water load assessment 
due to an empty bladder. She also had great difficulty with some aspects of the 
test, particularly the linear analogue assessment of nausea, due to her depression 
induced pseudodementia. The dilution of urine, and therefore CH20 were 
abnormal with uOSmin 172mOsm/g and CH2Omax 1.39m1/min. These 
abnormalities could not be attributed to reduced renal function since C,,., was 
101 ml/min. The pAVP response was appropriate to change in pOS and 
remained below the limit of detection at 4hr. Thus the abnormality of urine 
dilution remains unexplained but allowed excretion of 85 % of the water load. It 
is possible that the uOS abnormality was related to the hypertension and 
antihypertensive therapies with salt loss from the proximal renal tubule. 
Subject E4 (Figure 4.14) 
This subject had a normal excretion of the water load with normal suppression 
of pAVP and urinary dilution. Basal pOS was lower than predicted from the 
ELDERLY group but as discussed above this may be attributable to the age of 
the subject. 
EnbiW 5' (Figure 4.15) 
This subject, as discussed above had abnormal renal function with abnormal 
excretion of the water load. At the time of the water load assessment she 
appeared clinically hypovolaemic (postural drop in systolic BP > 20mmHg) and 
this was substantiated by the high pOS. The changes in pOS, uOS and pAVP 
after ingestion of the water load are abnormal. pAVP remained detectable at all 
time points and C1120 changed only minimally. uOS was 272mOsm/kg. pOs Ir" 
however, fell to the mid normal range. 
Two explanations are possible: 
a) That this subject had inappropriate AVP secretion with retention of 
the fluid due to inability to dilute urine and increase CH2O and that a pOS of 
287mOsm/kg was abnormally low for this subject. 
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b) That the subject was initially hypovolaemic with plasma 
hyperosmolality and the oral water load merely allowed return to a normal 
osmotic status. The pAVP concentration of 0.5pmol/1 would be appropriate for 
a pOS of 287mOsm/kg. 
Since basal pOS in this subject was 299mOsm/kg with pAVP concentration of 
2.5pmol/l it would seem that the second of these two explanations is the more 
likely. 
Subject E (Figure 4.16) 
This subject had a marked fall in pOS after ingestion of the water load, and 
consequent appropriate responses in pAVP, uOS and CN2O. He excreted 85% 
of the water load and pOS returned to basal concentration. 
Depression and osmoregulation 
Figure 4.17a shows that there was no direct relationship between severity of 
depression and basal pOS (r=0.487, p>0.05) and Figure 4.17b shows that the 
severity of depression was not related to the excretion of the oral water load in 
these subjects (r=-0.378, p>0.05). 
DISCUSSION 
There was no evidence from this study of osmoregulation in six subjects treated 
with Fluoxetine to suggest an abnormality in basal osmotic status or 
inappropriate AVP secretion in response to the hypo-osmolality after water 
loading. Although subject F5 had an abnormal water load assessment it would 
seem likely that this was not primarily due to abnormal AVP secretion since 
pOS was elevated at baseline. 
There was no evidence from this study that the severity of depression was 
related to any alteration in osmoregulatory function. The very small number of 
subjects and the narrow range of severity of depression does not, however, allow 
any degree of certainty in this conclusion. 
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a) The relationship between the basal plasma osmolality and the severity of depression (HRSD 
score) for each depressed patient treated with Fluoxetine (r=0.487 p>0.05). 
b) The relationship between the percentage of the water load excreted after 4hr and the HRSD 
score for each Fluoxetine treated depressed patient (r=-0.378 p>0.05). 
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4.3 DISCUSSION 
The methodological difficulties inherent to patient studies, and perhaps 
particularly to patients with depression, are apparent from this research. Study 
4.1 was abandoned because of the problems of patient recruitment discussed 
above. This study would have answered very important and interesting 
questions about water balance in depression and the influence of drug treatment. 
Although it might have been possible to fulfil the aims of the study by 
approaching patients in the community through general practitioners, it was felt 
that this would have been impractical for the researcher working alone. 
Elderly subjects were selected for this study because of the preponderance of 
reports of Fluoxetine associated hyponatraemia in patients over 50yr, although 
the possibility of this being a false overrepresentation of this age group has 
already been discussed (Section 3). Study 4.2 has provided new and 
controversial data on osmoregulation in normal healthy elderly which suggests a 
deficiency of AVP secretion. It is possible that subjects who volunteered for 
this study did so because of osmoregulatory dysfunction and polyuria, and a 
desire to understand and perhaps receive treatment, thus biasing the study 
population. Even if this is true the presence in the community of such a large 
group of healthy individuals with dysfunction of AVP secretion requires further 
study and possibly therapeutic action. 
It is possible that this age related osmoregulatory abnormality makes elderly 
depressed patients particularly vulnerable to the hyponatraemia associated with 
Fluoxetine and other drugs. As discussed in Section 4.2.1 it is possible that the 
dysfunction of osmoregulated AVP secretion in the elderly relates to an 
imbalance of afferent stimuli to the magnocellular AVP secreting neurons. 
Bevilacqua et al (1987) found that normal elderly had an augmented AVP 
response to metaclopramide. This was directly related to a diminished AVP 
response baroregulatory stimuli. This imbalance may be more marked in 
depression where there is a putative abnormality of 5HT neurotransmission. 
Fluoxetine, by stimulation of 5HT neurotransmission, may cause further 
imbalance of these afferent stimuli and thus lead to AVP secretion inappropriate 
to the osmotic stimulus. 
Dothiepin treatment had no significant effect on osmoregulation in the ten 
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subjects studied. There is one report of SIAD associated with Dothiepin (Fort 
et al 1985). This patient had liver disease and was taking diuretics in addition to 
the Dothiepin. Thus it would seem that Dothiepin rarely leads to problems of 
water balance. 
There was no evidence from this study that the treatment of depression with 
Fluoxetine lead to abnormal osmoregulation in any of the six subjects studied. 
The small number of subjects, the relatively mild severity of depression and the 
long duration of treatment with Fluoxetine in most subjects has not allowed full 
exploration of the hypotheses of the study. In addition the large inter-individual 
variation in water load assessment enabled only marked abnormalities of 
osmoregulation to be detected. 
There was no evidence from this study that depression per se leadto abnormal 
osmoregulation. The small number of subjects and the narrow range of HRSD 
scores does not, however, allow a conclusion about this hypothesis. 
The only conclusion that can be made with confidence from this study is that 
hyponatraemia associated with the Fluoxetine treatment of depression is not a 
common problem. Appendix 10 presents two brief case reports of patients who 
were brought to my attention during this research, with hyponatraemia 
associated with major depression. Both patients developed hyponatraemia 
during treatment of their depression with a SSRI. One patient had a severe 
major depressive episode, evidence of physical illness and was taking 
prednisolone at the time of onset of the hyponatraemia. The other patient had 
severe psychotic depression and was taking a variety of medications, including 
diuretics, for her ischaemic heart disease. Both declined further assessment of 
osmoregulated AVP secretion but fortunately both responded promptly to fluid 
restriction. It is possible that exclusion of patients with significant physical 
illness who were taking other medications, and the absence of patients with 
severe mental illness from this research, has lead to omission of the very 
patients who are most vulnerable to Fluoxetine associated SIAD. Further work 
is needed to explore this and to elucidate the markers and predictors of such 
putative vulnerability. 
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SECTION 5 
STUDIES OF THE EFFECT OF 
5HT ON 
OSMOREGULATED AVP SECRETION 
IN RATS 
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INTRODUCTION 
This section comprises 'a series of studies in rats to explore the effect of 
5HT on osmoregulated AVP secretion using the model described in Section 
2.1.2.1. For clarity the raw data for each Study has been included in Appendix 
11. Except where otherwise discussed the results were analysed by un-paired t 
tests or analysis of variance (ANOVA) as appropriate and have been presented 
as mean±SD or mean±SE respectively. The standard deviation has been used 
to indicate the variation in response within the group since this is of some 
interest in addition to the mean response. Analysis of variance involves multiple 
significance testing and where this has been used for data analysis a1% 
probability level has been accepted as a significant difference between means. 
For t-test and other analyses a significant difference at a5% probability level 
has been accepted. 
Where groups of rats have been allotted a two letter label the first letter refers to 
the treatment type and the second letter refers to the osmotic stimulus type. 
5.1 THE EFFECT OF PLASMA HYPEROSMOLALITY ON SilT 
NEUROTRANSMISSION IN THE NEUROIIYPOPIIYSIS 
BACKGROUND 
Anatomical evidence for the involvement of 5HT in the release of AVP from the 
neurohypophysis has been discussed in Section 1.4.1.5HT nerve fibres have 
been identified in the neurohypophysis and there is a relatively high 
concentration of 5HT present. 5HT2 receptors have been identified in 
relatively high density in the neurohypophysis of rats (de Souza 1986) and the 
isolated rat neurohypophysis has been shown to release AVP when stimulated by 
exogenous 5HT (Lemay et al 1979). Piezzi & Wurtman (1970) found that the 
5HT content of the neurohypophysis was significantly decreased after a period 
of water deprivation. Handley & McBlane (1991) have also found alteration in 
5HT metabolism after water deprivation and suggested that there was an 
increase in 5HT turnover in the rat whole brain. 
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1 
These factors would suggest that 5HT may be involved in the release of AVP 
from magnocellular nerve endings in the neurohypophysis. This study was 
undertaken to further explore this possibility. 
GENERAL HYPOTHESES 
1. That 5HT is involved in the release of AVP from the neurohypophysis in 
response to plasma hyperosmolality. r, ' 4' 
2. That hyperosmotic stimulation leads to an increase in 5HT turnover with a 
reduction in 5HT concentration and an increase in the ratio of 5HIAA: SHT. 
SPECIFIC AIMS 
1. To 'pilot' the techniques of the animal model of osmoregulation of AVP 
descri bed in Section 2.1.2.1. 
2. To 'pilot' the use of HPLC to measure changes in 5HT and 5HIAA in the 
neurohypophysis described in Section 2.7.1. 
3. To investigate the effect of plasma hyperosmolality on the 5HT content and 
5HT turnover in the rat neurohypophysis. 
METHODS 
Day 1: Female Wistar rats, of two litters were randomly allocated to 2 groups: 
N(normal controls), H (hypertonic stimulus). 
Day 2: Rats were alternately taken from each of the two groups and received 
20m1/kg IP 0.9% NaC1(N) or 3% NaCI (H). 30min after the injection rats were 
killed and trunk blood and neurohypophysis collected as described in Section 
2.1.2.1. 
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RESULTS 
The analysis of data has excluded Rat 6, which received hypertonic saline, since 
it showed a highly atypical AVP response with a rise in AVP to 77.8pmoll (see 
discussion). 
Plasma measurements 
Table 5.1.1 shows the changes in plasma in response to the hypertonic stimulus. 
The stimulus caused a significant rise in pNa and pAVP but pOS was not 
significantly different between the two groups. The lack of significant effect of 
the hypertonic stimulus on pOS was thought to be masked by the large 
variability within the normal group. Comparison of the pOS results by one 
tailed t-test (ie consideration only of a significant increase in pOS) showed a 
significant effect of hypertonic saline administration (p < 0.005). 
Neurohypophysial measurements 
The Neurohypophysis 5HT content and turnover (ratio 5HIAA: 5HT) of the two 
groups is shown in Figure 5.1. Non-parametric statistical analysis, by 
Wilcoxon rank sum, found no significant differences between the groups. 
DISCUSSION 
The first aim of this experiment was as a pilot study of this animal model of 
osmoregulated AVP. Two problems were apparent. Firstly that one rat had a 
pAVP response which was very different from the remainder of the group. The 
magnitude of this response would suggest that the release of AVP was 
stimulated by other factors, ie. non-osmotic release. This may have been pain, 
barometric stimulation secondary to blood loss or secondary to stimulation of 
the gut wall. In order to try to explain this result haematocrit samples would be 
taken in future studies as an indication of blood volume. 
The second problem was the lack of statistically significant effect of hypertonic 
saline on pOS. This was thought to be due to a greater variability than 
anticipated. This was attributable to one rat with a very low pOS 
(282m0sm/kg), If this variability were to persist in other experiments a group 
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Table 5.1.1 The effect of hypertonic saline on plasma biochemistry and 
AVP concentration, (mean±SD) comparison by t"test 
N=normal, H=hypertonic 
Group N Weight pNa pOS pAVP 
(g) (mmol/I) (mOsm/kg) (pmol/I) 
N6 200.5±19.4 141.0±1.4 
H5 199.4±20.7 145.4±0.5 
P=0.927 p<0.001 
298.5±9.2 2.7±1.6 
307.6±2.4 12.1±2.7 
pß. 061 p4.001 
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Figure 5.1 
30 p>0.05 p>0.05 
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p>0.05 
0 
5HT 5HIAA 5HIAA/5HT 
The effect of plasma hyperosmolality on SHT concentration and turnover (SHIAA: SHT) in the 
neuropituitary (mean±SEM). There was no significant difference in the pituitary amine content 
or SHT turnover in those rats treated with 3% NaCI compared to rats treated with 0.9 % NaCI 
ý> 0. O5). 
size of over 50 (power 90%) would be required to detect a difference in mean 
pOS of 5mOsm/kg between groups, or a group size of about 15 to detect a 
difference in mean pOS of 1OmOsm/kg. 
The second aim of the study was to pilot the HPLC analysis of neuropituitary 
amine content. The very small amount of tissue present in the neurohypophysis 
allowed measurement of 5HT and 5HIAA on only one aliquot of homogenate, 
therefore increasing the possibility of experimental error. In addition there was 
a large amount of variability observed. It was therefore unlikely that accurate 
and useful results could be provided by this technique. Three groups have 
previously measured the 5HT content of the neurohypophysis in rats. Saavedra 
et al (1977), using an enzymatic-isotopic technique found a concentration of 
4.0± 1. Ong/mg protein, equivalent to 18.8pmol/mg protein. Koulu et al (1989) 
found a concentration of approximately 15pmol/mg protein using HPLC, whilst 
Piezzi & Wurtman (1970) found a concentration in normal rats of 752pmol/mg 
protein using fluorometric analysis of the homogenate. The reason for this 
variation in magnitude is likely to be methodological. The mean concentration 
of 5HT in the neurohypophysis of the normal group of rats in this study 
(18.5±3. Opmol/mg protein) was very similar to the concentration of the first 
two studies. 
Taking into account these experimental limitations there was no evidence from 
this study to suggest that 5HT is involved in the release of AVP from the 
neurohypophysis consequent to plasma hyperosmolality. Piezzi & Wurtman 
(1970) found a significant decrease in neurohypophysial 5HT content in rats 
after 5 days of water deprivation. This prolonged period of fluid deprivation 
would have caused a marked rise of pOS but would also have lead to blood 
volume depletion. Thus the alteration in 5HT content may have been a 
consequence of baroregulated AVP secretion. Similarly Handley & McBlane 
(1991) found that 5HT turnover (in whole brain) was significantly elevated only 
after water deprivation for 36hr or longer. 
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5.2 THE EFFECT OF ACUTE FLUOXETINE TREATMENT ON 
OSMOREGULATED AVP SECRETION. 
BACKGROUND 
Fluoxetine has been shown to acutely stimulate both pituitary portal and 
systemic plasma AVP secretion in anaesthetised rats (Gibbs & Vale 1983). 
However Stein et al (1987), -in a study of serotonergic influences on electrolyte 
and water excretion in vivo in rats, found that Fluoxetine had no effect on basal 
excretion of sodium, potassium or urine. The association of Fluoxetine with 
hyponatraemia in its clinical use in depression in man has been discussed in 
Section 3 and Section 4. Since the evidence discussed in Section 1.4 would 
suggest that 5HT has a role in modulation of AVP secretion in rats and other 
animals, with 5HT agonism leading to AVP release and antidiuresis, it may be 
that Fluoxetine stimulates AVP through increase in 5HT neurotransmission. 
There has been little exploration of the role of 5HT in dynamic, osmoregulated 
AVP secretion. The purpose of this and following studies was to explore 
further the influence of 5HT on osmoregulation using Fluoxetine and other 5HT 
active agents discussed in Section 2.3. 
GENERAL HYPOTHESES 
1. That increase in synaptic 5HT has a modulatory effect on secretion of AVP 
in response to experimentally induced change in pOS. 
2. That systemic Fluoxetine administration leads to an increase in central 
synaptic 5HT concentration. 
SPECIFIC AIM 
To explore the effect of acute treatment with Fluoxetine on osmoregulated AVP 
secretion. 
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STUDY 5.2.1 
METHODS 
Day 1: rats were randomly allocated to 6 groups; NN FN NL FL Nil FH. All 
F groups then received 10mg/kg IP Fluoxetine (1mg/ml in 0.9% NaCI) and all 
N groups received 10ml/kg IP vehicle (0.9% NaCI). 
Day 2: 18hr after the injection rats were given 20ml/kg IP 0.9% NaCl (N), 
distilled water (L) or 3% NaCl (H) according to their group. 30min after the 
osmotic stimulus rats were killed and trunk blood collected as described in 
Section 2.1.2.1. 
RESULTS 
Plasma biochemistry 
The plasma biochemical measurements for each of the 6 groups of rats is shown 
in 'Fable 5.2.1. Analysis by ANOVA showed that the experimental design 
provided significant changes in pOS (p<0.001). Fluoxetine treatment had no 
significant effect on the change in pOS (p=0.441). Similarly pNa was 
significantly effected by osmotic stimulus (p<0.001) but not by Fluoxetine 
(p =0.575). 
Plasma AVP 
Figure 5.2.1 shows a scattergram of log, ppAVP in each group of rats. 
This 
shows that there were many rats, including those in groups NN, Nil and NL, 
which had a pAVP of > 30pmol/l, suggestive of a non-osmotic stimulus to AVP 
secretion. The fact that many rats in the normal control groups had pAVP of 
high concentration indicates that this should be attributed to an effect of the 
experimental technique, rather than an effect of Fluoxetine. 
Figure 5.2.2 shows the pAVP for each group omitting rats with plasma 
concentrations > 30pmol/1. The relationship between pAVP and pOS has been 
plotted in Figure 5.2.3 for these rats and the linear regression analysis plotted. 
If this data can be taken to represent the underlying trend of pAVP response 
Fluoxetine had no significant effect on basal AVP concentration or on AVP 
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Table 5.2.1 The effect of acute Fluoxetine (10mg/kg IP) (F) and osmotic 
stimulus (N, H, L) on plasma biochemistry (mean±SEM). The p value 
results, from ANOVA, test the hypothesis that osmotic stimulus and 
Fluoxetine had no effect. The weights of the rats are presented as mean±SD. 
Group N Weight pNa pOS 
(g) (mmoUI) (mOsm/kg) 
NN 10 256.6±8.7 143.5±1.9 298.9±2.4 
FN 10 249.1±8.4 142.4±1.9 296.7±2.4 
NL 10 251.5±11.8 139.4±1.8 288.8±2.3 
FL 10 250.7±13.1 138.2±1.9 288.8±2.3 
NH 10 244.7±10.7 147.2±1.9 307.9±2.4 
FH 11 250.3±10.1 146.9±1.9 305.5±2.4 
EFFECTS 
Osmotic stimulus pc0.001 p<0.001 
Fluoxctine p=0.441 pß. 575 
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The effect of Fluoxetine treatment (10mg/kg IP) on plasma AVP 30min after an osmotic 
stimulus of 20m1/kg IP 0.9% NaCI (N), 3% NaCL (H) or distilled H2O (L). 
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Figure 5.2.2 
The effect of Fluoxetine treatment on osmoregulated AVP secretion in each osmotic stimulation 
group, omitting those rats with a very high AVP concentration (> 30pmolll). Results are 
presented as mean :t SD. 
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Figure 5.2.3 
The effect of Fluoxetine treatment (10mg/kg) on the relationship between AVP and pOS after a 
normal, hypertonic or hypotonic osmotic stimulus. The analysis by linear regression suggests 
that there was no significant effect of treatment with Fluoxetine on either the osmotic threshold 
or the osmotic sensitivity of AVP secretion. 
concentration after hypo or hyper-osmotic stimulation. Further more it would 
seem that Fluoxetine had no significant effect on the sensitivity (slope of 
regression line) of AVP release in response to change in plasma osmolality (N 
0.30, F 0.40 pmol/l per mOsm/kg) or on the osmotic threshold of AVP release 
(N 277.9, F 285.4 mOsm/kg). Simple linear regression analysis may not, 
however be the most appropriate method of analysis of the data and is discussed 
further in Section 5.2.5. 
Table 5.2.2 shows the plasma biochemistry of the 6 groups omitting the data for 
rats with pAVP > 30pmol/1. 
DISCUSSION 
The most striking result of this study was the large, and apparently random, 
variability in AVP response to osmotic stimulus. The occurrence of this within 
the normal control groups suggests that this was due to the experimental 
technique or inherent to the rats. The following were considered as possible 
explanations: 
1. Vehicle and Fluoxetine were administered 18hr prior to the osmotic 
stimulus. This may have physically damaged rats (eg. by injection into internal 
organ with subsequent blood loss) and the time interval to collection of blood for 
analysis had, in comparison to Study 5.1, allowed such disturbance to become 
apparent in the plasma parameters. However none of the rats appeared unwell 
at the time of injection of the osmotic stimulus suggesting that severe physical 
trauma was unlikely. 
2. The vehicle and Fluoxetine injection fluids may have been contaminated and 
rats may have been infected and septicaemic at the time of osmotic stimulation. 
There was no evidence to support this. 
3. The injection of Fluoxetine or vehicle 18hr prior to the osmotic stimulus may 
have altered osmoregulation of AVP secretion by stimulation of the 
magnocellular neurons by afferent "stress" impulses. The role of stress in 
modulation of AVP secretion is controversial (see Section 1.1.2.2.5) but it 
seemed possible that this may have had a significant role and could explain 
variability of AVP response, although a recent study would suggest that 
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Table 5.2.2 The effect of acute Fluoxetine (10mg/kg IP) (F) and osmotic 
stimulus (N, IH, L) on plasma biochemistry omitting rats with high AVP 
response (mean±SD) 
Group N pNa pOS 
(mmoVI) (mOsm/kg) 
NN 8 142.1±7.9 295.9±5.6 
FN 9 143.2±4.6 298.3±5.6 
NL 10 140.4±5.5 289.7±6.1 
FL 10 138.2±4.3 288.8±5.7 
NH 8 145.1±4.5 304.8±7.9 
FH 9 146.3±5.0 305.1±6.9 
emotional stress, at least chronically, inhibits normal AVP responses to dynamic 
stimuli (Yagi & Onaka 1991). 
Exclusion of the extreme AVP responders from the data analysis still, however, 
showed that the experiment had not provided a good model of osmoregulated 
AVP secretion since mean pAVP in NL was 5.6pmol/1 (Figure 5.2.2). A 
hypotonic stimulus would be expected to suppress AVP to < lpmol/l. In 
addition the low correlation coefficient of pAVP to pOS (N r=0.394, p>0.05) 
(Figure 5.2.3) suggested that the model was unsuccessful. 
It was impossible therefore to draw conclusions from this study about the effect 
of Fluoxetine on osmoregulated AVP secretion, although Figure 5.2.3 might 
suggest that the underlying trend was of no significant effect. 
STUDY 5.2.2 
The hypotheses and aims of this study were identical to Study 5.2. The study 
design was altered in the light of the discussion above. 
METHODS 
Day 1: Male Wistar rats randomly allocated to 4 groups; NII, FH, NL, FL 
Day 2: Rats received in F groups 10mg/kg IP Fluoxetine (1 mg/ml in 0.9% 
NaCl) and in N groups l0ml/kg IP vehicle (0.9% NaCl). This was followed 
30min later by osmotic stimulus of 20ml/kg IP 3% Nacl (Ii) or distilled water 
(L). Rats were killed 30min subsequent to the osmotic stimulus injection and 
trunk blood collected. 
RESULTS 
Plasma biochemistry and haematocrit 
The plasma biochemistry and haematocrit (HCT) values for the 4 groups of rats 
are shown in 'Fable 5.2.3. ANOVA showed that the osmotic stimulus caused 
significant change in pOS (p<0.001) and pNa (p<0.001). Fluoxetine had no 
significant effect on this stimulus (p=0.240 for pOS and p=0.338 for pNa). 
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Table 5.2.3 The effect of acute Fluoxetine (10mg/kg IP) (F) and osmotic 
stimuli (II, L) on plasma biochemistry and haeniatocrit (mean±SEM). The p 
value results, from ANOVA, test the hypothesis that osmotic stimulus and 
Fluoxetine had no effect. The weights of the rats are presented as mean±SD. 
Group Weight pNa pOS NCT 
(g) (mmol/l) (mOsm/kg) (%) 
NH 265.0.0±28.5 155.7±1.2 315.3±2.1 43.1±0.8 
FH 270.2±15.9 154.6±1.2 315.8±2.1 44.1±0.9 
NL 258.9±24.4 149.2±1.2 298.5±2.1 45.2±0.8 
FL 267.9±23.0 149.2±1.4 303.5±2.4 46.8±0.9 
EFFECTS 
Osmotic stimulus p<0.001 pc0.001 
Fluoxcdnc p=0.338 p=0.240 
pß. 006 
p=0.128 
Haematocrit was significantly affected by the osmotic stimulus (p=0.006) but 
Fluoxetine had no significant effect (p=0.128). 
Plasma AVP 
The pAVP concentrations of the 4 groups are shown in Figure 5.2.4. The 
distribution of pAVP was apparently random and not related to osmotic stimulus 
or treatment with Fluoxetine. 
DISCUSSION 
The AVP response to osmotic stimulation was extremely variable in these 
groups of rats and seemed unrelated to osmotic stimulus or treatment with 
Fluoxetine. This result was disappointing and perplexing since it implied that 
the model of osmoregulation of AVP secretion in the rat was incorrect. 
Comparison of the pOS changes with those of rats in Study 5.2.1 (Table 5.2.1) 
showed that the magnitude of change of pOS between groups within each study 
was similar (5.2.1 NI1-NL = 19mOsm/kg, 5.2.2 NII-NL = 16.8mOsm/kg) but 
the mean pOS of comparable groups were lower in Study 5.2.1 than Study 
5.2.2. This would imply that the basal pOS of rats in Study 5.2.2 was higher 
than in Study 5.2.1. In retrospect it was unfortunate that a basal group (NN) 
was not included in the study design. The reason for this basal difference of 
approximately lOmOsm/kg between the two study groups was not clear. Rats 
were of the same strain, all imported from the same supplier and housed under 
similar conditions. 
It was possible that the higher basal pOS of rats in this experiment prevented the 
water load from providing adequate plasma hypo-osmolality to suppress AVP 
secretion in the NL and FL groups but it would not explain the large variation 
of AVP concentration in the group. In addition many of the rats had AVP 
concentrations > 3opmol/l, suggestive of a non-osmotic stimulus to secretion. 
The total volume of fluid administered to each rat was 30m1/kg. This would 
present a significant intra-peritoneal volume load and may have lead to non- 
osmotic AVP secretion by stimulation of pain or nocioceptors in the peritoneal 
cavity. This hypothesis was explored in Study 5.2.3. 
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The effect of Fluoxetine (IOmg/kg IP) on the AVP response to an osmotic stimulus of 3% NaCI 
(H) or distilled H 20 (L). 
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STUDY 5.2.3 THE EFFECT OF INJECTION VOLUME ON 
OSMOREGULATED AVP SECRETION 
HYPOTHESIS 
That the volume of injection of drug or vehicle preceding the osmotic stimulus 
alters the AVP response to the osmotic stimulus. 
AIM 
To see if there was a significant effect of volume of Fluoxetine injection on the 
AVP response to plasma hypo-osmolality. 
METHODS 
Fluoxetine solutions: 1mg/ml in 0.9%NaC1(L), 10mg/ml in water (Il). 
Male Wistar rats were randomly allocated to two groups and each were given 
10mg/kg of Fluoxetine either as solution L (10ml/kg) or 11 (lml/kg). 30min 
later all rats received a hypo-osmotic stimulus, 20m1/kg IP distilled water, and 
trunk blood was collected 30min after this injection. 
RESULTS 
Figure 5.2.5 shows that the volume of Fluoxetine injection had no significant 
effect on either the degree of plasma hypo"osmolality induced by the water load 
(L 292.2±3.7, H 292.0±4.5 mOsm/kg, p=0.946), or on the AVP response to 
this plasma hypo-osmolality (L 0.6±0, H 0.7±0.1 pmol/1, p=0.341). AVP 
was suppressed to minimal concentration in both groups of rats. This would 
suggest that Fluoxetine does not prevent the suppression of AVP consequent to 
plasma hypo-osmolality. 
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DISCUSSION 
The lack of significant effect of injection volume on the AVP response to 
plasma hypo-osmoality was unexpected and refutes the hypothesis of this study. 
Both groups of rats in this study showed very low variability of AVP response. 
The only apparent reason for this difference to studies 5.2.1 and 5.2.2 was that 
in this study rats were allocated to groups on the same day as the experiment 
was carried out. This suggested that randomisation to groups with "alien" rats 
might have effect on the AVP response to osmotic stimulus, implying that social 
stress stimulated AVP secretion, both increasing basal release and altering the 
characteristics of osmoregulated secretion. This was explored further in Study 
5.2.4. 
It was interesting that the mean pOS of both groups of rats was similar to that of 
NL in Study 5.2.1 and lower than that of comparable group in Study 5.2.2. 
The reason for these changes was not clear. 
It may be tentatively concluded from this study that Fluoxetine had no 
significant effect on the AVP response to hypo-osmotic stimulus since it would 
be anticipated that the normal response of rats would be suppression of AVP to 
minimal plasma concentration (< 0.6pmol/1). 
STUDY 5.2.4 THE EFFECT OF HANDLING AND "SOCIAL STRESS" ON 
OSMOTIC STATUS 
HYPOTHESIS 
That the handling of rats and random allocation to groups may have effect on 
basal and osmoregulated AVP secretion. 
SPECIFIC AIMS 
To see if the basal osmotic status of rats is altered by handling and the "social 
stress" of contact with alien rats. 
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METHODS 
Day 1: Group (A). Six male Wistar rat were removed from the animal breeding 
store and randomly allocated to two cages. 
Day 3: Group (B). Six male Wistar rats were similarly allocated to 2 cages. 
Day 4: Trunk blood was collected from all rats. 
RESULTS 
The plasma results for the two groups of rats are shown in Table 5.2.4. 
Although there were no significant differences between the two groups in the 
mean value of any of the parameters measured, rats in B showed more 
variability of pAVP concentration. This might suggest that first handling and 
allocation to a new group on the day preceding the experiment had had effect on 
basal AVP secretion. Allocation to a group 3 days prior to blood collection 
apparently allowed return of AVP secretion to normal. 
DISCUSSION 
The hypothesis that stress modulates AVP secretion is controversial and 
contradictory (see Section 1.1.2.2.5). Some authors have suggested that AVP is 
a stress hormone in a similar manor to cortisol and prolactin, although others 
have not verified this. Such experiments have usually used physical stressors. 
The role of emotional and social stressors is even less clear and may vary with 
the animal group. The findings of this study would suggest that social 
disturbance by allocation to a new group may transiently alter basal AVP 
secretion. It does not seem that this is mediated through an alteration in 
drinking behaviour since the pOS of both groups was similar. 
Although the evidence for a modulatory effect of stress on osmoregulated AVP 
secretion was not substantial it seemed that it would be good scientific practice 
to assume that social disturbance might be a confounding variable in the study of 
osmoregulated AVP secretion. For this reason all further studies were carried 
out with randomisation of rats 3 days prior to the experimental procedure. 
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Table 5.2.4 The effect of handling and "social stress" on basal osmotic status 
Results are presented as mean±SD 
Group Weight pNa pOS pAVP IICT 
(g) (mmoUI) (mOsm/kg) (pmol/1) (%) 
A 266.5±5.6 150.2±4.3 301.1±3.0 1.9±1.7 
B 275.0±13.3 148.8±5.4 299.2±4.0 3.0±4.5 
42.3±2.0 
41.5±1.6 
pß. 179 pß. 647 p=0.373 p=0.587 p=0.444 
STUDY 5.2.5 
The hypotheses of this study were those of Study 5.2.1. 
SPECIFIC AIMS 
To study the effect of acute Fluoxetine treatment on basal and osmotically 
stimulated AVP secretion under "optimal" experimental conditions. 
METHODS 
Day 1: Male Wistar rats were randomly allocated to 6 groups; NN FN NIi F!! 
NL FL. 
Day 4: Rats received either 10mg/kg IP Fluoxetine (10mg/ml in water) (F) or 
lml/kg IP vehicle (water) (N). 30min later rats received either no further 
injection (NN, FN), or 20m1/kg IP 3 %NaCI (NH, F I) or water (NL, FL). Trunk 
blood was collected 30min after the osmotic stimulus. The frontal cortex of 
groups NN and FN were collected as described in Section 2.1.2.1 for 
measurement of changes in 5HT related neurochemistry and 5HT receptor 
density (Section 2.7). 
RESULTS 
The data analysis was carried out with omission of one rat in group FN. The 
AVP response of this rat was > 40pmo1/l and highly atypical of the underlying 
group mean response. Inclusion of the data from this rat may have lead to a 
false positive conclusion of the effect of Fluoxetine on osmoregulated AVP 
secretion. 
Plasma biochemistry (Table 5.2.5). 
The osmotic stimulus caused a significant change in pOS (p <0.001) and pNa 
(p<0.001). Fluoxetine had no significant effect on either the changes in pOS 
(p=0.718) or pNa (p=0.098). 
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Table 5.2.5 The effect of acute Fluoxetine (10mg/kg IP) and osmotic stimuli 
(N, II, L) on plasma biochemistry and haematocrit (mean±SEM). The p 
value results, from ANOVA, test the hypothesis that osmotic stimulus and 
Fluoxetine had no effect. The weights of the rats are presented as mean±SD. 
Group Weight pNa pOS HCT 
(g) (mmoUl) (mOsm/kg) - (%) 
NN 268.4±6.8 149.1±1.5 299.0±1.7 40.8±0.9 
FN 265.3±7.1 150.1±1.6 300.0±2.1 46.8±0.9 
NH 260.8±6.3 154.6±1.5 309.4±1.7 40.4±0.9 
FH 259.0±9.2 157.6±1.5 309.5±2.0 443±0.9 
NL 269.3±7.2 146.4±1.5 293.0±1.8 43.3±0.9 
FL 258.4±10.3 149.0±1.5 291.9±2.0 47.0±0.9 
EFFECTS 
Osmotic stimulus p<0.001 p<0.001 X0.007 
Fluoxcdnc p=4.078 p0.721 pc0.001 
Haematocrit (Table 5.2.5). 
The osmotic stimulus had a significant effect on HCT (p=0.007) explained by 
the increase in HCT with water loading. Fluoxetine significantly increased 
HCT (p<0.001), independent of the osmotic stimulus effect (p=0.619). 
Plasma AVP 
The relationship between pAVP and pOS for each rat is shown in Figure 5.2.6 
with simple linear regression analysis. Fluoxetine appeared to significantly 
increase the sensitivity of AVP secretion per unit change in pOS but had no 
significant effect on the theoretical threshold of AVP release. The data, 
however, contains several rats in each treatment group with pAVP S 0.6pmol/l, 
the detection limit of the assay. All these data points have been attributed the 
value of the detection limit for the purposes of data analysis (see Section 2.2.6). 
Thus for any individual rat the attributed AVP concentration will be 0.6pmol/l 
at any pOS below the osmotic threshold of AVP secretion, whatever the pOS. 
These data points cause a shift of the x-axis intercept of linear regression and a 
decrease in gradient of the regression line. Thus there was a potential error in 
this statistical model for data analysis. Data points with AVP value of 
0.6pmol/1 would significantly and inappropriately influence the analysis of the 
relationship of AVP and pOS above the osmotic threshold of AVP secretion. A 
more accurate analysis of the AVP response to change in pOS above the osmotic 
threshold was necessary. 
This could be perhaps achieved by linear regression analysis, omitting data 
points with pAVP 50.6pmol/l. The types of SIAD discussed in Section 1.2.2.3 
suggest that Fluoxetine might have any of at least 4 patterns of modulation of 
osmoregulated AVP secretion either alone or in combination. 
a) Effect on basal secretion. 
b) Effect on the osmotic threshold of AVP secretion. 
c) Effect on the sensitivity of AVP secretion to change in pOS. 
d) Loss of linear relationship to plasma osmolality. 
The need to consider any of these possible effects of Fluoxetine lead to the 
analysis of the data by piece-wise regression analysis. 
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The effect of acute Fluoxetine treatment (10mg/g IP) on osmoregulated AVP secretion. Linear 
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Piece-wise regression analysis 
Piece-wise regression analysis allows consideration of a linear relationship of 
two variables which may alter in characteristics consequent to change in one of 
the variables. Piece-wise regression analysis with one change point fits a 
regression line to the data with two segments, allowing the characteristics of the 
relationship to vary either side of this change point. For analysis of the data in 
the two treatment groups of this study the change point was the theoretical 
osmotic threshold of AVP secretion. The first line segment represented mean 
basal secretion and was assumed to have a slope of zero. The second line 
segment, the sensitivity of AVP secretion per unit change in pOS above the 
osmotic threshold, was continuous with the first segment at the change point. 
The statistical analysis allowed both the basal AVP concentration and the 
sensitivity of AVP response to be variable for each treatment group. Separate 
regression lines were estimated for each group in two models. 
The analysis was done twice, firstly estimating a common threshold for both the 
Fluoxetine group and the vehicle group and secondly by allowing different 
thresholds to be estimated for each group. The optimum threshold values for 
each model were estimated by repeatedly entering different thresholds in the 
regression analysis and finding the values which minimised the residual 
variation (see Figure 5.2.7). The residual variations for each model were then 
compared by a likelihood ratio test, allowing a statistical test for the effect of 
Fluoxetine on the threshold. 
After the optimum model of common or separate change points for each 
treatment group had been established, differences in basal secretion and the 
sensitivity of AVP response were than compared by standard analysis of co- 
variance based upon that model. 
Analysis was performed by Mr T Butler, Department of Medical Statistics, 
University of Newcastle upon Tyne, using the ' GLIM' statistical computing 
package (Royal statistical society, 1986) with custom written macros to carry 
out the repeated regression. The mathematical model is shown in Appendix 12. 
Parameters are expressed as estimate±SE. 
Analysis of the effect of Fluoxetine on osmoregulated AVP secretion by piece- 
wise regression analysis is shown in Figure 5.2.8. 
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The effect of Fluoxetine (10mg/kg IP) on osmoregulated AVP secretion analysed by piOCC-Wise 
regression. Since there was no significant effect of Fluoxetine on the osmotic threshold 
(p=0.160) a common threshold model has been used. Fluoxetine had a significant effect on 
basal AVP secretion (p <0.001) and significantly increased the osmotic sensitivity of AVP 
secretion above the threshold (p<0.001). 
Fluoxetine had no significant effect on the osmotic threshold of AVP secretion 
(p=0.160) which was estimated as 298.5mOsm/kg. It had a significant effect 
on basal secretion of AVP (N 1.55± 1.03pmol/l, F 3.06± 1.25pmol/l , 
p<0.001) and significantly increased the AVP response to change in pOS (N 
0.71±0.41, F 1.66±0.17 pmol/1 per mOsm/kg, p<0.001). 
Neurochemistry 
The effect of Fluoxetine on brain neurochemistry was assessed by measurement 
of changes in 5HT turnover and receptor binding in the frontal cortex of the NN 
and FN groups of rats (Table 5.2.6 and Figure 5.2.9). There was a non- 
significant trend in reduction of 5HT turnover in the forebrain samples. 
Fluoxetine treatment had no significant effect on 5HTla receptors ([3H]DPAT 
binding) but significantly increased 5HT2 binding sites ([3H]ketanserin binding) 
in the forebrain homogenate preparation. 
DISCUSSION 
Acute Fluoxetine administration to rats significantly increased basal AVP 
secretion and increased the sensitivity of AVP response to change in pOS within 
60min of drug administration. In Section 2.2.7 it was noted that at high 
concentration Fluoxetine may significantly increase the assay estimate of AVP 
concentration. This could not explain the approximately 2 fold increase in basal 
secretion and increase in AVP response to hyperosmolality even assuming the 
worst scenario of 30% over-estimate of pAVP. 
Fluoxetine may stimulate AVP secretion in a variety of ways. Through 
alteration of barometric stimuli to magnocellular neurons; through stimulation of 
release of AVP from the pituitary, or by direct or indirect stimulation of AVP 
secreting magnocellular neurons. In man 5HT agonism may lead to AVP 
secretion secondary to an emetic effect. In rats, however the emetic reflex is 
incomplete and stimulates OXY not AVP secretion (see Section 1.1.2.4). 
Although blood pressure (BP) was not recorded in the rats in this experiment it 
is well documented that 5HT agonism either has no effect or a hypertensive 
effect on BP (McCall et al 1987), and Fluoxetine has been observed to have no 
effect on BP in normal rats (Fuller, personal communication). It is intriguing 
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Table 5.2.6 The effect of acute Fluoxetine (10mg/kg IP) on brain 
neurochemistry in rat groups receiving no osmotic stimulus (Mean±SD) 
Group No [3H]Ketanserin [3H] DPAT SHIAA: SHT 
fmol/mg fmol/mg 
NN 8 300.6±170.6 
FN 8 687.3±285.1 
98.0±33.5 1.32±0.39 
125.5±130.2 1.08±0.28 
pß. 005 pß. 572 p=0.180 
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The effect of acute Fluoxetine treatment (10mg/kg IP) on forebrain ligand binding. 
[3H]ketanserin with and without the presence of methysergide estimated 5HT2 binding sites and 
[3H]DPAT with and without the presence of SHT estimated the density of 5HT1a sites in 
membrane homogenates. Fluoxetine significantly increased the binding of [3H]ketanserin to 
5HT2 sites (p<0.05) but had no significant effect on the [3H]DPAT binding to 5HTIa sites. 
Results are presented as meant SEM 
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that some authors have postulated that the hypertensive effect of 511T agonists is 
mediated through AVP since AVP antagonists block the effect (Pergola & Alper 
19 91; Dedeogld & Fisher 1991). 
The effect of Fluoxetine on haematocrit measurements in this experiment would 
suggest that there was a significant effect either on circulating red cell mass, or 
an effect on plasma volume. Haematocrit estimation is a very crude estimation 
of plasma volume. However the effect of Fluoxetine is present in all three 
treated groups and would suggest that this was a robust result. It was possible 
than that Fluoxetine decreased plasma volume and caused stimulation of AVP 
release through firing of atrial stretch receptors. The mechanism of this 
reduction in plasma volume is not apparent. There was no peritoneal pooling of 
fluid in dissected rat carcasses and Fluoxetine is not known to have effect on 
capillary permeability. 
Fluoxetine may have direct effect on the neurohypophysis, not requiring 
penetration of Fluoxetine into the CNS. It would seem unlikely that this could 
be a 5HT mediated effect since SIAD has not been routinely associated with 
conditions of high blood 5HT content ie the carcinoid syndrome. There may, 
however, be an indirect effect of Fluoxetine on the release of AVP from 
neurons in the neurohypophysis. Similarly Fluoxetine may stimulate 
magnocellular cell bodk directly or indirectly by influencing the numerous 
putative afferent pathways (see Section 1.1.3). 
The effect of Fluoxetine on AVP secretion, analysed by piece-wise regression, 
has shown a pattern similar to type C SIAD (Section 1.2.2.3), the "leaky 
hypophysis", together with a change in the sensitivity of AVP response to rise in 
pOS above the osmotic threshold. It has been suggested that this pattern of AVP 
secretion is due to a loss of inhibitory neurons. If it is assumed that Fluoxetine 
modulates AVP secretion by effect on the magnocellular neurons it is possible 
that this is through loss of inhibitory tone, or increase in excitatory tone since 
either effect would permit increase in basal AVP secretion and sensitise 
neurons to afferent osmotic stimuli. 
These hypotheses of the mechanism of the effect of Fluoxetine on osmoregulated 
AVP secretion require further exploration not only to determine the site and 
physiology of the effect but also to establish whether the effect is unique to 
Fluoxetine or a more general effect of 5HT and, if the latter, which 5HT 
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receptor subtypes are involved. Some of these questions have been explored in 
the studies that follow. 
Section 2.3.1 discussed that pharmacodynamics and neurochemical effects of IP 
Fluoxetine. This study found no significant effect on 5HT turnover. This is in 
disagreement with previous studies (Section 2.3.1.2.2) but may be explained by 
the known regional differences in effect of Fluoxetine. There was, however, 
evidence that Fluoxetine had penetrated into the brain since there was a 
SIMC 
significant increase iný5H binding sites in the forebrain homogenate. This 
was an unexpected finding. It would suggest either an increase in number 
5 +Tlc/ 
and/or affinity of15HT2 receptors. The 5HT2 receptor is a unique receptor with 
characteristics that differ from receptors of other neurotransmitters (Section 
1.3.4). It has been observed that rapid down regulation of 5HT2 receptors 
occurs with administration of 5HT2a agonists (Buckholtz et al 1988). Change in 
5HT2 receptors after acute Fluoxetine administration has not previously been 
explored and the reason for this finding is unclear. It is possible that the effect 
was an autoregulatory response to acute increase in 5HT neurotransmission. 
Further study of this change would be interesting and perhaps increase 
understanding of the regulation of 5HT neurotransmission. 
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5.3 THE EFFECT OF ACUTE ANTAGONISM OF 511T2/SIITIC 
RECEPTORS BY RITANSERIN ON BASAL AND OSMOREGULATED 
AVP SECRETION 
BACKGROUND 
The 5HT2 antagonist, LY5387, has been shown to block the MK212 (5HT1 and 
5HT2 agonist) stimulated rise in plasma AVP in rats (Brownfield et al 1988). 
Ritanserin was found only partial lyJantagonise the AVP rise in rats induced 
by the 5HT1c and 5HT2 agonist mCPP (Bagdy et al 1992). As discussed in 
Section 2.3.2 Ritanserin is a 5HT antagonist with high affinity for 5HT2 
receptors but does have some affinity for the 5HTlc receptor subtype. As 
discussed in Section 1.4.3 it has been postulated that 5HT stimulates AVP 
secretion through the 5HT2 or perhaps the 5HT1c receptor subtype. This was 
the first of three studies to explore this hypothesis further. 
GENERAL HYPOTHESES 
1. That 5HT has a role in the physiological AVP response to change in pOS. 
2. That the 5HT2 or 5HT1c receptor mediates this effect of 5HT in 
osmoregulated AVP secretion. 
3. That Ritanserin may cause an abnormality of osmotically stimulated AVP 
secretion due to antagonism of 5HT at 51177 and/or 5HT1c receptors. 
SPECIFIC AIMS 
To study the effect of acute 5HT2/5HT1c antagonism by Ritanserin on basal 
AVP secretion and on the AVP response to change in pOS. 
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METHODS 
Day 1: Male Wistar rats were randomly allocated to 6 groups NN RN NIi RII 
NL RL 
Day 4: All R groups received Iml/kg IP Ritanserin (lmg/ml)l and all N groups 
received 1 ml/kg IP vehicle (4% ethanol 0.05M tartaric acid). 30min later rats 
received 20m1/kg IP 3 %NaC1(11), water (L) or no further injection (N). 30min 
after the osmotic stimulus trunk blood and forebrain samples were collected as 
described in Section 2.1.2.1. 
RESULTS 
Seven rats were excluded from data analysis because of an AVP response 
> 30pmol/l. The rats were fairly evenly distributed through the groups (2NN, 
1RN, 2NH, 1RH, 1RL). None of these rats appeared unwell at the time of 
sample collection although one had been demonstrating aggressive behaviour. 
Plasma biochemistry 
The effect of the osmotic stimuli and Ritanserin treatment on plasma 
biochemistry is shown in Table 5.3.1. The experimental model caused a 
significant change in pOS (p<0.001) and pNa (<0.001). Ritanserin had no 
significant effect on the changes in pOS (p=0.289). Ritanserin lowered pNa 
but the effect was significant only at a 5% probability level (p=0.048). In 
addition there was a suggestion of an interaction between osmotic stimulus and 
the effect of Ritanserin on pNa, but this was not significant (p=0.044). 
Haematocrit 
Blood haematocrit was not significantly affected by the osmotic stimulus 
(p=0.051) or Ritanserin treatment (p=0.470). 
Plasma AVP 
Figure 5.3.1 shows the relationship of pAVP to pOS of each rat in the two 
treatment groups with analysis by piece-wise regression. Ritanserin had no 
effect on the osmotic threshold of AVP secretion (294.2mOsm/kg, p=0.570), on 
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Table 5.3.1 The effect of acute Ritanserin (1mg/kg IP) and osmotic stimuli 
(N, H, L) on plasma biochemistry and haematocrit (mean±SEM). The p 
value results, from ANOVA, test the hypothesis that osmotic stimulus and 
Ritanserin had no effect. The weights of the rats are presented as mean±SD. 
No N Wt pOS pNa PICT 
(g) (mosm/kg) (mmol/1) (%) 
NN 8 282.4±9.1 295.6±1.3 140.4±1.3 40.5±0.9 
RN 10 281.5±12.5 295.2±1.2 141.0±1.3 41.9±0.9 
NH 8 283.1±12.1 308.5±1.3 150.5±1.3 40.5±0.9 
RH 9 280.0±8.4 305.3±1.3 146.9±1.3 41.6±0.9 
NL 10 280.1±9.1 287.6±3.0 137.6±2.8 43.4±0.8 
RL 9 289.9±11.8 286.8±4.7 134.3±5.2 42.7±3.1 
EFFECT 
Osmotic stimulus p<0.001 p<O. 001 pß. 051 
Ritanscrin p=0.289 p=O. 048 p=0.470 
Interaction pß. 367 p=0.044 pß. 085 
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Sensitivity AVP 0.73 ±0.11 0.54+0.11 0.63 ±0.18 0.229 
(pmol/1 per mosm/kg) 
Figure 5.3.1 
The effect of Ritanserin treatment (lmg/kg IP) on osmoregulated AVP secretion. Analysis by 
piece-wise regression showed that Ritanserin had no significant effect on the osmotic threshold 
of AVP secretion (pa0.570) or on the basal concentration (pm0.240) or osmotic sensitivity of 
AVP secretion (p=0.230). 
the basal concentration of AVP secretion (N 1.16±0.88, R 0.95±0.85 pmol/1, 
p=0.240) or on the sensitivity of AVP secretion above the osmotic threshold (N 
0.54±0.11, R 0.73±0.11 pmol/1 per mOsm/kg, p=0.230). 
Neurochemistry 
Ritanserin treatment significantly increased 5HT turnover in the forebrain 
(5HIAA: SHT NN 1.44±0.29, RN 2.07±0.46, p=0.001). 
DISCUSSION 
The results of this study suggest that Ritanserin had no significant effect on 
either basal or osmotically stimulated AVP secretion. Since Ritanserin is a 
5HT2 and 5HT1c antagonist it may be concluded that either 5HT is not involved 
in basal and osmoregulated AVP secretion, or that these 5HT receptor subtypes 
do not mediate the effect of 5HT in basal and osmoregulated AVP secretion. 
The results of HPLC measurement of 5HT and 5HIAA in the forebrain samples 
showed that Ritanserin penetrated into the CNS and in this region at least, 
altered 5HT metabolism. The increase in 5HT turnover might be interpreted as 
an autoregulatory attempt to overcome the post-synaptic antagonism by 
Ritanserin. Ritanserin has been shown to have significant effect on central 
5HT2 functions within 30min of subcutaneous (SC) administration, with peak 
effect after 2-4hr (Awouters et al 1988). The absorption from IP administration 
would probably be faster than after SC administration thus significant effect on 
central 5HT metabolism would be anticipated within the time period of this 
study although peak effect on 5HT2 function may not have been achieved. 
The effect of Ritanserin on pNa and its interactive effect with the osmotic 
stimulus is worthy of note although it did not reach the level of significance 
accepted in this study. The absence of a significant effect on pOS would 
suggest that the difference in group means was due to experimental variability in 
the measurement of pNa. 
Ritanserin has previously been shown to blunt the pharmacologically stimulated 
rise in AVP attributed to 5HT agonism in a study which used similar 
concentration of drug and experimental time scale as this work (Bagdy et al 
1992). This would suggest that in rats 5HT may modulate AVP secretion 
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pharmacologically, and that the 5H72 and/or the 5HTlc receptor is important in 
this. In physiological osmoregulated AVP secretion, however, either 5HT does 
not have a role or it does not have effect through the 51117 and/or the 5HTlc 
receptors. 
Nelson et al (1987) found that infusion of Ritanserin into sheep caused a 50% 
decrease in water intake at 24hr but no significant effect on urine output in this 
period. Plasma sodium concentration was significantly elevated at 24hr but 
AVP was not significantly different to pre-infusion plasma concentration. This 
would suggest that Ritanserin significantly reduced both thirst and AVP 
secretion and that the normal rise in AVP secretion with increase in pOS was 
prevented. There was apparent "fatigue" of the effect however since all 
parameters had returned to normal by 48hr of continued infusion of Ritanserin. 
It is possible then that the role of 5HT in osmoregulated AVP secretion varies in 
different animal species. 
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5.4. DOES THE 51IT2/5HT1C ANTAGONIST RITANSERIN INHIBIT 
THE FLUOXETINE AUGMENTED AVP RESPONSE TO PLASMA 
HYPEROSMOLALITY? 
BACKGROUND 
As discussed in Section 1.4.3 the 5HT2 and/or 5HT1c receptors have been 
implicated in the stimulation of AVP secretion by 5HT. It was shown in Study 
5.2.5 that Fluoxetine stimulated basal AVP secretion and augmented the AVP 
response to plasma hyperosmolality. If this effect was secondary to increase in 
5HT neurotransmission it was possible that Ritanserin might inhibit the 
augmented stimulation of AVP secretion. 
GENERAL HYPOTHESES 
1. That Fluoxetine modulate the osmoregulated secretion of AVP by enhancing 
5HT neurotransmission. 
2. That this effect is through the 5HT2 or 5HTlc receptor. 
3. That Ritanserin would inhibit the Fluoxetine augmented AVP response to 
plasma hypo-osmolality. 
SPECIFIC AIM 
To explore the effect of Ritanserin on the Fluoxetine augmented AVP response 
to hyperosmotic stimulus. 
METHODS 
Day 1: Male Wistar rats were randomly allocated to 4 groups NN RN NF RF 
Day 4: At time zero rats in groups RN and RF received lml/kg IP Ritanserin 
(1mg/ml in vehicle) and rats in groups NN and NF received lml/kg IP vehicle 
(10% ethanol 0.02M tartaric acid). This was followed 60min later by lml/kg IP 
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Fluoxetine (NF RF) (10mg/ml in water) or water (NN RN). 30min subsequent 
to this injection all rats received 20m1/kg IP 3 %NaC1 and trunk blood was 
collected after a further 30min (120min after initial injection). 
RESULTS 
Two rats were excluded from the data analysis because of an AVP response 
> 30pmol/1. Both were in the NF group and inclusion of their results may have 
lead to a false positive conclusion of the effect of Ritanserin on the Fluoxetine 
augmented AVP response to rise in pOS. 
Plasma biochemistry ('fable 5.4.1) 
Neither Fluoxetine (p=0.658) or Ritanserin (p=0.152) or the combination 
(p=0.918) had significant effect on the pOS after the hyperosmotic stimulus. 
Similar results were found for the effect on pNa. 
Haematocrit ('fable 5.4.1) 
Fluoxetine treatment significantly increased the haematocrit (p < 0.001). 
Ritanserin had no effect alone (p =0.42q or in combination with Fluoxetine 
(p=0.091) on the haematocrit. 
Plasma AVP 
The AVP response in each group is shown in Figure 5.4.1 and Table 5.4.1. 
Fluoxetine significantly augmented the AVP response to plasma hyperosmolality 
(p<0.001). Ritanserin had no significant effect on the AVP response to plasma 
hyperosmolality (p=0. Ob0) and did not significantly alter the Fluoxetine 
augmented AVP response (p=0.0$. 
DISCUSSION 
The effect of Fluoxetine of the AVP response to hyperosmolality was very 
similar to that found in Study 5.2.5. In addition the effect of Fluoxetine on 
blood haematocrit(»as reproduced in this study. Ritanserin had no significant 
effect on either of these changes attributable to Fluoxetine treatment. 
166 
Table 5.4.1 The effect of Ritanserin (1mg/kg IP) on the Fluoxetine 
(10mg/kg IP) augmented AVP response to hypertonic saline (mean±SEM). 
The p value results, from ANOVA, test the hypothesis that Ritanserin 
and Fluoxetine, alone and in combination, had no effect. 
Croup N pAVP 
(pmoUl) 
pOS 
(mOsm/kg) 
pNa 
(mmoN) 
HCT 
(%) 
NN 8 8.2±23 310.3±1.7 151.8±1.1 38.6±1.1 
RN 8 13.3±2.3 312.8±1.7 152.7±1.1 38.4±21.1 
NF 6 18.5±2.6 311.3±1.9 151.0±1.2 45.3±1.3 
RF 9 20.3±2.1 313.3±1.6 151.0±1.0 42.6±1.1 
EFFECTS 
Ritanserin p-O. 0bO X4.152 p=0. ßb0 p=0.429 
Fluoxetine p<0.001 pes. pß. 268 p<0.001 
Interaction pß. 468 P=4. C{ 1$ p=0.690 pß. 091 
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Figure 5.4.1 
The effect of Ritanserin (R) (1mg/kg IP) on Fluoxetine (F) (10mg/kg IP)W eC'4AVP 
secretion. Fluoxetine significantly increased the AVP response to hyperosmolality (P <0.001) 
but Ritanserin had no significant effect on the response either when given alone (p-0-OW) or 
when given with Fluoxetine (p=0.1 $). Results are shown as mean±SEM with analysis by 
ANOVA. 
NN RN NF RF 
These findings would suggest either that the Fluoxetine-augmented osmotically 
stimulated AVP secretion was not mediated by an effect on SHT 
neurotransmission or that the effect was mediated through receptors other than 
the 5HT2 and 5HTlc subtypes. In addition, as had been found previously in 
Study 5.3, the normal AVP response to plasma hyperosmolality was not 
apparently mediated through the 5HT2 and/or 5HT1c receptors since 
antagonism of these receptors had no significant effect on the response. 
Exclusion f "m the data analysis of 2 rats in group NF allowed analysis of the 
underlying mean trend. The AVP response in these rats, > 30pmol/l, may have 
beýa facet of the experimental model or may have been a true effect of 
augmentation of AVP secretion by Fluoxetine treatment. 
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5.5 THE EFFECT OF THE 511T2A AGONIST DOI ON 
OSMOREGULATED AVP SECRETION 
BACKGROUND 
The hypothesis that an increase in 5HT neurotransmission stimulates AVP 
secretion and its postulated mechanism through the 5HT2 and/or 5HT1c 
receptors, has already been discussed in some detail . Bagdy et at (1992), 
however, found that the 5ITr2 agonist DOI did not stimulate secretion of AVP. 
There has been no previous exploration of the effect of 5HT2 or 5HT1c agonists 
on osmoregulated AVP secretion. 
GENERAL HYPOTHESES 
1. That the 5HT2 and/or the 5HT1c receptors mediates the stimulatory effect of 
5HT on AVP secretion. 
2. That stimulation of the 5HT*2 and 5HT1c receptors by the agonist DOI may 
alter basal and osmotically stimulated AVP secretion. 
SPECIFIC AIM 
To study the effect of DOI on basal and osmotically stimulated AVP secretion. 
METHODS 
Day 1: Male Wistar rats were randomly allocated to 6 groups NN DN NL DL 
NH DH 
Day 4: All D groups received lml/kg IP DOI (lmg/ml)1 and all N groups 
received lml/kg IP vehicle (water). 30min later rats received 20ml/kg IP 
3 %NaC1 (H), water (L) or no further injection (N). 30min after the osmotic 
stimulus trunk blood and forebrain samples were collected as described in 
Section 2.1.2.1. 
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RESULTS 
All rats that received DOI and none that received vehicle exhibited "wet-dog 
shakes" (see Section 2.3.3). This occurred from 15min after the injection of 
drug. 
Two rats in group DN were extremely disturbed at the end of the experiment 
and the AVP responses were highly atypical of the mean group response 
(> 30pmol/1). One rat in group NIi had an absence of AVP response to plasma 
hyperosmolality. These rats were excluded from the data analysis. 
Plasma biochemistry (Table 5.5.1) 
The experimental model provided significant changes in pOS (p<0.001). DOI 
treatment had no significant effect on the change in pOS (p=0.304) or pNa 
(p=0.438). 
Haematocrit 
The osmotic stimulus significantly altered the haematocrit (p=0.007) but 
treatment with DOI had no significant effect on (p=0.394). 
Neurochemistry 
Table 5.5.2 shows that treatment with DOI had no significant effect on the 
forebrain neurochemistry of rats. 
Plasma AVP 
Figure 5.5.1 considers the relationship of pAVP and pOS for the two treatment 
groups and the analysis of the data by piece-wise regression according to the 
statistical model explained in Section 5.2.5. DOI had no significant effect on 
the estimated threshold of AVP secretion which was 299.1mOsm/kg (p=0.18). 
Basal secretion of AVP below pOS 299.1 mOsm/kg was not significantly 
affected by DOI treatment (N 0.31±0.79, D 1.28±0.86 pmol/l, p=0.879), nor 
was the osmotic sensitivity of AVP secretion above the estimated threshold (N 
0.8±0.08, D 0.68±0.08 pmol/1 per mOsm/kg, p=0.276). 
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Table 5.5.1 The effect of acute DOI (1mg/kg) and osmotic stimuli (N, II, 
L) on plasma biochemistry and haematocrit (mean±SEM). The p value 
results, from ANOVA, test the hypothesis that osmotic stimulus and DOI had 
no effect. 
Group N 
(mPOS Osm/kg) 
(mmoUl) 
%ý 
NN 10 301.5±1.2 152.611.0 41.210.8 
DN 8 303.8±13 154.211.1 42.9±0.9 
NL 10 293.811.2 149.211.0 42.2: 0.9 
DL 10 294.811.2 150.411.0 42.4±0.9 
NH 10 315.511.3 161.911.1 40.510.9 
DII 10 315.4±1.2 160.911.0 39.6±0.8 
EFf'ECIS 
Osmotic stimulus pc0.001 pc0.001 
DOI p-0304 p=0.438 
p=0.007 
p=0394 
Table 5.5.2 The effect of DOT (1mg/kg IP) on forebrain neurochemistry in 
rats receiving no osmotic stimulus (Mean±SD) 
Group No 5HT 5HIAA 5H1AA: 5IIT 
pmot/mg pmol/mg 
NN 10 153±5.1 
DN 10 12.1±3.1 
19.4±5.7 1.38±0.68 
19.5±4.0 1.74±0.48 
P=0.110 p=0.979 X0.178 
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Figure 5.5.1 
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302.6 299.1 0.176 
0.31±0.79 0.76±0.58 0.879 
0.80±0.08 0.74±0.06 0.276 
The effect of DOI (1mg/kg IP) on osmoregulated AVP secretion. Analysis by piece-wise 
regression showed that DOI had no significant effect on the osmotic threshold of AVP secretion 
(Piz0.180) or on the basal concentration (p"0.879) or osmotic sensitivity of AVP secretion 
(p=0.276). 
DISCUSSION 
The results of this study would suggest that DOI had no significant effect on 
basal or osmoregulated AVP secretion. 
It was apparent from behaviour observations that DOI had penetrated into the 
CNS causing "wet-dog shakes" due to 5HT agonism. This was not reflected in 
biochemical measurements of change in 5HT function. Previous studies have 
shown that acute administration decreases frontal SHT and 5HIAA 
concentrations (Wright et al 1990). The reason for the absence of 
neurochemical changes in this study is unclear. 
The results of this study concur with those of Bagdy et al (1992) and Saydoff et 
al (1990) who found that DOI had no effect on basal AVP secretion. This 
would indicate that either 5HT is not involved in basal or osmoregulated AVP 
secretion, or its effect is not mediated through the 5HT2a receptor subtype. 
DOI has a moderately high affinity for the 5HT1c receptor subtype and, 
although this is 40 fold lower than its very high affinity for the 5HT2a receptor, 
it is likely that administration of lmg/kg would have had some effect on this 
receptor. It is therefore unlikely that 5HT stimulates AVP secretion through the 
5HTlc receptor subtype. It is possible that the effect of 5HT on AVP secretion 
is mediated through the 5HT2b receptor subtype although the lack of significant 
antagonism, by Ritanserin, of Fluoxetine augmented AVP secretion in Study 5.4 
would militate against this. 
Dedeoglu & Fisher (1991) showed that DOI administered either intra-venously 
(IV) or intra-cerebro-ventricularly (ICV) significantly increased mean arterial 
blood pressure. The pressor response of IV administration appeared to be 
peripherally mediated whilst that after ICV administration was centrally 
mediated and partially blocked by AVP antagonists. On this evidence the 
authors suggested that DOI stimulated AVP secretion, possibly indirectly though 
an increase in sympathetic activity. Plasma AVP concentrations were not 
measured however, and the inferred difference of these findings and the results 
of this and other studies discussed above remain unresolved. 
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5.6. THE EFFECT OF LESION OF 5I1T NEURONS OF THE DORSAL 
AND MEDIAN RAPIiE NUCLEI ON BASAL OSMOREGULATION 
BACKGROUND 
The 5HT neurons of the brain may be lesioned in a variety of ways (see Table 
1.3.1). The synthesis inhibitor pCPA is 5HT specific but depletes 5HT in all 
neurons. The neurotoxin 5,7-DHT is selectively transported into 5HT neurons 
by the 5HT reuptake site. Some non-specific effects in noradrenergic neurons 
may occur but this is prevented by prior inhibition of noradrenergic reuptake 
sites by the inhibitor desipramine (Bjorklund et al 1975). Infusion of 5,7-DHT 
into the raphd nuclei of rats leads to a 75-90% depletion of telencephalic 5HT 
with little effect on other monoamines (Schallert & Wilcox 1985). One major 
advantage of this neurotoxin is its use as a site specific neurotoxin when injected 
into anatomically selected neuron populations. 
Tangapregassom et al (1974) found that electrolytic lesion of the DRN increased 
daily urine output and Iovino & Steardo (1985) found that although generalised 
lesion of 5HT neurons had no effect on basal plasma AVP concentration it 
prevented the increase in AVP in response to 24hr water deprivation. 
Brownfield et al (1987) found that generalised lesion of 5HT neurons by ICV 
administration of 5,7-DHT significantly inhibited the AVP response to 
hypertonic stimulus but had no effect on basal AVP concentration or on the 
AVP response to barometric stimuli (plasma volume depletion). 
Section 1.4.1 discussed the controversy of the origin of 5HT neuronal 
projections to the region of the SON and PVN in the hypothalamus and it is not 
clear if the DRN and/or the MRN send afferent fibres to these magnocellular 
nuclei. This study explored the effect of lesion of both raphd nuclei on basal 
osmoregulation in rats. 
GENERAL HYPOTHESES 
1. That 5HT has a role in osmoregulated AVP secretion. 
2. That lesion of 5HT neurons decreases AVP secretion. 
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3. That lesion of 5HT neurons of the DRN and MRN may disturb normal 
osmoregulation subsequent to the decrease in AVP secretion. 
SPECIFIC AIM 
To study the effect of lesion of the DRN and MRN by 5,7-DHT, on basal 
osmotic status. 
METHODS 
Male hooded Wistar rats were randomly allocated to 2 groups (SHAM, 
LESION). Rats received 25mg/kg IP desipramine and were anaesthetised with 
45mg/kg IP pentobarbitol. 25nmol 5,7-DHT in 0.2% ascorbic acid 0.9%NaC1 
or vehicle was infused into the DRN and MRN 30min after the desipramine 
injection. The DRN and MRN were identified by streotaxic co-ordinates 
according to Paxinos & Watson (1982). (7.3mm posterior to the bregma, 
6.2mm and 8.4 mm below the dura respectively). 
Post-operatively rats were housed with ab libitum food and water for 21 days. 
Trunk blood was then collected and brain dissected. Forebrain samples were 
taken for homogenate ligand binding and neurochemistry, and hypothalamic 
blocks were collected for use in the Study 6.2. 
The operative procedures and post operative care were carried out by Mr S 
Keith, MRC Neurochemical Pathology Unit, Newcastle upon Tyne. 
Results were compared by Mann Whitney U tests. 
RESULTS 
Neurochemistry 
The 5HT content of 2 LESION rat brain samples were below the limit of 
detection by HPLC analysis (0.5pmo1/2Oµ1 sample). Two other LESION rat 
brains showed > 80% depletion of 5HT compared to SHAM rats but 2 
LESION rats had no significant decrease in 5HT concentration, suggesting that 
the lesion was inadequate in these rats. These latter 2 rats were excluded from 
further data analysis. 
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Homogenate ligand binding 
The effect of lesion on 5HT1a and 5HT2 ligand binding sites is shown in Figure 
5.6.1. There was no significant effect of the lesion on ligand binding to either 
5HT receptor. 
Plasma biochemistry and AVP 
Table 5.6.1 shows the effect of lesion on basal osmotic status. There were no 
significant differences between the basal pOS of SITAM and LESION nor in the 
plasma AVP concentration of the two groups. 
DISCUSSION 
There was no evidence from this small study that normal osmoregulation 
required the presence of intact 5HT neurons of the DRN and/or MRN. The 
similar basal pOS and pAVP of the sham and lesioned rats suggested that neither 
thirst nor osmoregulated AVP secretion were significantly altered by loss of 
5HT neurons, at least after a period of 21 days. It would be interesting to 
pursue this model to see if, as suggested by others, 5,7-DHT lesion of 5HT 
neurons has effect on dynamically stimulated osmoregulated AVP secretion. 
The exclusion of 2 rats from the data analysis resulted in a very small group of 
lesioned rats. The mean and individual pOS and pAVP of the two groups were 
so similar that it was unlikely that a significant effect has been missed because 
of paucity of numbers. 
The findings of this study are therefore in agreement with some of the previous 
work discussed above which involved study of rats with less selective lesioning 
of 5HT neurons. The increase in urine output observed by Tangapregassom et 
at (1974) , suggestive of loss of AVP secretion, remains unexplained. There are 
three possiblýfoe findings of this study; (i) that 5HT is not involved in basal 
homeostatic osmoregulation; (ii) that 5HT is involved in osmoregulation but 
adequate compensation for the loss of 5HT neurons had occurred after 21 days; 
(iii) that 5HT neurons other than those of the MRN and/or DRN are important 
for the osmoregulatory role of 5HT. 
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Figure 5.6.1 
The effect of lesion of 5HT neurons of the DRN and MRN by 5,7-DHT on forebrain ligand 
binding. Neither [3H]ketanserin binding to SHT2 sites of [3H]DPAT binding to SHTIa sites 
was significantly altered by the lesion (p>0.05). 
Results are presented as mean ± SD. 
[3H]KETANSERIN [3H]DPAT 
Table 5.6.1 The effect of lesion of SHT neurons of the DRN and 
MRN by 5,7-DHT on basal osmotic status (mean±SD) 
Group No pOS pAVP HCT 
(mOsm/kg) (PmoUI) (%) 
SHAM 6 303.0±4.2 1.4±03 36±1 
LESION 4 303.3±1.3 2.2±0.8 38±1 
p>0.05 p>0.05 p>0.05 
5.7 THE EFFECT OF CHRONIC TREATMENT WITH FLUOXETINE 
OR RITANSERIN ON OSMOREGULATED AVP SECRETION 
BACKGROUND 
The 5HT nervous system is capable of many autoregulatory processes 
consequent to alteration in 5HT neurotransmission and synaptic 5HT 
concentration (see Section 1.3.4). As discussed in Section 1.5.3.2. recent 
psychopharmacological research in depression has focussed on the changes in 
the 5HT system subsequent to chronic administration of antidepressant drugs, 
given for time periods which mimic therapeutic action (usually 14-21day). 
Section 2.3.1.2. discussed the acute effect of Fluoxetine on 5HT 
neurotransmission. Within 2 days autoregulatory adaptation occurs and a 
marked decrease in neuronal firing has been found with continued Fluoxetine 
treatment (Clemens et al 1977). However, after 14 days of continued 
administration the neuronal firing rate returns to normal and Fluoxetine appears 
to again augment 5HT neurotransmission. The putative mechanisms for this 
have been discussed in see Section 1.3.4.3. 
The reports of hyponatraemia associated with the clinical use of Fluoxetine in 
depression have been discussed in Sections 3 and 4 with the evidence that 
hyponatraemia occurs early in drug administration and persists. In Section 3.3 
it was suggested that the mechanism of this hyponatraemia may be due to an 
inability of some depressed patients to re-establish osmoregulatory homeostasis 
consequent to the acute stimulation of AVP secretion by Fluoxetine treatment, 
due to dysfunction of 5HT neurotransmission in depression. In Study 5.2.5 
Fluoxetine was found acutelyis 
imulate AVP secretion. There was a 
suggestion in the results of Study 5.2.1 that after l8hr, Fluoxetine no longer 
caused abnormal osmoregulated AVP secretion. This study was to explore the 
effect of more prolonged treatment with Fluoxetine on osmoregulated AVP 
secretion using a duration of administration of the drug which mimics its 
therapeutic effect (21day). 
The effect of chronic administration of Ritanserin was also studied. Ritanserin 
has been identified as having both anxiolytic and antidepressant properties with 
therapeutic effect in depression after 14-21 days although its anxiolytic effects 
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may occur more rapidly. Chronic administration of Ritanserin in rats has been 
shown to lead to 5HT2 receptor down-regulation (Leysen et al 1986). Since it is 
postulated that 5HT modulates osmoregulated AVP secretion through Qe5HT2 
receptor it could be that down regulation of these receptors might have I)effect on 
h 
osmoregulated AVP secretion. 
GENERAL HYPOTHESES 
1. That 5HT modulates osmoregulated AVP secretion. 
2. That this is mediated by the 5HT2 receptor. 
3. That pharmacological manipulation of brain 5HT receptor numbers and 5HT 
function by chronic administration of antidepressant drugs may cause observable 
abnormalities in osmoregulated AVP secretion. 
SPECIFIC AIMS 
To explore the effect of Fluoxetine and Ritanserin, administered for a time 
period to mimic their therapeutic effect in depressed patients, on brain 
neurochemistry, receptor density and osmoregulated AVP secretion. 
METHODS 
Male Wistar rats were randomly allocated to 9 groups NN, NH, NL, FN, FII, FL, 
RN, RH, RL. 
Each rat received 21 daily SC injections of 1mIkg vehicle (N), Ritanserin (R) 
or Fluoxetine (F) according to their treatment group. Drugs were made up in 
10% ethanol 0.02M tartaric acid. 
Rats were weighed every other day to assess well being and injection volume. 
Day 22: The protocol for assessment of osmoregulated AVP secretion was 
carried out as described previously and in Section 2.1.2.1 according to the 
group allocation of each rat. 
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RESULTS 
All rats tolerated the daily injections well. There was some scab formation at 
injection sites in the second week of treatment but this resolved without evidence 
of infection or distress to the animals. 
Rats treated with Ritanserin were noted to be more irritable than either vehicle 
or Fluoxetine treated rats in which groups no abnormal behavioural effects were 
noted. 
Three rats in group RN and one in group RH were excluded form data analysis 
due to an atypical AVP response to osmotic stimulus of > 30pmol/l. 
Weight gain 
Rats treated with Fluoxetine gained 13 % less weight than rats treated with 
vehicle (N 123.6±24g, F 108.5±19g, p=0.031). There was no significant 
effect of Ritanserin on weight gain. 
Plasma biochemistry (Table 5.7.1) 
The osmotic stimulus caused a significant change in pOS (p <0.001) and pNa 
(p<0.001). Neither Fluoxetine (p=0.634) or Ritanserin (p=0.399) had 
significant effect on the change in pOS. A similar absence of effect on change 
in pNA was found for each drug. 
Haematocrit 
The osmotic stimulus did not significantly affect the HCT (p=0.02) but both 
Fluoxetine treatment (p=0.004) and Ritanserin treatment (p=0.006) 
significantly decreased HCT. 
Plasma AVP 
Figure 5.7.1 shows the piece-wise regression analysis of the relationship 
between pAVP and pOS for rats treated with Fluoxetine compared to control, 
rats. Fluoxetine had no significant effect on the osmotic threshold of AVP 
secretion which was estimated as 300.1 mOsm/kg (p =0.170). Basal AVP 
secretion was not significantly effected by Fluoxetine treatment (N 0.65±0.66, 
F 1.4±0.57pmol/1, p=0.580). Fluoxetine treatment did, however, significantly 
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Table 5.7.1 The effect of chronic treatment (21 day) with Rltanserin (1mg/kg 
SC) (R) or Fluoxetine (10mg/kg SC) (F) on plasma biochemical and 
haematocrit changes in response to osmotic stimuli (N, H, L) (meantSEM). 
The p value results, from ANOVA, test the hypothesis that osmotic stimulus 
and Fluoxetine or Ritanserin treatment had no effect. 
Group N Wt gain pOS pNa IICT 
(g) (mosm/kg) (mmoil) M 
NN 6 1083±7.2 301.212.2 142.2±13 43.7±0.9 
FN 10 104.4±6.2 303.111.9 146.9±13 41.9±0.9 
RN 10 120.4±6.2 300.6±1.6 145310.9 42.0t1.0 
NL 6 117.717.2 292.5±2.2 1403113 45.0±0.9 
FL 11 117.715.8 292.6±1.8 142.611.2 44.0±0.7 
RL 10 124.0±6.2 293.911.6 141.3±0.9 42.911.0 
NH 6 1343±7.1 314.012.2 151.7± 1.5 44.0±0.9 
FH 10 102.2±6.2 313.4=1.9 152.4±1.3 40.9±0.7 
RH 10 127.6±6.2 308.0±1.6 149.1±0.9 40.3±1.0 
EFFEC 
Osmotic stimulus p<0.001 p<0.001 p=0.020 
Fluoxetine p=0.634 p=0.030 p=0.004 
Ritanserin p=0.399 p=0.548 p=0.006 
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Figure 5.7.1 
The effect of treatment with Fluoxetine (10mg/kg) for 21day on osmoregulated AVP secretion 
analysed by piece-wise regression. Fluoxetine had no significant effect on the osmotic threshold 
of AVP secretion (p=0.170) or on the basal concentration of AVP secretion (p"0.580) but 
significantly decreased the osmotic sensitivity of AVP secretion above the osmotic threshold 
(p=0.030). 
decrease the osmotic sensitivity of AVP secretion (N 0.64±0.08, F 0.43±0.06 
pmol/1 per mOsm/kg, p=0.030). 
Figure 5.7.2 shows the effect of Ritanserin treatment of the relationship of 
pAVP and pOS. Ritanserin had no significant effect on osmotic threshold 
(estimated as 300.5 mOsm/kg, p=0.470), basal AVP secretion (N 0.73±0.4, R 
0.75±0.07 pmol/l, p=0.240) or the osmotic sensitivity of AVP secretion (N 
0.66±0.04, R 0.52±0.07 pmol/1 per mOsm/kg, p=0.120). 
Changes in forebrain samples 
Table 5.7.2 shows the effect of treatment with each drug on ligand binding to 
5HT1a and 5HT2 receptors and 5HT turnover. Results, compared by Wilcoxon 
rank sum analysis, showed that neither drug treatment had significant effect on 
ligand binding density to either receptor type, or on the turnover of 5HT in the 
forebrain as quantified by the ratio of 5HIAA to 5HT concentration. 
DISCUSSION 
The results of this study indicate that chronic treatment with Ritanserin had no 
effect on osmoregulated AVP secretion. Chronic treatment with Fluoxetine 
caused a significant decrease in the AVP response to change in pOS but had no 
effect on basal AVP secretion or the osmotic threshold of secretion. The 
decrease in AVP responsiveness to change in pOS would mean that for an 
increase in pOS of lOmOsm/kg rats treated with Fluoxetine would have a rise in 
AVP of 2. lpmol/l less that normal control rats. This would certainly be 
biologically significant and it is possible that, due to the interference of 
Fluoxetine with the RIA of AVP (Section 2.2.7), this was an underestimate of 
the effect. The lack of significant effect of Fluoxetine on pOS, however, would 
suggest, that either an increase in fluid ingestion or perhaps an increase in renal 
sensitivity to plasma AVP had adequately compensated for the relative 
deficiency of AVP in these rats. 
In Study 5.2.5 Fluoxetine was found to acutely stimulate AVP secretion and 
increase the osmotic sensitivity of AVP secretion. This effect has been lost after 
21 daily treatments. Consideration of the findings of Study 5.2.1 Might suggest 
that the effect was lost l8hr after one dose of Fluoxetine, although it is known 
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The effect of treatment with Ritanserin (lmg/kg) for 21day on osmoregulated AVP secretion 
analysed by piece-wise regression. Ritanserin had no significant effect on the osmotic threshold 
of AVP secretion (p=0.470) or on the basal concentration (p=0.240) or the osmotic sensitivity 
of AVP secretion above the osmotic threshold (p=0.120). 
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Table 5.7.2 The effect of chronic treatment (21day) with Fluoxetine 
(10mg/kg SC) (F) or Ritanserin (1mg/kg SC) (R) compared to vehicle treated 
(N) rats on forebrain neurochemistry and ligand binding (mean±SD). 
Group No [3H]Ketanserin [3H] DPAT 5I IAA: SHT 
fmoUmg fmoUmg 
N5 360±109 91±46 2.18±0.6 
F8 434±201 108±40 2.29±03 
R8 3051176 113±52 2.89±0.6 
P>0.05 p>0.05 p>0.05 
that the drug still has significant effect on 5HT reuptake at this time (Wong et al 
1975. See Section 2.3.1.2). Thus osmotic homeostasis is apparently acutely 
disturbed by Fluoxetine treatment but equilibrium is re-established, possibly as 
rapidly as within 18hr. It could be postulated that the decrease in osmotic 
sensitivity after chronic Fluoxetine treatment was an overcompensation for the 
increase in osmotic sensitivity after acute treatment. 
Assuming that Ritanserin had significant penetration into the CNS in this study 
the lack of significant effect of chronic treatment on osmoregulated AVP 
secretion would suggest that either the 5HT2 receptor was not important in 5HT 
modulated osmoregulated AVP secretion, or that adequate compensation for any 
disturbance has occurred. It is of course also possible that 5HT does not 
modulate osmoregulated AVP secretion and that the effect of Fluoxetine was not 
mediated through its inhibition of 5HT reuptake and the consequent effects on 
5HT neurotransmission. 
Neither drug has lead to significant neurochemical change or change in density 
of 5HT receptors. 
The literature contains contradictory results of the effect of chronic Fluoxetine 
treatment on 5HT receptor density. Some authors have shown no effect on 
5HT1 receptors (Peroutka & Snyder 1980, Maggi et al 1980, Stoltz et al 1983) 
whilst others have suggested 5HT1 receptors are significantly decreased 
(Walmsley et al 1987, Wong & By master 1981, Wong et al 1985, Dumbrille- 
Ross & läng 1983). Only one group has studied the 5HT1a receptor subtype 
but this was specifically in the brainstem and hippocampus where there was a 
differential effect (Weiner et at 1989). The effect of chronic Fluoxetine 
treatment on 5HT2 receptor is no more clear. Peroutka & Snyder (1980) 
b 
suggested no significant effect, whilst Dumbrille-Ross & Tang (1983) found a 
25% increase in [3H]spiperone binding in frontal cortex and Stoltz et al (1983) 
found a 27% decrease in the same region with the same tritiated ligand.. 
Walmsley et at (1987), in an autoradiographic study, found a decrease in 5HT2 
receptors in all layers of the frontal cortex but an increase in other brain areas. 
Some of these differences are undoubtedly due to experimental techniques but 
some might be explained by differences in the duration of treatment with 
Fluoxetine since, as discussed above, Fluoxetine decreases 5HT 
neurotransmission between 2 and 14 days and increases it both acutely and after 
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14 days continuous treatment. 
In addition to the absence of significant change in 5HTla or 51M receptors the 
study has shown no neurochemical changes after chronic Fluoxetine treatment. 
These findings are unexplained since the significant lack of weight gain in 
Fluoxetine-treated rats, thought to be mediated by a central effect of appetite, 
would suggest that Fluoxetine had penetrated into the CNS and had discernible 
effect on 5HT function. It could be that the lack of significant neurochemical 
and receptor changes are due to a summation of regional differences of effect. 
Leysen et al (1986) and Twist et al (1990) found that chronic treatment with 
Ritanserin caused a 30-50% decrease in [3H]ketanserin binding in frontal cortex. 
The findings of this study have not shown any change in ligand binding to either 
of the 5HT receptor types considered, or in 5HT turnover. This is unexplained. 
The behavioural observations would suggest that Ritanserin had significant ro 
central effect but, since the study was not designed specificallyAnote changes 
in behaviour, this can be no more than subjective evidence of significant effect 
of Ritanserin at 5HT2 receptors. 
The changes in haematocrit consequent to chronic treatment with Fluoxetine or 
Ritanserin are different to the effect of acute treatment (Sections 5.2.5,5.3 and 
5.4). The decrease in haematocrit after chronic treatment with Fluoxetine, 
suggestive of an increase in plasma volume, may have lead to a decrease in 
barometric stimulation of AVP secretion, with consequent decrease in sensitivity 
of osmoregulated AVP secretion (see Section 1.1.2.3). However Ritanserin had 
a similar effect to Fluoxetine on haematocrit after chronic treatment with bQ 
significant effect on AVP secretion. It is more likely that the apparent, small 
differences are largely due to experimental error since the technique is a very 
rough guide to plasma volume and probably only useful in detecting changes of 
at least 10%. 
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5.8 CONCLUSIONS and DISCUSSION 
The major conclusions of this series of studies are: 
1. Acute Fluoxetine stimulates basal AVP secretion and increases the sensitivity 
of osmoregulated AVP secretion. 
2. This acute effect on AVP secretion is no longer apparent after 21 daily 
treatments of Fluoxetine and is possibly 
lost as early as 18hr after one dose of treatment. 
3. Chronic treatment with Fluoxetine allows return of basal AVP secretion to 
normal concentration and leads to a decrease in the osmotic sensitivity of AVP 
secretion, perhaps as an overcompensation to the initial increased sensitivity of 
osmoregulated secretion. 
4. The effect of Fluoxetine on osmoregulated AVP secretion is not blocked by 
antagonism of 5HT2/5HT1c receptors with Ritanserin nor reproduced by the 
selective 5HT2a agonist DOI which also has some 5HTIc agonist effects. 
5. Osmoregulated AVP secretion is not altered by antagonism of 5HT2and/or 
5HT1c receptors either acutely or after chronic antagonist administration. 
6. Lesion of 5HT neurons of the DRN and MRN does not alter osmotic 
homeostasis at least at basal pOS. 
Each of these conclusions has already been discussed in some detail in the 
relevant sections. 
The work has explored the hypothesis that 5HT has effect on AVP secretion 
through the 5HT2/5HT1c receptor. Since neither of these receptors appears to 
influence Fluoxetine-stimulated AVP secretion it could be concluded that the 
5HT1a or 5HT3 receptor or a receptor type or subtype as yet uncharacterised is p fIve 
important in this effect. Brownfield et al (1988) found that a selective 5HT1a 
agonist had no effect on AVP secretion and Bagdy et al (199 ) found a similar 
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lack of significant effect of a different, but highly selective 5HTla agonist. 
5HT3 agonistare not available and 5HT3 antagonishave not been used in the 
study of the neuroendocrinology of AVP secretion, although it has been shown 
that 5HT3 antagonists block the increase in plasma AVP concentration 
associated with nausea (Edwards et al 1989). This effect, however, is probably 
secondary to the anti emetic effect of such drugs and not a direct effect of the 
drug on AVP secretion. The clarification of receptor subtypes involved in 5HT 
modulated AVP secretion awaits further development of pharmacological agents 
and knowledge of receptor subtypes. 
It could be concluded from these studies that Fluoxetine stimulated basal and 
osmoregulated AVP secretion through a non-511T mediated mechanism. It is 
unlikely that this was through barometric or emetic stimulus as discussed in 
Section 5.2.5 although the effect of Fluoxetine on haematocrit perhaps requires 
further investigation of changes in plasma volume using a more sensitive 
technique. Although the pharmacological effects of Fluoxetine are thought to be 
highly specific to 5HT neurotransmission effects on other neurotransmitter 
systems have also been shown (Fuller & Wong 1990). Chronic administration 
to rats has been shown to cause down regulation of ß-adrenoreceptors 
(Walmsley et al 1987), and to decrease noradrenergic mediated growth hormone 
release in depressed patients (0' Flyn et al 1991). Both these findings suggest 
that Fluoxetine, at least in chronic administration, may have significant effect on 
noradrenergic function. It is possible that it stimulates AVP secretion in this 
way. 
181 
SECTION 6 
SEROTONIN RECEPTORS IN 
THE SON AND PVN 
OF THE RAT HYPOTHALAMUS 
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6.1 INTRODUCTION 
The anatomical evidence suggesting that 5HT might have a direct influence on 
AVP secretion from magnocellular neurons has been discussed in Section 
1.4.1. There is evidence of a sparse but specific 5HT innervation of these 
neurons. Autoradiographic ligand-binding studies in human brain have shown 
the presence of a low density of 5HT1a receptors in the vicinity of the SON and 
PVN but a slightly higher density of 5HTlc receptors in the PVN than the SON 
(Pazos et al 1987a) . Studies in rat brain have not specifically examined these 
hypothalamic nuclei but Pazos & Palacios (1985) and Pazos et al (1985a) have 
suggested that both 5HT1 and 5HT2 receptors are of low density in these areas 
of the hypothalamus. 
This Section of the research has explored the possibility that 5HT may have a 
direct influence of secretion of AVP from magnocellular neurons by 
examination of the 5HT receptor density localised to the SON and PVN. 
GENERAL HYPOTHESES 
1. That 5HT has a direct mode of influence on AVP secretion from 
magnocellular neurons of the PVN and/or SON through stimulation of 5HT 
receptors. 
2. That the 51M receptor subtype is of particular importance in this mode of 
action. 
3. That 5HT receptors may be identified anatomically and quantified by 
autoradiographic receptor ligand binding. 
4. That the density of receptors identified by autoradiography is directly related 
to the functional importance of 5HT as a neurotransmitter. 
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SPECIFIC AIMS 
1. lb anatomically localise magnocellular AVP secreting neurons in the SON 
and PVN. 
2. To quantify 5HT receptor density in the SON and PVN by autoradiography 
with particular reference to the 5HT2 receptor. 
6.2.1 METHODOLOGY 
Tissue preparation. 
Rat brains were collected in the manor described in Section 2.1.2.1. The brains 
were placed intact in a brain mould and a blocks containing the hypothalamus 
were dissected by cutting anterior to the optic chiasm and posterior to the 
median eminence. The blocks were immediately frozen in the vapour of liquid 
N2. Blocks were stored, air sealed at -80°C 
20µm coronal sections were cut by cryostat microtome (Bright instrument 
company, Cambs) at -15°C using an orientating object holder to an achieve the 
anatomical plain according to the atlas of Paxinos & Watson (1982). Sections 
were thaw mounted on to microscope slides, air dried for 1-3hr and stored, air- 
tight, at -80°C. 
Slide preparation. 
Washed microscope slides (1.2mm BDH) were coated according to the 
experimental use. 
a) Histology: No coating. 
b) Immunocytochemistry: 2% Gelatin coating. 
c) Autoradiography: 0.1 % Poly-l-lysine coating. 
6.3 THE ANATOMICAL LOCALISATION OF THE SON AND PVN IN 
THE RAT HYPOTHALAMUS 
In order to quantify 5HT receptors in the SON and PVN it was important to be 
able to identify these nuclei with accuracy. There is evidence that AVP and 
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OXY secreting neurons are differentially distributed in the two nuclei 
(Sternberger 1974; Vandesande & Dierickx 1975; Swaab et at 1975) (Section 
1.1.1). In rats AVP-secreting cells may be more concentrated in the mid and 
dorsal parts of each nucleus and form a ventral cluster in the mid portion of the 
SON. In the PVN AVP cells form a cluster in the centre of the outer wing of 
magnocellular neurons. This difference in anatomical localisation of neurons of 
the two hormone types could perhaps be important in the study of 5HT receptor 
localisation since there is some evidence to suggest that the direct 5HT 
innervation of the magnocellular neurons is preferentially to OXY type neurons 
(Sawchenko et at 1983). 
The immunocytochemistry (ICC) of AVP secreting neurons has previously been 
performed on brain sections of animals which have been perfused with fixative 
or immersed as a block in fixative. For the purposes of this research unfixed, 
thaw mounted cryostat sections would be used since sections from the same 
tissue block would be used for autoradiography. It was not known if the 
antigenicity of AVP would be preserved under these conditions. 
6.3.1 HISTOLOGY OF MAGNOCELLULAR NEURONS IN THE 
HYPOTHALAMUS OF THE RAT 
A Nissl stain, cresyl violet was used for histological staining of tissue sections. 
This stain identified the perikarya and proximal dendrites of neurons. A "fast 
cresyl" preparation was used (0.1 % cresyl violet in 1% acetic acid). (Drury & 
Wallington 1967). 
Methods 
20µm frozen sections were warmed to room temperature and incubated for at 
least 12hr in 10% formalin fixative, buffered with marble chips. Sections were 
washed in tap water, incubated with cresyl fast violet dye 10-20min and then 
washed in tap water. 
Sections were differentiated in 70% methanol and progressively dehydrated by 
increasing concentration of alcohol before immersion in xylene and coverslip 
application with DBX xylene based mountant (BDH). 
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Figure 6.1 show typical sections of the hypothalamus at various points through 
the SON and PVN. 
6.3.2 THE IMMUNOCYTOCHEMICAL LOCALISATION OF AVP 
SECRETING NEURONS 
ICC utilises antibodies to localise specific antigens in tissue sections. In essence 
a tissue section is incubated with a labelled antibody, the section is then washed 
and the sites of the antibody-antigen interaction identified by a visual label. In 
this research an indirect, immunoperoxidase technique was used where the 
visual label was formed by the oxidation and precipitation of the chromagen 
diaminobenzidine (DAB) subsequent to the reaction of the enzyme horse radish 
peroxidase (HRP) with the substrate H202. The specific antibodies to AVP used 
in the experiments were polyclonal, derived from rabbit sera during 
development of the specific anti-AVP antibody for RIA (Rooke & Baylis 1982) 
(Section 2.2). 
6.3.2.1 Basic protocol for ICC by an indirect immunoperoxidase method: 
Buffer: 0.01 Phosphate buffered saline (PBS) pH 7.2 (Appendix 4). 
a) Pre-incubation of tissues sections: 2x5min, 20°C. 
b) Block non-specific antibody binding sites: 5% dried milk powder in PBS. 
c) Incubation with 1" antibody: variable 
d) Wash: 2x5min PBS, 20°C. 
e) Incubation with 2"d antibody: Biotinylated donkey anti-rabbit IgG, 1: 100 
dilution, 30min, 20°C. 
f) Wash: 2x5min PBS, 20°C. 
g) Incubation with enzyme-linked avidin: Strep-avidin HRP, 1: 200,30min, 
20°C. 
h) Wash 2x5min PBS, 20°C. 
i) Substrate addition: DAB 0.25mg/ml with 2% H202,10min 20°C. 
j) Wash: 10min, tap water. 
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Figure 6.1 
Coronal sections of the rat brain to show the anatomical location of the SON and PVN. Frozen 
sections were thaw mounted and post-fixed in 10% formalin. Nissl substance was stained with 
cresyl fast violet. The stained section was used as the 'negative' for the photographs. 
ýý 
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6.3.2.1 The experiments: 
The following experiments were carried out to identify "P-secreting 
magnocellular neurons the hypothalamus. Frozen tissue sections from human 
neurohypophysis were used as positive controls and step (c) in the protocol was 
omitted to generate "negative", non-specific binding, controls. 
a) Comparison of ICC in tissue sections from perfusion-fixed hypothalamic 
blocks (1% gluteraldehyde, 1% formaldehyde, 0.8M PBS) and unfixed, frozen 
tissue sections. 
Results 
It was possible to identify AVP secreting neurons in the hypothalamus in frozen 
sections but the staining pattern was less intense than in perfusion fixed tissue. 
There was poor preservation of the quality of the unfixed frozen tissue section. 
b) Comparison of post-fixation techniques on ICC in frozen tissue sections. 
Methods 
Absolute alcohol, absolute acetone, 2.5 % gluteraldehyde in 0.2M PBS, 0.4 % 
periodate-lysine paraformaldehyde (PLP). 
Results 
Acetone fixation caused complete loss of AVP antigenicity. This was perhaps 
not surprising since acetone is used in the extraction of AVP from plasma 
samples (Section 2.2). 2.5 % gluteraldehyde provided best results. 
c) Comparison of the effect of different antibodies and antibody dilutions on 
ICC in frozen tissue sections post-fixed by 2.5% gluteraldehyde. 
Methods 
4 different antibodies used at dilutions of 1: 100,1: 500,1: 1000,1: 5000 in PBS. 
Incubated with tissue sections 4°C, 18hr. 
Results 
One antibody (A) appeared to have particular superiority of specificity density 
and of staining. This was optimal at a dilution of 1: 1000. 
d) Comparison of 111 antibody (A, 1: 1000) incubation times and temperature 
conditions on ICC in frozen tissue sections post-fixed by 2.5% gluteraldehyde. 
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Methods 
60min, 37°C and 18hr 4°C. 
Results 
Incubation for 18hr at 4°C gave slightly better staining characteristics. In a 
further experiment it was found that using antibody dilution of 1: 200 similar 
results could be obtained with shorter incubation at a higher temperature. 
Figure 6.2 shows a tissue section stained by ICC and counterstained with cresyl 
fast violet prepared by this, optimal, methodology. 
6.3.2.3 Discussion and conclusions 
This series of experiments has shown that ICC of AVP may be performed on 
frozen tissue sections with post-fixation. There was, however, loss of intensity 
of staining pattern compared to perfusion fixation of tissue. It has been assumed 
that the antibodies used were specific for AVP. No purification or cross 
reactivity studies were undertaken and it is possible that at least some of neurons 
stained may be OXY-secreting. Light microscopic study of the sections 
suggested that there was more intense staining in the neurons and dendrites in 
the ventral portion of the mid SON but there was also staining of cells in the 
most rostral portion of the SON where, it is proposed, OXY neurons 
predominate. 
Comparison of staining of magnocellular neurons of the SON and PVN by ICC 
and cresyl violet suggested that ICC had no advantage over Nissl staining in 
anatomical identification of these nuclei since they have very distinct anatomical 
appearance and landmarks. ICC did perhaps yield more information about the 
hormone type of the individual cell but this was inconclusive without further 
work on antibody specificity. Since the autoradiographic image would not 
provide cellular resolution it was decided that Nissi staining of histology sections 
would be adequate - anatomically localise the nuclei for image analysis. 
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Figure 6.2 
Coronal sections of the rat brain with immunocytochemical staining for AVP in the 
magnocellular neurons of (a) and (b) the SON and (c) the PVN. Thaw mounted frozen section 
were post fixed in 2.5% Gluteraldehyde before ICC. Sections were lightly counterstained with 
cresyl fast violet. 
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6.4 THE DENSITY OF 511T RECEPTORS OF THE MAGNOCELLULAR 
NEURONS OF THE SON AND PVN 
6.4.1 LIGAND BINDING 
Ligand binding experiments involve reversible and saturable interaction of a 
specific ligand (L) with a binding site (putative receptor). If the ligand is 
specific for one binding site (R) then, by the law of mass action, 
K1 
R+L == RL and at equilibrium [R][L]/[RL] = k-1/k1 =KD 
K-1 
where [R] is the concentration of the binding site. 
[L] is the concentration of the ligand. 
[RL] is the concentration of the binding site-ligand complex. 
KD is the dissociation constant of the equilibrium. 
In any preparation the total number of binding sites Bnx = [R] +[RL]. 
Therefore [RL] = BnuX/1+(KD/[L]). 
Since [RL] is the amount of ligand bound (B), therefore 
B= Brmx/l+(KDI[L]) or B= BMX [L]/ (Kp+[L]) 
When an increasing concentration of a ligand is added to a preparation of 
binding sites an increasing number of sites are occupied. A graphic 
representation of the percentage of ligand bound with respect to the 
concentration of ligand added yields a hyperbolic curve. When [L] = KD than 
B= 50% BMX ie. 50% of the total binding sites are occupied. 
The hyperbolic curve may be transformed to a linearity by plotting B/[L] with 
respect to B this derives from the Scatchard equation 
B/[L] = B, x/Ko - 
B/K D (Scatchard 1949). 
Representation of the data in this way allows linear regression analysis and B.. 
to be estimated from the x-axis intercept of the line and the KD calculated from 
the slope of linear regression analysis. This linear relationship only holds true 
when there is a single population of binding sites with one affinity state. More 
complex transformations of ligand binding data allows identification of multiple 
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binding sites and affinity states and allosteric interaction of ligand binding 
(Cross & Owen 1986). 
The introduction of a competitive ligand, at varying concentrations, displaces 
the specific ligand from the binding site and generates a series of parallel 
displacement curves which allows specific definition and description of the 
binding site characteristics and estimation of the equilibrium dissociation 
constant of the inhibitor K.. 
K= IC501(1 + [L]/KD) 
Where IC50 is the concentration of the inhibitor required to produce 50% 
inhibition of ligand binding. 
The use of multiple competitive ligands with the same specific ligand establishes 
rank potency and defines the binding site pharmacologically (see Section 1.3.3). 
6.4.2 AUTORADIOGRAPHY 
Autoradiography is the localisation of a radiolabel within a solid specimen, by 
placement of the specimen against a detector material. The principle of the 
autoradiographic process is that the radiolabel within the specimen undergoes 
decay with emission of particles of radiation which, after a suitable exposure 
time, cause a change in the detector. The image produced relates to both the 
distribution and quantity of radiolabel. This has advantages over homogenate 
radiolabel binding since anatomical resolution is possible. Autoradiography is 
in addition 103-104 quantitatively more sensitive than homogenate ligand binding 
(Kuhar 1988). 
The development of in vitro autoradiographic techniques has allowed application 
of the principles of homogenate ligand binding to specific 5HT receptor 
subtypes in tissue sections (Palacios & Dietl 1988; Pazos et al 1988). The 
radioligands commonly used for identification of 5HT receptors and receptors 
subtypes have been outlined in Thble 1.2.3. 
Initial studies dipped radiolabelled tissue sections in detector emulsion but found 
that the temperature and moisture of this process allowed dissociation of the 
ligand (Kuhar 1985). The more recent development of dry detector emulsion on 
sheet film has lead to more satisfactory results with the added benefit of 
allowing computer assisted image analysis to quantify the resulting 
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autoradiographic image (Palacios et at 1981). 
The experimental conditions required for in vitro autoradiographic receptor 
labelling are established after biochemical studies of the characteristics of the 
binding of ligands to mounted tissue sections. Initially the conditions are 
adapted from those of membrane homogenate binding experiments and tailored 
to provide the best ratio of specific to non-specific binding and selectivity of 
binding-site labelled. 
6.4.2.1 Choice of radioligand 
In order to obtain a good radiographic image the ligand of choice must have a 
high affinity for the binding site of interest (KD< 10nM). It should ideally also 
have pharmacological selectivity for the site of interest eg. be a 5HTla selective 
ligand with low affinity for other 5HT1 receptor subtypes. These two features 
will ensure a high ratio of specific to non-specific binding in the resulting 
autoradiograph. In addition the ligand must be metabolically stable, chemically 
pure and have a high specific activity to detect a low density of binding sites in 
the tissue section. 
The most commonly used radio isotopes for binding studies are 3H and 1251. 
The advantages of a tritium-labelled ligand are a very long t,, 4 (12.5yr) and the 
lack of disturbance of biological activity of the ligand (125I-labelled ligands may 
significantly alter the pharmacological properties of ligands due to its much 
larger structure). Tritium-labelled ligands also produce good autoradiographic 
image resolution since they emit low energy ß-particle radiation with a short 
track. 
In general the use of a ligand at a concentration similar to its KD for the binding 
site yields an autoradiograph with optimal ratio of specific to non-specific 
binding. From the discussion above this will achieve 50% total possible 
binding-site occupancy by the ligand. If labelling of the total binding site 
population is required (Bnux) a concentration of ligand of approximately IONKD is 
required to ensure saturation. The disadvantage of this is the increase in non- 
specific binding. 
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6.4.2.2 Choice of inhibitor 
The choice of competing inhibitor and the concentration at which it is used is an 
important consideration of autoradiography since specific binding is defined as 
the difference in amount of radioligand bound in the absence and presence of an 
excess of competing ligand. Thus best results will be obtained from an inhibitor 
with high affinity and selectivity for the binding site of interest. If the 
radioligand has high affinity for two binding sites it is useful to employ an 
inhibitor with high affinity for only one of these sites. The inhibitor 
concentration should be high enough to occupy all specific binding sites without 
displacement of ligand from non-specific binding sites. In practice this requires 
a concentration of 100-1000xIC50. If the radioligand is used at the KD 
concentration then the inhibitor concentration is 200-2000xI c (see above). 
6.4.2.3 Assay conditions 
The conditions of autoradiography are optimised to obtain the best ratio of 
specific to non-specific binding. For quantitative analysis the experiment must 
be carried out under conditions which ensure equilibrium of binding site-ligand 
interactions. 
a) Tissue preincubation: 
Initial preincubation of tissue sections in ligand-free buffer is used to dissociate 
endogenous ligand from the binding site and to stabilise binding sites in a high 
affinity state. The introduction of ions to the buffer may significantly increase 
specific binding (Leslie et al 1988). 
b) Incubation buffer: 
Radioligand incubation with binding sites should ideally be carried out in 
physiological conditions. However, the presence of physiologic ions (eg Na+) 
in buffers of agonist radioligands may reduce specific binding due to 
conformational change of the binding site and therefore a reduction in affinity. 
Radioligand binding assays are usually carried out at lower than physiological 
temperatures in order to preserve tissue quality, binding site numbers and 
metabolic integrity of the ligand. The rate of ligand-binding site interaction 
reduces with temperature such that longer incubation times are required to reach 
a state of equilibrium. 
The volume of incubation buffer is important since equilibrium assumes that the 
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concentration of bound ligand is very small compared to the concentration of 
free ligand. This is particularly important in experiments where ligand is placed 
over the tissue section rather than the tissue section dipped into a trough of 
ligand. In such "drop assay" experiments there may be significant ligand 
depletion if the volume "dropped" is insufficient. This can be estimated and 
checked by measurement of ligand concentration at the start and end of the 
incubation time. 
c) Incubation time: 
Initial kinetic experiments should be undertaken to determine the time course of 
binding site-ligand interaction and the establishment of equilibrium. While 
specific binding achieves a plateau at equilibrium, non-specific binding 
continues to increase with time. The optimal incubation period is defined as the 
minimum time required to reach steady-state binding conditions. While shorter 
incubation periods may increase the ratio of specific to non-specific binding the 
quantitative analysis of the resultant autoradiographs is not valid. 
d) Wuhout conditions: 
Following incubation tissue sections are rinsed to dissociate loosely bound 
radioligand and to optimise specific to non-specific binding ratios. Since 
radioligand dissociation rates are inversely related to binding site affinity, non- 
specific, low-affinity binding dissociates more rapidly than high-affinity, 
specific binding. The rate of dissociation of specifically bound ligand is 
diminished by temperature. 
6.4.2.4. Standards and controls 
The main difficulty in quantification of autoradiographs is the non-linear 
relationship between autoradiographic grain density in the emulsion and the 
tissue content of radioactivity ie. binding site density. Radioactive standards are 
exposed to the detector emulsion together with the radiolabelled tissue sections 
in order to derive a mathematical relationship between grain density and 
radioactivity. The exposure time of radiolabelled tissue sections must be such 
that the change in grain density produced by the tissue section image lie within 
the linear range derived from the radioactive standards. This can be predicted to 
some extent from the specific activity of the ligand and approximate density of 
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binding sites, but test autoradiographs are employed to ensure correct exposure 
duration. 
Inter and intra-assay tissue section controls, for both total and non-specific 
binding, may be used as a measure of experimental variability. 
For the purpose of this research 5HT1a and 51M receptors were localised and 
quantified by adaptation of the method of Pazos et al (1985a; 1988) and Pazos & 
Pabcios (1985). Some initial experiments were performed with variation in 
wash characteristics and competitive inhibitor type and concentration to optimise 
the ratio of specific: non-specific binding by comparison of density of ligand 
binding in cortex, caudate and hypothalamus. 
6.4.2.5 The protocols of optimal autoradiography conditions 
5HTI 51M 
Ligand [3H]DPAT [3H]ketanserin 
Buffer A B 
Inhibitor 1µM 5HT 1µM methysergide 
Preincubation 30min 20°C 15min 20°C 
Incubation 60min 20°C 120min 20°C 
Wash lxl5min 4°C 2xl5min 4°C 
tap water dip 4°C 
Dry Fan assisted ihr 20°C 
Ligands 
5HT1a: The potent 5HT agonist 8-hydroxy-n-n-dipropyl-2-aminotetralin 
(8OHDPAT) (Arvidsson et al 1981) has been shown to be a selective ligand 
with high affinity for the 5HTla receptor subtype (K, =0.4-4nM depending on 
assay conditions) (Middlemiss & Fozard 1983; Gozlan et al 1983). The tritiated 
ligand [3H]DPAT is well established as a useful ligand for 5HTla 
autoradiography (Marcinkiewicz et al 1984; Nelson 1988). [3H]DPAT was 
obtained from Amersham. Specific activity was 240ci/mmol. 
5HT2: The 5HT antagonist ketanserin (Leysen et al 1981) has a high affinity 
for 5HT2 receptor sites (Ko=0.4-3nM in rat frontal cortex). It also has affinity 
for the 5HT1c site although this is lower than that for the 5HT2 site (Hoyer 
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1988). The tritiated ligand [3H]ketanserin is well established for use in the 
autoradiography of 51M receptors although there is high non-specific binding 
(20%) and approximately 10% binding to al-adrenergic receptors (Leysen et al 
1982). [3H]ketanserin was obtained from NEN. Specific activity was 
60ci/mmol. 
Inhibitors 
SHT1a: 5HT has a high affinity for the 5HT1a receptor and has been shown to 
reduce [3H]DPAT specific binding by 80-85% at a 1µM concentration, yielding 
a specific: non-specific binding ratio of at least 8: 1 (Marcinkiewicz et al 1984). 
5HT was obtained from Research Biochem. Inc. 
SHT2: Methysergide has a high affinity for the 5HT2 receptor but, unlike 
ketanserin, lacks affinity for the cri-adrenergic receptor (Leysen et al 1981). It 
has a high affinity for the 5HT1c and other 5HT1 receptor subtypes (see Table 
1.3.4) (Leysen et al 1982).. Specific binding of [3H]ketanserin is reduced by 
80% at a 1µM concentration (Leysen et al 1982). Methysergide was obtained 
from Sandoz. 
Buffers 
SHT1a: Buffer A (Appendix 4). 0.17M Tris, pH7.6 with 4mM CaC12,0.01% 
ascorbic acid, 10µM pargyline. CaClz enhances specific binding whilst ascorbic 
acid prevents degradation of 5HT. Pargyline, a SSRI, prevents uptake of the 
competitive inhibitor, 5HT, into the tissue neurons. 
SHT2: Buffer B (Appendix 4). 0.05M Tris, pH7.7. There are no specific 
requirements of the ligand or competitive inhibitor for this receptor type. 
6.4.3 THE DENSITY OF 5HT RECEPTORS IN THE SON AND PVN OF 
THE NORMAL RAT 
Methods 
Serial 20Am sections were taken through the SON and PVN of six normal rat 
brain hypothalamic blocks. Adjacent sections in the mid rostro-caudal portion 
of each nucleus taken in triplicate and thaw mounted alternately for specific and 
non-specific binding. Histology sections were also collected from each nucleus. 
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20µm tissue standards for inter and intra-assay comparisons were cut from a 
block of normal rat frontal cortex. 
Sections and tissue standards were processed as described above. Incubation 
with ligand was carried out using the "drop-assay" technique with Iml buffer 
volume per slide. Tissue' sections and radioactive standards 
([3H]microstandards, Amersham) were exposed to tritium-sensitive film 
(Hyperfilm, Amersham) for 26day, 4°C. 
The latent image on the detector film was developed by the reduction agent D 19 
(Kodak) and subsequent fixation (Unifix, Kodak) and hardening (Kodak) of the 
gelatin film. The autoradiographs were analysed using a Magiscan 2A image 
analysis system (Joyce Loebl) according to the method of Bell et al (1987). A 
"best-fit" curve for changes in grain density was calculated from the image of 
the radioactive standards by polynomial regression analysis according to the 
equation y=(a+cx)/(l+bx+dx"2). Results are expressed as fmollmg tissue. 
Average background grain density change was subtracted from each image. The 
SON and PVN were identified by comparison of image landmarks with the light 
microscopic view of stained histological sections. Triplicate readings of grain 
density change in each nucleus were taken in the total and non-specific binding 
tissue sections and mean values subtracted to calculate average specific binding. 
Results 
Figures 6.3 and 6.4 show the specific binding of [3H]ketanserin and[3H]DPAT 
in the SON of five and the PVN of the six rat brains. The mean values are 
summarised in Table 6.1. There was a low density of 5HT2 receptors in both 
the SON and PVN. The 5HT1a receptors appear to be even less numerous with 
a slight preponderance in the SON. Example autoradiographs are shown in 
Figure 6.5. 
6.4.4 THE DENSITY OF 5HT RECEPTORS IN THE SON AND PVN OF 
RATS WITH SHAM OR 5,7-DHT LESION OF THE DORSAL AND 
MEDIAN RAPHE NUCLEI 
Lesion of 5HT neurons by the selective neurotoxin 5,7-DHT has been reported 
to have variable effects on 5HT receptor subtypes. Some of these studies have 
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Figure 6.3 
The specific binding of [3H]ketanserin to 5HT2 receptors in the SON of five and the PVN of six 
normal rat brains. 
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Figure 6.4 
The specific binding of [3HJDPAT to 5HT1a receptors in the SON of five and the PVN of six 
normal rat brains. 
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Table 6.1 The density of [311] Ketanserin and [311] DPAT binding in the 
SON and PVN of normal rats (mean±SEM) 
[3H]Ketanserin [3H] DPAT 
(fmoUmg) tissue (fmol/mg) tissue 
SON 30.6±2.8 12.9±1.1 
PVN 29.5±4.2 7.9±0.4 
Frontal section 
(control) 
High density area 210.0±12.0 30.2±2.9 
Low density area 43.6±4.3 11.2±1.9 
Figure 6.5 
Examples of autoradiographic images of ligand binding to coronal sections of normal Wistar rat 
brains. The autoradiograph was used as the "negative" for the photograph. 
(a) Total [3H]ketanserin binding to a tissue section containing the SON and PVN. 
(b) Enlarged image of the hypothalamus of the same section showing the SON and PVN. 
(c) The non-specific binding of [3H]ketanserin in the presence of methysergide to an adjacent 
tissue section. 
(d) The total and (e) non-specific binding of ['H]DPAT in sections of the hypothalamus adjacent 
to (a). 
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been discussed in Section 1.3.3.1. 
The differences in observation are perhaps dependent on the receptor subtype 
and brain region examined and the duration of post-lesion receptor modification 
time. 
The purpose of this study was to examine the effect of loss of presynaptic 5HT 
neurons from the raphe nuclei, on the 5HT receptor density in the SON and 
PVN. 
GENERAL HYPOTHESES 
1. That receptors for 5HT are present on magnocellular neurons in the SON 
and PVN. 
2. That these receptors may be increased in density due to up-regulation after 
lesion of serotonergic neuronal cell bodies in the raphe nuclei. 
SPECIFIC AIMS 
To study the change in 5HTla and 5HT2 receptor density in the SON and PVN 
after bilateral ablation of serotonergic neurons from the dorsal and medial raphd 
nuclei. 
Methods 
Hypothalamic blocks and tissue sections were prepared from rats with specific 
and sham lesion of the dorsal and median raphd nuclei previously described in 
Section 5.6. The density of 5HTla and 5HT2 receptors was determined 
autoradiographically as described in Study 6.4.3. 
Results 
Figure 6.6 shows the density of [3H]ketanserin binding in the nuclei of rats with 
lesion of the 5HT neurons of the raphd nuclei together with sham lesioned rats 
and the "normal" rats of Study 6.4.3. Figure 6.7 shows the mean density of 
[3H]DPAT binding for the same rat groups. 
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Figure 6.6 
The specific binding of [3H]ketanserin to 5HT2 receptors in the SON the PVN of normal Wistar 
( ) and SHAM (o) and 5,7-DHT LESION (a) rat brains. 
There wasignificant differences between the SHAM and LESION groups when compared by 
the Mann Whitney U Test (P>0.05). 
Results are presented as mean ± SEM. 
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Figure 6.7 
The specific binding of [3HIDPAT to 5HT1a receptors in the SON the PVN of normal Wistar 
( ) and SHAM 00 and 5,7-DHT LESION (a) rat brains. 
There was 
significant 
differences in binding between the SHAM and LESION groups in either 
the SON or PVN when results were compared by the Mann Whitney U Test (P>0.05). 
SON PVN 
Results were compared by the Mann Witney U Test and showed no significant 
differences between 5HT lesioned and sham lesioned rats and sham lesioned 
(hooded Wistar) and "normal" rats (albino Wistar). 
6.4.5 DISCUSSION 
The receptor binding studies suggest that the 5HT2 receptor was present, in low 
density, in both the SON and PVN and that the density was similar in both 
nuclei. 5HTla receptors were also present but at a very low density. This 
receptor subtype was more numerous in the SON than the PVN. There was no 
evidence to suggest that either receptor subtype increased (up-regulated) in 
density consequent to loss of 5HT pre-synaptic neurons. 
The localisation and quantification of receptors by autoradiography is fraught 
with potential for experimental error, of which some have been discussed above. 
The autoradiography of 5HT receptors in the SON and PVN has, in addition, 
particular problems. The location of the SON, adjacent to the optic chiasm at 
the base of the brain, makes it particularly vulnerable to damage during tissue 
sectioning and autoradiographic processing. This was noted to lead to both 
decreased and increased ligand binding dependent on the nature of the tissue 
damage. The anatomical localisation of the SON and PVN on the 
autoradiographic image was difficult. Images were magnified (16x) for 
analysis. Further magnification was limited by the resolution of the hyperfilm 
(approximately 150µm) and the Magiscan system. It is possible to increase 
anatomic detail by using a high resolution autoradiographic technique, such as 
detector dipped cover-slip application to the ligand labelled tissue section. Using 
this method it would perhaps be possible to discretely identify the 5HT receptors 
for the OXY and AVP secreting neurons of the SON and PVN. The use of 
other autoradiographic techniques such as 1251 labelled ligand or ex vivo 
autoradiography might also aid anatomical resolution and improve the accuracy 
of quantification of such low receptor density. 
Incorporation of tissue standards allowed an estimate of intra-assay variability. 
There was no inter-assay variation since ligand binding was carried out on tissue 
from all rat groups in one experiment. For [3H]ketanserin binding 
@200fmol/mg tissue cv14%, @40fmol/mg tissue cv24% and for[3H]DPAT 
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binding @30fmol/mg tissue cv23%, @ 10fmol/mg tissue cv42%. There was 
therefore a high degree of intra-assay variation at the low density of receptors 
present in the SON and PVN. It was unlikely that receptor density was 
overestimated since the binding density was similar to the general "low density 
binding" of Pazos & Palacios (1985) and Pazos et at (1985a), and measurement 
of ligand binding in cortical areas of was similar to those found by others. It is 
possible that the receptor density is lower than that suggested. This is 
particularly so for 5HTla binding since there is a high percentage of error at 
such low binding densities. 
If 5HT receptors are present in low density and do not up-regulate consequent to 
the loss of pre-synaptic 5HT neurons this could mean that 5HT is not important, 
at least directly, in the regulation of AVP secretion from the magnocellular 
neurons. However research has shown that occasionally there is a "mis-match" 
of receptor density and functional importance (Kuhar 1985b) and that lesion of 
5HT neurons has been found to lead to functional receptor supersensitivity 
without change in receptor density (Section 1.3.4). This could be explained by 
differences in affinity state of receptor subtype but there is, as yet, little 
understanding of these paradoxes. 
The data presented in Section 5.6 has suggested that osmotic homeostasis 
continues despite lesion of 5HT neurons of the raphd nuclei. The lack of 
significant changes in 5HT receptor density in the SON and PVN would be 
compatible with this finding. 
These studies have essentially provided very preliminary evidence that 5HT is 
not important as a direct modulator of magnocellular AVP secreting neurons. 
Different techniques of receptor identification with greater anatomical resolution 
are required ' fully 
disprove 
this hypothesis. 
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SECTION 7 
GENERAL DISCUSSION 
AND 
CONCLUSIONS 
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The results of this research have already been discussed in considerable detail in 
each Section together with some criticism of experimental techniques and 
methodological sources of error. This discussion brings together the major 
conclusions in the light of the hypotheses and aims of the research set out in 
Section 1.7 and puts forward proposals for future work in the area. The major 
objective of the research was to explore the hypothesis that 5HT modulates 
osmoregulated AVP secretion. 
The first aim of this work was to study the effect of pharmacological 
manipulation of central 5HT neurotransmission on osmoregulated AVP secretion 
in normal man. The two studies in Section 3 found no evidence that 7 days 
treatment with the SSRI, Fluoxetine, significantly altered either basal or 
dynamically assessed osmoregulated AVP secretion. There are three possible 
interpretations for this negative finding. Firstly that 5HT does not have a role in 
osmoregulated AVP secretion. Secondly that Fluoxetine did not increase 
synaptic 5HT in these normal subjects. Thirdly that 5HT does modulate 
osmoregulated AVP secretion but this was not apparent after 7 days treatment 
with Fluoxetine. These hypotheses have been discussed in Section 3.3 and it 
has been postulated that 5HT may acutely increase AVP secretion but that rapid 
adaptation occurs to re-establish osmotic homeostasis. 
To explore further the putative role of 5HT in osmoregulated AVP secretion in 
man it would be important to study the effect of very acute increase in 5HT 
neurotransmission. This would require intravenous administration of a 5HT 
active agent. There are two such drugs presently available, L-tryptophan and 
clomipramine, a tricyclic antidepressant with inhibitory activity at the 5HT 
reuptake site. Unfortunately L-tryptophan has recently been associated with the 
eosinophilic myalgic syndrome and, although this was probably attributable to a 
constituent of the oral medication, it would be unethical to use this for research 
purposes at present. A major problem of using clomipramine, and many other 
agents which increase 5HT neurotransmission, is the marked nausea inducing 
effect. This would undoubtedly lead to abnormal osmoregulated AVP secretion 
(Section 1.1.2.3). It is difficult therefore, to see how progress can be made in 
the further study of 5HT and osmoregulated AVP secretion in man. It is 
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possible that agonist and antagonist drugs of the various 5HT receptor subtypes 
may provide some answers. Investigation of the effect of more prolonged 
administration of antidepressant or other 5HT active drugs may also prove 
interesting since, as discussed in Section 1.5.3.2, such drugs initially increase 
5HT neurotransmission with a subsequent period of autoregulatory 
compensation followed by a recurrence of a net increase in 5HT 
neurotransmission after about 14 days of continued administration. 
The modulatory effect of 5HT on osmoregulated AVP secretion was more 
extensively explored in rats by pharmacological manipulation of 5HT 
neurotransmission. The studies in Section 5 have shown that Fluoxetine, when 
administered acutely, significantly altered osmoregulated AVP secretion. The 
analysis of the data by piece-wise regression has suggested that there was an 
increase in basal secretion and an increase in the osmotic sensitivity of AVP 
secretion above the osmotic threshold. The osmotic threshold itself was not 
apparently altered by acute Fluoxetine treatment. This pattern of alteration of 
AVP secretion was similar to that described in type C SIAD, thought to be due 
to loss of inhibitory stimuli to AVP secreting magnocellular neurons (Section 
1.2.2.3). Chronic administration of Fluoxetine for 21 days allowed basal 
secretion to return to normal but significantly decreased the sensitivity of AVP 
secretion to change in plasma osmolality. The evidence presented in Study 
5.2.1 might suggest that this effect was lost as early as 18hr after one dose. The 
possible reasons for this have been discussed in Sections 5.2.5 and 5.8. If it 
might be assumed that the effect was mediated through alteration of 5HT 
function the chronological change in effect is in keeping with the ideas put 
forward in Section 3.3, that SHT is involved in osmoregulated AVP secretion 
but that the two systems can adjust very rapidly to stimulation of 5HT 
neurotransmission achieving a new equilibrium and re-establishing osmotic 
homeostasis. Nelson et al (1987) found similar "fatigue" of the inhibition of 
AVP secretion by the SHT antagonist, Ritanserin (Section 5.3). 
The Studies in rats were unable to identify the 5HT receptor subtypes involved 
in Fluoxetine-modulated osmoregulated AVP secretion. The results of Sections 
5.3,5.4 and 5.5 would suggest that the 5HT2 and 5HT1c receptors were not 
important in the effect since Ritanserin did not inhibit the Fluoxetine-augmented 
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AVP response to plasma hyperosmolality and DOI had no significant effect on 
osmoregulated AVP secretion. This might indicate that the mechanism of 
Fluoxetine stimulated AVP secretion was non-serotonergic. It has previously 
been shown that the stimulatory effect of two 5HT agonists on AVP secretion 
was inhibited by prior treatment of the animals with the 5HT synthesis inhibitor 
pCPA (lovino & Steardo 1985). It would be interesting to see the effect of 
depletion of central 5HT or lesion of 5HT neurons on Fluoxetine"stimulated 
AVP secretion. 
Since it is possible that the 5HT3, or an as yet uncharacterised 5HT receptor 
subtype is important in the effect, the identification of the receptor subtypes 
involved in Fluoxetine-stimulated osmoregulated AVP secretion could be further 
explored using 5HT agonist and antagonist drugs to other receptor subtypes. 
The hypothalamic explant system (Section 1.1.3.2.2) would be a useful system 
to explore this before further in vivo studies are performed. 
The anatomical studies in rats (Section 6) have suggested that 5HT2,5HTlc and 
5HTla receptors are present only in low density in the region of the SON and 
PVN. Although there is some evidence for a direct influence of 5HT on AVP 
secretion it would seem most likely that the effect is mediated by a complex 
interaction of several neurotransmitter systems and afferent inputs to the 
magnocellular neurons. The 5HT neurotransmitter system is extensive and 
innervates most regions of the brain (Section 1.3.1). It may influence any of the 
neurotransmitter systems involved in osmoregulated AVP secretion (Section 
1.1.3). In addition the SFO and other circumventricular organs have relatively 
dense 5HT innervation (Bouchaod & Bosler 1986) and 5HT could have affect on 
afferent stimuli from these osmosensitive areas to the magnocellular neurons in 
the hypothalamus. 5HT is generally an inhibitory neurotransmitter and it could 
be that stimulation of 5HT neurotransmission inhibits afferent stimuli to the 
magnocellular neurons which exert inhibitory control on AVP secretion eg. DA, 
opioids. This would be a difficult hypothesis to explore but could be studied 
using neurobiochemical and electrophysiological in vivo systems (Section 
1.3.3.2). 
The third objective of this research was to explore water balance and the effect 
of 5HT active antidepressant drugs in depression, a putative "disease state" of 
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5HT neurotransmission. The studies of water balance in elderly depressed 
patients (Section 4) found all but one of 16 subjects to have remarkably normal 
osmoregulation in response to water loading. This would suggest that problems 
of water balance in depression are infrequent. The subjects in this study, 
however, had only mild to moderate depression. In addition the water load test 
could only discern large individual differences from the population norm 
(approximately 40%). A more detailed longitudinal study of osmoregulation in 
depression, including patients with more acute and severe stages of illness, 
would be extremely valuable to assess the influence of disease state and its 
progressive improvement, together with the putative changes in 5HT function. 
In such a study repeated water load tests in the same individual could probably 
detect a z20% significant change in water load excretion (derived from Section 
3.1). 
Similar studies have been undertaken on the abnormalities of function and 
regulation of the HPA axis (Schatzberg & Nemeroff 1988) and useful 
information has been obtained about a subgroup of patients with implications for 
prognosis. In addition such research leads to further understanding of the 
puzzle of the pathophysiology of depression (see Section 1.5.2.4). 
Abnormalities of AVP secretion associated with depressive illness, particularly 
psychotic depression have been discussed in Section 1.6. Further information 
about pathophysiology might be gained from studies of water balance and 
osmoregulatory function in these patients although the practicalities of even 
simple assessment such as fluid balance are often insurmountable in such 
disturbed patients. 
Five of the six patients with depression treated by Fluoxetine had no apparent 
abnormality of water balance compared to depressed patients treated with 
Dothiepin or normal elderly subjects. The abnormal result of one patient was 
probably attributable to her impaired renal function. This was a small study and 
it may be that a larger study would have detected a significant effect of 
Fluoxetine on water balance. It is possible, however, that by excluding patients 
taking certain medications such as diuretics and patients with physical illness, 
the very population that was most vulnerable to the effects of Fluoxetine on 
water balance had been excluded from study. The reports of Fluoxetine- 
associated hyponatraemia and the cases presented in Appendix 10 might suggest 
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that it is elderly patients with severe mental illness, and concomitant physical 
illness, who are particularly vulnerable to 5HT associated SIAD. This group of 
patients would be extremely difficult to study either by water load test or 
infusion of 5% saline. This putative vulnerability has implications for clinical 
management and it would perhaps be prudent to monitor the plasma sodium of 
such patients by weekly blood samples during the first 4-6 weeks of treatment 
with Fluoxetine and perhaps other SSRI. 
Other SSRI have not been reported in the literature as associated with SIAD or 
hyponatraemia although there is one report of fluvoxamine to the Committee on 
Safety of Medicines and Appendix 10 presents a case of paroxitene-associated 
hyponatraemia. Although this might suggest that the mechanism of Fluoxetine - 
associated hyponatraemia is not through its inhibition of 5HT reuptake, other 
SSRIs have perhaps not as yet been as widely used in the treatment of severe 
depressive illness. It may be, therefore, that these drugs have not yet been 
prescribed to patients who are particularly vulnerable to disturbance of 
osmoregulation by increase in 5HT neurotransmission. It is also known that at 
least some of the SSRIs have regional variation in effect on 5HT reuptake in the 
CNS (Wong et al 1975; Section 2.3.1.2). This might also explain the apparent 
differences of drug effect. 
Sections 1.1.1,1.1.2.4 and 1.3.1 discussed some of the species differences in 
AVP secretion, osmoregulation and the central 5HT nervous system. If the 
results of the studies in rats in Section 5 may be extrapolated to man, the 
following conclusions and hypotheses may perhaps be drawn from this research. 
Acute increase in 5HTneurotransmission leads to a rise in basal AVP secretion. 
This modulatory effect of 5HT on osmoregulated AVP secretion is probably 
mediated indirectly, possibly by inhibition of inhibitory afferent stimuli. 
Both the AVP- secreting neurons and the 5HT system rapidly accommodate, by 
autoregulatory processes, to the increase in 5HT neurotransmission and AVP 
secretion. The 5HT autoregulatory process have been discussed in Section 
(1.3.4). The magnocellular autoregulatory processes are less well understood 
(Section 1.1.3) but the studies of Section 6 would suggest that changes in 5HT 
receptor density do not play an important role. With continued drug 
administration the 5HT autoregulatory processes are overcome and there is 
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again a net increase in 5HT neurotransmission. This does not lead to increased 
AVP secretion in normal man and the normal rat since the autoregulatory 
processes of the magnocellular neurons are still apparent, indeed the studies in 
rats may suggest that some overcompensation occurs (Section 5.7). In the 
"disease state" of 5HT neurotransmission present in depression, where there is 
also some evidence of AVP dysregulation (Section 1.6), there may be 
dysfunction of these regulatory processes and ensuing abnormality of 
osmoregulation. 
The neuroendocrine regulation of AVP is thought to have such adaptive and 
homeostatic ability and some parallels may perhaps be drawn to the effect of 
nicotine on AVP secretion. Nicotine has been shown to alter AVP secretion in 
vitro and in vivo and is important in osmoregulated AVP secretion (Section 
1.1.3.2.2) . Acute administration of nicotine 
in man leads to secretion of AVP 
but it has been suggested that chronic administration, by cigarette smoking, 
leads to blunting of the response (Burn et al 1945; Rowe et al 1980; Lightman et 
al 1982). 
The commencement of antidepressant therapy with 5HT active drugs leads to 
several clinical adverse effects (eg. nausea, disturbed sleep) most of which 
habituate within 3-4 days presumably due to autoregulatory features of 5HT 
neurotransmission (see Section 1.3.4). Continued administration of 
antidepressant drugs leads to a net increase in 5HT neurotransmission after 14- 
21 days and the concomitant onset of therapeutic action (Section 1.5.3.2). The 
adverse effects of treatment do not, however, recur with the onset of therapeutic 
action. The paradox of how these adjustments to adverse effects occur but 
therapeutic effect is still evident is probably explained by the putative 
abnormality of 5HT in depression and a dysfunction of normal regulatory 
processes. Failure of these compensatory mechanisms might explain why 
Fluoxetine- associated hyponatraemia occurs early in depression and persists, but 
does not appear to occur in normal man. The apparent abnormality of 
osmoregulated AVP secretion that occurs with normal ageing (Section 4.2.1) 
may play an additional role in the vulnerability of elderly depressed patients to 
SHT associated SIAD. It may be postulated that the more severe the 
dysfunction of 5HT neurotransmission, ie. the more marked mental disturbance, 
the greater the vulnerability to 5HT SIAD. As discussed above it would seem to 
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be important that when Fluoxetine or other potent 5HT active agent is used in the 
treatment of elderly depressed patients with severe mental illness, perhaps 
particularly those with psychotic depression, their osmotic status is monitored. 
Based on the results of these studies it is my view that 5HT modulation of AVP 
secretion is of little physiological consequence in normal man and the normal 
rat. In situations where there is a dysfunction of normal adaptive mechanisms, 
such as in depression, the role of 5HT is more important and occasionally may 
lead to severe hyponatraemia and death. 
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APPENDIX 1 
The nausea scales used in Studies 3.1,3.2,4.1 and 4.2 
a) Daily nausea scale during 7 days drug treatment 
b) Nausea scale used during water load and hypertonic saline infusion 
assessments. 
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FLÜOXETINE: ORAL WATER LOAD IN DEPRESSED PATIENTS 
B1Y-EW-E087 1 81 Oi 11 1 81 0l Iiii 
Study Code Investigator No. Patient No. Visit No. 
PLEASE COMPLETE LEGIBLY USING A BLACK BALL-POINT PEN 
Protocol Time (mins) 
(Circle one) 
Actual Time (24 hour clock) 
LINEAR ANALOG SCALE ASSESSMENT 
Pre 
30 
60 
120 
180 
240 
W"W 
HHMM 
Please mark each scale (use a small vertical line) to indicate how 
nauseous and thirsty you feel at the present time. 
1. NAUSEA 
Not i Very 
Nauseated I Nauseated 
2. THIRST 
Not Very 
Thirsty Thirsty 
OFFICE NAUSEA (mm) THIRST (mm) NOTE: Always measure from 
USE left end of scale 
APPENDIX 2 
The extraction and radioimmunoassay of vasopressin 
IODINATION OF AVP 
Preparation of the reaction vessels: - 
Dissolve 1mg of IODOGEN (P, ierce Warriner, cat. no. 28600) in lml of 
dichloromethane. Take 100ul of this solution and make upto 1ml with 
dichloromethane (100ug/ml). Aliquot 100ul of this second solution (10ug) into 
plastic eppendorf tubes (12x75mm) and dry down under nitrogen at room 
temperature. These vessels can be stored at 4°C for 3months. 
Iodination method: - 
l6ug of AVP in 200u1 of 0.25M phosphate buffer (pH 7.5) is added to a 
reaction vessel. 0.5mCi of Na1'I is added to the vessel and the reaction allowed 
to proceed for 10-15min at room temperature whilst the mixture is gently 
shaken. The sample is removed from the vessel to stop the reaction procedure 
and the volume made upto lml with column eluant and then applied to the G25 
column. 
COLUMN ELUANT 
1.25m1 of conc. acetic acid added to 400m1 water . O. lg sodium azide and 
0.625g bovine serum albumin (by sprinkling on top) added. BSA left to dissolve 
and pH to 2.5 with HCI. Solution made upto 500m1 and storca J at 4°C. 
CHROMATOGRAPHY COLUMN 
Sephadex G25F and the above column eluant. Collect 2m1 fractions. AVP will 
elute after the iodine peak so it is better to take the fractions from the 
descending side of the peak, about half way down. 
EXTRACTION OF AVP FROM PLASMA 
Plasma defrosted, centrifuged 15min, 1500 RPM at 4°C. 2m1 sample aliquots 
placed in small glass test tubes (round bottomed, 5m1 capacity, silicon- coated). 
Approximately 20mg of activated Florisil added to each tube. Tubes mixed on a 
cell mixer for 20min at room temperature. Florisil manoeverd to the bottom of 
the tube and plasma aspirated. 2m1 distilled water added to each tube and 
briefly shaken. Water aspirated. 2m1 0.2M HC1 added and briefly shaken. Acid 
aspirated leaving a little remaining in the tube. 500ul of 90% acetone added to 
each tube, and mixed on cell mixer for 10min. Florisil brought to the bottom of 
the tube and acetone -aspirated with a glass pasteur pipette and transfe to a 
glass siliconised centrifuge tube. Acetone procedure repeated. lml o diethyl 
ether (Analar) added to acetone in to each centrfuge tube and mixed vigoraxly. 
Solution left for 5min until two layers are apparent. The top layer is removed 
with a fresh glass pasteur pipette for each sample and the bottom layer, contaii 
the extracted, conc. eotrated AVP is dried a gentle stream of air at 37°C. The 
dried extracts are stored at -40°C until assayed. 
ACTIVATION OF FLORISIL 
Florisil (100-200 mesh) Sigma F7752 (250g) 
Using a 500m1 glass beaker, put Florisil in till it reaches the 50m1 mark 
approximately. Add approx. 300ml of dist. water and stir vigorously with a 
magnetic stirrer for a few seconds. Allow the Florisil to settle and a 9irate off 
the water. Repeat this procedure till the water becomes clear, about 10 washes. 
Then repeat washing procedure with 1MHC1,3 water washes, iM NaOH, 10 
water washes until the water is clear. Aspirate off all of the water and cover the 
beaker with aluminium foil. Place in an oven at 120°C for 18h. When cool, 
loosen the Florisil and dispense into several small containers. 
THE RADIOIMMUNOASSAY OF AVP 
STOCK STANDARD SYNTHETIC AVP DILUTIONS 
Ferring AVP, 2mg aliquots (Ferring Pharmaceuticals, Malmö, Sweden). 
2mg is dissolved in 2m1 of distilled water containing 0.25 % acetic acid. 
Buffer A: - 0.25 % acetic acid with 0.02 % sodium azide. 
Buffer B: - 50mM TRIS + 1mg/ml BSA + 0.02% sodium azide. 
Buffer C: - Assay Buffer. 
1) 400ul of standard diluted with B 1: 100 (10ug/ml). Stored in iml aliquots. 
2) Iml of solution 1 diluted with solution B 1: 100 (100ng/ml). Stored in lml 
aliquots. 
3) lml of solution 2 diluted with solution C 1: 20 (5ng/ml). Stored in Iml 
aliquots. 
4) Iml of solution 3 diluted with solution C 1: 100 (50pg/ml). Stored in lml 
aliquots. This is INTRA-ASSAY CONTROL. 
5) Iml of solution 2 added to 77.125m1 of solution C (1280pg/ml). Stored in 
0.5m1 aliquots. This is ASSAY STANDARD. 
ASSAY PROCEDURE EQR ARGININE VASOPRESSIN (AVP) 
Preparation of standards 
Stock standard = 1280pg/ml stored at -20°C in 0.5ml aliquots. Defrost standard 
and make upto 2m1 with assay buffer (1: 4 dilution) now 320 pg/ml. Prepare and 
label standard tubes; 16,8,4,2,1,0.5,0.25,0.125,0.06,0.03. Add 800u1 
assay buffer to all tubes. To the "16" tube add a further 400u1 of assay buffer 
and 400u1 of standard (320pg/ml), total volume now 1600u1, mix. Transfer 
800u1 of standard from the "16" tube to the "8" tube and mix. Repeat serial 
dilution to all tubes so that each tube contains 800u1 except for the last standard 
tube (0.03) which contains 1600u1. Add 200u1 of each standard in triplicate to 
each standard tube set up for the standard curve. 
Samples 
Add 800ul of assay buffer to the dried extracts in the centrifuge tubes and mix 
vigorously. Centrifuge at 1500 RPM for 15min at 4°C. Take out 200u1 in 
triplicate, from each sample tube and add it to each triplicate sample tube in 
assay. Do not disturb the sediment in the bottom of the centrifuge tube when 
dispensing out the 200ul aliquots, leave the remaining 200u1 in the bottom of the 
centrifuge tube. If you suspect that the sample that you are about to measure will 
be very high i. e. too high to read accurately from the standard curve then the 
sample could be resuspended in, 1000ul of assay buffer instead of 800ul. 
Alternatively, the sample could be resuspended in 800u1 as usual but 200u1 taken 
in duplicate only, then 100ul is taken and made upto 1000ul with assay buffer, 
mixed and 3X 200u1 assayed i. e. a 1: 10 dilution has been made of the sample 
so that it can be read accurately from the standard curve. 
Intra-assay control (IAC) 
Dilute stock intra-assay control ( stored at -20°C) from 50pg/ml to lOpg/ml. 
Take 200u1 of 50pg/ml and add to 800u1 of assay buffer mix, this is now 
IOpg/ml. Add 200u1 of 10pg/ml, in triplicate, to IAC tubes in assay, this should 
read 2pg/tube from the standard curve. 
Dilution of first antibody(AVP-Ab) 
Stock first antibody is stored at -20°C at 1: 10000 dilution in lml aliquots. Take 
lml of 1: 10000 and add to 11.5mis of assay buffer to give an antibody dilution 
of 1: 125000.100ul of this is added to zero binding tube, all standard tubes, all 
sample tubes, extraction control and intra-assay control tubes. 
Buffer addition 
200u1 of assay buffer is added to zero binding tubes (Bo). 300u1 of assay buffer 
is added to non-specific binding tubes (NSB). 
Incubation 
Mix all the tubes from the assay and cover well with plastic. Leave at 4°C for 
24h. 
Pax2 
Dilute stock 125I-AVP with buffer to a count of 2000 in a minute in 100ul. Add 
100ul of 125I-AVP to all tubes. Add 100ul to 3 tubes containing nothing else and 
put a stopper on these, these are the total count tubes and must have nothing else 
added to them (TC tubes). Mix all tubes and recover. Store at 4°C for 18h. 
Diu 
Dilute second antibody ( goat anti-rabbit IGG ) 1: 40 with separation buffer, 
0.5m1 of second antibody with 19.5ml of separation buffer and mix. Add 100ul 
of diluted second antibody to all tubes except total count tubes. Mix, recover 
and store at 4°C for 48-72h. 
LUD a 
Centrifuge all tubes except total count tubes at 4°C for 30min at 2500RPM. 
Aspirate off all of the supernatant to leave the pellet containing bound fraction at 
the bottom of the tube. Count every tube including total count tubes, for 10min 
on a gamma-counter. 
Total counts, non-specific binding and zero binding tubes repeated at the end of 
each assay and counted at the end of the assay to check for assay drift. When 
the calculations are performed the tubes from the beginning and the end of the 
assay must be used. 
CALCULATIONS 
Total counts= TC - Background (bg) 
Non-specific binding= NSB-bg x 100% 
TC-bg 
Zero binding= Bo-NSB x 100% 
TC-bg 
Standard or sample binding (B/Bo) = sample or standard -NSB x 100% 
Bo-NS B 
Graph: - Plot on log linear graph paper, x axis (log) AVP concentration pg/tube, 
y axis (linear) is B/Bo % for standards. 
Read B/Bo for samples off standard curve, this is pg/200u1 extract (800u1, total 
volume). If extract is of 2m1 of plasma, then AVP (pg/ml)=reading from graph 
x 4/2. For extract of I ml volume assay buffer from 2m1 of plasma, then 
AVP(pg/ml) = reading x 5/2. For extract of 800u1 from I ml plasma, then AVP 
(pg/ml) = reading x 4/ 1. 
ASSAY BUFFER FOR AVP 
All chemicals must be ANALAR grade 
Dissolve 6.057g TRIS [Tris(hydroxymethyl)methylamine] and 0.2g sodium 
azide in 800-900m1 of distilled water. Sprinkle on the top, 3.5g of bovine serum 
albumin fraction V (Sigma A 9647) and leave to dissolve. Bring to p117.4 by 
adding 5M HCI. make volume to 1 litre. Store at 4°C. 
SECOND ANTIBODY SEPARATION BUFFER 
9.306g EDTA (Disodium salt) added to 200m1 of assay buffer. Dissolved by 
stirring aided by 8-10 pellets of NaOH. Leave for 10 min. pH to 7.4 with 2M 
NaOH. Add 0.5m1 of normal rabbit serum ( Wellcome Labs. Beckenham, Kent) 
and make upto 250m1 with assay buffer. Store at 4°C. 
SILICON COATING OF GLASSWARE 
Both the extraction tubes and the conical centrfuge tubes need to be silicon 
coated every 6 weeks to prevent AVP sticking to the glass. Use "Repelcote" 
from Hopkin & Wiliams cat. no. 63216 ( dimethyldichlorosilane). Add 1-2m1 of 
Repelcote to each tube, rotate and pour back into the bottle. Leave the tubes to 
dry at room temperature. All new glassware must be acid washed then 
Repelcoted prior to use for the first time. 
APPENDIX 3 
The data sheets for Fluoxetine, Ritanserin and DOI 
'PROZAC' V 
Name of Product 
'PROZAC', fluoxetine hydrochloride. 
DATA SHEET 
Presentation 
Capsules (green and off-white, coded 3105) each containing 20mg fluoxetine 
hydrochloride. 
Uses 
Depression: Prozac is indicated for the treatment of the symptoms of depressive 
illness, especially where sedation is not required. 
Bulimia nervosa: Prozac is indicated for the reduction of binge-eating and purging 
activity. 
Dosage and Administration 
For oral administration to adults only. 
Depression - adults and the elderly: A dose of 20mg, day is recommended. 
Bulimia nervosa - adults and the elderly: A dose of 60mg; day is recommended. 
Fluoxetine has a half-life of 2 to 3 days. and Its major active metabolite has a half-life 
of 7 to 9 days. Steady state plasma concentrations are only achieved after continuous 
dosing for weeks. When dosing is stopped, active drug substance will persist in the 
body for weeks. This should be borne in mind when starting or stopping treatment. 
Children: The use of Protac in children is not recommended, as safety and efficacy have 
not been established. 
Patients with renal and/or hepatic dysfunction: See 'Contra-indications' and 
'Precautions' sections. 
Contraindications, Warnings, etc. 
Contraindications 
Hypersensitivity to fluoxetine. 
Fluoxetine should not be administered to patents with severe renal failure tGFR t1 Cml, 
min) because accumulation may occur in these patients during chronic treatment. 
Usage in nursing mothers: Prorac should not be prescribed to nursing mothers. In one 
breast milk sample the concentration of fluoxetine. plus norfluoxeune. was 70.4ng ml. 
compared to 295. Ong ml in the mother's plasma. No adverse effects on the infant were 
noted. 
Monoamme oxidase inhibitors: At least 14 days should elapse between discontinuation 
of an MAOI and initiation of treatment with Prozac. At least five weeks should elapse 
between discontinuatton of Prozac and initiation of therapy with an MAOI. 
Serious, sometimes fatal reactions lincluding hyperthermia, rigidity. myoclonus. 
autonomic instability with possible rapid fluctuations of vital signs. and mental status 
changes that include extreme agitation progressing to delirium and comat have been 
reported with concomitant use or when fluoxetine had been recently discontinued and 
an MAOI started. Cyproheptadine or dantrolene may benefit patients experiencing 
such reactions. 
Warnings 
Rash and allergic reactions: Upon the appearance of rash or of other allergic 
phenomena for which an alternative aetiology cannot be identified, Protac should be 
discontinued. 
Pregnancy: The safety of fluoxetine in human pregnancy has not been established: 
accordingly, the drug should be avoided in pregnancy unless there is no safer 
alternative. There was no evidence of teratogenicity from animal studies but full testing 
was limited by maternal toxicity. 
Lactation: See 'Contra-indications'. 
Precautions 
Prozac should be discontinued In any patient who develops seizures. Prozac should be 
avoided In patients with unstable epilepsy; patients with controlled epilepsy should be 
carefully monitored. There have been rare reports of prolonged seizures in patients on 
fluoxetine receiving ECT treatment. 
Fluoxetine is extensively metabolised by the liver and excreted by the kidneys. A lower 
dose, e. g. alternate day dosing, is recommended In patients with significant hepatic 
dysfunction or mild to moderate renal failure (GFR 10-50ml/min). 
Clinical experience In acute cardiac disease Is limited, therefore caution is advisable. 
However, the ECG of 312 patients who received fluoxetine in double-blind trials were 
retrospectively evaluated; no conduction abnormalities that resulted in heart block 
were observed. 
Prozac may cause weight loss which may be undesirable In underweight depressed 
patients. Only rarely have depressed or bulimic patients been discontinued for weight loss 
when treated with fluoxetine. 
In patients with diabetes, fluoxetine may alter glycaemic control. Hypoglycaemia has 
occurred during therapy with fluoxetine and hyperglycaemia has developed following 
discontinuation. Insulin and/or oral hypoglycaemic dosage may need to be adjusted. 
There have been reports of abnormal bleeding in several patients, but causal relationship 
to fluoxetine and clinical importance are unclear. 
Although fluoxetine has been shown not to affect psychomotor performance in healthy 
volunteers, any psychoactive drug may impair judgement or skills. Therefore patients 
should be cautioned that their ability to perform potentially hazardous tasks (e. g. 
driving, operating machinery) may be impaired. 
As improvement may not occur during the first two or more weeks of treatment, 
patients should be closely monitored during this period. The possibility of a suicide 
attempt is inherent in depression and may persist until significant remission occurs. 
Drug Interactions 
Monoamme oxidase inhibitors: (see 'Contra-tndications'). 
Caution is advised if the concomitant administration of Prozac and CNS active drugs, 
including lithium, is required. There have been reportsof both increased and decreased 
lithium levels when used concomitantly with fluoxetine. Cases of lithium toxicity have 
been reported. Lithium levels should be monitored. 
Greaterthan 2-fold increases of previously stable plasma levels of cyclic antidepressants 
have been observed when Prozac has been administered in combination. 
Agitation, restlessness and gastro-intestinal symptoms have been reported in a small 
number of patients receiving fluoxetine in combination with tryptophan. 
The long elimination half-lives should be borne in mind (see'Dosage and Administration') 
when considering pharmacodynamic or pharmacokinetic drug interactions. 
In formal testing, no drug interaction of clinical significance has been observed 
between fluoxetine and chlorothiazide. ethanol, secobarbital, tolbutamide and warfarin 
Fluoxetine is bound to plasma protein and concurrent administration may alter plasma 
concentrations of other plasma protein bound drugs, or conversely fluoxetine 
Fluoxetine does not appear to potentiate the effects of alcohol. 
Adverse Effects 
Body as a whole: asthenia, fever. 
Digestive system: nausea, diarrhoea, dry mouth, appetite loss, dyspepsia, vomiting 
Nervous system: headache, nervousness. insomnia, drowsiness. anxiety, tremor, 
dizziness, fatigue, decreased libido. seizures (see'Precautions'). Hypomania or mania 
occurred in approximately one per cent of fluoxetine treated trial patients. 
Respiratorysystem: pharyngitis, dyspnoea. Pulmonary events (including inflammatory 
processes of varying histopathology and/or fibrosis) have been reported rarely. 
Dyspnoea may be the only preceding symptom. 
Skin and appendages: a small percentage of patients developed rash and/or urlicaria 
(see 'Warnings'). Serious systemic reactions, possibly related to vasculihs, have 
developed in patients with rash, and rarely death has been reported. Excessive 
sweating, serum sickness and anaphylactoid reactions have also been reported. 
Urinogenital system: sexual dysfunction (delayed or inhibited orgasm). 
Hyponatraemia (including serum sodium below 110mmol, l) has been rarely reported 
and appeared to be reversible when Protac was discontinued. Some cases were 
possibly due to the syndrome of inappropriate antidiuretic hormone secretion. The 
majority of reports were associated with older patients, and patients taking diuretics 
or otherwise volume depleted. 
The following have been reported in association with fluoxetine but no causal 
relationship has been established: cerebral vascular accident, confusion, dyskinesia, 
ecchymoses, gastro-intestinal haemorrhage, hyperprolaamaemia, pancreatitis, suicidal 
ideation, thrombocytopenia, thrombocytopenic purpura. vaginal bleeding after drug 
withdrawal and violent behaviour. 
Overdose 
On the evidence available, fluoxetine has a wide margin of safety In overdose. Since 
Introduction. a single death, attributed to a large overdose of fluoxetine alone, has been 
reported. 
One patient who reportedly took 3000mg of fluoxetine experienced 2 grand mal 
seizures that remitted spontaneously. Nausea aria vomiting were prominent in 
overdoses involving higher fluoxetine doses. Agitation restlessness, hypomama and 
other signs of CNS excitation were also observed. 
Management: No specific antidote is known. 
An airway should be established. Cardiac and vital signs monitoring is recommended. 
along with general symptomatic and supportive measures. 
Based on experience with animals, fluoxetine-induced seizures which fail to remit 
spontaneously may respond to diazepam. Due to the , arge volume of distribution of 
fluoxetine. forced diuresis, dialysis. haemoperfusion ano exchanoe transfusion are 
unlikely to be of benefit. Activated charcoal, which may be used with sorbitol, may be 
as or more effective than emesis or lavage. 
Pharmaceutical Precautions 
Store at room temperature 115-"25 C). 
Legal Category POM 
Package Quantities 
Calendar packs of 28 capsules: 2 strips of 14 capsuies 
Further Information 
Fluoxenne is chemically unrelated to tricyclic and tetracyclic antidepressant agents. It 
is a specific serotonin 15-hydroxytryptamine, 5-HT) reuct3ke inhibitor, whose specificity 
is unaltered by its major metabolite. 
Product Licence Number, Name and Address 
0006/0195 
Dista Products Limited 
Kingsclere Road 
Basingstoke. Hampshire RG21 2XA 
Telephone: Basingstoke (0256) 52011 
Date of Preparation or Last Review April 1991 
'PROZAC' is a Dista trade mark PZ. 259 
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FLUO rINE HYDROCHLORIDE (LYL0140) 
CHEMISTRY 
Fluoxetine hydrochloride, (±)-N-methyi-3-phenyl-3- 
[(a, a, m-trifluro-p-tolyl)-oxyJ propylamine hydrochloride, has 
an empirical formula of C17H18F3N0'HCI and a molecular 
weight of 345.79. Its formula is shown below. 
Fluoxetine is a white to off-white crystalline solid which 
is soluble at a coricentrati on of 14 mg/ml in water, 250 mg/ml 
in methanol, and 125 mg/ml in chloroform. Less than 1 percent 
is soluble in benzene, ethyl acetate, and hexane. 
Stability assays have shown fluoxetine to be stable for 
periods of 24 months when exposed to temperatures of 250, 
400, r 50°C. 
F3 C 
2CH2NHCH3 " HCI 
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itmyound: LY110140 - Fluoxetine Hydrochloride 
sue Date: July, 1987 (will be updated July, 1988) 
his document should not be used for registration purposes. These data, and the resulting 
Gution statement, are provided so that proper protective measures can be taken by persons 
to may be exposed to the compound during initial research and development activities. 
Lautfon Statement: DANGER, fluoxetine is a severe eye irritant and toxic by inhalation. 
ogestion and dermal contact should be avoided. Based on human clinical data, fluoxecine 
hould be handled as a potential sensitizer. 
'RELIMINARY TOXICOLOGY DATA: 
cute Exposure: Severe and irreversible damage occurred when fluoxetine was placed in the 
yes of rabbits whether a posttreatment rinse was employed or not. The application of 500 
' of fluoxetine per kg of body weight to the backs of rabbits caused a transient loss of 
bdy weight. The median lethal dose (LDso) of fluoxetine, when administered by oral gavage 
o rats, %was approximately 400 mg/kg of body weight. Ante mortem signs of toxicity were 
remors, convulsions, and myoclonus. Other signs were hyperirritability, limb weakness, 
rd salivation. The median lethal concentration (LC50) of fluoxetine was 0.8 to 1.0 mg/L 
'f air in rats exposed for one hour to a solid particulate aerosol. Surviving animals 
tchibited difficult breathing, hypoactivity, nasal mucosal irritation and weight loss. 
zeproduction: Reproduction studies in rats '(2,5,12.5 mg/kg) and rabbits (2.5,7.5,15 
"g/kg) indicate that fluoxetine is not teratogenic. In a rat fertility study at doses of 5, and 12.5 mg/kg/day, there was no impairment of reproductive performance or evidence 
if teratogenicity. There was a slight decrease in survival and weight gain of offspring at 
she highest dose level. In a two-generation fertility study in rats fed diets containing 
1.002,0.005, and 0.0125% fluoxetine, there was no impairment of reproductive performance 
-r evidence of teratogenicity. Only minor effects, which included depressed food 
-onsumption and weight gain of F0 animals curing the premating treatment period and a 
, light decrease in survival and weight gain of the F1 neonatal progeny, were observed when 
'o rats were given diets at the highest dose level, ca 7.4 mg/kg/day. The no-effect level 
ka this study was 0.005%, equivalent to ca 3.1 mg/kg/day during the premating and gestation 
leriod. 
3ubchronic Exposure: Studies of three months duration have been completed in rats (ca 10, 
5,75 mg/kg) and dogs (5,10,20 mg/kg) to evaluate the effects of daily oral 
administration of fluoxetine. Compound effects in rats were deaths at' the high dose, 
lepressed weight gain and dose-related incidence and severity of pulmonary histiocytosis (phospholipidosis). Treatment related changes in dogs included decreased weight gain, 
transiently increased platelet count, anorexia, transient mydriasis, occasional fine 
tremors and vomiting. In rats and dogs, 10 mg/kg fluoxetine was tolerated with minimal 
Vert effects. In a 90-day dietary study in mice at doses nominally equivalent to 1.6, 
'. 9, or 31 mg/kg/day, the significant toxicological effects were essentially limited to the 
high dose and included hyperactivity; decreased body weight gain; minimal and reversible 
generative hepatic changes and pulmonary phospholipidosis; and focal testicular 
'pospermatogenesis. This latter effect appeared to be species specific and was 
sentially restricted to the high dietary level of 0.02% (ca 31 mg/kg/day), which is 
proximately 30 times the clinical dose. 
Lronic Exposure: In a one year dietary study with a two-month recovery phase in rats at 
poses nominally equivalent to 0.5,2.5, or 10 mg/kg/day, significant toxicological effects 
zcluded phospholipidosis, anorexia, slight hepatic fat deposition, and minimal 
'tticuloendothelial cell hyperplasia; these effects were essentially reversible during the 
'ecovery phase. There were no significant toxicological effects at the lowest dose. In a 
Ie year study with a two month recovery phase in dogs at doses of 1.0,4.5, or 20 
, 
4/kg/day (decreased to 10 mg/kg/day), the most significant effects were associated with 
he high dose group. These effects consisted of deaths at 20 mg/kg and moderate 
ttadycardia, physical signs of toxicity including anorexia and aggressive behavior, and 
Qospholipidosis at 10 (20) mg/kg/day. The effects were reversible in all surviving 
himals. At 4.5 and 1.0 mg/kg; day, the effects ""erc minimal and reversible. In a two year 
tironic toxicity and carcinogenicity study in rats fed diets containing 0.001,0.0045, and 
. 02% 
fluoxetine, there was no evidence of carcinogenicity and no adverse effects on 
4rvival. In addition to decreased body weight gain, significant accumulation of 
uoxetine and norfluoxetine occurred in the lung and was associated with pulmonary 
ospholipidosis. In the liver, moderate lipid deposition and phospholipid accumulation 
kre demonstrated at various times during the first 17 months of treatment, but were not 
parent after two years of fluoxetine administration. These changes observed at 0.02% in 
de lung and the liver were without apparent long-term detrimental effects. The effects 
%served at the low and middle dose after two years of treatment were limited primarily to 
de liver changes and were considered to be of minimal toxicologic significance. In a 
Lo-year chronic toxicity and carcinogenicity study, mice received average daily dietary 
bses of 1.14,4.46, or 11.87 mg of fluoxetine/kg body weight for males and 1.23,4.64, or 
11.86 mg/kg for females. There was no evidence of carcinogenicity, and no overall effect 
+a survival. Treatment-related effects of chronic fluoxetine administration included 
I-peractivity with associated mortality in high-dose females, minimal to moderate fatty 
bange in the liver and hepatocellular cytomegaly at the mid- and high-dose, and 
tose-related handling-induced clonic seizures at all doses in females. 
, 
Ltagenicity Data: Fluoxetine was not mutagenic in the modified Ames bacterial mutagen 
essay, the DNA repair assay in primary rat hepatocytes, the sister chromatid exchange assay 
6 Chinese hamster bone marrow cells, and the mouse lymphoma assay. 
nclusion: The toxicity seen with chronic fluoxetine administration was consistent with 
that expected based on its pharmacology, the toxicity evident in preclinical studies of 
tther drugs in its therapeutic class, and the effects seen with other 
Ihospholipidosis-inducing drugs. Moreover, no mutagenic, carcinogenic, teratogenic, or 
ldverse reproductive effects have been associated with fluoxetine administration to 
laboratory animals. In human clinical trials, a small percentage of patients developed 
sashes suggestive of sensitization. Fluoxetine should be handled as a potential 
ensitizer. 
FIRST AID AND HANDLING 
kluoxetine is an experimental material and no specific antidote is known. If systemic 
effects are suspected, consult a physician for supportive treatment as indicated. 
ºe: Flush immediately with large amounts of water and contact a physician if irritation 5evelops. 
min: Wash all areas with soap and water. Preferably use a tub or shower. Wash all Contaminated clothing thoroughly before reuse. inhalation: Remove individual to fresh air. If breathing difficulty occurs, get medical 
attention. If not breathing, give artificial resuscitation, preferably mouth-to-mouth. tL02 SDS1 LY110140 
q.,:.. r. 
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COMPOUND INFORMATION 
R 55667 : Authentic Substance 
Graphic formula : 
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O 
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Chemical name : 6-(2-(4-(bis(4-fluorophenyl)methylene)-l-piperidinyl) 
ethyl]-7-methyl-5H-thiazolo(3,2-a)pyrimidin-5-one. 
International non-proprietary name : ritanserin 
Molecular formula : C27H25F2H3OS 
Molecular weight : 477.57 
Sample Data. 
Sample No. :V 880-275 
" QUALITY DATA 
A. 1. Appearance : light-yellow powder. 
A. 2. Heltinc temperature : 144.1-145.1'C 
a 
A. 3.0Spectroticop techniques : 
A. 3. a. fl : 
Maxima Minima 
nm c IIm c 
228 
323 
24700 
13300 
219 
286 
22400 
3570 
A. 3. b. IR : confirms the structure; polymorph I. 
A. 3. c. MR : confirms the structure. 
A. 3. d. ME : confirms the structure. 
B. 1. Liquid chromatography : one peak corresponding to R 55667 
i. e. 100 fR 55667. 
B. 2. Colour and clarity. 
The solution is clear. 
It has a transmittance of 80 f at 450 nm. 
C. l. Basic equivalent : molecular weight : 477.39 (100.0 f) 
one equivalent per mole. 
D. Elemental analysis. 
Element Calculated (%) Found (%) Difference 
Carbon 67.90 67.99 " 0.09 
Hydrogen 5.28 5.21 - 0.07 
Nitrogen 8.80 8.79 - 0.01 
Fluorine 7.96 7.70 - 0.26 
Sulfur 6.71 6.66 - 0.05 
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Gt. No. D-101 
(i)-DOI HYDROCHLORIDE 
Potent and Kladve 5-}113/1-}1T1c $tonist that troves the blood brain burier. 
Mol. Formula: C11Hi6WOt HC1 
Mol. Wt: 337.6 (anhyd. ) 
m. p.: 198-200'C 
CAS Resütr7 No.: 82830-44-2 
III 
0 HHa 
Cbeminl Name: (t). I (4-lodo-25dimethoayphenyl)-2-aminopropane hydrochloride 
Physicai Properties: While solid. 
Caution: The pharmacology of this compound is incomplesely characterized and due can: should be 
axer. ised in i: a oss. (void skin contac4 ingestion or inhuuion. 
Storage: Store tightly sealed it room temperature. 
Solubility: Soluble in water. moderately soluble in ethanol. 
Disposal: Dissolve or mia the compound with a combustible solvent and bum in a chemical incinerator 
equipped with an afterburner and scrubber. 
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sgonist high affinity state of 3-NT= serotonin receptors. 'J. Mel Chem 31.5 (1988). 
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APPENDIX 4 
The buffers for immunocytochemistry and radioligand binding 
a) Phosphate buffered saline (PBS) 
b) Buffer A: [3H]DPAT binding to 5HTla receptors 
c) Buffer B: [3H]ketanserin binding to 5Ht2 receptors 
Phosphate Buffcred Salinec 
0.002M NaE 2PO4; 0.08M Na2HPO4; 0.145M NaCl 
Buffer ,& 
0.17M Tris pH7.6 
4mM CaC12 
0.01% ascorbic acid 
10µM pargyline 
Buffe B 
0.0SM Tris pH7.7 
JANSSEN PHARMACEUTICA 
Chemical Quality Control. 
SPR-DS 90-4 (900212) -R 55667 
PRODUCT INFORMATION 
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1. Solubility 
a. Solubility in different solvents. 
Solvent Solubility in g/100 ml solution 
water (pH = 7.1) <0.001 
methanol 3.5 
ethanol 2.3 
2-propanol 1.1 
dichloromethane >50 
2-propanone 7.7 
ethyl acetate 10 
diethyl ether 1.7 
hexane 0.042 
toluene 18 
N, N-dimethylformamide 21 
tetrahydrofuran 44 
4-methyl-2-pentanone 6.2 
propylene glycol 0.82 
polyethylene glycol 400 5.3 
diinethylsulfoxide 6.4 
2-butanone 12 
acetonitrile 1.7 
tetrachloroethene 6.1 
b. Solubility in aqueous medium as a function of pH. 
Solvent pH of solution Solubility In 
q/100 ml solution 
HC1 0.1 N 1.2 0.048 
HC1 0.01 N 3.2 0.39 
citrate-IWI buffer pH 2.0 2.4 0.062 
citrate-HC1 buffer pH 4.0 4.1 0.007 
citrate-NaOH buffer pH 6.0 6.0 0.003 
borate-HC1 buffer pH 8.0 "7.9 <0.001 
borate-KC1-NaOH buffer pH 10.0 10.0 <0.001 
NaOH 0.1 N 12.5 <0.001 
APPENDIX 5 
The measurement of tissue protein (Bradford's Method) 
I 
PROTEIN ASSAY 
From Bradford, 1976. Anal Biochem 248-254 
INTRODUCTION 
Protein concentration measured is proportional to blue colour of dye in 
protein environment range 5-50ug. * 
METHOD 
1)Set up standard curve in the range 5-50ug of protein. This is done by 
adding 10,20,50,100ul of 0-05Ä SSA to clean test tubes which gives 
5,10,25,50uo of protein per tube respectively. A reagent blank is also set 
up by aading 10ul of a buffer (usually the same buffer which is present in 
the samples to be measured). e 0. OSj_ýp"ýr 
2)Aad 10ul of sample to a clean test tube. 
3)Add 3.3m1 of Brao ord Reagent [i] and mix. 
4)Incubate at room temp for 5-30 mins. 
5)Trans; er contents to a cuvette and reaa absorbance at 595nM 
6)Draw a graph of OD against PROTEIN for the standard curve and read 
the amount of protein present for the given OD. 
[i] COOMASSIE BRILLIANT BLUE SOLUTION 
A)Dissoive 100mg of coomassie brilliant blue-G (Sigma B-1131) in 50m1 of 
ethanol. 
B)Transfer to 1L flask on ice. 
C)Add 100ml of 85% AnalaR phosphoric acid (85% w/v) 
D); Mix until all blue colour disappears leaving a readish brown solution. 
r 
t )AGG drum i or water . VCIý F )Ei 1 ter through 2 sneets of Whatman_ No.. 1paper. Lý_ L(ti,. - 
wýº-ý; " 
`mal 
ýý . 'y 
LV. - Wýýw"ý'ý. ' `rl 
2t L`j ý, 
Vý. 
*N. B. In the presence of 1M NaCl the sensitivity seems to be increased 10 
folg, (See MELS LAB BOOK 1 P. 57. DATE-13,06,86) 
REFERENCE 
BRADFORD M. M (1976) A rapid and sensitive method , or the quantitation of 
microgram quantities of protein utilising the principle of protain. dye 
oinding. 
Analytical Biochemistry 72,248-254. 
APPENDIX 6 
The protocol for Study 4.1 
Study 4.1. A randomised single-blind study to determine the effect of 
Fluoxetine, compared with Dothiepin, on water balance in elderly, unipolar 
depressed patients. 
EXPERIMENTAL PLAN 
Patients 
Forty male or female out-patients. This number is based on the ability to detect 
a statistically significant difference in water excretion (> 10%) between 
treatments, as determined from study 3.1. 
Inclusions 
Patients between the ages of 55 and 75 with major depressive illness defined by 
DSM IIIR criteria and Hamilton rating equal to or greater than 17 on the 17 
point scale. 
Biochemical normality (total protein, albumin, calcium, urea, creatinine, fasting 
blood glucose, total bilirubin, alkaline phosphatase, SGGI', gamma-G7, plasma 
Na, K, HCO3, urinalysis, FBC), medical history and physical examination. 
Exclusions 
Patients with significant hepatic, renal, respiratory, cardiac, haematological or 
gastrointestinal diseases or requiring concomitant therapy. 
Patients with any central nervous disorder other than depressive illness,. 
Patients with any history of mania. 
Patients considered a high suicide risk. 
Patients with narrow angle glaucoma. 
Patients with prostatism. 
1 
Patients who had taken any of the following medication in the previous 4 weeks. 
antidepressants 
neuroleptics 
diuretics 
drugs affecting cardiovascular system except calcium 
channel blockers 
anticonvulsants 
Patients should not have taken monoamine oxidase inhibitors (MAOI's) or 
lithium within 2 weeks prior to commencing the study. 
Patients taking benzodiazepines except in low doses as a hypnotic. 
STUDY PROCEDURES 
Fluoxetine: Initial dosing will be 20mg daily for first 3 weeks, optionally 
increasing at the discretion of the psychiatrist to 40 mg daily. 
Dothiepin: 25 mg day 1-3 
50 mg day 4-6 
75 mg day 7-21 
Allocation of treatment and randomisation 
Randomisation was made by Lilly Research Centre. Allocation was made by 
the staff pharmacist at the Royal Victoria Infirmary once the patient had entered 
the trial. 
Study period 1 
Psychiatric rating (Hamilton Rating Scale) will be conducted at initial 
consultation. 
The patients will undergo a pre-treatment standard oral water load test according 
to protocol 2.1.1.1.1. This will be followed by the Dexamethasone Suppression 
Test (see protocol below). 
2 
Fluoxetine or dothiepin will be given for one week, after which the patient will 
be visited or will attend the hospital, and a blood sample taken for 
urea/electrolytes. Linear analogue scales for nausea and thirst from the 
previous week will be collected. 
Any adverse events will be recorded. 
After 3 weeks of treatment the patient should be assessed by Global Clinical 
Impression and a decision taken either to continue or change the treatment. 
Should a change in treatment (drug therapy) be indicated the patient should be 
withdrawn from the study and the investigator informed. 
Study period 2 
After 6 weeks of treatment the water load and Dexamethasone Suppression Test 
will be repeated. Formal psychiatric re-evaluation and rating will be conducted. 
Dexamethasone Suppression Test 
On the night of the water load test each patient will take 1 mg of dexamethasone 
orally on retiring to bed. 
At 4pm the next day, a5 ml blood sample for plasma cortisol will be taken. 
3 
APPENDIX 7 
The DSM-IIIR criteria for major depression 
E2 "«ty 
dbvy 
3mc ._ "- 
y0OmV 
-0 .1 ri 
e 
G r. 4 y fH 
OOa 
_v 
T ti 
EE-Z] 
>0 -0 41 
I .ca, r. « 
Ea.. t 
o .C UI 
E E: °, ° En 
O Ncýao 
v oc ,c>, 
Z cc CU -Na, 
- 
'n 
W i; o, 'o N 
o =M c 7cO 
. '^ °0Ec0b 
äö ö 
OäNQCW 
,c 
<-oac 
c au. O$ 0 CL 
Z 
vVi }1 
Lý. 
> 
CI C pÖ 
Ä 
"C` 
c 
M bI Mýýý 
3 
vý 
, 
w. i NM 
_ 
^y 
0! 0NWy .C vvi 
MOO 
d 
-2 Z -A' 2 aN ücý Eb 2, e 
S. 9 
E599 
EN ÄN dýcffi 
ofb ar0 
ä. C a! O, c 22,13 .. 
-0vöäQ'3QCC, °1 Ä' c ý. c ý. ý E ü"ý 
ý.., cM4d ýw 
-CoCNcdO w) 
E (L, JS la w. 29 3c >. =eyNpä 
3ceöE 2 io 
Qg a27 N 
NL g. NQ«. 4J QO 
ýiý. Z, t7 C 
EI 12 E 
OA 4) w 
NN 
EüEEU;; 
ulb d rx0 m Z. M JO : '. '4 v 
qj c CLJ cv cä by 4, au tt_ t'c N2 Kýc is hE 1 40 
M aý dE 
_c 
tea, ý° v2°_ 
moo ;ýN 
^ÖpÖcE2 w0 o; N 't 
N ai 
Öc 
aCi 
C "fl O- yüO 
:a .2 
°E cWöN 41 c A ,ýäN .v 
a9 vb 
41 r. 
L Z' N .`oaE a"i 
'ß. 3a, ä '(J aEi ý 
2e 'c oc "ý 'e °c 'g Ä vl te a, 'v pööc 
Chi `= -- to-ý 1y 
-ý'c '° yyM7.0 rvöo E> 0cö"c N-c 
$ 
>ý z 
4v" w 3' W 
40 . C` 
hE2 
1110 ;_"? g "111777-111 ° v ä- 
_3 oN_ 
>_ ; `cb v .r°t 
3 
IHIIILUIVI ýY '$ý, " 
ý i,; V 'ß ö 
ö 
`xeM a=is 
=cý mx 
c %e NcMc 
"9uý 
^O 't 
2o Hi! II 'p MbLv 
C>! t 
cS 
-, 
- xC 'r -% sü Ný = C! 
ö. ro N 'ý 
> j2 
o t'- E^ "- Ve -- 
Zw fý 
, ;? 
Nc 
'^ ^ eo 
oA Ui8 o-il 
ill 
1111! cai 
.. 
d ö'ý ä 3. N- ^J ý 
ihä H 
QEb w^: EE0N 
N 
"N EL 'ý 
c°EEöMN 
1' 
g 
>- 2 
.U 
79 E Üdh. 4) 
... Z 
15 COsd7 '0 
mii 
. oY 
, Cp 
C 
6i v7a 'ý 6i 8^ la 7j J'ys 
r- vgl" -e- w H 
! 'J1 ýf 
N 
ýÖ C 
mvc ýý' 
APPENDIX 8 
Consent forms and letters to consultants and GP's of patients 
and volunteers in Studies 4.1 and 4.2 
STUDY 4.1 INSTRUCTIONS TO PSYCHIATRISTS. 
INMALYM 
Age 55-75 
Hamilton rating > 17 on 17 point scale. 
Check for exclusions. 
If patient seems to be eligible discuss the study briefly and contact Dr Faull bleep 2229 
ßw'1 
1. Explain the study in depth. 
2. Take a medical and drug history. 
3. Perform a brief physical examination. 
4. Consent the patient. 
5. Organize waterload and Dexamethasone tests. 
6. Give the patient the antidepressant medication. 
7. Send you a letter about the medication to be filed in the patients notes. 
8. Send you a prescription form to complete at the next visit. 
Arrange to see the patient in 3 weeks. 
If you need to see the patient sooner, or wish that the patient does not have 3 weeks supply of 
antidepressant please inform Dr. Fault. 
2WEEK REVIEW. 
Assess the patient by global clinical impression analogue scale: improved, ISQ, Deteriorated. 
Decide whether to continue in the study. 
If the patient is to be withdrawn, contact Dr. Faull. 
She will 
1. Take blood tests. 
2. Arrange to do a waterload test if agreed by the patient. 
3. Take data about the reason for withdrawal. 
If the patient continues in the study: 
Decide whether to increase the dose of antidepressant. 
Complete the prescription form for your hospital pharmacy for further antidepressant 
for 4 weeks treatment and record the dose clearly on the patient information study sheet. 
Arrange to see the patient in a further 3 weeks. 
6 WEEK REVIEW> 
Complete the global impression analogue scale. 
Find out the time of the second waterload test (this will have been arranged with the patient by 
Dr. Faull. ). 
Plan further clinical management for after completion of the study, ie. after the waterload. 
Department of Medicine, 
Floor 4- Clinical Block, 
Medical School, 
Framlington Place, 
Newcastle. NE2 4HH. 
Dear Dr. 
.. 4 
As you know your patient ........................................................... has been recruited 
into the study of the effect of Fluoxetine on water balance in depression and underwent the first 
waterload test today. The dexamethasone suppression test will be completed tomorrow and 
antidepressant treatment will start that night. 
The medication randomly selected for your patient is ........................................... and a 
four week supply has been given. A further supply for this patient is in your hospital pharmacy. 
A prescription form for access to this supply is attached. When you review the patient, please 
complete it for the same dose or increased dose of antidepressant for a further 3-4 weeks'. 
As you are aware the protocol involves review by me at 1 and 6 weeks. If however if any of the 
following occur I should be most grateful if you could contact me on bleep 2229. 
a) Patient wishes to withdraw from the study. 
b) You decide to withdraw your patient from the study. 
c) Medication, other than antidepressant, is altered. 
d) The patient is admitted to hospital. 
e) Any other problems occur. 
If the patient withdraws from the study prematurely I would like to perform a waterload test at 
that point, or at least take a blood sample for electrolytes and osmolality before the medication is 
altered in any way. 
'Please note that this is a single blind trial. If you wish to increase the dose of antidepressant 
please try to do this at three weeks after starting treatment. You 42 nj need to inform me at 
this point but record the change in dose on the study information sheet in the patients notes. 
Your pharmacy has tablets available for your patient if they need to be increased. 
Please place this information sheet with the consent form in your patients notes for future 
reference. Thank you for your co-operation. 
Yours sincerely, 
Christina Faull. 
Research Registrar. 
46 
APPENDIX C 
PATIENT/SUBJECT INFORMATION AND CONSENT FORM 
The Effect of Fluoxetine or Dothiepin 
on Water Balance in Depression Compared to 
Water Balance in Healthy Subjects 
[Protocol No. BlY-EW-EO87] 
Purpose of Study 
It is thought that depression is in part due to an imbalance of biochemistry in 
some areas of the brain. Many of the drugs used to treat depression do so by 
correcting these imbalances. Sometimes these drugs also affect other areas of 
the brain which are not involved in depression. We are particularly interested 
in the way the antidepressant drug fluoxetine compared with another called 
dothiepin, may affect water balance in people with depression. There is some 
suggestion that very occasionally fluoxetine may disturb water balance, as do 
many other drugs used in the treatment of depression and other illnesses. 
We are seeking 40 male or female patients aged 55 to 75 years for this 
research study comparing the effects of fluoxetine and dothiepin in water 
balance. Twenty volunteer subjects within the same age group will also be 
studied to act as a control panel. This may help us to understand why some 
drugs upset water balance and therefore prevent it from happening. 
Study Description 
Your suitability for the study will be assessed by your psychiatrist or the 
medical researcher. If you consent to participate in the study your involvement 
will be as follows: - 
1. You will have a blood test to measure sore biochemist-, - as a 'baseline'. 
2. You will then have a test of water balance. This means coming to the 
Royal Victoria Infirmary with no breakfast or drink and taking no 
alcohol for 24 hours beforehand. A needle will be put in your arm 
through which to sample blood. Then you will drink about 3 pints of 
water. You will then have blood taken about every half hour and be 
asked to collect urine during the morning. You will also be asked 
how thirsty or nauseated you feel every hour. The test will last 
about 44 hours. You will not be able to eat until afterwards and 
will be asked not to smoke before or during the test. You will also 
be interviewed that morning about your symptoms if you are taking 
fluoxetine or dothiepin. 
Protocol Fluoxetine B1Y-EW-E087 - Draft 3- October 1990 
3. You should inform the researcher of any medicines taken within 4 weeks 
before or during the study period. 
You should be aware that fluoxetine or dothiepin in common with other drugs 
used in psychiatry, may impair your driving skills or mental performance. 
You should avoid taking other medicines during the study. You should 
inform the investigator of the names and doses of any medication that is 
taken. 
The study has been approved by the Ethical Committee of the Health Authority 
and you will be informed of significant new findings during the study which may 
relate to your willingness to continue participation in the study. 
Insurance exists to ensure that compensation can be paid in the rare event of 
anyone suffering harm or injury. Please ask if you require further information. 
Your participation is completely voluntary and you may withdraw your consent at 
any time during the study. The investigator reserves the right to withdraw you 
from the study at any time. 
Your General Practitioner will be informed about your participation in this 
study, and if you are currently having treatment with either Fluoxetine or 
dothiepin the Psychiatrist will also know that you are having this test, which 
will not affect the treatment you have been prescribed. 
If you have any questions concerning the study please do not hesitate to ask. 
The Consultant in charge of the study is Dr. P. Baylis, and Dr. Christina Faull 
will be organising the study. Please sign the consent form if you then decide 
to take part in the study. 
Protocol Fluoxetine B1Y"EW-E087 - Draft 3" October 1990 
CONSENT FORM 
I 
The Effect of Fluoxetine Compared with Dothiepin 
on Water Balance in Depression 
(Protocol No. BIY-EW-E087] 
I have received a copy of "Patient/Subject Information' and the purpose, 
procedures and effects of this study have been explained to me by 
Dr. 
I understand the requirements and agree to cooperate with the study procedures 
and disclose all the necessary information to the Doctor's involved. I 
understand that the results of the water load research may not be directly of 
benefit to me. 
I understand that I am under no obligation to take part and may withdraw from 
the study at any time. Withdrawal from the study will not affect any trea --ent 
I may be receiving. 
I consent to all information obtained being put at the disposal of medical 
authorities, should this be required and that this information will remain 
completely confidential. 
I have read and understand this information and consent form. I voluntarily 
consent to participate in the research outlined. 
Full Name: ............................................ 
Date of Birth: .................... 
Present Address: ............................. 
Patient's Signature: ............................. 
Telephone No: ............. 
Date: ................. 
'Witness' Signature ............................. Date: .................. 
Protocol Fluoxetine BIY"EW"E087 " Draft 3- Octohar 1990 
The hormonal gad biochemical responses 
healthy elderly people IQ water j4, ß . Qf 
It is thought that as we grow older our bodies are less able to respond to 
certain situations, in particular there may be some change in the way we excrete 
water. Our group of researchers has a particular interest in problems of water 
balance and we have already done a lot of research in people who have known 
problems. In order to fully understand the problems we need a very clear 
understanding of the normal changes with age. 
This study is to establish the hormonal and biochemical responses of a 
group of healthy elderly people to an oral water load. We are seeking people in 
the age group of 55 to 75 years who are physically well. 
Study Description 
Your suitability for the study will be assessed by the medical researcher. 
If you consent to participate in the study your involvement will be as follows: - 
1. You will have a physical examination and a blood test to exclude any other 
problems with your health and to make a 'baseline' assessment. 
2. You will then have a test of water balance. This means coming to the Royal 
Victoria Infirmary with no breakfast or drink and taking no alcohol for 24hrs 
beforehand. A needle will be put in your arm through which to sample blood. 
Then you will drink about 3 pints of water (20m1/kg body weight). You will 
then have blood taken about every half hour and be asked to collect urine during 
the morning. You will also be asked about how thirsty or nauseated you feel. 
The test will last about 41f2hrs. You will not be able to eat until afterwards and 
will be asked not to smoke before or during the test. 
Your family Doctor will know about your participation in the test . If 
any of your results are not normal you will be told about them by the 
researchers and you will be given any advice necessary. 
Insurance exists to ensure that compensation can be paid in the rare event of 
anyone suffering harm or injury. Please ask if you require further information. 
Your participation in the study is completely voluntary and you can withdraw 
from the study at any time. If you have any question about the study at any 
point please do not hesitate to ask. 
Please sign the consent form if you decide to take part in the study. 
The hormonal and biochemical responses 
Qf healthy elderly people IQ QMI water 14ad 
I have received a copy of the information about the study and the purpose, 
procedures and effects have been explained to me. 
I understand the requirements and agree to cooperate and disclose all the 
necessary information. I realise that the results of the water load research may 
not be directly of benefit to me. 
I consent to all information obtained being put at the disposal of medical 
authorities, should this be required and that this information will remain 
completely confidential. 
I have read and understood this information and consent from. I voluntarily 
consent to participate in the research outlined. 
Full name .................................................................... . 
Date of Birth ............................................................ Tel. 
No ................ 
Present address: ....................................................... 
.................................................... . ....... 
............................................ . .......... . .... 
...................................... . .................. ... 
Signature .......................................................... Date.................. 
Witness's signature ................................................ Date.................. 
Department of Medicine, 
Floor 4- Clinical Block, 
Medical School, 
Framlington Place, 
Newcastle. NE2 411H. 
Dear Dr. 
Your patient ........................................... has volunteered to take part in 
a study we are performing, at the Royal Victoria Infirmary, to explore the effect of age on 
waterbalance. I enclose a copy of the information that has been given to your patient for your 
interest. 
If you have any questions about this work or are in any way concerned about 
your patient in connection with this study, please do not hesitate to contact me. I can be reached 
through the Royal Victoria Infirmary switchboard (232-5131) on bleep 2229. 
Yours sincerely 
Dr. Ch istina Fault. 
Research Registrar. 
Department of Medicine, 
Floor 4" Clinical Block, 
Medical School, 
Framlington Place, 
Newcastle. NE2 4HH. 
Dear Dr. 
Your patient ........................................... who was referred to 
Dr ............................. for treatment of depression has consented to take part in a study we 
are performing, at the Royal Victoria Infirmary, to explore the interaction of serotonin and 
waterbalance. I enclose a copy of the information that has been given to your patient for your 
interest. 
If you have any questions about this work or are in any way concerned about 
your patient in connection with this study, please do not hesitate to contact me. I can be reached 
through the Royal Victoria Infirmary switchboard (232-5131) on bleep 2229. 
Yours sincerely 
Dr-Christina Faull. 
Research Registrar. 
Department of Medicine, 
Floor 4- Clinical Block, 
Medical School, 
Fmmlington Place, 
Newcastle. NE2 41111. 
Dear Dr. 
As you know your patient ........................................................... has been 
recruited into the study of the effect of Fluoxetine compared with Dothiepin on water balance in 
depression and underwent the waterload test today. The results of this test appear to be 
abnormal. I have discussed this with the patient and will be continuing to follow the course of 
his/her serum biochemistry on a weekly basis. If the abnormality becomes clinically important I 
shall obviously be discussing this with you in more detail. If you have any queries about this 
please do not hesitate to contact me on RVI bleep 2229. 
Thank you for your help in this research. 
Yours sincerely, 
Christina Faull 
Research Registrar 
Department of Medicine, 
Floor 4- Clinical Block, 
Medical School, 
Framlington Place, 
Newcastle. NE2 41H. 
Dear Dr. 
As you know your patient ........................................................... has been 
recruited into the study of the effect of Fluoxetine compared with Dothiepin on water balance in 
depression and underwent the waterload test today. The results of this test appear to be normal 
and I do not need to follow the patient further. I have discussed this with the patient. I should 
be very interested to hear if problems with hyponatraemia do arise at any point in this patient's 
illness. 
Thank you for your help with this project. 
Yours sincerely, 
Christina Faull 
Research Registrar 
APPENDIX 9 
The Hamilton rating scale for depression (HRSD) 
FLUOXETINE DEPRESSION 
ItIiIIttI t-0 1 01 
Study Code Investigator No. Patient No. Visit No. 
FLUOXETINE DEPRESSION " 
IIIttIIIIt 0i Of t 
Study Code Investigator No. Patient No. Visit No. 
PLEASE COMPLETE LEGIBLY USING A BLACK BALL-POINT PEN 
HAMILTON RATING SCALE FOR DEPRESSION " HAMD Conrd 
0 Absent PhyaMiagWal concomitants of anxiety. such a: 
11 ANXIETY I Mild 
Gastro"snteitinal-dry mouth wind. indigeslion. purrnea. Cramps. belching 
" 
SOMATIC 2 ilk, " 
'. + I": Cardio-vascular-palpitations, neadactles Moderate Rhpiratory-hyperventilalion. sighing 
3 Severe Urinary frequency 
a- Incapacitating Sweating 
12 SOMATIC 0 None 
SYMPTOMS 
CASTRO. 
I Loss of appetite but eating without Stall encouragement Heavy feelings in aocomen 
INTESTINAL 2 OilfiCulty eating without stall urging Requests or requires laxatives or medication for bowels or 
medication for GI symptoms 
13 SOMATIC 
0 None 
SYMPTOMS 1 Heaviness in limos. back or head Backaches. headache. muscle aches loss of energy and fatigability 
GENERAL 2 Any clear-cut symptom rates 2 ý-u (3'_%0 
to GENITAL 
0 Absent Symptome such as: Loss of libido 
SYMPTOMS I Mild Menstrual disturbances 
2 Severe 
0 Not present 
15 HYPOCHON" 
I Self-absorption (bodily) 
ORIASIS 2 Preoccupation with health 
3 Frequent complaints. requests for help. etc 
4 Hypochondriacal Delusions 
ACTUAL. WEIGHT CHANGE (since last visit) 
0 No weight loss or weight loss NOT Caused by present illness 16 LOSS OF 
WEIGHT I Weight loss probably caused by present illness 
2 Definite weight loss Caused by present illness 
cknowledges being depressed and ill 
I? INSIGHT 
r 
1 cknowledges illness but attributes cause to bad food. Climate. Overwork virus. need for rest. etc 
2 being ill at all 0enies 
TOTAL 17 POINT SCORE 
APPENDIX 10 
Case reports of depression and hyponatraemia 
This appendix presents two patients with depression who developed 
hyponatraemia during treatment with a SSRI. Both patients declined further 
investigation. These case reports help to illustrate the clinical relevance of some 
of the work of this thesis and the paucity of understanding of hyponatraemia in 
mental illness. 
1. CH, a 43yr male was diagnosed as having systemic lupus erythematosus 
(SLE) in 1981. He had received a variety of treatments with little response. 
There was initially only cutaneous involvement but the disease had gradually 
progressed to be more systemic with occasional episodes of dysphasia and gate 
disturbance but with no residual symptomatic deficit. He had been admitted to a 
dermatology ward with an acute episode of SLE in April 1991 which was 
complicated by short episode hyponatraemia (lowest pNa 124mmol/1). Because 
of his physical illness he had not been working for 6 months before he presented 
to a psychiatric unit in August 1991 with attempted suicide by overdose. This 
was not physically serious but as he had had marked depressive symptoms for 
the previous 18 months and these were gradually worsening he was admitted for 
observation and treatment. 
Other significant features of his history and examination were 
He appeared very agitated. 
He had increased his alcohol intake to 10units/day over 6months. 
He had no previous history of mental illness despite severe physical illness for 
many years. 
There was no family history of psychiatric illness. 
Several neurological features were noted on examination: Mild disorientation in 
time. Mild impairment of short term memory with confabulation. 
Mild hypertension was also noted. 
Medications on admission: - 
Prednisolone 25mg daily. 
Intermittent amitriptyline and temazepam as hypnotic. 
Differential diagnosis: - 
Major depression. 
Adjustment disorder 
Organic mood disorder secondary to SLE or steroids. 
Alcohol related mood disorder and possible neurological damage. 
Invesdgadons: - 
Neurological investigations: 
CT scan showed multiple small infarcts, mostly old. 
LP showed normal protein and cell content of CSF suggestive of 
quiescent SLE. 
Electrolytes: 
pNa 136mmol/1. Creadnine 74mmol/1 urea 1.7 mmol/1. 
Management: - 
He was commenced on regular amitriptyline, thiordiazine and lorazepam and his 
oral steroids gradually reduced. 
Progress at 4 weeks: - 
There was no improvement in his affect and some worsening of agitation. 
Some worsening of skin lesions was also noted. He developed severe back pain 
consequent to a vertebral crush fracture (secondary to steroid induced 
osteoporosis). 
The amitriptyline was stopped and the SSRI paroxitene commenced. 
Progress at 6 weeks: - 
He had a grand mal fit with prolonged post ictal drowsiness and confusion. 
Investigations: - 
pNa 115mmol/1 pOS 247m0sm/kg urea 1.4 mmol/l Creatinine 79mmol/l. 
Volume status: Thought to be normovolaemic. 
CT scan showed a small, new frontal infarct. 
Diagnosis: - 
SIAD probably secondary to worsening of cerebral SLE, although possibly 
associated with the paroxitene treatment. 
Management: - 
500m1 1.8 %NaC1(50m1/hr). 
Fluid restriction: 500m1/24hr 
Commenced on phenytoin. 
Paroxitene stopped. 
Progress: - 
Conscious level and pNa returned to normal over 7 days. 
He has remained an inpatient because of continued, resistant depression and 
worsened cutaneous SLE. His pNa remained within the normal range for 3 
months until late January 1992 when it was noted to be failing (122mmol/1). He 
was taking no psychoactive medications at that time. Fluid restriction was 
reinstituted and the pNa returned to normal in 14 days. Due to persistent 
depression he was commenced on trazadone on 31/3/92 (metabolite mCPP) with 
no adverse effect on pNa after 14 days. 
2. MD, 60yr female had had multiple episodes of unipolar major depression 
with psychotic features over 10 years. She also had the physical illnesses of 
ischaemic heart disease and hypothyroidism, for both of which she was 
receiving medications. Her electrolytes had been measured in November 1991 
and were normal at that time. 
Regular medications: - 
Frusemide 40mg, Amiloride 5mg, Thyroxine 125mcg, Isosorbide dinitrate 
20mg TDS, Aetenolol 75mg, Depixol 60mg 2 weekly, procyclidine 5mg BD. 
She was commenced on Fluoxetine 20mg daily in late January 1992 for 
recurrence of depression. The dose was increased to 40mg daily after 2 weeks 
due to lack of mood improvement. She was admitted to hospital in mid February 
due to worsening psychotic symptoms and her pNa was found to be 129mmol/1. 
She was also noted to have a urine infection and mild urinary retention (possibly 
behavioural, secondary to mental illness). 
Five days later her pNa was 124mmol/l. Her volume status was not 
determined. 
Management: - 
Fluoxetine and were diuretics stopped. 
Fluid restriction: 500m1/24hr. 
Depression was treated by ECT and chlorpromazine 50mg TDS with good 
effect. 
Progress: - 
Her pNa returned to normal over 10 days with no apparent adverse effects. 
DISCUSSION 
These brief case histories have shown that it is often difficult to discern 
aetiology of the hyponatraemia which occurs in association with depression. 
Both subjects had physical illness and were taking multiple drug therapies. 
SSRIs were associated with the occurrence of hyponatraemia in both cases. This 
may only reflect the increase in clinical use of theses drugs, particularly in 
resistant mental illness, or it could indicate that hyponatraemia in depression 
treated with drugs that increase 5HT neurotransmission is indeed related to 
dysfunction of central 5HT neurotransmission. Subject one had had a previous 
episode of hyponatraemia and the hyponatraemia recurred when drug free, 
suggesting that it was related to his physical and/or mental illness and not to 
drug therapy. Subject two had a very severe mental illness but had had previous 
similar episodes without hyponatraemia developing. These had not been treated 
with Fluoxetine. This fact and the timing of onset of hyponatraemia in relation 
to the commencement of antidepressant therapy would suggest that there was an 
association with Fluoxetine treatment in this woman. 
APPENDIX 11 
The data of the rat studies in Section 5 
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Study 5.2.1 The effect of acute Fluoxetine on osmoregulated AVP secretion 
Group: Normal saline pretreatment : normal saline stimulus (NN) 
No Wt pOs pNa pAVP 
(g) (mosm/kg) (mmol/1) (pmol/l) 
.P 
6 250 288 125 0.7 
18 242 290 136 22 
22 260 303 150 6.2 
28 263 315 151 130 
30 254 291 144 1.0 
38 245 296 145 1.1 
43 270 301 144 0.7 
48 260 298 146 0.7 
55 263 307 147 160 
60 259 300 147 0.9 
Group: Fluoxetine pretreatment : normal saline stimulus (FN) 
No Wt pOs pNa pAVP 
(g) (mosm/kg) (mmol/l) (pmol/I) 
1 245 296 139 2.4 
10 239 290 136 0.8 
13 240 282 132 34.0 
17 244 296 140 13.3 
24 244 311 151 3.8 
34 250 299 145 1.9 
36 250 297 146 1.0 
44 ', 260 296 143 0.6 
50 255 300 146 132 
56 264 300 146 0.5 
Study 5.2.1 (Cont/d) The effect of acute Fluoxetine on osmoregulated 
AVP secretion 
Group: Normal saline pretreatment : hypotonic stimulus (NL) 
No wt pOs pNa pAVP 
(g) (mosm/kg) (mmol/I) (pmol/l) 
3 246 280 129 170 
9 237 287 134 14.7 
12 249 282 133 <0.6 
20 240 281 135 0.8 
26 255 288 139 0.8 
27 250 298 144 15.6 
39 249 285 142 0.8 
41 243 297 142 1.4 
46 266 291 139 <0.6 
57 254 293 146 <0.6 
61 278 295 150 20.0 
Group: Fluoxetine pretreatment : hypotonic stimulus (FL) 
No Wt pOs pNa pAVP 
(g) (mosm/kg) (mmol/1) (pmol/1) 
4 224 282 131 <0.6 
7 238 296 133 1.0 
16 250 278 133 0.6 
23 260 289 139 0.6 
31 247 285 140 0.6 
35 250 295 143 1.6 
47 257 288 139 <0.6 
57 271 292 141 0.6 
53 261 292 140 0.8 
59 249 291 143 6.0 
Study 5.2.1 (Cont/d) The effect of acute Fluoxetine on osmoregulated 
AVP secretion 
.. t 
Group: Normal saline pretreatment : hypertonic stimulus (Nil) 
No wt pOs pNa pAVP 
(g) (mosm/kg) (mmol/I) (pmol/I) 
2 220 309 142 25.0 
8 244 295 142 9.1 
14 236 294 139 4.7 
15 255 298 142 3.0 
21 242 311 146 4.4 
323 256 314 150 10.0 
33 245 310 149 8.4 
49 253 328 159 250 
52 250 313 152 430 
54 246 307 151 7.1 
Group: Fluoxetine pretreatment : hypertonic stimulus (Fii) 
No wt pOs pNa pAVP 
(g) (mosm/kg) (mmol/1) (pmol/1) 
5 238 300 141 2.9 
11 251 298 141 9.1 
19 249 292 140 0.7 
25 259 310 144 6.2 
29 244 313 151 23.2 
37 236 309 152 76 
40 250 307 153 6.6 
42 251 307 147 6.2 
45' 1 271. 310 149 1.3 
58 254 309 151 24.8 
Study 5.2.2 The effect of acute Fluoxe(ine on osmoregulated AVP 
Group: Normal saline : hypertonic stimulus (Nil) 
No wt pOs pNa pAVP IICT 
(g) (mosm/kg) (mmol/I) (pmol/1) (%) 
4 304 314 155 5.6 41 
5 294 320 157 173 47 
12 297 309 154 120 42 
18 265 326 64 43 
20 280 308 157 27.2 41 
25 225 304 157 8.4 46 
30 244 313 153 192 39 
34 268 317 155 16.8 41 
35 237 324 158 136 45 
39 236 318 155 >400 46 
Group: Fluoxetine: hypertonic stimulus (F!! ) 
No wt pOs pNa pAVP HICT 
(g) (mosm/kg) (mmoIII) (pmolll) (%) 
1 245 310 154 16.8 40 
6 279 321 153 400 43 
8 268 314 155 44 33 
13 250 322 161 256 45 
16 252 312 155 148 42 
23 283 312 153 15.6 43 
24 279 325 154 256 48 
29 275 314 40 44 
33 292 316 152 10 44 
40 276 310 154 16.8 48 
Study 5.2.2 (Cont/d) The effect of acute Fluoxetine on osmoregulated AVP 
Group: Normal saline : hypotonic stimulus (NL) 
No Wt pOs pNa pAVP IICT 
(g) (mosm/kg) (mmol/1) (pmol/1) (%) 
3 288 291 147 6.5 46 
7 277 291 - 360 48 
11 274 293 145 92 46 
15 290 295 141 <0.6 45 
17 276 311 155 112 50 
22 249 313 150 192 44 
26 228 295 149 >400 40 
27 238 298 155 400 44 
32 236 304 153 4.2 46 
37 233 294 148 <0.6 43 
Group: Fluoxetine : hypotonic stimulus (FL) 
No wt pOs pNa pAVP HHCT 
(g) (mosm/kg) (mmoIII) (pmoUl) (%) 
2 233 299 151 6.5 45 
9 250 84 46 
10 241 - - 240 46 
14 262 305 - 3.6 45 
19 260 307 152 >400 50 
21 293 307 154 9.2 46 
28 305 291 144 <0.6 46 
31 283 305 149 4.4 46 
36 280 309 145 88 49 
38 272 305 141 5.6 47 
Study 5.2.3 The effect of volume of Fluoxetinc injection on AVP response 
to hypotonic stimulus 
Group: High volume fluoxetinc : hypo-osmotic stimulus (II) 
No Wt pOs pAVP 
(g) (mosm/kg) (pmol/I) 
1 255 288 <0.6 
4 242 288 <0.6 
5 234 292 <0.6 
7 257 297 <0.6 
11 225 289 <0.6 
12 242 298 <0.6 
Group: Low volume fluoxetine : hypo-osmotic stimulus (L) 
No wt pOs pAVP 
(g) (mosm/kg) (pmol/I) 
2 250 287 <0.6 
3 262 296 <0.6 
6 259 294 <0.6 
8 241 288 <0.6 
9 266 294 0.9 
10 282 294 0.6 
Study 5.2.4 The effect of handling and social stress on osmoregulation 
Group: Early randomisation (A) 
No Wt pOs pNa pAVP PICT 
(g) (mosm/kg) (mmol/1) (pmol/1) (%) 
2 260 154 - 1.4 42 
3 270 148 298 1.4 41 
6 275 156 306 1.0 39 
8 268 144 300 5.2 41 
10 264 150 302 <0.6 46 
11 262 149 300 1.7 43 
Group: Late randomisation (B) 
No Wt pOs pNa pAVP DUCT 
(g) (mosm/kg) (mmol/I) (pmol/1) (%) 
1 285 155 298 1.4 44 
4 269 150 298 2.5 41 
5 263 155 307 12.0 40 
7 258 145 299 0.7 43 
9 288 142 297 0.8 40 
12 287 146 296 <0.6 41 
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Study 5.3 To explore the effect of Ritanserin, a 5IIT2/51IT1C Antagonist, 
on osmotically stimulated AVI' release 
Group: Vehicle pretreatment : no osmotic stimulus (NN) 
No Wt pOs pNa pAVP IICT SIIT: 5IIlAA 
(g) (mosmlkg) (mmol/1) (pmol/1) (%) 
2 290 297 143 1.0 42 1.54 
8 292 297 131 <0.6 41 1.44 
16 303 293 141 >40 45 1.36 
22 276 295 142 1.0 38 1.46 
30 270 296 141 1.2 46 1.80 
33 285 298 142 >40 44 1.60 
40 272 290 138 <0.6 39 1.10 
45 281 296 141 5.0 38 1.80 
51 285 294 140 1.9 40 1.38 
57 293 300 147 2.0 40 0.88 
Group: Ritanserin pretreatment : no osmotic stimulus (RN) 
No Wt pOs pNa pAVP IICT SIIT: 5II1AA 
(g) (mosm/kg) (mmol/l) (pmolIl) (%) 
5 266 297 142 1.6 41 1.47 
7 294 301 140 1.6 42 1.69 
13 290 292 139 <0.6 42 2.06 
20 270 292 140 0.8 41 1.71 
25 288 295 143 <0.6 41 2.32 
31 267 295 143 5.1 45 3.14 
35 267 297 142 1.1 45 1.84 
42 270 293 142 >40 44 2.14 
48 197 290 139 3.2 41 1.95 
54 285 296 146 1.2 39 1.94 
59 291 297 138 1.0 41 2.49 
Study 53 (Cont/d) To explore the effect of Ritanscrin, a SIITT/SIITic 
antagonist, on osmotically stimulated AVI release 
Group: Vehicle pretreatment : hypertonic stimulus (NII) 
No Wt pOs pNa pAVP IICT 
(g) (mosm/kg) (mmol/1) (pmol/1) (%) 
4 278 308 148 5.6 45 
9 276 309 148 9.6 40 
15 279 310 150 14.8 34 
21 279 307 150 >40 40 
26 292 313 152 2.7 40 
36 288 306 148 4.0 41 
39 277 312 149 >40 42 
46 280 313 154 16.0 42 
53 264 304 152 8.4 39 
58 283 305 152 14.4 43 
Group: Ritanserin pretreatment : hypertonic stimulus (Rif) 
No Wt pOs pNa pAVP IICT 
(g) (mosm/kg) (mmolIl) (pmolIl) (%) 
3 288 304 146 6.8 46 
14 277 308 148 11.6 38 
18 286 301 146 3.7 38 
23 299 311 150 >40 
28 278 315 150 28.8 45 
32 296 305 141 4.0 42 
41 281 298 142 8.0 44 
43 273 307 149 11.2 41 
49 268 304 149 8.8 43 
60 276 315 154 6.8 41 
Study 5.3 (Cont/d) To explore the effect or Ritanserin, a 5lIT, /Si! T1C 
antagonist, on osmotically stimulated AVI' release 
Group: Vehicle pretreatment : hypotonic stimulus (NL) 
No Wt pOs pNa pAVP IICT 
(g) (mosm/kg) (mmol/1) (pmol/1) (%) 
6 284 285 134 <0.6 43 
10 287 291 138 <0.6 42 
17 299 285 136 2.1 44 
27 272 291 139 4.9 48 
29 279 290 136 <0.6 43 
34 282 284 136 <0.6 41 
47 270 290 140 <0.6 42 
50 274 286 137 1.1 43 
52 284 284 136 <0.6 43 
56 270 290 144 <0.6 40 
Group: Ritanserin pretreatment : hypotonic stimulus (RL) 
No Wt pOs pNa pAVP UICT 
(g) (mosm/kg) (mmolIl) (pmolIl) (%) 
1 293 284 136 <0.6 44 
11 294 288 137 <0.6 41 
12 276 285 135 <0.6 47 
19 278 291 139 >40 42 
24 280 296 142 9.6 44 
37 297 287 123 <0.6 40 
38 287 284 134 <0.6 46 
44 295 279 134 <0.6 43 
55 275 290 131 <0.6 37 
61 312 288 137 1.1 42 
Study 5.4 Does Ritanserin Inhibit the fuoxetine augmented AVI' 
response to plasma hyperosmolalily? 
Group: vehicle and vehicle (NN) 
No Wt pOs pNa pAVP IICT 
(g) (mosm/kg) (mmol/l) (pmol/l) (%) 
4 292 299 147 5.2 37 
7 297 309 152 4.8 37 
11 280 313 155 12.8 40 
15 291 311 154 9.6 41 
19 308 314 149 6.8 39 
22 291 306 151 6.0 34 
27 295 316 153 17.6 41 
30 301 314 153 2.6 40 
Group: Vehicle and fluoxetinc (NF) 
No Wt pOs pNa pAVP IICT 
(g) (mosm/kg) (mmol/l) (pmoUI) (o) 
3 285 309 152 27.3 47 
5 287 315 156 >32 40 
10 284 312 153 27.1 44 
13 289 310 151 17.7 48 
17 278 306 149 21.6 46 
21 295 313 148 6.0 40 
25 289 313 154 >32 48 
31 293 317 153 11.4 47 
Study 5.4 (Cont/d) Does Ritanserin inhibit the tluoxctine augmented AVi' 
response to plasma hyperosmolality? 
Group: Ritanserin and vehicle (RN) 
No Wt pOs pNa pAVP IICT 
(g) (mosm/kg) (mmolIl) (pmol/l) (v) 
1 283 308 148 8.0 42 
6 294 320 158 11.6 38 
8 302 316 153 26.1 40 
12 286 312 151 13.2 40 
20 296 309 154 15.6 34 
23 286 310 152 9.2 36 
28 289 312 152 8.4 37 
29 294 315 153 14.0 40 
Group: Ritanserin and fluoxetine (RF) 
No wt pOs pNa pAVP IICT 
(g) (mosm/kg) (mmol/1) (pmo111) (%) 
2 301 320 153 21.6 37 
9 287 309 152 23.1 42 
14 295 319 158 20.0 48 
16 296 313 148 27.8 41 
18 283 314 151 15.2 39 
24 298 308 152 12.0 40 
26 291 317 144 11.0 48 
32 300 306 149 23.6 48 
33 303 314 152 28.0 40 
I 
*Study 5.5. The effect of the 5IIT2 agonist DOi on osmoregulatcd AVI 
Group: Vechide pretreatment : no osmotic stimulus (NN) 
No wt pOs pNa pAVP IUCT S11T: 3111AA 
(g) (mosm/kg) (mmoVl) (pmoV1) (%) 
10 283 303 154 2.6 38 0.90 
11 297 300 152 3.6 41 0.94 
16 296 300 151 1.4 40 0.94 
23 305 305 150 2.0 44 1.94 
27 308 300 ISO 1.4 43 1.70 
38 288 302 153 1.1 40 1.03 
45 288 303 155 1.2 43 1.42 
49 290 302 154 1.6 40 0.84 
53 293 302 153 2.8 42 2.98 
59 296 298 154 1.0 41 1.06 
Group DOI: pretreatment: no osmotic stimulus (DN) 
No wt pOs pNa pAVP IICT SIIT: SIIIAA 
(g) (mosm/kg) (mmoUl) (pmoVl) (%) 
6 305 303 153 10.8 44 1.58 
13 287 314 153 3.8 43 1.26 
20 293 302 156 1.4 43 1.89 
25 266 302 156 2.2 40 1.93 
29 283 299 154 1.1 44 2.58 
36 266 335 168 >50 48 1.37 
43 294 304 156 IA 40 1.78 
47 270 302 153 2.0 45 1.18 
54 293 298 150 1.1 44 1.41 
57 262 210 157 373 46 2.45 
Study 5.5 (Cont/d) The effect of the 511'agonist DO! on usmorcgulatcd 2 VP. 
Group: Vehicle pretreatment: hypertonic stimuls (Nil) 
No wt pOs pNA pAVP PICT 
(g) (mosm/kg) (mmokl) (pmoVl) (%) 
4 299 316 159 5.6 44 
5 278 316 163 0.6 44 
14 280 320 161 18.8 41 
18 280 319 166 24.0 39 
30 290 318 166 7.8 44 
34 304 308 157 7.2 42 
41 304 318 163 19.2 39 
42 284 313 163 12.0 38 
50 280 314 160 12.0 36 
55 280 313 161 15.6 38 
Group: DOI pretreatment: hypertonic stimulus (DII) 
No wt 
(g) 
pOs pNa 
(mosm/kg) (mmoV1) 
pAVP 
(pmoVI) 
IICT 
(Z ) 
2 288 316 161 18.4 39 
7 290 318 162 8.4 39 
17 288 309 158 9.6 40 
21 299 321 164 12.0 40 
26 303 316 167 14.0 31 
33 280 314 158 17.2 43 
37 278 321 162 14.8 40 
44 274 313 161 8.0 42 
52 293 317 163 17.6 40 
58 299 309 153 15.6 42 
Study 5.5 (Cont/d) The effect of the 51IT2 agonist DO! on osmoregulated 
AVE 
Group: Vehicle pretreatment : hypotonic stimulus (NL) 
No Wt 
(g) 
pOs pNa 
(mosm/kg) (mmoVI) 
pAVP 
(pmoVl) 
}{CT 
(%) 
3 274 296 151 <0.6 46 
8 310 299 149 <0.6 41 
12 290 291 145 <0.6 44 
19 288 294 150 0.7 41 
24 289 299 153 <0.6 41 
32 291 299 154 <0.6 40 
40 290 291 149 <0.6 42 
48 293 286 145 <0.6 42 
51 296 294 149 0.7 41 
60 292 289 147 <0.6 44 
Group: DOT pretreatment : hypotonic stimulus (DL) 
No Wt 
(g) 
pOs pNa 
(mosm/kg) (mmoUI) 
pAVP 
(pmoVI) 
11GT 
(%) 
1 276 297 154 <0.6 41 
9 277 297 151 1.0 39 
15 285 297 153 0.8 44 
22 260 290 153 1.1 43 
28 276 299 151 0.9 45 
31 291 298 154 0.9 46 
35 295 291 147 0.6 
39 286 292 151 0.6 41 
' 46 295 295 139 <0.6 37 
56 278 292 ="" 151 46 
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APPENDIX 12 
The mathematical Model of Piece-Wise regression analysis 
Analysis was performed in the 'GLIM' statistical computing 
package (© The Royal Statistical Society 1986) with custom written macros 
to carry out the repeated regressions. 
The model TIN. ,,., p 
Let yij be the vasopressin response of the ith rat in the jth group 
for i-1....... n3 and j-1 or 2 depending on the group. 
Similarly let xii be the measured osmolality of the ith rat in the 
jth group. 
Then the equation of the lines can be given by 
A 
Y1 ja ai 
+ ßi (x 
j 
t') 
ll (xI 
j> 
ti) 
where 
9 is an indicator function such that 
JJ is zero when 
(x1 
j> 
ti) 
xij s tj and is one when xii > ti . 
In the case when a common change point is used tl - t2 . 
Thus the residual variation of a model can be considered in terms of 
a residual sums of squares given by 
A 
(y1 
j- yi j) 
i. j 
i*i 
where yij is the fitted value of the yiith observation. Obviously the yip's 
are functions of the change point and minimising the above equation (*) with 
respect to the change point gives the required change point. In the case of 
two separate change points, the two groups are independent and thus the 
procedure is identical, only separate for each group. 
